Btk at the Pre-B Cell Receptor Checkpoint by Middendorp, S.
Btk at the Pre-B Cell Receptor Checkpoint
ISBN 90-73436-66-4
© 2004 Sabine Middendorp
No part of this thesis may be reproduced or transmitted in any form by any 
means, without permission in writing from the author. 
Illustrations :  Rudi Hendriks, Edwin Dokter, Sabine Middendorp
Printing :  Ridderprint B.V., Ridderkerk
Cover:  : Danny Roso, Ridderprint B.V.
Lay-out : Wendy Netten, Marcia IJdo, Sabine Middendorp
Btk at the Pre-B Cell Receptor Checkpoint
Bruton’s tyrosine kinase en het pre-B cel receptor controlepunt
Proefschrift
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam
op gezag van de Rector Magnifi cus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
woensdag 19 mei 2004 om 13.45 uur
door
Sabine Middendorp
geboren te Amsterdam
Promotiecommissie
Promotor:  Prof.dr. R. Benner
Overige leden: Prof.dr. F.G. Grosveld
Prof.dr. A.G. Rolink
Prof.dr. I.P. Touw
Co-promotor:  Dr. R.W. Hendriks
The studies described in this thesis 
were performed at the Department of 
Immunology, Erasmus MC, Rotterdam, The 
Netherlands and partly at the Department 
of Molecular and Cellular Biology, 
University of California-Berkeley, USA.
The studies were fi nancially supported by NWO (901-07-209 and 901-07-
224), and partly by the ‘Trustfonds’ Erasmus University Rotterdam and the 
Dutch Society for Immunology (NVvI).
The printing of the thesis was supported by the Erasmus MC Rotterdam.
Btk at the Pre-B Cell Receptor Checkpoint
Table of contents
6
Btk at the Pre-B Cell Receptor Checkpoint
Table of Contents
General introduction       
    Parts of this chapter are published as a review in Trends in Immunology.
 
Chapter 1.  Btk and Ig L chain rearrangement
1.1 Dingjan, G.M., S. Middendorp, K. Dahlenborg, A. Maas, F. 
Grosveld, and R.W. Hendriks. Bruton’s tyrosine kinase regulates 
the activation of gene rearrangements at the λ light chain locus in 
precursor B cells in the mouse. J Exp Med 2001, 193:1169.
1.2  Middendorp S., S.A. Muljo, M.S. Schlissel and R.W. Hendriks.  
  Evidence for the involvement of Bruton’s tyrosine kinase in the  
 regulation of V(D)J recombinase activity at the Ig L chain loci. 
Work in progress.
Chapter 2. Btk and pre-B cell differentiation 
2.1 Middendorp, S., G.M. Dingjan and R.W. Hendriks. Impaired 
precursor B cell differentiation in Bruton’s tyrosine kinase- 
defi cient mice. 
 J Immunol 2002, 168: 2695.
2.2 Middendorp S., G.M. Dingjan, A. Maas, K. Dahlenborg and R.W. 
Hendriks. Function of Bruton’s tyrosine kinase during B cell 
development is partially independent of its catalytic activity. J 
Immunol 2003, 171: 5988.
2.3 Middendorp S., R. Kersseboom, G.M. Dingjan, M. van der Zee, 
A. Maas and R.W. Hendriks. Expression of the constitutive active 
Bruton’s tyrosine kinase mutant E41K mimics pre-B cell receptor 
signalling in pro-B cells. To be submitted.
Chapter 3.      Btk and SLP-65-defi ciency
3.1 Kersseboom R., S. Middendorp, G.M. Dingjan, K. Dahlenborg, 
M. Reth, H. Jumaa and R.W. Hendriks. Bruton’s tyrosine kinase 
cooperates with the B cell linker protein SLP-65 as a tumor 
suppressor in pre-B cells. J Exp Med 2003, 198:91. 
3.2  Middendorp S., A.J.E. Zijlstra, R. Kersseboom, G.M. Dingjan, H. 
Jumaa and R.W. Hendriks. Tumor suppressor function of Btk in 
SLP-65-defi cient pre-B cells is independent of its kinase activity. 
To be submitted.
6
9
57
59
75
87
89
105
121
133
135
149
Table of contents
7
Chapter 4.      Btk and cellular maturation
Middendorp, S. and R.W. Hendriks. Cellular maturation defects in 
Btk-defi cient immature B cells are amplifi ed by premature B cell 
receptor expression and reduced by receptor editing. J Immunol 
2004, 172:1371. 
General discussion        
  Parts of this chapter are published as a review in Trends in Immunology. 
Summary
Samenvatting voor iedereen
List of abbreviations
Dankwoord
Curriculum vitae
List of publications
161
163
179
202
204
207
209
213
215

General 
introduction
Parts of this chapter are published as a review in Trends in Immunology
General introduction
10
General introduction
11
1. The immune system
The immune system is the defence mechanism by which the body protects 
itself against environmental agents that are foreign and possibly dangerous, such 
as micro-organisms. The fi rst line of defence is non-specifi c (innate) and consists of 
physical components, such as the skin and mucous membranes to prevent agents 
invading the body. The second line of defence is either non-specifi c or specifi c 
and consists of specialized cells whose purpose is to destroy the invader once 
it has managed to pass the fi rst line of defence.  The foreign agent can either be 
destroyed by cells of the innate immune system (including natural killer (NK) cells, 
macrophages, granulocytes and the complement system) or it can trigger a chain 
of events that induces a specifi c immune response. The latter is also referred to 
as acquired immunity as the response is specifi c for the invader only and provides 
immunity to withstand and resist another exposure to the same agent, also called 
antigen.  There are three major cell types involved in acquired immunity. Two of 
these cell types arise from a common lymphoid precursor cell, but differentiate in 
different developmental ways and in separate organs. One cell type matures in the 
thymus and is called T cell; the other matures in the bone marrow (BM) and is called 
B cell. Lymphocyte antigen receptors, in the form of immunoglobulin (Ig) molecules 
or B cell receptors (BCR) on B cells and T-cell receptors (TCR) on T cells, are the 
means by which lymphocytes sense the presence of antigens in their environment. 
The receptors produced by each lymphocyte have a unique structure of their 
antigen-binding site in order to respond to a wide variety of antigens the organism 
may encounter. The third type of cell participating in the acquired immune response 
is the antigen-presenting cell (APC), such as the macrophage or the dendritic 
cell. They take up, process and present the antigen with major histocompatibility 
complex (MHC) proteins to the specifi c receptors on T cells. 
Immunity to bacterial antigens is mediated by recognition of the antigen by 
the B cells or antibodies that circulate throughout the body. Once the antigen is 
recognized and bound to the BCR, the B cell is activated and receives signals 
to differentiate into a plasma cell and make the secreted form of its BCR, the 
antibody. 
This thesis focuses on the development of B cells and the role of specifi c signal 
transduction proteins in this process. 
2. The B cell
In mice, B cells are generated from hematopoietic stem cells that commit to 
the B-cell lineage in response to signals from a variety of soluble factors, called 
cytokines. The development of B cells takes place in the BM and the spleen. The 
early B cell development in the BM is ordered into several stages according to the 
rearrangement status of the immunoglobulin gene loci. After production of a proper 
BCR on their surface, B cells migrate to the spleen to differentiate into mature B 
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cells and circulate throughout the body to search for antigens they can respond to. 
When the BCR recognizes and binds an antigen, B cells differentiate into antibody 
producing plasma cells or into memory B cells to provide memory and effi ciency 
when the same antigen is encountered again. 
2.1  Antibody receptors
Ig molecules or BCRs are composed of two identical heavy (H) chains and two 
identical light (L) chains, which are bound to each other by a disulfi de bridge. Both 
chains have a constant (C) region and a variable (V) region (Figure 1). The C region 
of the Ig molecule is involved in membrane expression, complement binding and 
binding to other cells of the immune system. The V region is the part of the BCR that 
recognizes and binds antigen and consists of three hypervariable complementary 
determining regions (CDR). This restricts the antibody to combining only with one 
particular antigenic structure. Therefore it is necessary to produce a large repertoire 
of specifi cities, which is achieved by variation in the amino acid sequence at the 
antigen-binding site. The V regions of the receptor chains are encoded in several 
pieces, called the V (variable), D (diversity, only for H chains) and J (joining) gene 
segments. There are multiple copies of these three V-region gene segments 
present in the genome. However only one copy of each gene segment is used to 
assemble a complete V-region in a process called V(D)J recombination.
Figure 1. Schematic (left) and molecular (right) model of human immunoglobulin protein 
showing the constant (C) and variable (V) regions of the two heavy chains in dark grey 
(CHVH) and the two light chains in light grey (CLVL). The heavy and light chain V-region 
domains are in close contact and function as the antigen-binding part of the molecule. In 
the schematic drawing, the two signalling molecules Ig-α and Ig-β are also depicted. The 
molecular model was constructed as described in ref. (1).
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2.2  V(D)J recombination
The Ig gene segments are organized into three clusters or genetic loci, the H 
chain loci and the κ and λ L chain loci. Each locus consists of separate clusters of V, 
D or J gene segments and of C-region genes. The DNA rearrangements are guided 
by conserved non-coding DNA sequences that are found adjacent to the points at 
which the recombination takes place. These sequences consist of a conserved 
block of seven nucleotides (the heptamer), a non-conserved region (the spacer, 
which is either 12 or 23 nucleotides long) and a second conserved block of nine 
nucleotides (the nonamer). The heptamer-spacer-nonamer sequence is called the 
recombination signal sequence (RSS). 
Recombination only occurs between gene-segments located at the same 
chromosome. Only a gene segment fl anked by an RSS with a 12-basepair (bp) 
spacer can be joined to another gene segment with a 23bp-spacer RSS. In the H 
chain locus, the V and J RSS regions contain 23bp-spacers and the D RSS regions 
contain 12bp-spacers. Therefore it is only possible to recombine D to J segments 
and V to D segments, but not V to J segments. In contrast, L chain genes only 
contain V and J regions, with 23 and 12bp-spacer RSSs, respectively.
Two recombination activating gene (RAG) proteins recognize the RSS 
Figure 2. Schematic drawing of V(D)J recombination of the heavy (left) and light (right) chain 
genes, which together form an immunoglobulin protein. See text for details.
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sequences and initiate the rearrangement by introducing DNA double strand 
breaks (DSBs) at the border of each RSS involved in the rearrangement. The DNA 
at the ends of the DSBs is left in a hairpin-sealed coding end, which has to be 
processed before the formation of a coding joint can take place. This DSB repair 
mechanism is called non-homologous end-joining (NHEJ). At least six factors 
participate in the rejoining phase of the V(D)J recombination. First the DNA binding 
proteins Ku70 and Ku86 bind as a complex to the DSBs. The DNA-Ku heterodimer 
complex can recruit the catalytic subunit (cs) of DNA-dependent protein kinase 
(DNA-PKcs) and associates with it. Activated DNA-PKcs recruits and activates the 
X-ray cross-complementation group 4 (XRCC4) and Artemis proteins, of which the 
latter cleaves the RAG-generated hairpins. Polymerase activity is supplied by DNA 
polymerase µ (Pol µ) and DNA ligase IV seals the signal and coding joints. The 
protein terminal deoxynucleotidyl transferase (TdT) can add additional nucleotides 
in order to make the religation imprecise. A defect in most of the components 
involved in V(D)J recombination aborts the completion of the process and leads 
to a complete arrest in B cell development at the pro-B cell stage. The molecular 
mechanism of V(D)J recombination is illustrated in fi gures 2 and 3 and is reviewed 
in references (2) and (3).
The mechanism of DNA rearrangement is similar for the H and L chain loci, 
although only one joining event is needed to generate a L chain gene and two 
events to generate a complete H chain gene (Figure 2).
Figure 3. V(D)J joining occurs by DNA recombination and non-homologous end-joining 
(NHEJ). RAG proteins bind to RSS sites and cleave the DNA (left). The resulting double 
stranded DNA break is repaired by NHEJ involving several factors as indicated (right). For 
details and abbreviations, see text. Figure adapted from (2).
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2.3  Antibody diversity
As the BCR is very specifi c for only one particular antigenic structure, the 
immune system requires a large repertoire of different antibody molecules. 
Antibody diversity is generated in four ways. 
First, there are multiple copies of each of the gene segments that make up an 
Ig variable region and different combinations of segments can be used in different 
rearrangement events. A second form of achieving diversity arises from the pairing 
of the H and L chains to form a complete Ig molecule as the ability of the H and L 
chains to pair is independent of the variable regions involved. Although there are 
two chromosomes containing the H chain gene segments and four chromosomes 
containing the L chain gene segments (the κ and λ L chain loci are located on 
different chromosomes), only one H chain and one L chain are fi nally expressed. 
This restriction is called allelic exclusion. The processes of V(D)J recombination 
and allelic exclusion are able to generate about 3x106 possible antibody molecules. 
In the third place, diversity can be introduced at the joins between the different gene 
segments. By the joining of V, D and J segments, some steps create diversity in 
the variable regions by inserting or deleting nucleotides (by TdT or exonucleases, 
respectively) at the joins between the segments. And fourthly, there is somatic 
hypermutation (SHM), which results in an increased affi nity of antibodies for antigen 
in the secondary immune response. The SHM process introduces point mutations 
into the V regions of rearranged H and L chain genes by which the specifi city of the 
Ig molecule is altered after antigenic stimulation. 
3. B cell development 
B-lymphocytes develop from haematopoietic stem cells in the bone marrow 
through distinct stages that are characterised by differential expression of various 
cell surface markers and the ordered rearrangement of Ig H and L chain gene 
segments (Figure 4; see (4, 5) for review). B cell differentiation is initiated by the 
progression from uncommitted progenitors with multi-lineage potential to a B-
lineage restricted stage and is dependent on the combinatorial action of specifi c 
transcription factors (reviewed in (6)). This differentiation program is dependent 
on a series of developmental cell fate decisions at specifi c antigen-independent 
checkpoints, controlled by the BCR and its immature form, the pre-BCR. The pre-
BCR is transiently expressed on the cell surface of pre-B cells that have performed 
a productive Ig H chain V(D)J rearrangement, and acts as a key checkpoint to 
monitor proper expression of functional Ig µ H chain on the cell surface. Pre-BCR 
signalling inhibits further H chain rearrangements and triggers clonal expansion 
and developmental progression of Igµ+ pre-B cells. The pre-B cells rearrange κ or 
λ L chains that together with the µ H chain form the BCR. These immature B cells 
are then allowed to go to the spleen to differentiate into mature B cells. Mature B 
cells recirculate throughout the body and screen for antigenic structures the BCR 
recognizes.  
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Transcription factors
Various transcription factors have been shown by loss- and gain-of-function 
experiments to be required for early B cell development, including Ikaros, PU.1, E2A, 
Pax5 and IRF-4,8 (reviewed in (7)).  Phenotypic analysis of mice with targeted null 
alleles of genes encoding these factors has been used to order their developmental 
functions in the B lineage. At the onset of B lymphopoiesis, the transcription factors 
E2A and EBF coordinately activate the B cell-specifi c gene expression program (8, 
9). Subsequently, activation of Pax5 commits B cell progenitors to the B cell lineage 
by repressing the transcription of lineage-inappropriate genes and activating B cell 
lineage-specifi c genes (10, 11). 
The generation of committed lymphocyte precursors is regulated by the Ikaros 
protein, which belongs to a family of Zinc fi nger transcription factors that includes 
two other members, Aiolos and Helios. Ikaros is expressed in stem cells and in 
mature lymphocytes and Ikaros-like proteins recognize binding sites in many 
lymphocyte-specifi c genes including TdT, VpreB and λ5 (12). In mice with a targeted 
mutation in the dimerization domain of Ikaros, no B cells in either the fetal or adult 
phase of life were detected and T cell development was defective (13). 
Ets proteins regulate gene expression during a wide variety of developmental 
and adaptive cellular responses, including cellular differentiation and lymphocyte 
activation. There are at least 18 different mammalian Ets proteins that bind to 
purine-rich DNA consensus elements. The Ets protein Spi-B is a hematopoietic-
specifi c transcription factor most closely related to another Ets family member 
PU.1 (also called Spi-1). PU.1 has been implicated in the myeloid versus lymphoid 
lineage decision by regulating cytokine-dependent proliferation and differentiation 
of precursor cells (14, 15). PU.1 is highly expressed in B cells, granulocytes and 
monocytes and many genes involved in lymphoid and myeloid development have 
been identifi ed as putative PU.1 target genes. For example: Ig µ H chain (16), Ig κ 
and λ L chains (17, 18), Ig-α and -β (19), and M-CSF receptor (20). PU.1 is shown 
to directly regulate the IL-7Rα gene and the activity of the IgH intronic enhancer 
(21).  In PU.1-/- progenitors the IL-7 dependent proliferation is defective (22) and 
PU.1-/- mice exhibit defects in the development of T and B cells, monocytes and 
granulocytes and die at gestation day 18.5 (14).  In contrast, Spi-B-/- mice are 
viable, fertile and possess mature B and T cells and Spi-B expression was not able 
to compensate for the absence of PU.1 in PU.1-/- mice (14). 
The initiation of B cell development in the BM critically depends on two 
transcription factors: the basic helix-loop-helix (bHLH) protein E2A and the early B 
cell factor (EBF). In the absence of either transcription factor, B cell development 
is arrested at the earliest stage, even before D-JH rearrangement of the Ig H chain 
(23-25). These regulators cooperatively induce the expression of several B cell 
specifi c genes, including those encoding the SLC genes λ5 and VpreB, the signalling 
molecules Ig-α and Ig-β and the RAG-1 and -2 proteins (8, 9).  EBF can directly bind 
and regulate the Pax5 promoter and encodes a B cell-specifi c transcription factor 
that binds DNA as a homodimer using a DNA-binding domain and a dimerization 
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domain related to the helix-loop-helix (HLH) motif of the bHLH family of transcription 
factors (26, 27).  EBF and E2A heterozygous mice exhibit an ~2 fold decrease in 
the number of pro-B cells, indicating that normal B cell development depends on 
two wild-type EBF alleles. E2A is expressed in two splice forms, E12 and E47, 
which differ in their bHLH domains. E2A binds a DNA sequence termed E-box, 
which is found in the promoter regions of many different cell type-specifi c genes. 
Although E2A is widely expressed, targeted disruption of E2A produces viable 
animals that have a severe defect in early B cell development, prior to the onset of 
Ig rearrangement (23, 24).  It has been shown that E2A and EBF, next to the RAG 
proteins are required for initiation of V(D)J recombination in a non-lymphoid cell 
line. The two transcription factors infl uence different types of rearrangement. Both 
E2A and EBF can induce DH-JH rearrangement, whereas Vκ-Jκ rearrangement is 
only induced by E2A and Vλ-Jλ rearrangement by EBF (28).
The Pax family of transcription factors has been shown to play a crucial role 
in organogenesis and development. The Pax5 gene, encoding the B cell-specifi c 
activator protein (BSAP) is expressed exclusively in B cells (29, 30). In Pax5-
defi cient (Pax5-/-) mice, B cell development is arrested at the pro-B cell stage 
in the BM. Importantly, Pax5-/- pro-B cells still retain a broad lympho-myeloid 
developmental potential characteristic of uncommitted hematopoietic progenitors. 
Upon appropriate cytokine stimulation, Pax5-/- pro-B cells are able to differentiate 
both in vitro and in vivo into functional T cells, NK cells, dendritic cells, macrophages, 
osteoclasts and granulocytes (10, 11, 31, 32).  Pax5-/- pro-B cells express various 
B cell-specifi c genes such as RAG-1 and -2, Ig-α (mb-1), Ig-β (B29), VpreB and λ5 
as well as sterile transcripts of the H chain locus. Pax5-/- pro-B cells are responsive 
to IL-7 and have the capacity to grow long-term in vitro on stromal cells. However, 
the cells can not differentiate into immature B cells upon withdrawal of IL-7 from the 
culture (11, 31). Furthermore, Pax5-defi cient pro-B cells were shown to have normal 
D-JH but reduced VH-DJH recombination (33). In experiments using conditional 
Pax5 inactivation in committed pro-B cells it was demonstrated that Pax5 is also 
required to maintain the B cell transcription program, next to its role to initiate it for 
B cell commitment. When Pax5 was inactivated, previously committed pro-B cells 
regained the capacity to differentiate into macrophages in vitro and to reconstitute T 
cell development in vivo in RAG-2-/- mice (34). Pax5 is also required for maintaining 
the identity and function of mature B cells during late B cell development. This 
function of Pax5 was demonstrated in a mouse strain where Pax5 was conditionally 
inactivated by the expression of CD19 (35). 
IRF-4 and -8 are two specialized members of the interferon regulatory factor 
(IRF) family that have been implicated in regulating Ig L chain gene transcription 
during B cell development (17, 36-39). They are selectively expressed in the 
lymphoid and myeloid lineages of the immune system. IRF-4 and IRF-8 bind 
very weakly to DNA-containing IRF sites, but are recruited to their binding sites 
via interactions with other transcription factors. In particular the related Ets family 
transcription factors PU.1 and Spi-B have been shown to recruit IRF-4 or IRF-8 
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to Ets-IRF composite elements (EICE) in Ig κ 3’ and λ enhancers (17, 36, 38). It 
remains to be determined whether PU.1/Spi-B regulates Ig L chain gene expression 
during the pre-B to immature B cell transition. IRF-4-/- mice exhibit profound defects 
in B and T cell activation, which are manifest in the failure to generate antibody, 
cytotoxic or anti-tumor responses. Loss of either IRF-4 or -8 does not block B cell 
development, however the combined loss of IRF-4 and -8 (IRF-4,8-/-) causes a 
lineage-specifi c block in early B cell development at the large pre-B cell stage 
(40). IRF-4 and -8 were shown to coordinate the pre-B to B cell transition in part 
by downregulation SLC gene expression, thereby facilitating cell cycle exit and 
upregulation of RAG gene and protein expression.  Concomitantly, IRF-4,8 directly 
induces enhancer-dependent L chain transcription and recombination, thereby 
enabling pre-B cell differentiation (40).
All the transcription factors discussed above can infl uence each other’s activity. 
For example, Ikaros and PU.1 appear to act upstream of E2A, EBF and Pax5 
(12-15). E2A, EBF and Pax5 directly control transcription of early B cell genes, 
such as Ig-α, Ig-β, VpreB, λ5, RAG-1 and RAG-2.  E2A appears to directly regulate 
Figure 4. B cell development in mouse BM. Blocks in different stages of B cell development 
by defi ciency of various molecules is indicated. BCR: B cell receptor; SLC: surrogate light 
chain; Ig H, Ig L: confi guration of heavy (H) or light (L) chain gene loci, respectively; GL: 
germ-line confi guration.
General introduction
19
transcription of the EBF gene (9) and EBF in turn is implicated in activating 
expression of the Pax5 gene (7).
Chemokines, Cytokines and cytokine receptors
The chemokine stromal cell-derived factor 1 (SDF-1) has complex effects on the 
migration, proliferation and differentiation of leukocytes. Chemokines are important 
in directing emigration of specifi c leukocyte subsets into sites of infection as well as 
in determining traffi cking patterns of recirculating lymphocytes. SDF-1 is involved in 
directing progenitor cells into appropriate microenvironments to receive expansion 
and differentiation signals. SDF-1 regulates B cell maturation and can stimulate 
pre-B cell proliferation (41). Mice defi cient in SDF-1 have severely reduced B cell 
lymphopoiesis and show no bone marrow myelopoiesis. SDF-1 defi cient mice die 
perinatally (42). In addition, SDF-1 functions as a chemo-attractant for T cells and 
monocytes and for CD34+ hematopoietic progenitors (43). 
The cytokine interleukin-7 (IL-7) is a 25 kD protein produced by stromal cells that 
promotes the proliferation and survival of T- and B-lineage precursors in the mouse, 
but does not appear to play a role in human B cell development (Reviewed in (44, 
45)). The IL-7R is composed of two chains, the IL-7Rα ligand-binding chain and 
the common γ (γc) signalling chain, which are both required for proper signalling 
(46, 47). The IL-7Rα chain also comprises part of the thymic stromal lymphoprotein 
(TSLP) receptor (48), while the γc chain is shared by the receptors for IL-2, -4, -9, 
-15 and -21 (49, 50). Lymphopoiesis is impeded at an early stage when mice are 
treated with neutralizing antibodies against IL-7 (51) or against the IL-7Rα chain 
(52). Mice with a targeted deletion in IL-7 or its receptor (IL-7R) show a block in 
B cell development at the pro-B cell stage, supporting the fact that IL-7 is very 
important in this stage of B cell development (53-55). 
In IL-7Rα−/− mice, D to JH recombination is not affected, but distal VH segments 
do not become accessible to the RAG proteins, resulting in impaired VH to DJH 
rearrangement (54). In IL-7 or γc chain-defi cient mice, the proliferative expansion of 
Igµ+ pre-B cells is abolished. Both pro-B and pre-B cells can be induced to proliferate 
in vitro in the presence of IL-7, but cells expressing a pre-BCR have a substantial 
proliferating advantage in limiting concentrations of IL-7 (56). It has been proposed 
that the location of B-lineage precursors in discrete micro-environmental niches in 
the BM may expose them to gradients of IL-7 that infl uence signalling through the 
pre-BCR (45). In this model, developing B cells move centrally toward and through 
sinusoids before migrating to the periphery. High levels of IL-7 promote an early 
proliferative phase of pro-B cells undergoing VH-gene rearrangements, while an 
adjacent area with limited amounts of IL-7, allows for the selective expansion of 
Igµ+ pre-B cells (45, 56). The transition of large cycling into small resting pre-B 
cells is accompanied by down-regulation of pre-BCR expression and loss of IL-7 
responsiveness.
Within the B lymphocyte lineage, only early B cells express the IL-7R, therefore 
IL-7 is very useful to study pre-B to immature B cell transitions in an in vitro culture 
General introduction
20
system. When BM cell suspension are cultured in the presence of IL-7 only pro- 
and pre-B cells are proliferating and immature and mature B cells and other cells 
that do not express the IL-7R will not survive. Upon removal of IL-7 from the culture 
system, pre-B cells are induced to differentiate into sIgM+ immature B cells as they 
stop dividing, activate the RAG proteins and initiate L chain rearrangements (57). 
3.1 Pro-B cells
Ig gene recombination starts in pro-B cells with the rearrangement of DH to JH 
gene segments and subsequently VH gene segments join to the DHJH composites. 
Upon productive VH(D)JH rearrangement, membrane Igµ protein associates with 
the non-rearranging λ5 and VpreB surrogate light chains (SLC) and the Ig-α/CD79a 
and Ig-β/CD79b signalling components to form the pre-BCR complex. Signalling 
initiated via the pre-BCR induces clonal expansion of Igµ+ pre-B cells, whereby 
IL-7 acts as a crucial pre-B cell-specifi c proliferation factor. As a result, pro-B cells 
differentiate to the next compartment of large cycling pre-B cells (Figure 4). 
On the surface of pro-B cells the SLC proteins are expressed in a complex, 
which contains a non-classical cadherin and several as yet unknown proteins 
(58). A second type of pro-BCR is composed of the Ig-α/Ig-β heterodimer and 
calnexin (59). This receptor is potentially functional, as its cross-linking with anti-
Ig-β induces rapid phosphorylation of several intracellular signalling molecules, 
including Syk and Btk, as well as the expression of pre-B cell-specifi c cell surface 
markers (60, 61).
A third type of immature antigen receptor expressed on the cell surface of pro-
B cells consists of Dµ, a truncated H chain product translated from the DHJH gene 
rearranged in a particular DH reading frame, RF2 (62, 63). Although DH segments 
can be joined to JH segments in any one of three reading frames, only RF2 leads 
to production of Dµ protein. This Dµ protein associates with the SLC and the Ig-α 
and Ig-β proteins and has therefore in principle the capability to transmit a signal 
that is similar to the pre-BCR (64). As mature B cells in the mouse that have D 
segments in RF2 are signifi cantly underrepresented, it has been concluded that Dµ 
protein expression inhibits further B cell development, possibly by inhibiting VH to 
DJH recombination. This was confi rmed by the fi nding of severely reduced VH(D)JH 
rearrangements, accompanied by an arrest at the pro-B to pre-B transition in Dµ 
transgenic mice (65). However, the mechanism by which Dµ protein expression 
blocks further B cell differentiation remains unknown and cannot be explained by 
the inability of Dµ protein to pair with L chains as the developmental block occurs 
before the stage of L chain expression. 
3.2 Pre-B cells
Signalling initiated via the pre-BCR induces clonal expansion of Igµ+ pre-
B cells, which is dependent on IL-7. As a result, pro-B cells differentiate to the 
next compartment of large cycling pre-B cells (Figure 4). In these cells, the 
recombination-activating genes RAG-1 and RAG-2 are transiently down-regulated 
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to terminate further Ig H chain rearrangements (66), ensuring allelic exclusion. 
Because of the intrinsic transient nature of pre-BCR expression, this also governs 
the next step in B cell development: after a limited number of cell divisions the 
large pre-B cells stop cycling and differentiate into small resting pre-B cells. This 
transition is associated with reactivation of the rearrangement machinery for the 
initiation of VL to JL rearrangements and signifi cant changes in cell surface marker 
profi les (Figures 5 and 6). Functional L chain gene recombination in pre-B cells 
leads to BCR expression and small pre-B cells are transferred to the immature B 
cell population (4, 5)
Activation of the pre-BCR involves phosphorylation of the cytoplasmic 
immunoreceptor tyrosine-based activation motifs (ITAMs) of the Ig superfamily 
members Ig-α and Ig-β  (Figure 7) and the formation of a lipid raft-associated 
calcium-signalling module. This complex contains the phosphorylated tyrosine 
kinases Lyn, Syk, and Btk, as well as other phosphorylated proteins including 
the adapter molecule SLP-65 (also known as BLNK (B cell linker) or BASH (B 
cell adaptor containing src homology 2 domain), phospho-inositide 3-kinase 
(PI3K), Vav and phospholipase Cγ2 (PLCγ2) (61, 68). Syk is strongly activated 
by binding to the phosphorylated ITAM tyrosines of Ig-α or Ig-β and most likely 
acts as a positive allosteric enzyme, thereby initiating a positive feedback loop at 
the pre-BCR (69). The apparent redundancy among the Src-like family members 
Lyn, Fyn, and Blk has complicated the clarifi cation of the role of the individual 
enzymes. Nevertheless, the ability of an activated Blk mutant to increase Ig-β and 
Figure 5.  Profi le of Ig rearrangement-related gene expression. Relative mRNA levels were 
assayed by RT-PCR on cells from the different B cell developmental stages. There is biphasic 
expression of RAG genes of which the fi rst wave is accompanied by sterile µ transcription 
for H chain rearrangement and the second wave is related to sterile κ transcription when 
most L chain rearrangements take place. MLP: multilineage progenitor; capitals indicate 
developmental stage of B cells. Adapted from (67). 
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Syk phosphorylation indicates a proximal point of action of Src-like kinases (70). 
One important substrate of Syk is SLP-65. Phosphorylation of SLP-65 provides 
docking sites for Btk and PLCγ2 SH2 domains (Figure 7; (71)). Activated Btk then 
phosphorylates PLCγ2, which leads to its full activation. Full activation of PLCγ2 
induces calcium signalling and Nuclear Factor κB (NF-κB) activation (61, 68, 72). 
This model is challenged by the recent description of a separate pre-BCR signalling 
pathway in which NF-κB activation is Syk-independent, but involves Src-family 
protein tyrosine kinases and protein kinase C-λ (73).
The transcription factor NF-κB mediates the regulation of some of the genes 
important in early B cell differentiation such as the Ig L chain genes. It also plays 
a role in signals mediated by growth factors and thereby is involved in prevention 
of apoptosis of precursor cells. NF-κB is a heterodimer of p50 and p65 subunits, 
whose activity is regulated by interaction with the inhibitory protein IκB. Both 
Figure 6.  Diagram of B cell development showing cell surface phenotype or B cell-specifi c 
gene expression. Relative expression levels are indicated by line thickness. PB493 is also 
known as AA4.1, HSA (heat stable antigen) as CD24 and CD25 as IL-2R. SLC, surrogate light 
chain; RAG-1/2, recombination activating genes 1 and 2; MHC II, major histocompatibility 
complex type II. Figure adapted from ref. (77).
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subunits of NF-κB belong to the Rel family of transcription factors, which also 
includes p52, RelB and c-Rel. Nuclear localization signal (NLS) sequences in 
NF-κB are masked by binding to IκB that localize NF-κB dimers to the cytoplasm 
(74). Activation of IκB kinase (IKK) regulates IκB phosphorylation, which in turn 
targets the inhibitory protein for degradation. The degradation of IκB reveals the 
NLS in the NF-κB subunits and promotes the translocation into the nucleus. Once 
in the nucleus, NF-κB dimers are further regulated through phosphorylation of 
the Rel proteins. The amplitude and duration of the calcium response in B cells 
differentially regulate the transcription factors NF-κB and NFAT. While NF-κB is 
activated by large transient calcium responses, NFAT is effi ciently activated by 
a low sustained calcium fl ux. Therefore, modulators of signalling that affect the 
quantity and quality of the cytoplasmic calcium response, such as PI3K, Btk and 
PLCγ2 activation, can change the pattern of gene expression and may determine 
subsequent B cell fate (75, 76).
Cell-autonomous pre-BCR signalling
Whereas the mature BCR initiates signalling through interaction with its cognate 
antigen, it is less clear how the pre-BCR is able to start the signalling cascade. It 
is possible that a ligand exists on stroma cells, on adjacent pre-B cells or on the 
membrane of the same cell. Two recent fi ndings would support that interaction 
with a stroma cell ligand triggers pre-BCR activity. First, a pre-BCR/galectin-1 
interaction is required to induce Ig-α/β phosphorylation in the human pre-B cell line 
Nalm6 (78). Second, soluble murine or human pre-BCR molecules show specifi c 
binding to stroma cell-associated heparan sulfate, controlled by the non-Ig-like 
unique tail of λ5 (79).
By contrast, other experiments indicate that pre-BCR signalling does not need 
a ligand, but specifi cally depends on the presence of λ5 protein. No cytokine or 
stroma cell support is needed for in vitro proliferation of single wild type (but not 
λ5-defi cient) pre-B cells (80). Using a panel of Abelson virus-transformed Igµ+ pre-
B cell lines, Ohnishi and Melchers (81) showed that the non-Ig-like unique tail of 
λ5 mediates cell-autonomous pre-BCR signalling, resulting in constitutive pre-BCR 
internalisation and phosphorylation of Ig-α. Two models were proposed: either the 
pre-BCR serves as its own ligand, whereby neighbouring pre-BCRs directly interact 
with each other, or alternatively pre-B cells express a molecule on their cell surface 
that has binding sites for the non-Ig-like unique region of λ5 (81). As in these 
experiments clonal populations of pre-B cell lines were used, they strongly support 
the idea that the pre-BCR does not require an exogenous ligand. Nevertheless, it 
cannot be excluded that λ5-mediated interaction of a pre-BCR with heparan sulfate 
could rescue pre-BCR signalling in some pre-B cells in which the pre-BCR is 
expressed at levels too low to initiate ligand-independent signalling (82). 
The issue of ligand-independent signalling was previously addressed in a 
series of experiments in which truncated or chimeric forms of Igµ proteins that 
cannot associate with SLC were expressed as transgenes (83, 84). As in these 
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models, allelic exclusion, pre-B cell surface marker changes and germline κ locus 
transcription was induced, it was concluded that SLC is not required for pre-BCR 
function. However, this does not necessarily imply that truncated Igµ induces 
signals that mimic pre-BCR signalling. The levels of surface expression of the 
truncated Igµ far exceeded those of the wild-type Igµ (83), which would again 
support the hypothesis that binding to λ5 is essential for pre-BCR internalisation. 
In these ligand-independent signalling systems not only pre-BCR but also BCR 
function is bypassed, allowing Ig-negative cells to colonize peripheral lymphoid 
organs. Taken together, these observations are consistent with a model of cell-
autonomous pre-BCR signalling that is crucially dependent on λ5.  
Figure 7. Pre-B cell receptor signalling model. Activation of the pre-BCR involves 
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the Ig-α and 
Ig-β scaffold proteins, thereby recruiting and activating Syk tyrosine kinase. A prominent 
substrate of Syk is the adapter protein SLP-65. Phosphorylated SLP-65 provides binding 
sites for Btk, (which is activated by Syk-mediated phosphorylation of Tyr551 in its kinase 
domain) and phospholipase Cγ2 (PLCγ2) SH2 domains. In an alternative pathway, PLCγ2 
can be activated via the homologous proteins ZAP70, SLP-76, LAT and Tec (not depicted). 
Btk: Bruton’s tyrosine kinase. PIP2: phosphatidyl-inositol-4,5-biphosphate; IP3: inositol-
trisphosphate; DAG: diacylglycerol.
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Differential role of the pre-BCR complex and signalling components 
In the last decade analyses of gene-targeted mice have defi ned differential 
roles of components of the pre-BCR complex or its downstream signalling pathways 
(Table 1). The pre-BCR utilizes sequential activation of three distinct families of 
non-receptor protein tyrosine kinases (PTKs), such as Src, Syk and Tec families 
for initial activation (85). Defi ciencies in any one of these PTK families result in 
defective or aberrant B cell function and development (86). Characterization of the 
substrates of these activated PTKs is helpful for understanding the mechanism of 
how BCR activation is regulated. The phosphorylation events performed by these 
PTKs modulate catalytic activity of effector enzymes and mediate protein-protein 
interactions that bring together signal transduction elements. A group of cellular 
proteins, called adapter proteins, regulate the interaction of effector enzymes with 
the BCR and their targets, thereby integrating multiple signalling pathways (87-89). 
PTK families, adapter proteins and other molecules involved in pre-BCR signalling 
have structural similarities as depicted in fi gure 8.  
As outlined in Table 1, the formation of large cycling pre-B cells is dependent 
on structural components of the pre-BCR (Igµ, SLC, Ig-α and Ig-β) and Syk 
tyrosine kinase, whereas the signalling molecule SLP-65 is important to limit pre-
B cell expansion and for the differentiation into small resting pre-B cells. Targeted 
Figure 8. Molecular structure of signalling molecules involved in the (pre-) BCR signalling 
pathway. Adapter proteins are defi ned commonly as proteins that posses protein–protein or 
protein–lipid interaction domains but do not have enzymatic activity. BCAP, B-cell adapter 
protein; BTK: Bruton’s tyrosine kinase; LAT: linker for activation of T cells; PH: pleckstrin 
homology; PI3K: phosphoinositide 3-kinase; PLCγ2: phospholipase Cγ2; SH2: SRC-
homology 2; SH3: SRC-homology 3; SHIP: SH2-domain-containing inositol 5 phosphatase; 
SHP1: SH2-domain-containing protein tyrosine phosphatase 1; TH, TEC-homology. Figure 
adapted from (90).
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disruption of the Igµ membrane exon (µMT mice), Ig-α or Ig-β in the mouse causes 
a block of B cell development at the pro-B cell stage (91-93). In µMT mice the pre-
B cells cannot deposit Igµ on the cell surface, they do not enter the cell cycle and 
allelic exclusion is lost. Conversely, transgenic Igµ inhibits endogenous Ig H chain 
rearrangement, which feature is dependent on the ability of Igµ to associate with 
the Ig-α/Ig-β heterodimer (92, 94, 95). Nevertheless, B cell development is not 
completely blocked in µMT mice, as some κ L chain gene rearrangement is still 
observed and IgA+ cells can be detected in spleen and Peyer’s patches (91, 96).
Mice defi cient in the SLC components λ5, VpreB1/VpreB2 or all of these also lack 
pre-B cell expansion and show decreased peripheral B cell numbers. However, they 
exhibit a more leaky phenotype than µMT mice, as allelic exclusion is not affected 
and mature B cells accumulate with age (91, 99). As κ L chain rearrangement 
may precede H chain rearrangement in up to 15% of normal pro-B cells, the leaky 
phenotype of SLC-defi cient mice could be explained by premature expression of 
conventional L chains, which would then substitute for the SLC in the pre-BCR 
complex. However, there is no evidence to suggest that the rescued B cells in 
a µMT: deletion of Ig µ membrane exon. b Targeted deletion of λ5, VpreB1/VpreB2 or all of these 
resulted in very similar phenotypes. c Ig-α∆c or Ig-β∆c: deletion of cytoplasmic tails of Ig-α or 
Ig-β.  d Double mutant. e N.a.: Not analysed.
Table 1. Phenotype of gene-targeted mice with respect to the pre-B cell receptor 
checkpoint
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SLC defi cient mice have rearranged their L chains at the pro-B cell stage, as a 
signifi cant fraction of λ5-/- B cells express λ L chain, and N regions are not inserted 
in VL-JL joints in λ5-/- B cells (discussed in (99)). In addition, a pre-rearranged VκJκ 
gene segment targeted into the Ig κ  locus failed to rescue B cell development in λ5-/- mice (116). It was also hypothesised that cell surface expression of the pre-
BCR is not required and Igµ signals from the endoplasmatic reticulum (ER), but the 
recent fi nding that ER-trapped Ig L chain-nonpairing Igµ does not induce tyrosine 
phosphorylation of Ig-α supports the idea that a pre-BCR must be transported 
to the cell surface to signal (117). As it appears that a substantial fraction of the 
Igµ proteins can be transported to the pre-B cell surface in the absence of SLC 
(118-120), this would provide a likely mechanism by which allelic exclusion and 
developmental progression is rescued in λ5-/- mice.
Additional mouse models provided evidence that clonal expansion and allelic 
exclusion are not only dependent on the correct pre-BCR assembly but also on pre-
BCR signalling. One cytoplasmic domain of either Ig-α or Ig-β is suffi cient to signal 
developmental progression of pre-B cells, but mice in which the ITAMs of both 
Ig-α and Ig-β are mutated manifest an absolute block of B cell development at the 
pro-B cell stage (101, 102). Mice defi cient in Syk show a partial block at this step, 
but mice mutant in both Syk and ZAP-70, the only other known Syk family kinase, 
show a complete block at the pro-B cell stage (104). This requirement for ZAP-70 
was unexpected, as ZAP-70 was previously reported to be expressed exclusively 
in T and NK cells but not in B cells, and shows that Syk and ZAP70 are essential 
to regulate H chain allelic exclusion and proliferative expansion of pre-B cells. 
Furthermore, λ5, Ig-α, Ig-β and Syk are involved in various additional immature 
BCR forms in particular for Dµ RF2 counterselection in pro-B cells (Table 1).
The pre-BCR signalling component SLP-65
Mice defi cient for the adapter protein SLP-65 (SH2-containing linker protein 
of 65 kD) show a partial block at the large cycling pre-B cell stage (Table 1; (105-
108, 113)). Consistent with direct down-regulation of SLC expression by pre-BCR 
signalling (66), pre-B cells that lack SLP-65 manifest elevated levels of SLC in 
the cytoplasm and on the membrane (109). Therefore, it seems likely that pre-B 
cells lose their proliferative capacity because they have used up the previously 
synthesised SLC for surface pre-BCR formation. Furthermore, the transition of 
large cycling into small resting pre-B cells is accompanied by down-regulation of IL-
7R expression. The fi nding that SLP-65 is involved in the transcriptional repression 
of the IL-7Rα gene upon pre-BCR signalling (72, 112), indicates that IL-7Rα 
expression is controlled by the pre-BCR. It is therefore possible that, in addition to 
down-regulating pre-BCR expression, SLP-65 may partly prevent excessive cell 
divisions of Igµ+ pre-B cells by regulating IL-7 responsiveness.
Importantly, SLP-65−/− mice spontaneously develop pre-B cell lymphomas 
expressing large amounts of pre-BCR on their cell surface. It was hypothesised 
that in SLP-65−/− mice, large cycling pre-B cells are trapped in a positive feedback 
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loop as they are arrested in development and cannot effi ciently down-regulate pre-
BCR or IL-7R expression, which signal for proliferation (109, 112). 
The incomplete block in SLP-65-defi cient mice prompted the investigation 
of alternative adapter proteins that could partially replace SLP-65 in pre-BCR 
signalling. The homologue of SLP-65 in T cells, SLP-76, and LAT (linker for 
activation of T cells), which is an integral membrane adapter protein essential in T 
cell development, can complement the function of SLP-65 in BCR stimulation (121, 
122). Recently, two LAT-like molecules named LAB (linker for activation of B cells) 
and NTAL (non-T cell activation linker) were identifi ed in the B cell lineage and were 
shown to be constitutively localized in lipid-rafts and are phosphorylated upon BCR 
stimulation, but their role in pre-BCR signalling is currently unknown (123, 124).
Remarkably, SLP-76 and LAT are also expressed in pre-B cells, where they 
are recruited to the pre-BCR, associate with Ig-α and become phosphorylated 
upon pre-BCR stimulation (110, 111). Concomitant absence of LAT enhances the 
pre-B cell defects in SLP-65-defi cient mice, while reconstitution of LAT expression 
in SLP-65/LAT double mutant pre-B cells restored their ability to mobilize calcium, 
to down-regulate pre-BCR expression and to initiate Ig κ L chain expression 
(110). Likewise, the Btk homologue Tec has the ability to compensate defective 
Btk function in pre-B cells in vivo (125), and ZAP-70 can compensate for Syk (as 
discussed above) (104). Taken together, these data suggest that PLCγ2 can be 
activated in pre-B cells by two parallel pathways, one containing Syk, SLP-65, Btk, 
and one containing ZAP70, SLP-76, Tec and LAT (110). 
3.3 Immature B cells
Differentiation into IgM+ immature B cells is dependent on the quality of the 
L chains produced. Each L chain must be able to pair with the µ H chain already 
expressed, thereby enabling the cell surface expression of a BCR. In addition, the 
newly formed BCR should not recognize self-antigens. 
Light chain rearrangements
The pre-BCR selects for those cells that produce µ H chains that are able to pair 
with the SLC by inducing proliferative expansion of pre-BCR expressing cells. Cells 
with non-productively rearranged H chain alleles, or cells expressing non-pairing 
µ H chains do not enter the proliferation step and are thereby negatively selected. 
Similarly, µ H chain-expressing small pre-B cells are allowed to develop into 
immature and thereafter into mature B cells when a pairing L chain is expressed, 
provided that the BCR formed does not recognize self-antigens (126).
The majority of B cell progenitors functionally rearrange either the κ or λ gene 
to generate κ or λ expressing immature B cells. However, the process of isotype 
exclusion makes sure that no cell expresses both κ and λ L chains. Most κ-expressing 
cells retain their λ loci in germ-line confi guration, whereas λ-expressing cells have 
non-functional κ rearrangements on both alleles (127-129). This indicates that the 
κ locus is rearranged earlier than the λ locus during B cell development. However, 
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in mice where κ rearrangement is not possible (iEκT mice), λ-expressing cells are 
generated, indicating that λ rearrangements are independent of κ rearrangements 
(130, 131). To study the kinetics of κ or λ expression on the surface of immature 
B cells, mice were injected intraperitoneally (i.p.) with Bromodeoxyuridine (BrdU). 
The BrdU, in which brome is coupled to the thymidine–analogue uridine, is 
incorporated into DNA when it is replicated during the cell cycle. In the BM, the 
large pre-B cell population is the cycling population and incorporates BrdU into its 
DNA and subsequently differentiates into small pre-B cells. The small pre-B cells 
then undergo L chain rearrangement and cells can be tracked back by using an 
antibody specifi c for BrdU. The probability of productive L chain rearrangements 
determines the rate of output of BrdU+κ+ or λ+ B cells in the BM (132, 133). By 
performing these experiments it was found that in normal mice as well as in iEκT 
mice, the λ+ cells appear ~24h after BrdU injection, whereas the fi rst κ+ cells appear 
Figure 9. In small pre-B cells, κ and λ L chain gene rearrangement is initiated. Only when 
a non-autoreactive functional BCR is expressed, the small pre-B cell is transferred to the 
immature B cell compartment. The lambda locus is opened 24h after the cell has become 
a small pre-B cell. Receptor editing takes at least 2h extra. See text for detailed description 
about rearrangements and receptor editing. 
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after ~8h.  This implies that the λ locus is opened at a fi xed time point after the pre-
B cells have stopped cycling and is not dependent on rearrangements of the κ loci. 
Enhancer sequences located in the L chain loci have been shown to regulate 
the gene rearrangement (131, 134).  Different regulatory sequences having 
different kinetics and strength of activity at the κ and λ loci are likely to account 
for the earlier initiation of rearrangements at the κ locus. There are two enhancer 
elements associated with control of transcription and rearrangement of the κ locus. 
The onset of Jκ germ-line transcription and Vκ-Jκ rearrangement requires the 
induction of the transcription factor NF-κB (135), which binds to the Igκ intronic 
enhancer (iEκ) located between the Jκ cluster and the Cκ exon (136, 137). The 
3’κ enhancer, located downstream of the Cκ exon (138, 139), also infl uences κ 
gene transcription and rearrangement and can be activated by binding of Pax5 
(140), PU.1 (17), CRE and PIP factors (37). In contrast to the regulation of Igκ 
rearrangements, little is known about the transcription factors and DNA elements 
that regulate recombination of the Igλ gene segments. It has been found that NF-
κB signalling is required to induce germ-line transcription and, next to EBF, for 
recombination of murine Vλ and Jλ gene segments in precursor B cells (28, 141). 
Only recently it was found that in IL-7 dependent PU.1-/-Spi-B-/- cµ+ pre-B cell lines, 
IgH transcription is increased and Igλ transcription is reduced upon IL-7 withdrawal, 
when compared to wild-type pro-B cells. This indicates a role for PU.1 and/or Spi-B 
in Igλ transcription and VλJλ recombination (142).  
In small pre-B cells the κ and λ L chain gene rearrangement is initiated and 
the κ locus is fi ve times more frequently rearranged than the λ locus in mice. L 
chain rearrangements can result in out-of-frame non-productive rearrangements 
or in-frame productive rearrangements producing L chains that (a) cannot pair 
with the µ H chains; (b) form an autoreactive BCR or (c) form a non-autoreactive 
BCR. When the rearrangement is successful and the L chain can pair with the µ 
H chain and the resulting BCR is not autoreactive, the cells are transferred to the 
immature B cell compartment. In situations where the rearrangement or pairing 
is not successful or the resulting BCR is autoreactive, cells are able to perform 
secondary rearrangements, a process called receptor editing. If these secondary 
rearrangements result in a pairing L chain, which combines with the µ H chains 
to form a non-autoreactive BCR, the cells are transferred to the immature B cell 
compartment. If not, the small pre-B cell keeps trying further rearrangements, also 
on the other alleles of the κ or λ loci. If none of these rearrangements yields a 
useful L chain, the cell dies by apoptosis (Figure 9; (143)). 
Receptor editing 
The progression from the immature to mature B cell stage represents another 
checkpoint in B cell development. This process has been examined in a number 
of autoreactive transgenic mouse models that have shown that when immature B 
cells encounter an antigen capable of crosslinking the BCR, this leads to one of 
three results: (a) cells are eliminated (clonal deletion) (144-147), (b) cells become 
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non-responsive (anergic) (148) or (c) cells revise the L chains of their BCR to 
eliminate self-reactivity (receptor editing) (149-152). It appears that the strength 
of the interaction between BCR and antigen regulates the choice of either one of 
these three options. High-affi nity interactions with membrane-bound antigen result 
in deletion, whereas lower-affi nity interactions and soluble antigens allow receptor 
editing or result in anergy. 
In the process of successfully generating L chains that can pair with the µ 
H chains there is a possibility that the BCR that is generated recognizes self-
antigens. The process of receptor editing can alter the V-regions of the L chains 
and thereby lose the self-reactive nature of the BCR. Receptor editing can continue 
on both alleles and eventually, when rearrangement is unsuccessful at the κ locus, 
proceed to the λ locus (150).  Besides increased usage of λ L chains, another 
sign of receptor editing is the use of downstream Jκ segments (149). Primary 
rearrangements at the κ chain locus are well suited for further rearrangements 
because unrearranged Vκ and Jκ gene segments usually fl ank the rearranged 
VκJκ gene segments. Depending on the orientation of the edited Vκ relative to 
the Jκ segment, the secondary rearrangement may delete the primary VκJκ or 
separate it from the Cκ by inversion (149) (Fig. 10).  
Receptor editing is not likely to take place at the H chain, as V(D)J 
rearrangements remove all available unrearranged D gene segments on the same 
allele. Moreover, secondary VH rearrangements to downstream JH gene segments 
are not compatible with the 12-23 spacer rule that governs the joining of the RSSs. 
Several studies have suggested that secondary L chain gene rearrangements can 
be readily observed and that they take place when initial rearrangement is not 
productive. 
Figure 10.  Receptor editing can take place by secondary rearrangements on the same L 
chain allele by deletion (left) or inversion (right). After a primary rearrangement (upper part) 
upstream Vκ segments and downstream Jκ segments may be recombined in a secondary 
rearrangement event (lower part).  
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Direct insight in receptor editing came from experiments in mice expressing a 
transgene encoding a BCR that recognizes mouse strain-specifi c MHC I molecules 
that are expressed on every cell of the body. These so-called 3-83µδ transgenic mice 
carry a BCR transgene consisting of pre-rearranged µ and δ heavy chain genes as 
well as a κ L chain gene (153). Because the expression of the 3-83µδ transgene 
is under the control of the Ig H chain enhancer, the 3-83µδ BCR is expressed from 
the pro-B cell stage onwards. The 3-83µδ BCR specifi cally recognizes MHC class I 
molecules of the H2-Kk/b allotype (153), and thus refl ects an innocuous BCR in mice 
that have an H2-Kd background. Mice with such a non-autoreactive background 
(also called non-deleting mice) contain a virtually monoclonal B cell population. 
As the prematurely expressed 3-83µδ BCR is able to promote B cell development, 
it appears that this BCR can functionally replace the pre-BCR and consequently 
B cell development is accelerated (153-155). On the other hand, when the 3-
83µδ BCR is expressed in mice of the MHC class I H2-Kb background, all B cells 
generated are autoreactive and are targeted for receptor editing in order to survive 
(150, 151, 156). By using BM from 3-83µδ transgenic mice, it was found that self-
antigen induces receptor editing in IgMlowIgD- and rapid apoptosis in IgMhighIgD- B 
cells (155). As IgM expression is also correlated to developmental progression, 
these results indicate that as B cells advance in development their competence 
to undergo tolerance-induced receptor editing decreases, whereas sensitivity 
to antigen-mediated cell death increases. This antigen-induced apoptosis was 
inhibited by enforced expression of the anti-apoptotic protein Bcl-2 (155).
Immature B cells from the BM of 3-83µδ transgenic deleting mice expressed 
elevated levels of RAG genes and produced higher amounts of endogenous λ 
chains in peripheral B cells (150). The increased L chain rearrangements led to the 
displacement of the transgenic L chains by endogenous L chains and resulted in 
BCRs with edited specifi cities that no longer resulted in B cell deletion (150, 157). 
As the receptor editing process includes recombination of the residual L chain gene 
segments, B cell development in these mice is delayed by ~ 2h (158, 159). 
Usually λ L chain genes rearrange after κ genes. Therefore, the extent of 
receptor editing in a normal, non-transgenic immune system was determined in Igλ+ 
cells by analysing how frequently in-frame κ genes had failed to suppress λ gene 
rearrangements. It was found that nearly half of the inactivated VκJκ joins were 
in-frame, indicating that receptor editing occurs at a surprisingly high frequency 
in normal B cells (160). In another approach, the extent to which editing occurs in 
developing B cells was measured using a generated allelic polymorphism of the 
mouse κ constant region (mCκ) by replacing it with the human counterpart (hCκ), 
the expression of which correlates with receptor editing (158). It was found that 
~25% of all antibody molecules are produced by gene replacement. Furthermore, 
it was found that B cells with innocuous receptors spend little or no time in the 
small pre-B cell stage, whereas B cells undergoing receptor editing are specifi cally 
delayed at this stage for at least 2h (158). Furthermore, overexpression of Bcl-2 
increased the relative frequency of λ versus κ expressing B cells, suggesting that 
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the Bcl-2 transgene promotes receptor editing (161).  
3.4 Late B cell differentiation in the spleen
Transitional B cells
Immature B cells that emigrate from the BM to the periphery are referred to 
as transitional B cells. Transitional B cells can be distinguished from mature B-2 
cells by differential surface expression of a variety of molecules, including IgM, 
IgD, CD23, CD21, CD24/HSA and PB493 (Figure 11). The transitional B cells were 
subdivided into two separate subpopulations, termed transitional 1 (T1) and T2 B 
cells on the basis of their surface phenotype and functional characteristics (162-
165). Transitional B cells are short-lived and only 10-30% of these cells enter the 
long-lived mature peripheral B cell compartment (166-168). 
Stimulation of the BCR on mature B cells leads to activation and proliferation, 
whereas the same signals on transitional immature B cells lead to anergy or cell 
death.  Although transitional B cells migrate to the spleen, they are excluded from 
the lymph nodes (162). Lack of surface CD62L (162, 169) or fi bronectin (170) might 
mediate this exclusion. The two transitional B cell subsets are also different in their 
localization in the spleen. The T1 cells appear to be limited to the outer periarteriolar 
lymphoid sheath (PALS), whereas the T2 cells are found within the B cell follicles 
(162, 163). Next to different localization, it was found that the T1, T2 and mature 
Figure 11.  Diagram of peripheral B cell populations showing cell surface phenotype. 
Relative expression levels are indicated by line thickness. B cells differentiate subsequently 
from T1 to T2 into MR or FO B cells, whereas the differentiation into B-1 or MZ B cells is 
not yet fully understood. PB493 is also known as AA4.1 and HSA (heat stable antigen) as 
CD24. a A part of B-1 cells is CD5+, another part is CD5-. T1, 2: transitional type 1 or 2 B cells; 
MR: mature recirculating B cells; FO: follicular B cells; MZ: marginal zone B cells. Figure is 
adapted from ref. (77).
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B cell subsets in the spleen are differentially responsive to BCR signalling (171). 
T2 B cells express higher basal and BCR-induced levels of activation markers 
and proliferate as well as mature B cells. In contrast to T1 cells, BCR stimulation 
in T2 cells induces expression of the pro-survival protein Bcl-xL and induces 
phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2), p38-
MAPK and Akt, whereas these inductions were only moderate in T1 cells. This 
enhanced response to BCR stimulation contributes to the positive selection and 
progression of T2 B cells into the long-lived mature B cell pool (171).
Follicular and Marginal Zone B cells
Newly formed B-lymphocytes enter the spleen via the blood, from which they 
migrate to the B cell area in the follicle or the marginal zone (MZ) in the white pulp. 
The MZ, located at the border of the white pulp, is a highly organized region whose 
function is not yet fully understood. It contains a unique population of B cells, the 
marginal zone B cells, which do not recirculate. These cells appear to be resting 
mature B cells and they have a different set of surface proteins then the major 
follicular population of B cells (Figure 11). For example, they express low levels 
of CD23, a C-type lectin, and high levels of MHC class I molecules, CD1 and the 
complement C3-fragment receptor CD21/35 (Figure 11). Furthermore, MZ B cells 
may have restricted antigen specifi cities. The MZ also contains dendritic cells 
as well as three different types of macrophages, two types of MZ macrophages 
expressing either MARCO or ER-TR9 and the MOMA-1+ metallophilic macrophages 
(172-174).
The peripheral lymphoid tissues have a highly organized architecture, with 
distinct areas for B and T cells. The organization and the survival of newly formed 
lymphocytes are determined by interactions between lymphocytes and other cell 
types in the lymphoid tissues, such as macrophages and dendritic cells. The spleen 
collects antigen from the blood. The bulk of the spleen is composed of red pulp, 
which is the site of red blood cell disposal that is collected from the blood. The 
lymphocytes surround the arterioles entering the organ forming areas of white pulp, 
the inner region of which is divided into the PALS containing mainly T cells and a 
fl anking B cell area containing follicles.
Within the splenic follicles specialized stromal cells, the follicular dendritic cells, 
play an important role in the development of antibody responses and the survival 
of B cells. B cells that manage to migrate into follicles and become part of the long-
lived mature B cell pool subsequently migrate from the follicles into the efferent 
lymphatic vessels and so return to the circulation. The system of lymphatic vessels 
collects extracellular fl uid from tissues and returns it to the blood. Lymph nodes are 
sites where lymphatic vessels converge. The afferent lymphatic vessels that can 
drain fl uid from the tissues also carry antigens from sites of infection in most parts 
of the body to the lymph nodes, where they are trapped. Within the lymph nodes, B 
cells are localized in follicles, with T cells more diffusely distributed in surrounding 
paracortical areas. Some of the B cell follicles contain central areas called germinal 
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centers, where B cells are undergoing intense proliferation and Ig H chain class 
switch after encountering antigen. 
B-1 cells
B-1 B cells represent a separate subset of mature B cells with distinct origins, 
cell surface phenotype, functional properties and anatomical distribution. The B-1 
cells were fi rst identifi ed by the surface expression of the protein CD5 and they 
are also characterized by high levels of IgM and low levels of IgD, even when 
mature (Figure 11). Initially these cells were shown to arise from precursors in the 
fetal liver, and were therefore called B-1 cells, whereas the conventional mature 
B cells are also referred to as B-2 cells. However, V-region sequence analysis 
indicated that the V-region repertoire in B-1 cells was very restricted, no somatic 
hypermutations were found and the isotype expressed was primarily IgM. More 
recently, studies using various lines of BCR transgenic mice demonstrated that 
the mature phenotype of the B cell population is dependent on the specifi city of 
the expressed BCR or on the strength of the BCR signal (175-178). Mutations 
in positive regulators of BCR signalling, such as CD19, SLP-65, PI3K and Btk, 
result in decreased numbers of B-1 cells. And in contrast, an increase in B-1 B cell 
numbers is seen in the absence of negative regulators of BCR signalling, such as 
CD22, Lyn and the tyrosine phosphatase SH2 domain-containing protein-1 (SHP-1) 
(77, 175, 178).  Regardless of how B-1 cells originate, they are certainly expanded 
and maintained by interaction with self-antigens or non-self antigens normally 
present in the body, such as those of the bacterial gut fl ora. In adult animals, the 
population of B-1 cells is maintained by continued division in peripheral sites such 
as the peritoneal and pleural cavities, a process that requires IL-10 in addition to 
BCR stimulation (179). 
Little is yet known about the function of B-1 cells. Their location suggests a 
role in defending the body cavities, while their restricted repertoire of receptors 
appears to equip them for a function in the early, non-adaptive phase of an immune 
response. In practice it is found that B-1 cells contribute little in adaptive immune 
responses to most protein antigens, but contribute strongly to some responses 
against carbohydrate antigens. Moreover, a large proportion of the IgM that 
normally circulates in the blood of non-immunized mice is derived from B-1 cells. 
The existence of these so-called “natural antibodies”, which are highly cross 
reactive and bind with low affi nity to both microbial and self-antigens, suggests 
that B-1 cells are partially activated as they are selected for self-renewal by 
ubiquitous self- and foreign antigens. The most compelling evidence for the role 
of self-antigens in positive selection of B-1 cells has become apparent in studies 
using the carbohydrate epitope of the glycoprotein Thy-1 as a self-antigen (180). 
Expression of Thy-1 did not interfere with the generation and accumulation of B-1 
cells expressing anti-Thy-1 antibody. In contrast, no anti-Thy-1 expressing B-2 cells 
were generated. However, the lack of the self-antigen in Thy-1-/- mice abrogated the 
development and selection of anti-Thy-1 expressing B-1 nut not B-2 cells (180).  
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B cell responses
The surface Ig that serves as the antigen receptor on B cells has two roles in B 
cell activation. First, it transmits signals directly into the cell when it binds antigen. 
Second, via receptor-mediated endocytosis the B cell can ingest antigen in order 
to degrade it into smaller peptides, which can be bound to MHC class II molecules. 
In this way the B cell functions as an antigen-presenting cell (APC) because it 
expresses the peptide-MHC II complex on its cell surface, which can be recognized 
by antigen-specifi c helper T (Th) cells. These cells produce cytokines that cause the 
B cells to proliferate and differentiate into plasma cells. Some microbial antigens 
can activate B cells directly in the absence of T cell help. Those antigens are 
often polysaccharides and are called thymus independent (TI) antigens. There 
are two classes of TI antigens, the TI-I and TI-II antigens, which activate B cells 
by different mechanisms. In contrast, antibody responses against protein antigens 
require antigen-specifi c T cell help and are therefore called thymus dependent (TD) 
antigens. 
When naive B cells are activated they differentiate into IgM-producing plasma 
cells or they undergo a so-called germinal center (GC) reaction. GCs are specialized 
micro-environments in peripheral lymphoid organs, where B cells undergo affi nity 
maturation through somatic hypermutation (SHM) and class switch recombination 
(CSR). During CSR the Cµ is removed from the recombinated V(D)J gene and is 
replaced by a new downstream CH region resulting in the generation of different 
antibody isotypes, like IgG, IgA or IgE. The specifi city of the CH region determines 
the effector function of the antibody. CSR occurs by a deletional recombination 
between switch regions located upstream of each CH gene segment (181). CSR 
is activated by specifi c cytokines resulting in production of different isotypes 
upon different stimulations of the BCR. The B cell-specifi c growth factor IL-4, for 
example, promotes the expression of IgE and IgG1, whereas transforming growth 
factor β (TGFβ) promotes switching to IgA (182).  
The CSR and SHM processes require the activation-induced cytidine 
deaminase (AID) protein as profound defects were found in AID-defi cient mice 
(183-185). Identical defects are seen in patients with a homozygous defect in the 
human AID gene, a condition known as the hyper-IgM syndrome 2. These patients 
have elevated levels of serum IgM because their B cells are impaired in CSR 
(186). 
4. Bruton’s tyrosine kinase
Bruton’s tyrosine kinase (Btk) is a cytoplasmic non-receptor protein tyrosine 
kinase (PTK) involved in regulating B cell development and function (187-194). 
PTKs are known to play a pivotal role in hematopoietic cell growth, differentiation 
and lymphocyte signalling pathways (195). Btk is a 659 amino acid 77kDa protein 
and belongs to a subfamily of tyrosine kinases, the Tec family kinases (196). The 
Btk protein is expressed in B cells, myeloid, erythroid and mast cells but not in T 
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cells. Similar levels of Btk expression was observed during B cell development from 
the pro-B cell to mature B cell stages, but not in plasma cells (191, 197). Btk has 
been implicated as a mediator of signals from various receptors in several different 
cell types (Table 2). 
The Tec family kinases are the second largest family of non-receptor tyrosine 
kinases and include Tec, Btk, Itk/Emt, BMX and TXK/Rlk (198, 199). The Tec 
kinases are structurally similar to Src family kinases and consist of Src homology 
(SH) 3 and SH2 protein-interaction domains and a tyrosine-kinase catalytic domain 
(Figure 8, (200, 201)). The Tec kinases also possess a Tec homology (TH) domain, 
just upstream of the SH3 domain, consisting of a GTP-ase-activating-protein 
(GAP)-Btk homology (BH) region and a proline-rich (Pr) sequence that is implicated 
in interaction with SH3 domains and kinase regulation (202). Most Tec kinases also 
possess an N-terminal pleckstrin homology (PH) domain that binds the products 
of PI3K, helping to recruit the Tec kinases to the plasma membrane upon PI3K 
activation (203-205) (Figure 8).
Tec family kinases are activated after stimulation of a variety of cell-surface 
molecules, for example, antigen receptors, receptor tyrosine kinases, cytokine 
receptors and G-protein-coupled receptors. The most intensely studied is the 
signalling pathway downstream the antigen receptors, which activates Btk and Tec 
in B cells. Activation of most Tec family kinases by antigen receptors requires two 
key steps: fi rstly membrane association, a process that requires interaction of the 
PH domain with the products of PI3K (203, 206) and secondly phosphorylation of 
a tyrosine in the kinase domain of the Tec kinase by a Src family kinase, such as 
Syk (207). Transactivation of Btk leads to auto-phosphorylation of a tyrosine in the 
SH3 domain (Y223) (208). Phosphorylation of this site changes the affi nity of the 
SH3 domain for certain binding partners (209) and facilitates an intramolecular 
Table 2. Btk is involved in signalling pathways of different receptors in various cell types.
R: receptor; Epo: Erythropoietin; GPVI: collagen receptor glycoprotein VI; IL: Interleukin; 
TLR4: Toll like receptor 4. TRAIL: tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand.
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interaction between the SH3 domain and the proline-rich TH domain that has been 
reported for Itk (202).
Regulation of Btk activation through phosphoinositide metabolism and 
membrane microdomains play an important role in optimal activation of the 
kinase. Btk kinase activity can be inhibited by the inositol phosphatase SHIP-1, 
leading to decreased phosphoinositol-3,4,5-trisphosphate (PIP3) levels (222-226). 
Phosphopeptide mapping of stimulated Btk has identifi ed two sites of tyrosine 
phosphorylation. Y551 corresponds to the regulatory tyrosine in the kinase domain 
(207, 227) and Y223 at the ligand-binding surface of the SH3 domain (228). The 
SH2 domain of Btk is required for induction of calcium mobilization and binds to the 
phosphorylated adapter molecule SLP-65 (Figure 8; (225, 229-231)). 
Defects in the Btk protein result in the B cell differentiation defects X-linked 
agammaglobulinaemia (XLA) in man and X-linked immunodefi ciency (xid) in mice. 
4.1 X-linked agammaglobulinaemia (XLA)
XLA is one of the most frequent inherited immunodefi ciency diseases in man 
and was fi rst described by Dr. Ogden C. Bruton in 1952 (232). Most boys with XLA 
remain well during the fi rst 6-9 months of age by virtue of maternally transmitted IgG 
antibodies (233). Thereafter, they repeatedly acquire infections with extracellular 
pyogenic bacteria such as pneumococci and streptococci unless they are given 
prophylactic antibiotics or gamma globulin therapy. Chronic fungal infections or 
pneumonia rarely occur, unless there is an associated neutropenia (234). Female 
carriers of XLA are healthy and demonstrate no abnormalities of the immune 
system as B cells expressing the mutated gene are selected against (235). Patients 
with XLA have less than 1% of the normal number of peripheral B cells resulting in 
an apparent absence of immunoglobulins in peripheral blood and therefore lack an 
antibody response and fail to clear microbial antigens. An international registry for 
XLA shows that mutations in all domains of the Btk gene cause the disease (236). 
However, no correlation has been described between the position of the mutation 
and phenotypic variables, such as the age at the time of diagnosis or severity of 
the disease (237, 238). XLA is a heterogeneous disease, even within one pedigree, 
and this heterogeneity might be related to difference in the nature of the mutations 
in combination with other genetic or environmental factors. A point mutation in the 
Btk gene can result in a change of the reading frame of Btk mRNA. This may result 
in the formation of a premature stop codon, leading to the formation of an instable 
or truncated protein, or no protein at all (187, 238, 239). 
In XLA patients the B cell differentiation arrest occurs in the BM, but the exact 
location of the blockade has been controversial for some time as the number of pre-
B cells in XLA BM are detectable in heterogeneous amounts (240-242). However, 
all patients had substantial numbers of pro-B cells resulting in an increased ratio of 
pro- to pre-B cells (242-245). The B cells present in the periphery have an immature 
IgMhighIgDhigh phenotype and show an increased κ to λ ratio within the IgM+ B cell 
population compared to controls (246). 
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Detailed fl ow cytometric studies, using specifi c antibodies for human VpreB, 
TdT, CD19, CD10, CD34 and cµ have shown that six B cell differentiation stages 
are distinguishable in human BM. On the basis of differential expression of the 
rearrangement status of the Igµ H loci and cytoplasmic or surface Igµ expression, 
human B cells can be subdivided in pro-B, large and small pre-B I, pre-B II, immature 
and mature B cells. Recently it was shown that the major blockade in XLA patients 
was at the transition from pro-B (cµ-SLCbright) into large pre-B I  (cµlowSLCbright) cells 
(243).  Patients had a relatively high number of pro-B cells and a low number of 
pre-B I cells. Normally the pre-B I population consists of large and small pre-B cells. 
However, in XLA patients the pre-B I cells were mainly small, suggesting that Btk is 
necessary for the proliferative expansion and the survival of cµ+ pre-B cells.  
Some XLA cases have been shown to exhibit a mild phenotype, manifested by 
a delayed disease recognition, mild bacterial infections and higher than expected 
levels of serum Ig (247-249). Another group of investigators tried to correlate the 
B cell differentiation defect to the specifi c Btk mutation in nine XLA patients (250). 
They used fl ow cytometry to unravel the precise B cell differentiation arrest and 
found that in the majority (eight out of nine) of the patients, ~80% of the IgM- 
precursor B cells in the BM were cµ- pro-B cells. Most of these eight patients 
(seven out of eight) did not express functional Btk protein, suggesting that Btk is 
required for the expansion of cµ+ pre-B cells by signalling via the pre-BCR (250). 
The fi nding that Btk is phosphorylated in a human pre-B cell line supports this 
idea (210). This group also found that one patient with low-level expression of Btk 
mRNA in peripheral blood granulocytes had normal numbers of cµ+ pre-B II cells 
in the BM. In this patient however, the number of mature B cells was reduced. This 
suggests that low amounts of Btk are suffi cient for pre-BCR signalling, whereas 
BCR signalling needs higher levels of Btk. This particular patient had a G99A 
mutation in exon 3 of the Btk gene, which resulted in the formation of a premature 
stopcodon at position L119 in the PH domain of the Btk protein. The defects found 
in this patient were very similar to the xid phenotype in mice, which is discussed 
below. As the other patients, each with a different mutation, showed quite similar 
blockades, no obvious correlation was found between the mutation in the Btk gene 
and the phenotype of the XLA patients analysed (250). 
Although approximately 80-90% of patients with an agammaglobulinemia have 
mutations in the Btk gene, mutations in other genes, like µ H chain (251), λ5 (244), 
Ig-α (245) and SLP-65 (252), also result in a clinical phenotype resembling XLA. 
4.2  X-linked immunodefi ciency (xid)
The animal model for human XLA is the X-linked immunodefi ciency (Xid) 
mutation in the CBA/N strain of mice (115). These xid mice have a missense 
mutation at a conserved arginine residue (R28) within the Btk PH domain (Figure 8; 
(189, 190, 253)). This R28C mutation changes the conformation of the Btk protein 
in such a way that it is not able to bind to the cellmembrane (113, 115). Targeted 
deletion of the Btk gene also causes a xid phenotype in mice (113, 115). Although 
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the same gene is affected, the B cell differentiation defect is less severe in xid mice 
than that seen in human XLA (Table 3).  
Studies in these xid mice revealed that the murine xid gene defects result 
in a reduced B cell number of  ~50%. Those B cells that are present have an 
immature phenotype (IgMhighIgDlow). The mice have low levels of serum IgM and 
IgG3, whereas the levels of other isotypes are normal and peritoneal B-1 B cells 
are absent (115). Peripheral B cells from xid mice are functionally impaired, as 
they do not respond to thymus-independent type 2 polysaccharide antigens, such 
as NP-Ficoll, but respond normally to thymus-dependent antigens (253, 254). 
Furthermore, xid B cells show a high rate of spontaneous apoptosis in vitro and 
they hardly respond to stimuli such as Ig-receptor crosslinking, IL-5, IL-10, CD38 
and LPS (213, 219, 255)
Despite obvious differences in severity of the phenotype, Btk appears to be 
a conserved factor involved in both murine and human B cell development. Btk 
has been shown to be involved in BCR signal transduction pathways in both 
human (211) and murine (212, 256) B cells. Because xid mice have such a milder 
antibody defi ciency than boys with XLA, it was speculated that XLA patients with 
mutations in the PH domain-encoding part of the Btk gene may have less severe 
immunodefi ciency. However, patients with classic XLA have been identifi ed with 
mutations affecting the same residue as in CBA/N xid mice (211). 
The genomic organization of the murine Btk gene is very homologous to the 
human Btk gene and the Btk proteins share 99.3% homology (187). Transgenic 
human Btk could fully compensate the absence of murine Btk (197, 257-259), 
indicating that the essential sites for Btk interaction with other signalling molecules 
References (113, 191, 246, 253, 263, 264).
Table 3. Comparison between human XLA and murine xid phenotypes.
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is very similar in man and mice. Studies done in human and murine heterozygous 
female carriers of Btk mutations have shown that Btk-defi cient B cell precursors 
have a selective disadvantage in proliferation, differentiation and survival compared 
to normal B cell precursors (235, 260-263).  
The absolute number of pre-B cells that are generated in the BM is similar in 
xid and wild-type mice, indicating that commitment to the B cell lineage is normal. 
Furthermore, Btk-defi cient B cell precursors in the BM have normal kinetics and 
turnover (114, 253). By examining the size, renewal and production rates within 
the B cell lineage subsets in xid and wild-type mice using BrdU, it was found that 
xid mice showed signifi cant cell loss at the early pre-B cell stage, placing the initial 
effects of murine xid and human XLA at the same stage of B cell development (265). 
However, normal numbers of immature B cells were found in BM and periphery of 
xid mice, indicating that compensation mechanisms are acting at this stage of B 
cell development. At the transition of immature into mature B cells, a Btk-mediated 
defi cit was observed, which reduced the rate of mature B cell production and thus 
the number of mature B cells. Xid immature B cells in the periphery were shown 
to have defects in their recruitment into the long-lived mature B cell pool. Ectopic 
expression of the anti-apoptotic protein Bcl-2 was not able to correct the pro-/pre-
B cell defects, but signifi cantly increased the numbers of BM pre-B cells as well 
as immature and mature peripheral B cells in xid/Bcl-2 mice, suggesting that the 
peripheral defects in xid mice are mainly caused by lack of survival (266).  
Tec and Btk are members of the Tec kinase family. While Tec single knockout 
mice have no obvious immune defects, Tec/Btk double defi cient mice have a 
severe B cell defi ciency due to a partial block at the pro- to pre-B cell transition 
in B cell development (125). This strongly suggests that Btk is required for this 
transition but that in the absence of Btk, its family member Tec can take over its 
function.  Other genetic analyses are consistent with the data that Btk is required 
for pro- to pre-B cell transition. The adapter proteins SLP-65, as well as the kinases 
Syk and PI3K, are directly involved in Btk activation and function (267), especially 
for the Btk-dependent sustained fl ux of calcium after BCR stimulation (225, 268). 
Targeted mutations of SLP-65 or the p85a subunit of PI3K resulted in phenotypes 
resembling xid (106, 269, 270). Developmental defects in these mice are fi rst seen 
at the pro- to pre-B cell transition, reducing the number of pre-B cells. 
To determine the exact stage of B cell development in which the function of Btk 
is required, a mouse model was generated in which the Btk gene was inactivated 
by insertion of a β-galactosidase (lacZ) reporter gene (263). The xid phenotype in 
these mice was similar to the fi ndings in Btk null-mutant mice generated in other 
labs (113). The presence of the lacZ reporter enabled the determination of Btk 
expression profi les in vivo. It was found that Btk expression was not restricted to the 
B cell lineage. In the BM, the ER-MP20high monocyte precursors showed high lacZ 
expression. Using the LacZ activity, Btk expression could be studied in vivo. The 
phenomenon of X-chromosome inactivation in Btk+/- heterozygous female carriers 
enabled the evaluation of the in vivo competition between B cells expressing the 
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wild-type Btk and those expressing the Btk-/LacZ allele in each successive step 
of B cell development. The model detected even subtle defects of Btk-defi cient 
cells, characterized by only moderate selective disadvantages, which were not 
recognized in the affected males.  Although Btk was already expressed in pro-B 
cells, the fi rst selective disadvantage only became apparent at the transition from 
small pre-B cells to immature B cells in the BM. A second differentiation defect was 
found during the maturation from IgMhighIgDlow (T2) to IgMlowIgDhigh (mature) stages 
in the periphery (263).  
4.3 Transgenic mice expressing Btk-mutants
Transgenic mice have been generated in which B cell-specifi c promoters 
drive expression of Btk in order to correct the xid phenotype in Btk-defi cient mice. 
For example, mice that express transgenic human Btk (hBtk) under the control of 
the class II MHC Ea gene locus control region provided transgene expression in 
myeloid cells and B cells from the immature B cell stage onwards (257). When 
the MHCII-hBtk transgenic mice were mated with Btk-defi cient mice, Btk protein 
expression was restored to normal levels in the spleen and the Btk-defi cient 
phenotype was corrected. B cells now differentiated into IgMlowIgDhigh mature B 
cells; peritoneal CD5+ B-1 cells were present and serum levels of all Ig classes and 
in vivo responses to TI-II antigens were in normal ranges. These results indicate 
that this transgenic system is suitable for Btk re-expression in the B cell lineage. 
Complete correction of all xid features was also observed by transgenic expression 
of hBtk under the control of the B cell-specifi c human CD19 promoter region (197). 
Expression of a hCD19 transgene was reported to be completely restricted to the B 
cell lineage from the pro-B cell stage onwards. This transgenic model is therefore 
useful for studying Btk expression in earlier stages of B cell development compared 
to the MHCII-hBtk model where Btk is expressed from the pre-B cells stage 
onwards. By introducing various mutations in the hBtk construct, various transgenic 
mouse models were generated. The mutations were located in different domains 
of the Btk gene, which enabled the analysis of the function of each particular Btk 
domain in vivo. 
Interestingly, the PH domain gain-of-function mutant E41K (Glu-to-Lys) shows 
increased membrane localization and phosphorylation of Btk in quiescent cells, 
independent of PI3K activity, bringing Btk in close proximity of other signalling 
molecules involved in downstream signalling from the BCR (204, 228, 271). The 
E41K mutation induces transformation of 3T3 fi broblasts in soft agar cultures, 
and this capacity is augmented by mutation of the main auto-phosphorylation site 
(Y223F; (271)). Expression of E41K-Btk in Ramos B cells enhances the sustained 
increase in intracellular calcium following BCR cross-linking (225). In transgenic 
mice, which use either the B-cell specifi c CD19 promoter or the MHC class II Ea 
locus control region to express E41K-Btk, B cell development is arrested in the BM 
or the spleen, respectively (197, 258). These fi ndings suggest that expression of 
the E41K-Btk mimics BCR occupancy by autoantigens. 
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Several additional mutant mouse strains were generated expressing hBtk under 
the control of the CD19 promoter with mutations at the Y223 autophosphorylation 
site in the SH3 domain (Y223F-Btk) or at the ATP-binding site in the kinase domain 
(K430R-Btk). These mutant mice were crossed onto a Btk-defi cient background 
(263) to analyse the role of the individual Btk domains in vivo. 
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5. Aim of the thesis
In XLA patients there is an almost complete arrest of the pre-B to immature 
B cell transition, whereas only a mild selective disadvantage for this transition 
was observed in Btk-defi cient cells in xid mice (Table 2). Biochemical studies in 
cultured B cells and fi broblasts have provided important insights into the molecular 
mechanism of BCR-mediated Btk activation. However, these systems have not 
allowed for the investigation of the involvement of Btk in pre-BCR checkpoint 
function in vivo.
This thesis focuses on the role of Btk in early B cell development and its role 
in pre-BCR checkpoint function in the mouse. For the studies in this thesis, the 
Btk-/ LacZ mouse model was used to identify the function of Btk in various cellular 
processes. 
One of the events initiated upon pre-BCR signalling is the rearrangement of 
the κ and λ L chains in small pre-B cells. Therefore, we analysed the role for Btk in 
λ L chain usage (chapter 1.1) and in activation of the V(D)J recombination at the L 
chain loci (chapter 1.2). 
To fi nd out if Btk is involved in pre-BCR signalling, we analysed pre-BCR 
checkpoint functions, such as clonal expansion of cµ+ pre-B cells and the transition 
of large into small pre-B cells in Btk-defi cient mice (chapter 2.1). Furthermore, we 
examined if Btk functions solely as a kinase protein or is also able to function as 
an adapter molecule in transgenic mice expressing the kinase-dead Btk mutant 
K430R (chapter 2.2). Next, we analysed the role of Btk in pro-BCR signalling by 
using transgenic mice expressing the gain-of-function mutant E41K (chapter 2.3). 
As it is known that Btk interacts with the adapter protein SLP-65, we analysed 
their synergistic role in Btk/SLP-65 double defi cient mice (chapter 3.1) and 
investigated whether Btk was able to function as an adapter molecule in the 
absence of SLP-65 (chapter 3.2). 
By using 3−83µδ transgenic mice, which prematurely express a complete B cell 
receptor (BCR), we analysed the role of Btk in accelerated B cell development and 
in the receptor editing process (chapter 4). 
Summarizing, this thesis provides detailed information about the role of the Btk 
protein during early and late B cell development in the mouse. Understanding the 
role of the Btk protein in mice provides important insights in its implication in human 
B cell development.   
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Introduction
During early B cell development in the bone 
marrow, Ig H and L chain variable region genes 
are assembled from component V, (D), and J 
gene segments (for reviews, see references (1-3). 
V(D)J recombination is a highly ordered process, 
initiated by DNA rearrangements at the H chain 
in pro-B cells. The expression of a functional µ 
H chain is monitored through the formation of a 
(pre-) B cell receptor (BCR) complex, together 
with λ5 and Vpre-B proteins. Signaling through the 
pre-BCR results in feedback inhibition of H chain 
VDJ recombination to ensure allelic exclusion 
and IL-7–dependent proliferative expansion. The 
rapidly proliferating pre-B cells then exit the cell 
cycle and perform Ig L chain rearrangements, 
leading to the deposition of complete Ig 
molecules on the cell surface (2, 3). The murine κ 
L chain locus contains 70–90 functional Vκ gene 
segments, present in both orientations relative to 
the four functional Jκ elements. By contrast, the λ locus in the mouse is very small; it consists of 
only three functional Vλ and three functional Jλ 
segments. Ig κ and λ L chain rearrangements 
occur independently and at different kinetics, with 
sequential activation of the κ and λ loci (4-6). The 
privileged activation of the κ locus is thought to 
determine the fi nal ratio of κ+ to λ+ mature B cells 
of 95:5 in wild-type (WT) mice. 
PCR analyses of the Ig κ L chain locus in 
single developing B cells in the bone marrow 
have demonstrated the presence of multiple 
in- and out-of-frame rearrangements in small 
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pre-B cells (6). These fi ndings indicated that the 
BCR does not signal allelic or isotypic exclusion 
of the Ig κ or λ L chain loci, allowing secondary 
L chain rearrangements to occur. Cells with a 
fi rst productive rearrangement on one allele are 
rapidly selected to enter the immature B cell 
compartment (6). The rearrangement machinery 
remains active in immature B cells and is only 
turned off at the transition to mature B cells (7-
9). If an immature B cell expresses an Ig that 
has reactivity with an autoantigen in the bone 
marrow, continued Ig L chain rearrangement 
can be induced to rescue autoreactive B cells 
from tolerance elimination, a phenomenon called 
receptor editing (10-12). 
One of the molecules that is involved in 
pre-BCR signaling and thereby directs B cell 
development is the Tec family nonreceptor 
Bruton’s tyrosine kinase (Btk; for a review, 
see reference 13). Upon BCR stimulation, 
Btk phosphorylation and kinase activity are 
increased (14-16) probably by the activity of 
Src family kinases (13, 17). Concomitantly, Btk 
is targeted to the plasma membrane by the 
binding of its pleckstrin homology (PH) domain 
to the second messenger phospatidylinositol-
(3,4,5)triphosphate (18). Binding of Btk to 
the linker protein BLNK/SLP-65 is crucial for 
phosphorylation and activation of phospholipase 
Cγ2 by Btk, implicating Btk as a mediator of BCR-
induced Ca2+ mobilization (19). 
Mutations in Btk lead to X-linked 
agammaglobulinemia (XLA) in humans and X-
linked immunodefi ciency (xid) in mice (for reviews, 
see references (20-23). XLA is characterized by 
an almost complete arrest of B cell development 
at the pre-B cell level (24, 25). As a result, XLA 
patients have profoundly reduced numbers of B 
cells in the peripheral blood, and serum Ig levels 
of all classes are very low (24). Btk-defi cient mice 
display a milder phenotype, mainly refl ecting 
poor survival of peripheral B cells. B cell numbers 
in the spleen and lymph nodes are reduced by 
50%, and IgM and IgG3 levels in the serum are 
low (20, 26). Nevertheless, mouse Btk-defi cient 
cells also showed an impaired transition from pre-
B to immature B cells by analysis of competition 
in vivo between Btk+ and Btk- cells in females 
heterozygous for a targeted mutation in the Btk 
gene (27). 
Both in XLA patients and in xid mice the 
absence of Btk appeared to result in a decrease 
of Ig λ L chain usage in peripheral B cells 
(24, 28, 29). The reduced frequency of Ig λ L 
chain–expressing cells could either refl ect an 
intrinsic feature of the L chain rearrangement 
process in the absence of Btk signaling or could 
alternatively be secondary to an altered antigen-
dependent peripheral repertoire selection in 
Btk-defi cient mice. To distinguish between these 
two possibilities, we determined the proportions 
of Ig λ+ B cells during B cell differentiation in Btk-
defi cient mice, as well as in transgenic mice that 
express a constitutively activated form of Btk, the 
E41K PH domain mutant (27, 30). As the κ to λ 
ratio is dependent on (a) the level and kinetics of 
the activation of the κ to λ loci for recombination, 
(b) the life span of pre-B cells that are in the 
process of L chain rearrangement, and (c) the 
extent of receptor editing of autoreactive B cells, 
we analyzed the involvement of Btk in these 
processes in detail. 
Materials and Methods
Mice.    Btk-/lacZ mice (27) were crossed on 
a C57BL/6 background for over fi ve generations. 
CD19-hBtkWT and CD19-hBtkE41K transgenic mice 
that express WT and E41K-mutated human Btk 
(hBtk), respectively, under the control of the 
CD19 promoter region have been described 
previously (30) and were on a mixed background 
containing 129/Sv, C57BL/6, and FVB. For the 
generation of λ5-hBtkE41K mice we used a 1.5-
kb NotI-BglII fragment containing the murine λ5 
promoter and a 6.5-kb ClaI-NotI fragment with 
the 3’ locus control region of the λ5-VpreB1 locus 
(31). The promoter and locus control region were 
cloned into the unique SwaI and SmaI sites, 
respectively, present in the cosmid vector pTL5 
containing a BglII-NotI-XhoI-SwaI-PvuI-KpnI-
SmaI-NotI-BglII polylinker (32). Next, an ~27-kb 
PvuI-NotI fragment containing the E41K-mutated 
hBtk cDNA/genomic DNA fragment (32) was 
cloned into the λ5/pTL5 vector, using the PvuI 
and KpnI sites in the polylinker. The ~35-kb NotI 
insert of the λ5-hBtkE41K construct was excised 
from the vector and purifi ed, using standard 
methods. DNA (~2–4 ng/µl) was injected into the 
pronuclei of FVB fertilized oocytes, which were 
subsequently implanted into pseudopregnant 
foster mice. Founder mice were crossed with Btk-
/lacZ mice. Eµ-2-22 Bcl-2 transgenic mice (33) 
and 3-83µδ mice (10) were on a C57BL/6 and a 
B10.D2 background, respectively. All mice were 
bred and maintained in the animal care facility at 
the Erasmus University Rotterdam. 
Mouse Genotyping.   To determine the Btk 
genotype and score the presence of the CD19-
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hBtkWT or CD19-hBtkE41K transgenes, tail DNA 
was analyzed by Southern blot analysis of BamHI 
digests, as described previously (27, 30). The 
presence of the Eµ-2-22 Bcl-2 transgene was 
evaluated by PCR, using primers that are specifi c 
for the SV40 DNA sequences fl anking the Bcl-2 
transgene: 5’-GGCACTATACATCAAATA TTC-3’ 
and 5’-TGAAGGAACCTTACTTCTGT-3’. The 
presence of the 3-83µδ transgene was identifi ed 
by Southern blot analysis of BamHI or EcoRI 
digests, using a Jκ-specifi c probe as described 
previously (34). 
Flow Cytometric Analyses. Preparation 
of single cell suspensions, fl ow cytometry, 
and determination of β-galactosidase 
activity by loading cells with fl uorescein-di-β-
galactopyranoside substrate have been described 
previously (27, 32). Events (5 x 104–5 x 105) were 
scored using a FACSCaliburTM fl ow cytometer 
and analyzed by CELLQuestTM software (Becton 
Dickinson). The following mAbs were obtained 
from BD Pharmingen: FITC-conjugated anti-
B220–RA3-6B2, anti-κ–R5-240, and anti-IgM, 
PE-conjugated anti-CD19, anti-CD43, and 
anti-H2–Kd; and CyChrome-conjugated anti-
B220–RA3-6B2 and biotinylated anti-CD19, 
anti-λ1 and λ2–R26-46, anti–IgM, and anti-H2–Kb. 
PE-conjugated anti-IgD was from Soutern 
Biotechnologies, Inc. The anti–3-83 clonotype 
54.1 antibody has been described previously 
(35). Secondary antibodies were PE-conjugated 
goat anti–rat, Tri-color, or allophycocyanin-
conjugated Streptavidin, purchased from Caltag. 
Affi nity-purifi ed polyclonal rabbit anti-Btk (BD 
Pharmingen) was used for intracellular fl ow 
cytometric detection of cytoplasmic Btk protein 
using FITC-conjugated goat anti–rabbit total Ig 
(Nordic) as a secondary antibody (32). 
IL-7–driven Bone Marrow Cultures.   Primary 
pre-B cell cultures were performed as described 
previously (36). In brief, bone marrow cells were 
depleted of erythrocytes by standard ammonium-
chloride lysis, and subsequently IgM- B cells were 
purifi ed by negative selection. Cell suspensions 
were labeled with biotinylated anti-IgM (BD 
Pharmingen) and incubated with Streptavidin-
coated microbeads (Miltenyi Biotec). After cell 
separation using MACS column purifi cation, 
the IgM- fraction was collected and purity was 
confi rmed by fl ow cytometry. Cells were cultured 
in IMDM medium, supplemented with 10% heat-
inactivated FCS at 2 x 106 cells/well in 24-well 
plates at 37°C in the presence of 100 U/ml of 
recombinant murine IL-7 (R&D Systems). After 
5 d of culture, cells were washed and recultured 
on S17 stromal cells with or without 100 U/ml IL-7 
for 48 h. 
Results
Reduced Ig λ L Chain Usage throughout B 
Cell Development in Btk-defi cient Mice. The 
expression of Ig λ L chain was investigated in Btk-
defi cient mice, in which the Btk gene is inactivated 
by a targeted insertion of a lacZ reporter (27). 
Total splenic cell suspensions were analyzed by 
three-color fl ow cytometry, using an antibody 
specifi c for the Ig λ1 and λ2 L chain constant 
regions in conjunction with anti-B220 and anti-
CD19. The proportions of B cells that expressed 
Ig λ L chain on the cell surface were 4.9% ± 0.2 (n 
= 7) and 5.0 ± 0.2 (n = 6) in the spleen of Btk+ and 
Btk+/- control mice, respectively. By contrast, we 
observed a signifi cant reduction of this proportion 
in Btk- mice (2.3 ± 0.4; n = 10). 
Next, λ expression was determined in 
individual B cell subpopulations in bone marrow 
and spleen. We performed four-color fl ow 
cytometry experiments, using anti-λ L chain 
antibodies in combination with mAbs specifi c for 
the B220, IgM, and IgD surface markers, which 
defi ne successive stages of B cell development 
(Fig. 1). In Btk+ mice, 10–16% of cells within 
the immature B cell subpopulations, including 
immature IgM+IgD- and transitional IgM+ IgDlow 
B cells in the bone marrow and immature IgMhigh 
IgDlow B cells in the spleen, were found to express 
Ig λ L chain. By contrast, in the Btk- mice only 
5–7% of cells within these subpopulations were 
λ+, i.e., about half the number found in WT mice. 
In the mature B cell subpopulations, including the 
IgM+IgDhigh cells in bone marrow and spleen, Ig λ 
L chain was expressed in 4–5% of cells in Btk+ 
mice and in 2.5–3.5% of cells in Btk- mice. Finally, 
we found that in the subpopulation of large 
lymphoblastoid cells in the spleen of Btk+ and 
Btk- mice 8–12% and 4–6% were λ+, respectively 
(Fig. 1). In Btk+/- heterozygous mice, intermediate 
values of λ+ cells were found in the bone marrow 
immature cells (data not shown). 
These fi ndings demonstrate that the absence 
of Btk leads to a signifi cantly reduced frequency 
of λ usage, already from the immature B cell 
stage onwards. 
Reduced λ L Chain Usage Is an Intrinsic 
Feature of Btk-defi cient B Cells.    Although we 
demonstrated that Ig L chain isotype usage is 
determined in the bone marrow, the possibility 
remained that the reduced λ usage did not 
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refl ect an intrinsic feature of Btk-defi cient B 
cells. Alternatively, this phenomenon could 
originate from the xid immune status of the Btk-
defi cient mice, which may, directly or indirectly, 
affect selection events at the pre-B to B cell 
progression. 
To address this issue, we analyzed 
heterozygous Btk+/- female mice, which do 
not manifest the xid phenotype due to the 
selective advantage of B cells that have the 
intact Btk+ allele on their active X chromosome 
(27). Because of the process of random X 
chromosome inactivation, ~50% of the B cell 
progenitors have the disrupted Btk-/lacZ+ allele 
on the active X chromosome. When cells reach 
a differentiation stage at which Btk is required, 
their further development is hampered. As a 
consequence of this selective disadvantage, the 
proportions of Btk-/lacZ+ cells decrease below the 
value of 50%, fi nally to undetectable levels in the 
mature peripheral B cells (27). 
We analyzed splenic cell samples from Btk+/- 
heterozygous females for λ usage in four-color 
fl ow cytometry experiments, using fl uorescein-
di-β-galactopyranoside as a fl uorogenic substrate 
in conjunction with surface labeling to defi ne 
the immature IgDlowB220+ B cell subpopulation 
in the spleen. In this fraction, ~30% of the cells 
expressed lacZ, enabling a separate analysis of 
the Btk+/lacZ- and Btk-/lacZ+ B cell populations. 
We found that the proportion of Ig λ+ cells within 
the Btk- immature IgDlowB220+ subpopulation was 
reduced to 3.6% ± 0.7, when compared with Btk+ 
immature B cells (6.3% ± 0.9; Fig. 2). 
These results show that reduced λ usage is 
an intrinsic feature of Btk-defi cient B cells, which 
is independent of the xid immune status of the 
mice. 
Bcl-2 Overexpression Does Not Alter the 
Btk Dependence of Ig L Chain Isotype Usage. 
The fi nding of reduced λ expression in Btk-
defi cient cells may be explained by a role for 
Btk signal transduction in extending the life 
span of pre-B cells that are in the process of L 
Figure 1. Ig λ L chain expression 
during B cell development in Btk+ 
and Btk- mice. Bone marrow and 
spleen single cell suspensions 
were stained with mAbs specifi c 
for B220, IgM, IgD, and Ig λ. 
Spleen lymphoblasts were 
gated based on large forward 
scatter values. The indicated B 
cell subpopulations were gated 
(top) and analyzed for B220 
and Ig λ L chain expression 
(bottom). On the basis of IgM 
and IgD expression, B cell subpopulations were defi ned in the bone marrow: E, IgM+IgD- immature B cells; ET, 
IgM+IgDlow transitional immature B cells; F, IgM+IgD+ mature recirculating B cells (reference (47)). In the spleen: I, 
mature IgMlow IgDhigh; II, IgMhighIgDhigh; III, immature IgMhighIgDlow B cells. Data are displayed as dot plots, and the 
percentages of λ+ cells of the B220+ B cell population are indicated. Data shown are representative of 10 Btk+ and 
8 Btk- mice animals examined.
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chain rearrangement. Enforced expression of 
the anti-apoptotic Bcl-2 gene results in elevated 
Ig λ expression in mature B cells (37). As the 
Ig κ and λ loci are sequentially activated for 
VL-JL recombination, Bcl-2 gene is assumed to 
provide an extended time window per cell for Ig 
L chain rearrangement (37). To investigate a role 
for Btk in pre-B cell survival, we have crossed 
Btk-/lacZ mice onto an Eµ-Bcl-2 transgenic 
background (33). We investigated λ usage in 
Eµ-Bcl-2 transgenic Btk+/- female mice, in which 
the Btk+ and Btk- immature splenic IgDlowB220+ 
B cell population can be analyzed within a single 
animal. In these mice the Btk+ subpopulation 
had a signifi cantly higher percentage (12.8% ± 
1.3; n = 4) of λ+ B cells, compared with the Btk- 
subpopulation (7.3% ± 1.5; Fig. 2). 
These analyses demonstrate that even if the life 
span of pre-B cells is extended by the presence 
of the Bcl-2 transgene, the Btk-defi cient B cell 
population still manifests an ~50% reduction in λ 
usage. Therefore, we conclude that protection of 
pre-B cells from apoptosis does not alter the Btk 
dependence of the frequency of λ usage. 
Expression of a Constitutively Activated Btk 
Mutant Increases λ Usage. To further test the 
involvement of Btk signaling in the mechanism 
that sets the κ to λ isotype ratio in vivo, we 
examined mice that express the constitutively 
activated BtkE41K mutant. This Glu-to-Lys PH 
domain Btk mutant shows increased membrane 
localization in quiescent cells, independent of 
phosphatidylinositol 3-kinase activity (38, 39). In 
CD19-hBtkE41K transgenic mice, which express 
BtkE41K under the control of the CD19 promoter 
region, B cell development is almost completely 
arrested at the immature B cell stage in the bone 
marrow, probably because the BtkE41K mutant 
mimics BCR occupancy by autoantigens (30; 
Fig. 3). 
In four-color fl ow cytometry experiments 
using antibodies to B220, IgM, IgD, and Ig λ, 
the CD19-hBtkE41K transgenic mice manifested a 
signifi cant increase in the frequency of λ usage 
(~11% in the IgM+IgD-/low immature B cell fraction 
in the bone marrow compared with ~6% in 
nontransgenic littermates; Fig. 3). This increase 
was specifi cally associated with the expression of 
the BtkE41K mutation, as the control CD19-hBtkWT 
transgenic mice in which the CD19 promoter 
drives expression of WT hBtk contained normal 
proportions of λ+ B cells (Fig. 3). We conclude 
that the presence of constitutively activated Btk 
enhances λ  usage. 
Ig λ Usage in CD19-hBtkE41K Eµ-Bcl-2 Double 
Transgenic Mice. To confi rm that Btk-mediated 
signaling increases λ usage, independent of the 
life span of pre-B cells, we crossed CD19-hBtkE41K 
and CD19-hBtkWT transgenic mice onto the 
Eµ-Bcl-2 background. The enforced expression 
of Bcl-2 partially prevented central deletion of B 
cells in CD19-hBtkE41K transgenic mice, as was 
evident from the presence of substantial numbers 
of mature B cells in bone marrow and spleen of 
CD19-hBtkE41K Eµ-Bcl-2 double transgenic mice 
(Fig. 3). We analyzed Ig λ L chain expression in 
the B cell populations in bone marrow and spleen 
from Eµ-Bcl-2 transgenic, CD19-hBtkE41K Eµ-Bcl-
2, and CD19-hBtkWT Eµ-Bcl-2 double transgenic 
mice (Fig. 3). Consistent with previous reports 
(37), Eµ-Bcl-2 mice or CD19-hBtkWT Eµ-Bcl-2 
double transgenic mice had signifi cantly higher 
percentages of λ+ cells in the immature IgM+IgD-
/low B cell population in the bone marrow (~24%), 
when compared with nontransgenic or CD19-
hBtkWT littermates (~7%). Most importantly, in 
CD19-hBtkE41K Eµ-Bcl-2 double transgenic mice 
we found even higher proportions of Ig λ+ cells 
(~35–40%). Similar signifi cant differences were 
found in the mature recirculating IgM+IgD+ B cell 
population in the bone marrow and in the spleen 
(data not shown, and  Fig. 3). Therefore, we 
conclude that the BtkE41K-mediated increase of 
λ usage cannot be explained by an effect of this 
mutant on pre-B cell survival. 
Figure 2. Separate effects of Btk and 
Bcl-2 on Ig λ L chain usage. Four-color 
fl ow cytometric analyses of spleen cells 
of the indicated mice. The immature 
IgDlowB220+ compartment was gated 
(top) and analyzed for lacZ and λ L chain 
expression (bottom). The percentages 
of λ+ cells within the indicated lacZ+ or 
lacZ- subpopulations are given. Data are 
shown as dot plots representative of the 
4–10 mice examined.
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Btk Signaling Is Not Essential for Receptor 
Editing. As receptor editing may occur frequently 
during normal B cell development and is 
accompanied by increased λ usage (10, 12, 40), 
we tested whether the reduced λ expression in 
Btk-defi cient B cells results from the inability 
of these cells to perform receptor editing. 
Therefore, Btk-defi cient mice were crossed with 
3-83µδ transgenic mice bearing rearranged H 
and L chain genes encoding an antibody that 
specifi cally recognizes MHC class I H-2Kk,b 
(10). On a nondeleting H-2Kd background, the 
3-83µδ mice contain a virtually monoclonal B cell 
population bearing the 3-83µδ BCR, as identifi ed 
by the antiidiotypic antibody 54.1 (Fig. 4). In 
contrast, centrally deleting 3-83µδ/H2-Kb mice 
exhibit the phenotype of central B cell tolerance 
in which idiotype-positive B cells are present in 
the bone marrow (Fig. 4 A), but are effi ciently 
deleted from the spleen and lymph nodes (10). 
Only small numbers of B cells are present in the 
spleen and lymph nodes and most of these lack 
the autoreactive specifi city (>94% and >99%, 
respectively; Fig. 4, B and C). These B cells, 
which have performed receptor editing, express 
the transgenic H chain together with endogenous 
L chain, a large fraction (~50%) of which is λ 
(10; Fig. 4, B and C). Btk-defi cient 3-83µδ/H2-
Kb mice manifested similar B cell numbers in 
the spleen and lymph nodes, when compared 
with Btk+ littermates. Deletion of autoreactive 3-
83µδ–expressing B cells occurred in the absence 
of Btk, but was less effi cient in the spleen than 
in lymph nodes (~70 and ~97% of B cells were 
54.1-, respectively; Fig. 4, B and C). In the Btk-
defi cient 3-83µδ/H2-Kb mice, signifi cant numbers 
of idiotype-negative B cells were present, 25–
40% of which expressed Ig λ L chain. Therefore, 
we conclude that receptor editing can occur in 
Btk-defi cient autoreactive immature B cells. 
Reduced λ Usage in Btk-defi cient B Cells 
Generated in Bone Marrow Cultures In Vitro. 
To further investigate the relation between 
Btk signaling and λ chain rearrangement, we 
Figure 3. Increased λ usage in CD19-hBtkE41K mice independent of cell survival. Four-color fl ow cytometric analyses of 
bone marrow and spleen of the indicated mice. Single cell suspensions were stained with mAbs specifi c for B220, IgM, 
IgD, and Ig λ. On the basis of IgM and IgD expression, the immature IgM+IgD-/low B cell population in the bone marrow 
(top, fraction E+ET; see legend to Fig 1) and the total IgM+IgD+ B cell population in the spleen (bottom) were gated and 
analyzed for λ usage. Data shown are representative of fi ve to nine mice examined per group. At the bottom, the total 
splenic B cell numbers of the indicated animals are given as mean values ± SD (determined by fl ow cytometric analysis 
using mAbs to B220 and CD19).
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performed IL-7–driven bone marrow culture 
experiments as described previously (7, 41). 
When surface IgM- bone marrow cell suspensions 
from WT or Btk-defi cient mice were cultured 
for 5 d in the presence of IL-7, the majority of 
cells consisted of B220+IgM- pre-B cells that 
expressed µ H chain in their cytoplasm. In these 
cultures, a considerable fraction of the WT B220+ 
cells (~15%) matured to surface IgM+ B cells, 
while <5% of Btk-defi cient B220+ cells were 
surface IgM+, suggesting that the progression 
from pre-B cell to sIg+ B cell is hampered in Btk-
defi cient mice. When cells were subsequently 
cultured without IL-7 on S17 stroma cells for 48 
h, allowing the cells to exit from the cell cycle and 
further differentiate (36), signifi cant fractions of 
the WT (~40%) and Btk-defi cient (~30%) B220+ 
cells were surface IgM+. In these cultures, in 
vitro–generated Btk-defi cient surface IgM+ B cells 
showed signifi cantly reduced usage of λ L chains, 
compared with WT B cells (Fig. 5 A). 
Reduced Cytoplasmic L Chain Expression 
in Btk-defi cient Pre-B Cells.   About one fi fth of 
all pre-B cells have been reported to express µ 
H chain and L chains in their cytoplasm without 
depositing IgM molecules on their surface (3). 
In the bone marrow of Btk+ and Btk- mice, we 
determined the proportions of sIgM- cells that 
express κ and λ L chain in their cytoplasm. In four-
color fl ow cytometry experiments, intracellular 
staining for H or L chain expression was combined 
with surface labeling to defi ne the IgM-IgD-B220+ 
pre-B cells. In Btk+ and Btk- mice, the proportions 
of sIgM- B cells that expressed cytoplasmic µ H 
chain were similar. By contrast, the percentage of 
sIgM- B cells that were positive for κ or λ L chains 
in their cytoplasm was signifi cantly reduced in 
Btk-defi cient mice, compared with WT mice (Fig. 
5 B). The absence of Btk had a much stronger 
effect on λ expression, resulting in decreased 
frequencies of λ usage in Btk-defi cient sIgM- cells 
(1.9 compared with 5.8% in WT mice). 
Transient Expression of BtkE41K in Pre-B Cells 
Increases λ Usage. To confi rm that the BtkE41K 
mutant exerts its role on λ L chain usage at the 
pre-B cell stage, we generated transgenic mice 
in which BtkE41K expression was driven by the 
λ5 promoter and the 3’ λ5-Vpre-B1 locus control 
region. As shown in Fig. 6 A, the transgene was 
selectively expressed in early CD43+B220+ B 
Figure 4. Analysis of receptor editing in 
3-83µδ transgenic Btk+ and Btk- mice. 
Single cell suspensions were stained 
with mAbs specifi c for B220, IgM, Ig 
λ, as well as the clonotype-specifi c rat 
mAb 54.1 that detects idiotype-positive 
B cells in 3-83µδ transgenic mice. The 
Btk dependence of receptor editing 
was analyzed in Btk+ and Btk- centrally 
deleting 3-83µδ transgenic mice on 
an H-2Kd/H-2Kb F1 background. As 
controls, nondeleting 3-83µδ transgenic 
mice (H-2Kd) and nontransgenic (H-2Kb) 
Btk+ mice are shown. (A) Presence of 
54.1+ B cells in the bone marrow of the 
indicated mice. In the spleen (B) and 
mesenteric lymph node (C), the B cell 
population was gated (numbers indicate 
the percentages of B220+IgM+ cells from 
total lymphoid cells) and analyzed for the 
expression of λ and the 54.1 idiotype. 
The numbers in the quadrants indicate 
the percentages of B220+IgM+ cells that 
are λ+54.1-, λ+54.1+, and λ-54.1+. Data 
shown are representative of the mice 
examined.
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cell precursors. In contrast to the CD19-hBtkE41K 
transgenic mice, the λ5-hBtkE41K mice did not 
manifest an arrest of B cell development, as the 
sizes of the B cell subpopulations in bone marrow 
and peripheral organs were in the normal ranges 
(Fig. 6, and data not shown). When λ5-hBtkE41K 
transgenic and nontransgenic mice on a Btk- 
background were compared, expression of the 
transgene was found to increase λ usage. The 
frequencies of λ+ cells in the IgM+IgD-/low immature 
B cell population were 4.9 ± 0.3 in Btk- mice (n 
= 4) and 8.9 ± 0.7 in λ5-hBtkE41K transgenic Btk- 
mice (n = 4; Fig.6 B). This fi nding showed that 
transient expression of BtkE41K in CD43+ pro- and 
pre-B cells increased the frequency of λ usage. 
Discussion
In this report we show that the absence of 
Btk during murine B cell development results in 
a 50% reduction of the proportion of Ig λ L chain–
expressing cells. Conversely, expression of the 
constitutively activated BtkE41K mutant signifi cantly 
promotes λ usage. The observed λ expression 
profi les of Btk-defi cient, CD19hBtkE41K, and λ5-
hBtkE41K mice during B cell development show 
that the effect of Btk signaling is at the level of the 
Ig L chain rearrangement events in pre-B cells, 
and not a result of antigen-dependent selection 
processes in the periphery. Moreover, the 
comparison of Btk+ and Btk- B cells in the spleen 
of heterozygous females shows that reduced λ 
usage is an intrinsic feature of Btk-defi cient B 
cells and not associated with the immunodefi cient 
status of Btk-defi cient mice. We conclude that the 
regulation of Vλ-Jλ recombination events in the 
bone marrow is partially dependent on Btk signal 
transduction. 
It has been shown that the κ to λ ratio of 
95:5 in murine cells refl ects a developmental 
hit-and-run program of B cells in which κ gene 
rearrangements precede λ rearrangements, 
whereby λ usage is also dependent on the pre-B 
cell life span and the extent of receptor editing in 
immature B cells (4-6, 37). 
Figure 5. Decreased λ L chain usage in in vitro–
generated Btk- B cells and in Btk- pre-B cells in vivo. (A) 
Fraction of B220+ cells that express κ and λ L chain on 
the cell surface in bone marrow cultures from Btk+ and 
Btk- mice (n = 10). Cells were grown in IL-7 for 5 d and 
subsequently recultured on S17 stroma in the absence 
of IL-7 for 48 h. Cells were stained with mAbs specifi c for 
B220, IgM, IgD, and either κ or λ. (B) Fraction of sIgM-
sIgD-B220+ cells that express L chains in their cytoplasm 
in the bone marrow of Btk+ and Btk- mice (n = 8). Figure 6. Increase of λ usage by transient BtkE41K 
expression in λ5-hBtkE41K mice. (A) Intracellular Btk 
expression in B cells from λ5-hBtkE41K transgenic mice 
on a Btk- background. Btk expression profi les are 
displayed as histograms for CD43+B220+IgM- pro-B 
cells, CD43- B220+IgM- pre-B cells, and B220+IgM+IgD- 
immature B cells of λ5-hBtkE41K transgenic mice (black 
lines), together with those of Btk- mice, which served 
as background stainings (thin lines). (B) Four-color fl ow 
cytometric analyses of bone marrow of the indicated 
mice. On the basis of IgM and IgD expression (top), the 
immature IgM+IgD-/low B cell population (fraction E+ET; 
see legend to Fig.1) and the IgM+IgD+ recirculating B cell 
population (fraction F) were gated and analyzed for B220 
and λ usage (bottom). Data shown are representative of 
the mice examined.
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The fi nding of increased λ L chain usage 
in Bcl-2 transgenic animals indicates that the 
extent of secondary rearrangement events 
in pre-B cells with a nonfunctional L chain 
rearrangement is dependent on their life span 
(37). Although Btk is involved in the survival of 
mature peripheral B cells (20, 42), a role for Btk 
in the survival of pre-B cells in the mouse is not 
very likely. The absolute numbers of pre-B cells 
that are generated in the bone marrow of Btk-
defi cient mice are normal, and Btk-defi cient B cell 
precursors in the bone marrow have the same 
kinetics of turnover (20, 26, 27, 43). Moreover, 
our analyses in Btk-defi cient and BtkE41K mice 
on an Eµ-Bcl-2 transgenic background show that 
protection of pre-B cells from apoptosis by the 
expression of the Bcl-2 transgene did not alter 
the Btk dependence of the frequency of λ usage 
(Figs. 2 and 3). Therefore we conclude that the 
infl uence of Btk on λ usage is not at the level of 
the regulation of the time window for Ig L chain 
rearrangements in pre-B cells. 
As our fi ndings argue against a role of Btk 
in pre-B cell survival, the relationship between 
Btk activity and λ usage would point at a role 
for Btk either in the regulation of the initiation of 
gene rearrangement at the λ L chain locus or in 
the induction of receptor editing. As comparable 
numbers of 54.1 idiotype-negative B cells were 
present in Btk+ and Btk- centrally deleting 3-83µδ 
autoantibody transgenic mice, we conclude that 
Btk signaling is not essential for receptor editing. 
Nevertheless, a 50% reduction of λ usage was 
found in the spleen and lymph nodes of Btk-
defi cient 3-83µδ transgenic mice (Fig. 4). This 
fi nding may indicate that in Btk-defi cient mice 
the mechanism of receptor editing is intact, but 
λ usage is decreased due to impaired initiation of 
λ L chain rearrangement, or alternatively that the 
overall level of Ig L chain replacement is reduced. 
Recent experiments indicated that receptor 
editing represents a major force in shaping the 
antibody repertoire in the mouse, as it was 
found that ~25% of all Ig L chains are produced 
by gene replacement (12). Whether all of these 
replacements are induced by self-reactive or 
nonpairing receptors is currently unknown. Thus, 
it is possible that the 15–20% of all small pre-B 
cells that have been reported to express Ig L 
chains in their cytoplasm (44) may have deposited 
IgM on the membrane, but sIgM expression 
has subsequently been downregulated due to 
binding of an autoantigen. Such cells would only 
be present in the bone marrow for a very short 
time, as receptor editing has been estimated to 
take only 2 h (12). In this model, the reduced 
cytoplasmic λ L chain expression observed in 
Btk-defi cient pre-B cells may refl ect reduced 
receptor editing in the absence of Btk signaling. 
Alternatively, the pre-B cells that express µ H 
chain and L chains in their cytoplasm, but not on 
their surface, may produce Ig L chains that are 
not capable of pairing with the µ H chain in that 
cell (6). On the basis of these fi ndings, it could 
be assumed that the κ to λ ratio in cytoplasmic 
L chain–positive pre-B cells refl ects the intrinsic 
probabilities for productive rearrangements on 
the κ and λ loci. In this alternative model, the 
observed signifi cant reduction of the frequencies 
of cytoplasmic λ L chain expressing pre-B cells 
would point at an intrinsic defect in λ gene 
rearrangement in Btk-defi cient cells. Such a role 
for Btk in the initiation of λ gene rearrangement 
would, together with the observation of hampered 
in vitro progression of Btk-defi cient pre-B cells 
into surface IgM+ B cells in IL-7–driven bone 
marrow cultures, implicate Btk in pre-BCR 
signaling in the mouse. In this context, impaired L 
chain rearrangement of Btk-defi cient cells would 
be consistent with their selective disadvantage 
at the transition from small pre-B to immature 
B cell, as we previously observed in an in vivo 
competition assay (27). Obviously, in this model 
Btk signaling could mediate developmental 
progression to a stage of B cell development in 
which λ L chain rearrangements are initiated, or 
alternatively Btk signaling could directly control 
the rate or effi ciency of L chain rearrangement. 
The observed increase in coding and signal 
broken DNA ends at multiple gene segments 
in the Ig κ locus across the pro-B to pre-B 
cell transition supported the hypothesis that 
the role of pre-BCR signaling is not limited to 
expanding the population undergoing L chain 
gene rearrangement, but actually increases the 
activity of V(D)J recombination at the Ig κ locus 
(45). During the rounds of DNA replication that 
follow pre-BCR expression, pre-BCR signaling 
could then, e.g., induce alterations of the 
chromatin structure of the L chain loci to provide 
accessibility to the V(D)J recombinase system 
(1, 46). As Btk does not appear to infl uence the 
size of the pre-B cell population or its kinetics of 
turnover in the mouse (20, 26, 27, 43), we would 
propose that Btk is most likely involved in the 
activation of the L chain loci, in particular the 
λ locus, for recombination. In this context, the 
differential effect of Btk signaling on the κ and 
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λ loci would refl ect a different regulation of the 
activation of the two loci for recombination. This 
is to be expected, as the loci become accessible 
for recombination at different stages of B cell 
development, i.e., large cycling pre-B cells for the 
κ locus and small quiescent pre-B cells for the λ 
locus (5). 
A role for Btk in the initiation of λ L chain 
rearrangement rather than receptor editing would 
be supported by the fi nding of increased Ig λ 
usage, when the constitutively activated BtkE41K 
mutant was selectively expressed in early CD43+ 
pro- and large pre-B cells, but not in CD43- small 
pre-B cells (Fig. 6). Normally, both the initiation 
of λ L chain rearrangement and receptor editing 
take place at the small pre-B cell stage (5, 12) 
where the BtkE41K mutant is no longer expressed 
in the λ5-hBtkE41K mice. Therefore, the increased 
Ig λ usage in λ5-hBtkE41K mice may refl ect 
premature initiation of Vλ-Jλ recombination. 
However, as our fi ndings do not provide direct 
evidence for the presence of a Btk-mediated 
signaling pathway controlling the initiation of L 
chain rearrangements, further experiments are 
required to directly demonstrate whether Btk 
signaling activates the λ locus for recombination, 
e.g., by changing its accessibility for the V(D)J 
recombinase. 
In summary, the observed correlation between 
Btk activity and the frequency of λ usage indicates 
a role for Btk-mediated signaling in the activation 
of Ig λ L chain locus for V(D)J recombination. As 
a result, Btk signaling contributes signifi cantly 
to the mechanism that sets the κ/λ isotype ratio 
in the mouse. Although we have shown that 
Btk is not essential for receptor editing in the 
3-83µδ autoreactive model, it remains possible 
that the absence of Btk signaling results in a 
decrease in the extent of L chain replacement 
events, and thereby in decreased λ usage in 
Btk-defi cient B cells. Alternatively, Btk could be 
involved in the activation of the λ L chain locus 
for recombination. A role for Btk in the initiation 
of L chain rearrangements may also explain the 
developmental arrest in those XLA patients with 
normal pre-B cell numbers that nevertheless 
show impaired maturation to surface Ig+ B cells 
(23). 
Acknowledgements
We thank N. Dillon (MRC Clinical Sciences 
Centre, London, UK), D. Nemazee (Scripps 
Research Institute, La Jolla, CA), C. 
Kanellopoulos-Langevin (Institut Jacques 
Monod, Paris, France), L. Braam, D. Drabek, W. 
van Ewijk, J.P. van Hamburg, J. Mahabier, and 
T. de Wit for assistance at various stages of the 
project. 
This work was supported by Netherlands 
Organization for Scientifi c Research grants 901-
07-224 to K. Dahlenborg and A. Maas and 901-
07-209 to S. Middendorp, as well as by the Royal 
Academy of Arts and Sciences to R.W. Hendriks. 
Submitted: 26 January 2001
Revised: 10 April 2001
Accepted: 13 April 2001
References
1. Alt, F.W., Blackwell, T.K., and Yancopoulos, G.D. 
1987. Development of the primary antibody 
repertoire. Science 238:1079-1087.
2. Rajewsky, K. 1996. Clonal selection and learning in 
the antibody system. Nature 381:751-758.
3. Melchers, F., ten Boekel, E., Seidl, T., Kong, X.C., 
Yamagami, T., Onishi, K., Shimizu, T., Rolink, A.G., 
and Andersson, J. 2000. Repertoire selection by pre-
B-cell receptors and B-cell receptors, and genetic 
control of B-cell development from immature to 
mature B cells. Immunol. Rev 175:33-46.
4. Arakawa, H., Shimizu, T., and Takeda, S. 1996. 
Re-evaluation of the probabilities for productive 
arrangements on the κ and λ loci. Int. Immunol 8:
91-99.
5. Engel, H., Rolink, A., and Weiss, S. 1999. B cells are 
programmed to activate κ and λ  or rearrangement at 
consecutive developmental stages. Eur. J. Immunol 
29:2167-2176.
6. Yamagami, T., ten Boekel, E., Andersson, J., Rolink, 
A., and Melchers, F. 1999. Frequencies of multiple 
IgL chain gene rearrangements in single normal or 
κ L chain-defi cient B lineage cells. Immunity 11:317-
327.
7. Rolink, A., Grawunder, U., Haasner, D., Strasser, A., 
and Melchers, F. 1993. Immature surface Ig+ B cells 
can continue to rearrange κ and λ L chain gene loci. 
J. Exp. Med 178:126-127.
8. Grawunder, U., Leu, T.M., Schatz, D.G., Werner, A., 
Rolink, A.G., Melchers, F., and Winkler, T.H. 1995. 
Down-regulation of RAG1 and RAG2 gene expression 
in preB cells after functional immunoglobulin heavy 
chain rearrangement. Immunity 3:601-608.
9. Hertz, M., Kouskoff, V., Nakamura, T., and Nemazee, 
D. 1998. V(D)J recombinase induction in splenic 
B lymphocytes is inhibited by antigen-receptor 
signalling. Nature 394:292-295.
10. Tiegs, S.L., Russell, D.M., and Nemazee, D. 1993. 
Receptor editing in self-reactive bone marrow B cells. 
J. Exp. Med 177:1009-1020.
11. Goodnow, C.C. 1996. Balancing immunity and 
tolerance: deleting and tuning lymphocyte repertoires. 
Proc. Natl. Acad. Sci. USA 93:2264-2271.
12. Casellas, R., Shih, T.A., Kleinewietfeld, M., Rakonjac, 
Btk regulates Ig λ L chain rearrangements
71
J., Nemazee, D., Rajewsky, K., and Nussenzweig, 
M.C. 2001. Contribution of receptor editing to the 
antibody repertoire. Science 291:1541-1544.
13. Yang, W.-C., Colette, Y., Nunes, J.A., and Olive, D. 
2000. Tec kinases: a family with multiple roles in 
immunity. Immunity 12:373-382.
14. Saouaf, S.J., Mahajan, S., Rowley, R.B., Kut, S.A., 
Fargnoli, J., Burkhardt, A.L., Tsukada, S., Witte, 
O.N., and Bolen, J.B. 1994. Temporal differences in 
the activation of three classes of non-transmembrane 
protein tyrosine kinases following B-cell antigen 
receptor surface engagement. Proc. Natl. Acad. Sci. 
USA 91:9524-9528.
15. de Weers, M., Brouns, G.S., Hinshelwood, S., 
Kinnon, C., Schuurman, R.K., Hendriks, R.W., and 
Borst, J. 1994. B-cell antigen receptor stimulation 
activates the human Bruton’s tyrosine kinase, which 
is defi cient in X-linked agammaglobulinemia. J. Biol. 
Chem 269:23857-23860.
16. Aoki, Y., Isselbacher, K.J., and Pillai, S. 1994. Bruton 
tyrosine kinase is tyrosine phosphorylated and 
activated in pre-B lymphocytes and receptor-ligated 
B cells. Proc. Natl. Acad. Sci. USA 91:10606-10609.
17. Rawlings, D.J., Scharenberg, A.M., Park, H., Wahl, 
M.I., Lin, S., Kato, R.M., Fluckiger, A.C., Witte, 
O.N., and Kinet, J.P. 1996. Activation of BTK by a 
phosphorylation mechanism initiated by SRC family 
kinases. Science 271:822-825.
18. Scharenberg, A.M., El-Hillal, O., Fruman, D.A., Beitz, 
L.O., Li, Z., Lin, S., Gout, I., Cantley, L.C., Rawlings, 
D.J., and Kinet, J.P. 1998. Phosphatidylinositol-
3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-
dependent calcium signaling pathway: a target for 
SHIP-mediated inhibitory signals. EMBO J 17:1961-
1972.
19. Kurosaki, T., and Tsukada, S. 2000. BLNK: 
connecting Syk and Btk to calcium signals. Immunity 
12:1-5.
20. Wicker, L.S., and Scher, I. 1986. X-linked immune 
defi ciency (xid) of CBA/N mice. Curr. Top. Microbiol. 
Immunol 124:87-101.
21. Vihinen, M., Kwan, S.P., Lester, T., Ochs, H.D., 
Resnick, I., Valiaho, J., Conley, M.E., and Smith, 
C.I. 1999. Mutations of the human BTK gene 
coding for Bruton tyrosine kinase in X-linked 
agammaglobulinemia. Hum. Mutat 13:280-285.
22. Conley, M.E., and Cooper, M.D. 1998. Genetic basis 
of abnormal B cell development. Curr. Opin. Immunol 
10:399-406.
23. Smith, C.I., Islam, K.B., Vorechovsky, I., Olerup, O., 
Wallin, E., Rabbani, H., Baskin, B., and Hammarstrom, 
L. 1994. X-linked agammaglobulinemia and other 
immunoglobulin defi ciencies. Immunol. Rev 138:
159-183.
24. Conley, M.E. 1985. B cells in patients with X-linked 
agammaglobulinemia. J. Immunol 134:3070-3074.
25. Nomura, K., Kanegane, H., Karasuyama, H., 
Tsukada, S., Agematsu, K., Murakami, G., 
Sakazume, S., Sako, M., Tanaka, R., and Kuniya, 
Y. et al. 2000. Genetic defect in human X-linked 
agammaglobulinemia impedes a maturational 
evolution of pro-B cells into a later stage of pre-B 
cells in the B-cell differentiation pathway. Blood 96:
610-617.
26. Khan, W.N., Alt, F.W., Gerstein, R.M., Malynn, B.A., 
Larsson, I., Rathbun, G., Davidson, L., Muller, S., 
Kantor, A.B., and Herzenberg, L.A. et al. 1995. 
Defective B cell development and function in Btk-
defi cient mice. Immunity 3:283-299.
27. Hendriks, R.W., de Bruijn, M.F., Maas, A., Dingjan, 
G.M., Karis, A., and Grosveld, F. 1996. Inactivation 
of Btk by insertion of lacZ reveals defects in B cell 
development only past the pre-B cell stage. EMBO J 
15:4862-4872.
28. Timmers, E., Hermans, M.M., Kraakman, M.E., 
Hendriks, R.W., and Schuurman, R.K. 1993. Diversity 
of immunoglobulin κ light chain gene rearrangements 
and evidence for somatic mutation in V κ IV family 
gene segments in X-linked agammaglobulinemia. 
Eur. J. Immunol 23:619-624.
29. Burkly, L.C., Zaugg, R., Eisen, H.N., and Wortis, H.H. 
1982. Infl uence of the nude and X-linked immune 
defi ciency genes on expression of κ and λ light 
chains. Eur. J. Immunol 12:1033-1039l.
30. Maas, A., Dingjan, G.M., Grosveld, F., and Hendriks, 
R.W. 1999. Early arrest in B cell development in 
transgenic mice that express the E41K Bruton’s 
tyrosine kinase mutant under the control of the CD19 
promoter region. J. Immunol 162:6526-6533l.
31. Sabbattini, P., Georgiou, A., Sinclair, C., and Dillon, 
N. 1999. Analysis of mice with single and multiple 
copies of transgenes reveals a novel arrangement 
for the λ5-VpreB1 locus control region. Mol. Cell. Biol 
19:671-679.
32. Dingjan, G.M., Maas, A., Nawijn, M.C., Smit, L., 
Voerman, J.S., Grosveld, F., and Hendriks, R.W. 
1998. Severe B cell defi ciency and disrupted splenic 
architecture in transgenic mice expressing the E41K 
mutated form of Bruton’s tyrosine kinase. EMBO J 
17:5309-5320.
33. Strasser, A., Whittingham, S., Vaux, D.L., Bath, 
M.L., Adams, J.M., Cory, S., and Harris, A.W. 1991. 
Enforced BCL2 expression in B-lymphoid cells 
prolongs antibody responses and elicits autoimmune 
disease. Proc. Natl. Acad. Sci. USA 88:8661-8665.
34. Melamed, D., and Nemazee, D. 1997. Self-antigen 
does not accelerate immature B cell apoptosis, but 
stimulates receptor editing as a consequence of 
developmental arrest. Proc. Natl. Acad. Sci. USA 94:
9267-9272.
35. Nemazee, D., and Buerki, K. 1989. Clonal deletion 
of autoreactive B lymphocytes in bone marrow 
chimeras. Proc. Natl. Acad. Sci. USA 86:8039-8043.
36. Rolink, A., Streb, M., and Melchers, F. 1991. The 
κ/λ ratio in surface immunoglobulin molecules on B 
lymphocytes differentiating from DHJH-rearranged 
murine pre-B cell clones in vitro. Eur. J. Immunol 21:
2895-2898.
37. Lang, J., Arnold, B., Hammerling, G., Harris, A.W., 
Korsmeyer, S., Russell, D., Strasser, A., and 
Nemazee, D. 1997. Enforced Bcl-2 expression inhibits 
antigen-mediated clonal elimination of peripheral 
B cells in an antigen dose–dependent manner and 
promotes receptor editing in autoreactive, immature 
Chapter 1.1
72
B cells. J. Exp. Med 186:1513-1522.
38. Li, T., Tsukada, S., Satterthwaite, A., Havlik, M.H., 
Park, H., Takatsu, K., and Witte, O.N. 1995. Activation 
of Bruton’s tyrosine kinase (BTK) by a point mutation 
in its pleckstrin homology (PH) domain. Immunity 2:
451-460.
39. Varnai, P., Rother, K.I., and Balla, T. 1999. 
Phosphatidylinositol 3-kinase-dependent membrane 
association of the Bruton’s tyrosine kinase pleckstrin 
homology domain visualized in single living cells. J. 
Biol. Chem 274:10983-10989.
40. Retter, M.W., and Nemazee, D. 1998. Receptor 
editing occurs frequently during normal B cell 
development. J. Exp. Med 188:1231-1238.
41. Melamed, D., Benschop, R.J., Cambier, J.C., and 
Nemazee, D. 1998. Developmental regulation of B 
lymphocyte immune tolerance compartmentalizes 
clonal selection from receptor selection. Cell 92:173-
182.
42. Woodland, R.T., Schmidt, M.R., Korsmeyer, S.J., and 
Gravel, K.A. 1996. Regulation of B cell survival in xid 
mice by the proto-oncogene bcl-2. J. Immunol 156:
2143-2154.
43. Reid, G.K., and Osmond, D.G. 1985. B lymphocyte 
production in the bone marrow of mice with X-linked 
immunodefi ciency (xid). J. Immunol 135:2299-2302.
44. Pelanda, R., Schaal, S., Torres, R.M., and Rajewsky, 
K. 1996. A prematurely expressed Igκ transgene, but 
not VκJκ gene segment targeted into the Igκ locus, 
can rescue B cell development in λ5-defi cient mice. 
Immunity 5:229-239.
45. Constantinescu, A., and Schlissel, M.S. 1997. 
Changes in locus-specifi c V(D)J recombinase activity 
induced by immunoglobulin gene products during B 
cell development. J. Exp. Med 185:609-620.
46. Stanhope-Baker, P., Hudson, K.M., Shaffer, A.L., 
Constantinescu, A., and Schlissel, M.S. 1996. Cell 
type-specifi c chromatin structure determines the 
targeting of V(D)J recombinase activity in vitro. Cell 
85:887-897.
47. Hardy, R.R., Carmack, C.E., Shinton, S.A., Kemp, 
J.D., and Hayakawa, K. 1991. Resolution and 
characterization of pro-B and pre-pro-B cell stages in 
normal mouse bone marrow. J. Exp. Med 173:1213-
1225.


Evidence for the involvement of Bruton’s tyrosine 
kinase in the regulation of V(D)J recombinase 
activity at the Ig L chain loci
Sabine Middendorp, Stefan A. Muljo, Mark S. Schlissel and Rudolf W. 
Hendriks
Work in progress
Chapter 1.2 
Chapter 1.2
76
Btk regulates recombinase activity at the Ig L chain loci
77
Evidence for the involvement of Bruton’s tyrosine 
kinase in the regulation of V(D)J recombinase activity 
at the Ig L chain loci
Sabine Middendorp*, Stefan A. Muljo#§, Mark S. Schlissel# and Rudolf 
W. Hendriks*
*Department of Immunology, Erasmus MC Rotterdam, P.O. Box 1738, NL-3000 DR Rotterdam, 
The Netherlands. #Division of Immunology, Department of Molecular and Cell Biology, University of 
California, Berkeley, Berkeley, CA 94720, USA. §Current address: The Center for Blood Research, 138 
Warren Alpert Building, 200 Longwood Avenue, Boston, MA 02115, USA.
Abstract 
Bruton’s tyrosine kinase is important for the developmental progression of large cycling 
into small resting pre-B cells, whereby it limits proliferative expansion and regulates the 
modulation of cell surface marker expression. As in Btk-defi cient mice the appearance 
of κ or λ+ immature B cells is delayed and λ usage is reduced, we investigated whether 
Btk signalling is involved in the regulation of V(D)J recombination activity at the L chain 
loci in pre-B cells. We compared the frequency of L chain-specifi c signal broken ends 
(SBE), produced in the process of V(D)J recombination, in Btk+ and Btk- mice. Whereas 
in wild-type mice the frequency of κ SBE was strongly increased in CD2+ pre-B cells, in 
Btk-defi cient mice the κ SBE were equally present in CD2- and CD2+ pre-B cells. This 
pattern is consistent with the previously observed delay in surface CD2 upregulation and 
suggests that in the absence of Btk the V(D)J recombinase activity at the κ locus is slightly 
reduced. In contrast, λ-specifi c SBE were low in all Btk-defi cient (pre-)B cell populations 
analysed. We conclude that Btk is involved in the regulation of L chain locus-specifi c 
V(D)J recombinase activity, particularly in the induction of λ L chain locus in pre-B cells.
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Introduction
The immunoglobulin heavy (H) and light (L) 
chains are assembled from the variable (V), 
diversity (D) and joining (J) gene segments 
through a process called V(D)J recombination 
during the early stages of B cell development 
(1, 2). V(D)J recombination proceeds in a tightly 
regulated and sequential manner, starting with 
DNA rearrangements at the H chain in pro-B cells. 
Productive H chain rearrangement is monitored 
by expression of the pre-BCR complex, which 
consists of the µ H chain and the λ5 and VpreB 
surrogate L chains (SLC) associated with the Ig-
α/Ig-β heterodimer (3, 4). Expression of the pre-
BCR induces allelic exclusion and proliferative 
expansion, which marks the progression of 
pro-B cells into large cycling pre-B cells (5, 6). 
Subsequently, the proliferation stops and the 
cells differentiate into small pre-B cells in which 
Ig L chain rearrangement takes place.  There are 
two isotypes of L chains, κ and λ, and L chain 
rearrangement involves the recombination of 
V and J gene segments.  The κ L chain locus 
contains ~80 functional Vκ gene segments and 
four Jκ elements, while the λ locus consists 
of only three functional Vλ and three Jλ gene 
segments.  Rearrangements of the κ allele are 
thought to occur earlier than λ rearrangements 
based on (a) the earlier appearance of κ+ than 
λ+ immature B cells in kinetic studies using BrdU 
labelling, (b) the observation that Igκ+ cells mostly 
retain their λ locus in germline confi guration and 
Igλ+ cells carry unproductive κ rearrangements or 
have the κ loci deleted (8), and (c) the fi nding that 
germ-line κ transcription precedes germ-line λ 
transcription (9). 
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Primary rearrangements mostly involve Jκ1, 
which is most proximal to the Vκ segments 
(8). However, productive VκJκ rearrangement 
does not inhibit secondary rearrangements at 
the rearranged locus or further rearrangement 
at the unrearranged κ allele. The secondary 
rearrangements, which involve upstream Vκ 
and downstream Jκ gene segments, lead to the 
deletion of previously rearranged VκJκ (10, 11) 
and are thought to play a role in autoantigen-
directed changes in BCR specifi city during 
receptor editing (12-14). 
The timing and effi ciency of rearrangement 
of the Ig loci must be determined by the 
activation of the proteins involved in the V(D)J 
recombination process (15, 16). The pre-BCR 
checkpoint is thought to regulate expression 
of the recombination activating genes RAG-1 
and RAG-2 and opening the L chain loci makes 
them accessible for RAG and transcription 
factors. Germline transcripts of the κ locus are 
fi rst detected in large cycling CD25+ pre-B cells, 
confi rming a role for pre-BCR signalling in the 
opening of the L chain loci for recombination (9, 
17, 18). One of the molecules involved in pre-BCR 
signalling is the Tec family nonreceptor protein 
Bruton’s tyrosine kinase (Btk) (19). 
Mutations in Btk lead to X-linked 
agammaglobulinemia (XLA) in humans and X-
linked immunodefi ciency (xid) in mice (20-23). 
XLA is characterized by an almost complete 
arrest in B cell development at the pre-B cell 
level. (24, 25), resulting in very low peripheral 
B cell numbers and low serum Ig levels of all 
classes (25).  Btk-defi cient mice show an impaired 
transition from pre-B into immature B cells (26) 
and have a more profound defect in the survival of 
peripheral B cells. In Btk-defi cient mice, peripheral 
B cell numbers are reduced by ~50% and IgM and 
IgG3 levels in serum are low (20, 27). 
Interestingly, both in XLA patients and xid mice, 
defi ciency in Btk results in a reduced frequency 
of Ig λ L chain usage already in the immature B 
cells in the BM (22, 28). The decrease in λ usage 
could either result from a defect in receptor editing 
or from a decreased rate or effi ciency of λ L chain 
rearrangement. By crossing 3-83µδ autoantibody 
transgenic mice with Btk- mice, we have shown 
that Btk is not essential for receptor editing. 
Furthermore, BrdU-labelling studies revealed 
a delay of ~3h at the small pre-B cell stage in 
Btk-defi cient mice supporting a role for Btk in the 
regulation of the initiation of L chain rearrangement 
events (29). However, it is unknown whether 
Btk signalling directly regulates the activation 
of L chain loci or whether Btk acts indirectly, 
e.g. by mediating developmental progression 
into the small pre-B cell stage in which L chain 
rearrangement is initiated, by regulating the 
survival of pre-B cells or by regulating the extent 
of receptor editing.
In this study we addressed the question 
whether Btk is involved in the regulation of the 
V(D)J recombinase activity at the Ig L chain 
loci. Therefore, we performed ligation-mediated 
polymerase chain reactions (LM-PCR) to detect 
signal broken ends (SBE) at specifi c Jκ and Jλ 
gene segments that are formed during primary as 
well as secondary rearrangements. 
Materials and Methods
Mice and genotyping. Btk-defi cient mice (26) 
were crossed onto the C57BL/6 background for 
>8 generations. Endogenous Btk WT and Btk 
knockout alleles (30) were identifi ed as described 
previously.
Flow cytometric analysis. Preparations of 
single-cell suspensions, standard and intracellular 
fl ow cytometry and all mAbs used have been 
described previously (26, 28, 29). 
MACS column purifi cation. IL-7 driven BM 
cultures were performed as described before (28, 
29). In short, BM cell suspensions were cultured 
for 5 days in the presence of 100U/ml IL-7 (R&D 
systems) and subsequently recultured for two 
consecutive days without IL-7. Cultured cells 
were harvested and labelled with biotinylated 
Igκ (187.1) and Igλ (R26-46) antibodies (BD 
Phamingen). Incubation with streptavidin-coated 
microbeads (Miltenyi Biotec) enabled separation 
by MACS column purifi cation and purity was 
confi rmed by fl ow cytometry. 
Cell sorting.  BM cell suspensions from 
Btk+ and Btk- mice from 4-5 mice per group 
were pooled and purifi ed for B-lineage cells 
by incubation with anti-B220-coated magnetic 
microbeads and subsequent MACS column 
purifi cation. The B220+ cell fractions were labelled 
with antibodies to CD19, IgM and CD2 and were 
either stored at 4ºC for sorting the next day or the 
labelled cells were fi xed with 0.25% PFA on ice for 
60 min. Fixed cells were then washed and kept 
at 4ºC overnight. The next day, fi xed cells were 
permeabilized twice by incubation at 37ºC for 15 
min with 0.2%Tween-20/PBS and incubated with 
polyclonal µ H antibody in permeabilization buffer. 
Cells were sorted using a FACS Vantage Cell 
Sorter (BD Pharmingen) and purity was confi rmed 
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by fl ow cytometry.
Ligation-mediated PCR. All purifi ed cell 
fractions were snap frozen before DNA isolation by 
use of a mammalian DNA purifi cation kit (Sigma). 
Isolated DNA was precipitated to a concentration 
of 0.2µg/µl and 2µg was linkerligated with a 
BW-1 linker (GCGGTGACCCGGGAGATCTG
AATTC) for >16h at 16ºC using T4 DNA ligase 
(Promega). LM-PCRs were performed by two 
consecutive rounds of PCR, the fi rst containing 
a locus-specifi c outside primer and the second 
a locus-specifi c inside primer. Both rounds of 
PCR contained the linker-specifi c primer BW-H 
(CCGGGAGATCTGAATTCCAC). Second round 
PCR products were run out on a 1.4% agarose gel 
for 90 min at 150V before blotting under alkaline 
conditions to a nitrocellulose membrane. Blots 
were hybridised with γ-AT32P end-labelled locus-
specifi c internal oligonucleotides and analysed 
using a PhosphorImager.
The following primer sets were used for PCR 
and hybridisation: Jκ1: inside κ05 (GCCCAAG
CGCTTCCACGCATGCTTGGAG), outside and 
hybridisation probe κ03 (TCCACGCATGCTT
GGAGAGGGGGTT); Jκ2: outside κ03, inside 
Jκ910F (GGGAATAGGCTAGACATGTTCTC), 
hybridisation probe Jκ1-2 (GTGTCCCTTCAC
TCAACCCCCATAC); Jκ5: outside Jκ1794F 
(ACTTGTGACGTTTTGGTTCTG), inside 
Jκ1847F (GCCATTCCTGGCAACCTGTGCA
TCA) and hybridisation probe Jκ2000F (TAG 
TTGGACTGGCTTCACAGGCA); Jλ2 and 3: 
outside Jλ2-3A (TCAAGTGAGGTCAYAGCT 
CCACCCA), inside Jλ2-3B (ACCCATTGTAGC
TAGCTAGTAGTTTGA) and hybridisation probe 
Jλ2-3C (CAGCTGTGAGAGAACAGGMCCAG). 
For the analysis of secondary rearrangements, 
the fi rst round PCR was performed with the 
outside probe VκS (CCGAATCGSTTCAGTGG
CAGTGGRTCWGGRAC) and the inside probes 
for Jκ2 (Jκ910F), Jκ4 (Jκ1474F: GGTCCCAT
TGTGTCCTTTGTATGAGTTTGTGG) and Jκ5 
(Jκ1847F). The accompanying hybridisation 
probes were Jκ1-2, Jκ1568F (TCTAGCTACT 
GTACAAGCTGAGCAAACAGAC) and Jκ2000F, 
respectively (31-34).  
Linker-ligated DNA samples were amplifi ed with 
specifi c forward (TTACGTCCATCGTGGACAGC) 
and reverse (TGGGCTGGGTGTTAGTCTTA) 
primers for the Myogenin (Myo) gene as a control 
for DNA concentration.  
Results and discussion
LM-PCR assay to analyse L chain specifi c 
SBE.  The initial step in V(D)J recombination 
involves the precise cleavage between a coding 
gene segment and its fl anking RSS (35, 36). The 
level of these broken-ended DNA intermediates, 
which are detected by means of a LM-PCR assay, 
can be used as a measure of V(D)J recombinase 
activity at a specifi c Ig locus (Fig. 1A; (33, 34, 37, 
38)). The LM-PCR technique also allows for the 
detection of secondary rearrangements when 
the V?S outside primer, which is designed to 
recognize any of the Vκ elements used during 
earlier rearrangements, is employed. This Vκ 
element is then in close proximity of the remaining 
Jκ elements and when the RSS of a downstream 
Jκ element is used for secondary rearrangements, 
PCR products are formed (Fig 1B).
Analysis of κ L chain specifi c SBE in cultured 
pre-B cells. The role of Btk in the initiation of L 
chain rearrangement was investigated in IL-7 
driven BM cultures. In these cultures (29, 39), 
pre-B cells that express a productive µ H chain 
undergo rapid proliferation in response to IL-7 and 
after 5 days, the majority of cells are B220+IgM- 
pre-B cells. When cells are subsequently cultured 
without IL-7, they exit the cell cycle, initiate L chain 
rearrangement and further differentiate into Ig+ B 
cells (39). We have previously shown that Btk has 
an inhibitory effect on the proliferation of pre-B 
cells as Btk-defi cient cells manifest increased IL-7 
driven proliferation and reduced progression into 
Ig+ immature B cells (29). 
Total BM cells from Btk+ and Btk- mice were 
cultured for 5 days in the presence of IL-7, 
recultured for 2 subsequent days without IL-7 in 
order to induce L chain rearrangement and IgM/
IgD profi les were determined by fl ow cytometry 
(Fig. 2A). In agreement with previous results (29), 
in both Btk+ and Btk- cultures ~30% expressed 
Igs on their surface, but the expression of IgD 
was signifi cantly reduced in Btk-defi cient cultures 
(12%, compared with 23% in Btk+ cultures). We 
separated Ig- pre-B cells from Ig+ immature B cells 
by MACS sorting, using antibodies specifi c for κ 
and λ L chains (Fig 2A). Equal amounts of DNA 
from the sorted populations (which were >90% 
pure) were subjected to ligation with a double 
stranded BW linker. Linker-ligated DNA was used 
for amplifi cation by PCR using a linker-specifi c 
primer and a pair of nested locus-specifi c primers 
(34). Control amplifi cation of the non-rearranging 
Myogenin (Myo) gene confi rmed that all samples 
contained comparable amounts of amplifi able 
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DNA and thymus (T) DNA was used as a negative 
control. As the detection of signal broken ends 
(SBE) is not strictly quantitative, we used template 
dilution controls, confi rming that the differences in 
the hybridization signals represent the differences 
in the initial frequency of the corresponding signal 
broken ends (34).
As expected, in Btk+ cultures κ L chain-specifi c 
V(D)J recombination activity was present in the 
IgM- pre-B cell fractions, and rearrangement was 
reduced when cells expressed κ or λ L chain as 
indicated by a reduction in the hybridisation signal 
in IgM+ B cells. In contrast, in Btk- cultures V(D)J 
recombination activity appeared to be slightly 
lower in IgM- pre-B cells and slightly higher in IgM+ 
B cells, when compared with the corresponding 
B cell populations in wild-type cultures. These 
results suggest that Btk may play a role both in 
the induction and in the downregulation of the L 
chain rearrangement process.
Analysis of κ L chain specifi c SBE in sorted 
pre-B cell fractions. B220-purifi ed BM cells were 
sorted into three separate fractions using mAbs 
for IgM and CD2. The populations isolated were 
IgM-CD2- pro-and large pre-B cells, IgM-CD2+ 
small pre-B cells and IgM+CD2+ immature B 
cells (Fig 3A). We have previously reported 
that Btk-defi cient pre-B cells are impaired in 
the upregulation of CD2 (29). Therefore, the 
absolute numbers of CD2- pre-B cells in the BM 
is increased, whereas the absolute number of 
CD2+ pre-B cells is decreased. However, the 
total number of large cycling pre-B cells is similar 
in Btk+ and Btk- mice, and they are all part of the 
CD2-cµ+ pre-B cell fraction. This implies that in 
Btk- BM the CD2-cµ+ fraction contains elevated 
numbers of small resting cells that are delayed in 
surface CD2 expression. 
With respect to the initiation of L chain 
rearrangements in Btk-defi cient pre-B cells, two 
possibilities exist. V(D)J recombination activity 
may be induced as soon as Btk-defi cient cells 
progress from large cycling into small resting 
pre-B cells. As a result, the frequency of κ 
locus-specifi c SBE products in CD2- pre-B cells 
would be enhanced in Btk-defi cient mice when 
compared with Btk+ mice. Or alternatively, V(D)J 
recombination activity is induced only when 
the Btk-defi cient cells have progressed to the 
CD2+ stage and in that case, the frequency of 
κ-specifi c SBE would be highest in the CD2+ B 
cell population. 
We found that Btk+ IgM-CD2- pro- and large pre-
B cells contained a low frequency of total κ-specifi c 
SBE, including secondary rearrangements at the 
κ locus (Fig. 3B). As expected, the frequency of 
κ-specifi c SBE was high in IgM-CD2+ small pre-B 
cells and was reduced upon IgM expression in 
Figure 1. Diagram of the LM-PCR assay for the detection of L chain-specifi c signal broken ends (SBE) produced during 
the process of V(D)J recombination. (A) Example of Jκ2-specifi c SBE detection after a primary rearrangement event. 
(B) Example of Jκ2-specifi c SBE detection after a secondary rearrangement event (VκS-Jκ2). The horizontal arrows 
represent the linker-specifi c primer (BW) and the inside and outside primers used, as described in the Materials and 
Methods section.
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Figure 2. Reduced κ L chain specifi c signal broken ends (SBE) in Btk-defi cient pre-B cells. IgM/IgD profi le of IL-7 driven 
BM cultures from Btk+ (A) and Btk- (B) mice. BM  was cultured for 5 days in the presence of IL-7 subsequently recultured 
for 2 days without IL-7 (upper part) and MACS-sorted using Igκ and Igλ antibodies to separate Ig- pre-B cells from Ig+ 
immature B cells (lower part). Sorted fractions were >90% pure. Percentages of cells within the indicated gates are given. 
(C) DNA was isolated from the Ig- and Ig+ cell fractions and ligated with BW-1 linker. Linker-ligated DNA was analysed 
for the frequency of specifi c SBE of the indicated Jκ elements. Secondary rearrangements were analysed by use of a 
Vκ-specifi c inside primer. Template dilution controls (U, 4, 16: undiluted, 4 and 16 times diluted, respectively) confi rmed 
that differences in hybridisation signal refl ected the frequency of the specifi c SBE. DNA from thymus (T) was used as a 
negative control. Data are representative for 3 mice per group. 
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Figure 3. Btk-defi cient mice manifest an altered distribution of κ-specifi c SBE over B cell subpopulations in the BM. 
(A-B) BM cells from 5 Btk+ (A) and 5 Btk- (B) mice were pooled and MACS-sorted for B220+ cells. B220+ cells were 
stained for CD19, IgM and CD2 and sorted for pro- and large pre-B cells (IgM-CD2-), small pre-B cells (IgM-CD2+) and 
immature B cells (IgM+). Sorted fractions were >90% pure. (C) DNA was isolated from the different fractions and ligated 
with the BW-1 linker. Linker-ligated DNA was analysed for the frequency of specifi c SBE involved in the indicated Jκ 
rearrangements. Secondary rearrangements were analysed using a Vκ-specifi c inside primer. Template dilution controls 
(U, 4, 16: undiluted, 4 and 16 times diluted, respectively) confi rmed that differences in hybridisation signal refl ected the 
frequency of the specifi c SBE. DNA from thymus (T) was used as a negative control.
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immature B cells. In contrast, in Btk-defi cient mice 
the frequency of κ-specifi c SBE was only slightly 
higher in IgM-CD2- pre-B cells when compared 
with the IgM-CD2+ pre-B and IgM+ immature B 
cell fractions. 
Taken together, the analyses show that there 
is an apparent difference between Btk+ and 
Btk- mice in the distribution of κ L chain-specifi c 
SBE frequencies over the three cell populations 
analysed. This difference could partly be explained 
by the fact that the CD2- pre-B cell population in 
Btk-defi cient mice contains a high proportion of 
small pre-B cells that have not yet expressed CD2 
on their cell surface. Therefore, we conclude that 
the initiation of Ig κ L chain rearrangement does 
not appear to be delayed in Btk-defi cient mice, but 
is induced as soon as Btk-defi cient cells progress 
from large cycling into small resting cells, 
regardless of their delayed cellular maturation into 
CD2+ pre-B cells. Nevertheless, the hybridisation 
signals for the κ-specifi c SBE in these CD2+ pre-B 
cell fractions are signifi cantly lower in Btk- than in 
Btk+ BM. As in both Btk+ and Btk- mice, the CD2+ 
pre-B cell population consists only of small resting 
pre-B cells, we conclude that Btk is required for 
full V(D)J recombination activity at the κ locus.
Btk is required for V(D)J recombination activity 
at the λ L chain locus. Previous studies revealed 
that the expression of cytoplasmic κ and λ L 
chains was reduced in Btk-defi cient surface IgM- 
pre-B cells, both in vivo and in IL-7 driven BM 
cultures, when compared to Btk+ IgM- pre-B cells 
(28). In these analyses, the frequency of cλ+ cells 
was much more decreased than the frequency 
of cκ+ cells in Btk- pre-B cells. Furthermore, it 
was found that the frequency of λ-expressing 
immature B cells was reduced by ~50% in Btk-
defi cient mice (28). 
To test if Btk signalling infl uences V(D)J 
recombination activity at the λ locus, we studied 
the frequency of λ L chain specifi c SBE in both 
Ig- and Ig+ cells from the IL-7 driven BM cultures 
and the sorted B cell fractions as described 
above. Figure 4A shows the hybridisation signals 
of the SBE specifi c for the Jλ2 and 3 (Jλ2-3) 
gene segments, analysed in two different mice 
per group. Similar to our fi ndings for κ-specifi c 
SBE, we observed a high frequency of λ-specifi c 
SBE in the surface Ig- pre-B cell fraction and a 
low frequency in Ig+ B cells in Btk+ BM cultures 
2 days after IL-7 withdrawal. In strong contrast, 
λ-specifi c SBE were hardly detectable in the Ig- or 
Ig+ fractions of Btk-defi cient cultured BM cells. 
Analysis of the sorted large and small pre-B 
and immature B cell fractions showed that in the 
presence of Btk, recombination activity at the Jλ2-
3 gene segments is high in Btk+ IgM-CD2+ small 
pre-B cells (Fig. 4B). Similar to the distribution 
of κ-specifi c SBE signals over the three cell 
populations analysed, as described above, we 
found that also the frequencies of λ-specifi c SBE 
signal in Btk-defi cient mice were more prominent 
in CD2- pre-B cells and signifi cantly reduced in 
CD2+ pre-B cells, when compared with Btk+ mice. 
Again, both in Btk+ and Btk- BM the CD2+ pre-
B cell fraction contains only small resting pre-B 
cells. Therefore, we conclude that in the absence 
of Btk V(D)J recombination at the λ L chain locus 
is signifi cantly reduced. As we have previously 
shown that the cellular maturation defects 
associated with Btk-defi ciency affects λ+ immature 
B cells to a lesser extent than κ+ immature B cells 
(40), the observed reduction in λ-locus specifi c 
V(D)J recombination activity cannot be explained 
by defective CD2 upregulation.
In summary, these LM-PCR analyses 
demonstrate the presence of κ and λ L chain-
specifi c SBE already in the CD2- pre-B cell 
fractions of Btk-defi cient mice. Assuming that 
these SBE are present in small resting pre-B cells 
that were delayed in surface CD2 expression, 
our fi ndings indicate that the absence of Btk 
does not signifi cantly affect the kinetics of the 
Figure 4. Impaired λ L chain rearrangement in Btk-
defi cient mice (A) Linker-ligated DNA of Ig- and Ig+ cells 
from Btk+ and Btk- BM cultures (as described in Fig. 2) 
were analysed for the frequency of Jλ2 and 3-specifi c 
SBE products (Jλ2-3).  Hybridisation signals for two mice 
per group are shown. (B) Linker-ligated DNA from sorted 
B cell fractions of Btk+ and Btk- mice (as described in 
Fig. 3) were analysed for the frequency of Jλ2-3-specifi c 
SBE products. Thymus (T) DNA was used as a negative 
control. The Myo control amplifi cations are shown in Figs 
2 and 3.
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initiation of L chain rearrangement in vivo. 
However, the observation that the frequencies of 
L chain-specifi c SBE were generally lower in Btk-
defi cient CD2+ small pre-B cells, when compared 
to Btk+ cells CD2+ small pre-B cells, indicates that 
Btk is involved in the regulation of the level of 
V(D)J recombination activity in pre-B cells. We 
therefore propose that Btk signalling regulates 
the accessibility of L chain loci, in particular of the 
λ locus. Further experiments are needed to fi nd 
out if Btk regulates RAG activity and which DNA-
binding factors required for L chain locus opening 
are controlled by Btk-dependent pathways. 
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secondary lymphoid organs. There is a severe 
defi ciency of peripheral B cells, and those B 
cells that are present have an aberrant IgMhigh 
phenotype (10). In the bone marrow (BM) of XLA 
patients, the numbers of cytoplasmic µ H chain 
(cµ)-expressing pre-B cells are variable, but in 
most cases reduced; those pre-B cells present 
are mainly nonproliferating small cells (11-13). 
The absence of Btk apparently results in defi cient 
expansion of the earliest cµ-expressing pre-B 
cells. Therefore, the XLA disease phenotype 
most likely refl ects defective signaling through the 
pre-BCR, by which the expression of a functional 
µ H chain normally is monitored, together with 
surrogate L chain (SLC; Ref. 14). As most 
patients have substantial numbers of pro-B cells 
in their BM, XLA generally results in an increased 
ratio of pro-B to pre-B cells (11-13). 
In contrast, Btk defi ciency in the mouse is 
associated with an impairment of peripheral 
B cell maturation, without a major early B cell 
developmental block (15-17). In xid mice the 
mature IgMlowIgDhigh B cell populations in spleen 
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Abstract
Bruton’s tyrosine kinase (Btk) is a cytoplasmic signaling molecule that is crucial for precursor 
(pre-B) cell differentiation in humans. In this study, we show that during the transition of 
large cycling to small resting pre-B cells in the mouse, Btk-defi cient cells failed to effi ciently 
modulate the expression of CD43, surrogate L chain, CD2, and CD25. In an analysis of 
the kinetics of pre-B cell differentiation in vivo, Btk-defi cient cells manifested a specifi c 
developmental delay within the small pre-B cell compartment of ~3 h, when compared 
with wild-type cells. Likewise, in in vitro bone marrow cultures, Btk-defi cient large cycling 
pre-B cells showed increased IL-7 mediated expansion and reduced developmental 
progression into noncycling CD2+CD25+ surrogate L chain-negative small pre-B cells and 
subsequently into Ig-positive B cells. Furthermore, the absence of Btk resulted in increased 
proliferative responses to IL-7 in recombination-activating gene-1-defi cient pro-B cells. 
These fi ndings identify a novel role for Btk in the regulation of the differentiation stage-
specifi c modulation of IL-7 responsiveness in pro-B and pre-B cells. Moreover, our results 
show that Btk is critical for an effi cient transit through the small pre-B cell compartment, 
thereby regulating cell surface phenotype changes during the developmental 
progression of cytoplasmic µ H chain expressing pre-B cells into immature IgM+ B cells. 
Introduction
Bruton’s tyrosine kinase (Btk) belongs to the Tec 
family of cytoplasmic protein tyrosine kinases 
and plays an essential role in B lymphocyte 
development and function (1, 2). In mature B 
cells, Btk is tyrosine phosphorylated and its 
kinase activity is increased upon B cell receptor 
(BCR) stimulation (3-5). 
Mutations in the Btk gene lead to X-linked 
agammaglobulinaemia (XLA) in humans and 
X-linked immunodefi ciency (xid) in the mouse 
(6-9). XLA is characterized by recurrent bacterial 
infections, and very low serum Ig levels of all 
classes due to the lack of plasma cells in the 
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and lymph nodes are severely reduced, B-1 
B cells are absent, and serum IgM and IgG3 
levels are low. Xid B cells do not proliferate upon 
surface IgM (sIgM) stimulation. The most obvious 
difference between the BM B cell compartment 
of wild-type (WT) mice and Btk-defi cient mice is 
the reduction in mature recirculating cells (15-17). 
The absolute numbers of pre-B cells that are 
generated in the BM of Btk-defi cient mice are 
normal, and Btk-defi cient B cell precursors in the 
BM have the same kinetics of turnover (18, 19). 
Nevertheless, several lines of evidence point at 
a role for Btk at the transition of pre-B cells into 
immature surface Ig+ B cells, thereby indicating 
the involvement of Btk in pre-BCR signaling in 
the mouse. Using an in vivo competition assay 
in heterozygous Btk+/- female mice, we identifi ed 
a small but signifi cant selective disadvantage of 
Btk-defi cient cells to contribute to the IgM+IgD- 
immature B cells stage in the BM (17). Our 
recent fi nding of an intrinsic reduction of Ig λ 
L chain usage in Btk-defi cient B cells in the 
mouse implicated Btk in the activation of gene 
rearrangements at the λ L chain locus (20). 
Furthermore, while mice defi cient for another 
Tec kinase family member, Tec, showed normal 
B cell development, an almost complete block 
at the CD43+B220+ stage of B cell development 
was observed in Btk/Tec double-defi cient mice 
(21). These results indicated that Btk is critically 
involved in pre-BCR-mediated signaling in the 
mouse and that Tec is able to compensate for 
the loss of Btk during early B cell development. 
A role for Btk in pre-BCR signaling would be 
consistent with the recent fi nding that Btk is able 
to function in CD79b (Ig-β)-mediated signaling in 
recombination-activating gene (RAG)-2-defi cient 
pro-B cells (22). 
To examine the role of Btk at the pre-BCR 
checkpoint in vivo, we compared the expression 
of early B cell surface markers in the BM from 
Btk-defi cient and WT control mice. In this report, 
we show that Btk is involved in the pre-BCR-
dependent induction of cell surface phenotype 
changes during the progression of large cycling 
cµ+ pre-B cells into surface Ig+ immature B 
cells, thereby affecting the transit time through 
the small pre-B cell compartment. In addition, 
we performed IL-7-driven BM cultures, which 
point at a role for Btk in the differentiation stage-
specifi c modulation of IL-7 responsiveness in 
early murine B cell development, even in stages 
preceding cµ expression. 
Materials and Methods
Mice and genotyping. Btk-/lacZ mice (17) 
were crossed onto a C57BL/6 background for 
>6 generations. Specifi c experiments were 
additionally performed with Btk mice on a mixed 
C57BL/6 x 129 or C57BL/6 x FVB background, 
but no signifi cant infl uence of the genetic 
background was observed. RAG-1-/- mice (23) 
were on a 129/Sv background. All mice were 
bred and maintained in the animal care facility 
at the Erasmus Medical Center, Rotterdam 
(Rotterdam, The Netherlands). To determine 
the Btk genotype, tail DNA was analyzed by 
Southern blotting of BamHI digests, as described 
(17). The RAG-1 genotype was determined using 
a 1.9-kb partial RAG-1 probe (encoding amino 
acid positions 387-1008, kindly provided by D. 
van Gent, Erasmus Medical Center) to hybridize 
to BamHI-NcoI genomic digests (23). 
Flow cytometric analysis. Preparations 
of single-cell suspensions, fl ow cytometry, 
and determination of β-galactosidase activity 
by loading cells with fl uorescein-di-β-D-
galactopyranoside substrate (Molecular Probes 
Europe, Leiden, The Netherlands), have 
previously been described (17, 24). Events 
(1-3 x 105) were scored using a FACSCalibur 
fl ow cytometer and analyzed by CellQuest 
software (BD Biosciences, Mountain View, CA). 
The following mAbs were obtained from BD 
PharMingen (San Diego, CA): FITC-conjugated 
anti-BP-1/6C3, anti-B220/RA3-6B2, anti-κ (R5-
240), and anti-IgM (II/41); PE-conjugated anti-
CD2, anti-κ (187.1), anti-CD25, and anti-CD43; 
CyChrome-conjugated anti-B220/RA3-6B2 and 
biotinylated anti-IL7R, anti-κ?(187.1), anti-λ1/λ2(R26-46), and anti-IgM (II/41). PE-conjugated 
IgD was obtained from Southern Biotechnology 
Associates (Birmingham, AL). Biotinylated anti-
SLC Ab LM34 (25) was kindly provided by A. 
Rolink (Basel Institute for Immunology, Basel, 
Switzerland). Secondary Abs were PE-, tricolor-
, or APC-conjugated streptavidin, purchased 
from Caltag Laboratories (Burlingame, CA).  
For intracellular fl ow cytometric detection of 
cytoplasmic Ig H or L chain or SLC, the following 
Abs were applied: FITC-conjugated anti-Igκ (R5-
240, BD PharMingen) or polyclonal anti-Ig µ H 
chain (Jackson Immunoresearch Laboratories, 
West Grove, PA) and biotinylated anti-λ1/λ2 (BD 
PharMingen), or anti-SLC (LM34). Cells were fi rst 
stained for cell surface markers and subsequently 
fi xed in 2% paraformaldehyde and permeabilized 
using 0.5% saponin. 
Pre-B cell defects in Btk-defi cient mice
93
Cell cycle analysis.  To analyze cell cycle status 
of cultured cell suspensions, cells were incubated 
in ice-cold ethanol for >2 h. Subsequently, cells 
were incubated at room temperature for 30 min 
in PBS containing 0.02 mg/ml propidium iodide, 
0.1% v/v Triton X-100, and 0.2 mg/ml RNase, 
left overnight at 4°C, and analyzed with a 
FACSCalibur fl ow cytometer. Doublet cells were 
excluded from the analysis by measuring peak 
area and width. For simultaneous analysis of cell 
surface markers, cµ expression, and DNA content, 
we used a method described by Constantinescu 
and Schlissel (26). Cells were sequentially 
stained for surface CD2 expression using PE-
labeled anti-CD2, for cµ using polyclonal anti-µ 
H chain, and 7-aminoactinomycin-D (7-AAD, 
Molecular Probes Europe). 
IL-7-driven BM cultures. Primary pre-B 
cell cultures were essentially performed as 
described previously (20), using erythrocyte-
depleted total BM cell suspensions. For specifi c 
experiments, BM cell suspensions were depleted 
of sIgM+ cells, using biotinylated anti-IgM and 
streptavidin-coated microbeads, as described 
(20). Recombinant murine IL-7 was from R&D 
Systems (Minneapolis, MN). To measure IL-7-
dependent proliferative responses, cells were 
cultured in fl at-bottom 96-well plates for 5 
days with various amounts of IL-7 at different 
cell concentrations (0.25–1 x 105 cells/well). 
Cultures were pulsed for 24 h with 0.5 µCi/well 
of [3H]thymidine, harvested on glass-fi ber 
fi lters, and the incorporated radioactivity was 
determined using a beta counter, according to 
standard procedures. 
In vivo 5-bromo-2’-deoxyuridine (BrdU) 
labeling.  BrdU (Sigma Aldrich, St. Louis, 
MO) was dissolved in PBS at 2 mg/ml. Mice 
were injected i.p. with 200 µl, and sacrifi ced at 
various time points. Total BM cell suspensions 
were analyzed by fl ow cytometry for BrdU 
incorporation, using the BrdU fl ow kit (BD 
PharMingen) in conjunction with cell surface 
marker expression. 
Results
Btk-cµ+ pre-B cells show a defective surface 
marker expression profi le. To investigate the 
involvement of Btk in pre-BCR signaling, we 
compared the pre-B cell compartment in the BM 
of Btk+ and Btk- mice. Consistent with published 
fi ndings (16, 17, 21), we did not observe a major 
early B cell developmental block in Btk- mice, but 
only a small increase in the fraction of CD43+ cells 
within the population of sIgM-B220+ pro-/pre-B 
cells: ~20–25% in Btk+ and ~50–55% in Btk- mice 
(Fig. 1A). 
About one-fi fth of all pre-B cells have been 
reported to express µ H chain and L chains in 
their cytoplasm, without depositing IgM on the 
cell surface (27). These cells may have down-
regulated sIgM expression due to autoantigen 
binding, or they may produce Ig H and L chains 
that do not pair (14, 27). As previously described 
(20), surface Ig- B cell precursors of Btk- mice 
showed reduced expression of cytoplasmic L 
chain. Surface Ig- B cells (16 ± 3%) expressed κ 
L chain in the cytoplasm, compared with 23 ± 2% 
in Btk+ mice, while the frequency of cytoplasmic 
λ expression pre-B cells was reduced by a factor 
~3 (Fig. 1B). These fi ndings suggest reduced or 
delayed Ig L chain rearrangement. 
Signaling through the pre-BCR initiates 
proliferative expansion of those cells with 
a productively rearranged Ig H chain. 
Subsequently, these cells progress into small 
resting pre-B cells that have changed their cell 
surface phenotype and initiate κ and λ L chain 
rearrangement (14). Therefore, we analyzed 
IgM-B220+ B cell precursors for the expression 
of several cell surface markers in four-color fl ow 
cytometric experiments (Fig. 1C). In Btk- mice, 
the IgM-B220+ compartment contained a unique 
subpopulation of CD43low cells which manifested 
increased expression of the BP-1 molecule, 
a metallopeptidase that is selectively induced 
coincident with IL-7-driven pre-B cell proliferation 
(28). As soon as a pre-BCR is expressed, the 
synthesis of SLC is turned off (29). However, Btk- 
cells had an increase in the fraction of IgM-B220+ 
cells that expressed SLC in their cytoplasm, as 
compared with Btk+ cells (Fig. 1C). In a specifi c 
analysis of cµ+ pre-B cells, Btk- mice showed 
signifi cantly reduced expression of the IL-2R 
CD25 (30 ± 6%), and the CD2 adhesion molecule 
(32 ± 4%), as compared with Btk+ mice (66 ± 7% 
and 70 ± 6%, respectively). These molecules 
were previously reported to be upregulated upon 
pre-BCR signaling (30, 31). 
Collectively, these fi ndings indicated that 
the absence of Btk resulted in a defective 
progression of SLC+CD43+CD2-CD25- into SLC-
CD43-CD2+CD25+cµ+ pre-B cells. Analysis of 
the absolute numbers of the various B-lineage 
subpopulations in the BM (Table I) revealed 
that in Btk- mice the size of the total population 
of CD2- cµ+ early pre-B cells was increased with 
a factor of ~2.4, whereas the total population of 
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CD2+ cµ+ late pre-B cells was decreased with a 
similar factor. 
The developmental progression to CD2+ late 
pre-B cells normally correlates with a change 
in cell cycle status, from large cycling into small 
resting pre-B cells (26). This was confi rmed by 
the fi nding in Btk+ mice of ~45% of CD2- and 
~10% of CD2+cµ+ pre-B cells in S, M, or G2 phase, 
using 7-AAD staining for DNA content (Fig. 1C). 
In contrast, the CD2-cµ+ pre-B cell population in 
Btk- mice contained only ~23% of cycling cells, 
i.e., about half the number found in Btk+ mice. 
However, as the size of the total population of 
CD2-cµ+ pre-B cells was increased with a factor 
~2.4 in Btk- mice, we conclude that Btk+ and 
Btk- mice contain comparable numbers of large 
cycling cµ+ cells (~0.8 x 106 cells per hind leg). 
In summary, the absence of Btk in pre-BCR 
signaling resulted in defective down-regulation 
of CD43 and SLC, defective up-regulation of 
CD2 and CD25, augmented expression of BP-1, 
whereas in vivo proliferative expansion of pre-B 
cells appeared to be unaffected. 
Figure 1. Characterization of the pre-B cell compartment in Btk+ and Btk- mice. A, BM cell suspensions were stained 
with mAbs to B220, CD43, and IgM. The expression profi les of B220 and sIgM are shown (top). sIgM- cells were 
analyzed for B220 and CD43 (bottom). Percentages of CD43+ cells within the indicated B220+ gate are given. B, 
BM cell suspensions were stained with mAbs to detect surface expression of IgM, IgD, B220, and cytoplasmic (c) 
expression of κ or λ L chain. The percentages of cκ+ and cλ+ cells within the IgM-IgD- B220+ subpopulation are given. 
C, Four-color fl ow cytometric analyses of BM cell suspensions, using mAbs to B220 and IgM, together with various 
additional mAbs. B220+IgM- pro-B/pre-B cells were electronically gated and analyzed for the indicated markers. Cell 
cycle status was determined in cµ+CD2+ and cµ+CD2- cells, using 7-AAD. The percentages of cycling cells (S, M, or G2 
phase) are indicated. Data shown are representative of three to eight mice examined.
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Btk- cells show a developmental delay within 
the small pre-B cell compartment in vivo. The 
ineffi cient induction of cell surface phenotype 
changes in Btk- mice at the pre-B cell stage 
was still noticeable at the next developmental 
stage of IgM+ immature B cells. As shown by 
fl ow cytometric analysis (Fig. 2A), IgM+B220low 
immature B cells in Btk- mice manifested lower 
expression of CD2 (66 ± 5%, n = 9) and CD25 (19 
± 1%, n = 12), compared with immature B cells in 
Btk+ animals (CD2+: 90 ± 3%, n = 8, and CD25+: 
36 ± 1%, n = 12). In addition, considerable 
fractions of Btk- immature B cells expressed 
surface BP-1 (45 ± 3%, n = 6) or cytoplasmic SLC 
(13 ± 3%, n = 8), which were not detected in Btk+ 
immature B cells (<3%; Fig. 2A). 
To investigate whether the ineffi cient induction 
of cell surface phenotype changes in Btk- pre-B 
and immature B cells would be associated with 
a delayed developmental progression into IgM+ 
immature B cells, we estimated the transit time 
through the small pre-B cell compartment. Btk+ 
and Btk- mice were injected with a single dose of 
the BrdU thymidine analog, which is specifi cally 
incorporated into the DNA of large cycling pre-
B cells (32-34). BM cells were stained with an 
anti-BrdU Ab, in conjunction with cell surface 
analysis for B220, IgD, and κ or λ L chain, 
and analyzed by fl ow cytometry. Twelve hours 
after injection, ~30–35% of Ig- B cell precursors 
incorporated BrdU, both in Btk+ and Btk- mice. 
At various time points after BrdU injection, we 
analyzed BrdU incorporation within κ+ and λ+ 
IgD- immature B cells. As shown for the 48-h 
time point in Fig. 2B, the fractions of BrdU+ cells 
within the surface κ+ or λ+ immature B cells were 
decreased in Btk- mice when compared with 
Btk+ mice. As small pre-B cells are noncycling 
cells, the fi rst appearance of BrdU+ cells within the 
surface Ig+ immature B cells refl ects the minimum 
transit time through the small pre-B compartment. 
When for κ+ immature B cells, the data from six 
time points were subjected to linear regression 
analysis (33), it was found that BrdU+κ+ immature 
B cells emerged ~8 h after BrdU injection in Btk+ 
mice and only after ~11 h in Btk- mice (Fig. 2C). 
In agreement with reported experiments (33, 
34), BrdU+λ+ immature B cells only emerged 
~30 h after BrdU injection. Likewise, linear 
regression analysis revealed a delay of ~3.5 h 
for Btk-defi cient λ+ immature B cells (~32.5 h), as 
compared with Btk+ cells (~29 h). 
In summary, we conclude that in Btk- mice the 
ineffi cient induction of cell surface phenotype 
changes in µ+ pre-B cells was accompanied by 
a specifi c developmental delay within the small 
pre-B cell compartment of ~3 h. In addition, the 
immature B cells generated manifest an aberrant 
Figure 2. Absence of Btk results in delayed 
developmental progression into immature B cells. A, 
Expression of CD2, CD25, cytoplasmic SLC (cSLC), 
and BP-1 on B220lowIgM+ cells in BM of Btk+ (thin lines) 
and Btk- mice (bold lines). For cSLC analysis, histogram 
overlays of gated B220- cells are shown as negative 
control stainings (dotted lines). The percentages of 
positive cells are indicated above the marker line 
(Btk+) and below the marker line in bold (Btk-). B, BrdU 
incorporation 48 h after BrdU injection in Btk+ and Btk- 
mice. BM cells were stained for surface expression 
of B220, IgD, and κ or λ, in conjunction with BrdU. 
Histograms show BrdU staining in B220+IgD- immature 
B cells, with the percentages of BrdU+ cells. C, Linear 
regression analysis of the appearance of BrdU+ κ+ and 
λ+ immature B cells over time in Btk+ (open symbols) and 
Btk- mice (fi lled symbols). Each point represents BrdU 
staining of B220+IgD-κ+/λ+ BM cells from three to six 
mice per group (except for Btk- mice, 30 h: n = 2). Entry 
points and slope values were 8 h and 1.3 (κ, Btk+), 11 h 
and 1.2 (κ, Btk-), 29 h and 1.7 (λ, Btk+), and 32.5 h and 
1.3 (λ, Btk-), respectively. As evaluated by Student’s t 
test, the fractions of BrdU+ cells were signifi cantly lower 
in κ+ Btk- cells as compared with Btk+ cells, with p values 
of <0.01 (12, 16, and 40 h), <0.02 (48 h), and 0.05 (21 
h). For the 30-h time point, the number of measurements 
was insuffi cient for a statistical evaluation. For λ+ B cells, 
the p values ranged from <0.0001 to <0.01 for the four 
time points shown.
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surface phenotype. 
Btk- pre-B cells show defi cient developmental 
progression in vitro. To further investigate the 
role of Btk in the developmental progression of 
cµ+ pre-B cells and the initiation of Ig L chain 
expression, IL-7-driven BM culture experiments 
were performed, as described (35, 36). Pre-B cells 
that have a productive Ig H chain rearrangement 
undergo rapid cell division in response to IL-
7. When IgM- BM cell suspensions from Btk+ 
mice were cultured in the presence of 100 U/ml 
IL-7 for 5 days, the majority of cells consisted 
of B220+IgM- cells, while a signifi cant fraction 
matured to sIgM+IgD- (~10%) or IgM+IgD+ B cell 
stages (~5%) (Fig. 3). This differentiation into 
IgM+ cells did not result from an IL-7 insuffi ciency 
in culture, as it was also present when higher IL-7 
concentrations were used. In contrast, only <5% 
and <0.5% of the Btk- cells exhibited an IgM+IgD- 
or IgM+IgD+ profi le in culture, respectively. 
Therefore, these fi ndings indicated that Btk 
signaling supported the progression from pre-B 
cell to surface Ig+ B cell in vitro in the presence 
of IL-7. Similar differences were observed, when 
cells were subsequently cultured for 48 h on S17 
stroma cells in the presence of IL-7: ~30% of 
Btk+B220+ cells were surface Ig+, but only ~5% 
of Btk-B220+ cells (Fig. 3). After removal of IL-7, 
which strongly induces the cells to exit from cell 
cycle and to further differentiate (36), signifi cant 
numbers of sIgM+ B cells were generated in the 
Btk- BM cultures. Nevertheless, when compared 
with Btk+ B cells, the maturation of Btk- B cells 
to the IgM+IgD+ stage was reduced (Fig. 3). 
Therefore, the analyses of IL-7-driven BM 
cultures showed that Btk signaling promotes the 
maturation of pre-B cells into surface Ig+ B cells in 
the presence of IL-7 in vitro. 
Btk- pre-B cells show enhanced IL-7-driven 
expansion in vitro. Next, we analyzed the kinetics 
of in vitro B cell development in IL-7-driven BM 
cultures, using total BM cells from Btk+, Btk-, and 
Btk+/- mice, without S17 stroma. Similar results 
were obtained in IL-7-driven BM cultures in the 
presence of S17 stromal cells, either throughout 
the 7-day culture period or from day 5 onwards 
(data not shown). 
In these experiments, we used biotinylated 
Abs to detect sIgM expression, which resulted 
in higher fl uorescence intensity values (up to 
2 x 103), as compared with the experiments 
described in Fig. 3 (up to 5 x 102). We observed 
that most Btk-B220+ cells stained with the anti-µ 
H chain Ab after culture with IL-7 (fl uorescence 
intensities ranging from 20 to 100; Fig. 4A). These 
cells were cµ positive, surface, or cytoplasmic κ 
or λ negative, and expressed SLC both in their 
cytoplasma and on the cell surface (see Results; 
Fig. 5). Therefore, we concluded that these cells 
Table 1. B-lineage subpopulations in Btk+ and Btk- mice. 
a Absolute number of cells (mean ± SD x 106) per hind leg
Figure 3. Developmental progression of Btk+ and Btk- 
cells in IL-7-driven BM cultures. BM cells were cultured 
in the presence of IL-7 for 5 days and subsequently 
analyzed (“0 h”) or recultured on S17 stroma cells in 
the presence or absence of IL-7 for 48 h. Cultured cells 
were stained for B220, IgM, and IgD. B220+ cells were 
gated and analyzed for the expression of IgM and IgD. 
Data shown are representative of 10 mice examined in 
each group.
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were pre-B cells, and that the anti-µ H chain Ab 
staining in Btk- cells refl ected high surface pre-
BCR expression. In contrast, the Btk+ cells with 
anti-IgM fl uorescence intensities ranging from 
20 to 100 were surface κ+ cytoplasmic SLC- 
immature B cells (see Results; Fig. 5). 
When compared with Btk+ cultures, Btk- and 
Btk+/- cultures were characterized by a more rapid 
loss of mature surface Ig+ cells (Fig. 4A, day 3), 
and a reduced appearance of newly formed Ig+ 
B cells (Fig. 4A, days 5 and 7). From the total 
cell counts and the fl ow cytometric analyses 
of the cells, the expansion rates of sIgM- and 
sIgM+B220+ cells during culture were calculated. 
As shown in Fig. 4B, pre-B cell expansion was 
signifi cantly higher in the cultures from Btk- mice 
(~30x) when compared with Btk+ mice (<10x). 
Only for Btk+ BM cells, the further differentiation 
of pre-B cells generated in the cultures in the 
presence of IL-7 resulted in an expansion of 
mature sIgM+ B cells (~4x). 
Increased proliferation of Btk- cells was 
confi rmed by analysis of cell cycle and cell size 
(Fig. 4C). After 5 days of culture, 53 ± 3% of the 
Btk- cells (n = 6) and only 25 ± 3% of the Btk+ 
(n = 6) were in the S, M, or G2 phase of the 
cell cycle. In these experiments, the Btk- BM 
cultures contained higher proportions (77 ± 6%) 
of large cells with high forward scatter (FSC) 
values than the Btk+ BM cultures (42 ± 7%). To 
Figure 4. Analysis of IL-7-driven BM cultures from Btk+, Btk-, and Btk+/- heterozygous female mice. A, IgM/IgD 
expression profi le of B220+ cells in uncultured BM samples, as well as after the indicated days of culture in the 
presence of IL-7. The gates for the pre-B cells (sIgM-/low), immature B cells (IgM+IgD-), and mature B cells (IgD+) are 
indicated, as well as the percentages of cells within the B cell gates. Note that the pre-B vs immature B gate settings 
for Btk+ and Btk- mice at days 3, 5, and 7 are almost one log different, as they are based on differential expression of 
κ, λ, and SLC in parallel stainings (see Results). Dot plots are representative of 8–11 mice per group. B, Expansion of 
IgM- pre-B cells and IgM+ B cells during culture with IL-7. The four bars per group indicate the expansion at days 3, 5, 
and 7, as compared with the IgM- and IgM+ (pre-)B cell numbers at the start of the culture, which were set to one. The 
plot is representative of six experiments using 2–4 mice per group. Error bars are the SD from three mice within every 
group. C, Cell cycle status and cell size after 5 days of culture with IL-7 from Btk+, Btk-, and Btk+/- mice. DNA content 
of total cultured cells was examined by propidium iodide staining. The percentages of cycling cells (S, M, or G2 phase) 
are indicated. Cell size was examined in B220+IgM-IgD- pre-B cells. Numbers indicate the percentage of cells with a 
FSC value >600. Histograms are representative of fi ve to six mice per group. D, Proliferative responses to the indicated 
concentrations of IL-7, as determined by [3H]thymidine incorporation after 5 days of culture. Error bars are the SD from 
three mice within every group. The plot is representative of three experiments.
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further quantify cell proliferation in the presence 
of various concentrations of IL-7, we performed 
[3H]thymidine incorporation experiments. After 5 
days of culture, Btk- cells showed signifi cantly 
higher proliferative responses to IL-7 when 
compared with Btk+ cells (Fig. 4D). These fi ndings 
in Btk+ and Btk- BM cultures demonstrated that 
in the absence of Btk, IL-7-driven pre-B cell 
proliferation in vitro is increased. 
Enhanced IL-7-driven expansion and 
decreased developmental progression is intrinsic 
to Btk- pre-B cells.  The observed differences 
in IL-7-driven proliferation between Btk+ and 
Btk- pre-B cells cannot easily be explained by 
increased surface expression of IL-7R on these 
cells in Btk- mice. In fl ow cytometric experiments, 
the proportions of IL-7Rα chain positive cells 
within the large pre-B cell population in Btk+ and 
Btk- mice were 77 ± 4% and 87 ± 2%, respectively, 
while the mean fl uorescence intensities of IL-
7Rα+ cells were comparable. 
To answer the question of whether the 
phenotype of Btk- cells in IL-7-driven BM 
cultures is an intrinsic feature of Btk- pre-B 
cells, or alternatively, originates from a defective 
BM microenvironment in Btk- mice, we also 
investigated BM cultures from Btk+/- mice. Due 
to random X chromosome inactivation, the pre-B 
cell compartment in these mice consists of two 
functionally different populations, i.e., Btk+ and 
Btk- (17, 37, 38). In Btk+/- heterozygous mice, IL-
7-driven pre-B cell proliferation was intermediate 
between Btk+ and Btk- mice, as measured by 
pre-B cell expansion, cell cycle status, and 
[3H]thymidine incorporation (Fig. 4, B–D). At days 
5 and 7, the surface Ig expression profi les and 
the FSC values in Btk+/- cultures were similar to 
those of Btk- cells (Fig. 4, A and C), indicating 
a proliferative advantage of Btk- over Btk+ cells. 
The presence of a lacZ reporter in the Btk- allele 
enabled a separate evaluation of the expansion 
of Btk+/lacZ- and Btk-/lacZ+ cells in Btk+/- cultures. 
At days 5 and 7, the proportions of lacZ+ cells 
in Btk+/- and Btk- cultures were comparable, 
indicating an intrinsic selective advantage of 
Btk-defi cient cells in culture. In these cultures, the 
majority of IgM+ cells were Btk+/lacZ-. Thus, the 
increased expansion and reduced differentiation 
in IL-7-driven pre-B cell cultures is an intrinsic 
feature of Btk- cells, which is independent of the 
Figure 5. Phenotypic characterization of IL-7-driven BM 
cultures from Btk+ and Btk- mice. The expression profi les 
of the indicated surface and intracellular markers are 
displayed as histogram overlays of Btk+ (thin lines) and 
Btk- mice (bold lines). The histogram plots of the fi rst 
column (the large sIgM- cells) include the background 
stainings of B220- (S17 stromal) cells, as negative 
controls (dotted lines). This is not shown for CD43, 
as the B220- fraction in the cultures expressed CD43. 
Large and small IgM- cells were gated on the basis of 
FSC characteristics. Results shown are representative 
of 2–6 mice per group.
Figure 6. Btk affects IL-7 responsiveness in pro-B cells. 
A, Proliferative responses of Btk+ and Btk- RAG-1-/- B 
cell precursors to IL-7, as determined by [3H]thymidine 
incorporation after 7 days of culture. B, BP-1 expression 
profi les are displayed as histograms for B220+ cells, 
either uncultured or after 5 days of culture in the 
presence of IL-7, from Btk+ (thin lines) and Btk- (bold 
lines) RAG-1-/- BM. Data are representative of four 
experiments using two mice per group.
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xid BM microenvironment in vivo, or coculture of 
Btk-defi cient stromal cells in the BM cultures. 
Aberrant phenotype of Btk- cells in IL-7-driven 
BM cultures.  Next, we investigated whether the 
ineffi cient pre-BCR-mediated induction of cell 
phenotype changes in Btk- pre-B and immature 
B cells in vivo were paralleled in the BM cultures 
in vitro. Large and small IgM- cells were obtained 
from total BM cultures in the presence of IL-7 
for 7 days. Small IgM+ cells were obtained from 
total BM cell suspensions that were cultured in 
the presence of IL-7 for 5 days and subsequently 
in the absence of IL-7 on S17 stromal cells for 
2 days. In agreement with our fi ndings in vivo 
(Fig. 1), we found by fl ow cytometric analysis 
that in Btk- cultures down-regulation of CD43 
and up-regulation of CD2 and CD25 at the 
large to small pre-B cell transition was impaired 
(Fig. 5). The expression of BP-1 was elevated 
in all three stages analyzed. Most importantly, 
we noticed that in the absence of Btk, SLC 
synthesis is not effi ciently turned off, resulting in 
signifi cantly enhanced cytoplasmic and surface 
SLC expression in Btk- large pre-B cells (96 ± 1% 
and 29 ± 2%, n = 3, respectively), compared with 
67 ± 5% and 2.9 ± 0.9% (n = 3) in Btk+ cells. Also 
in small pre-B cells, cytoplasmic SLC expression 
was enhanced in Btk- cultures (62 ± 5%), 
compared with Btk+ cultures (17 ± 3%; Fig. 5). A 
small but reproducible increase in the expression 
level of cµ was present in Btk-defi cient large and 
small pre-B cells. In addition, signifi cant fractions 
of cytoplasmic κ L chain-positive pre-B cells were 
only present in Btk+ cultures (~20% of small sIgM- 
pre-B cells, compared with <2% in Btk-defi cient 
pre-B cells). 
Taken together, these fi ndings in IL-7-driven 
BM cultures confi rm the involvement of Btk 
signaling in the pre-BCR-mediated down-
regulation of CD43 and SLC and the induction of 
CD2 and CD25 expression, and the initiation of Ig 
L chain rearrangements. 
Btk- pro-B cells show signifi cantly increased 
IL-7-driven proliferation in vitro.  To investigate 
whether Btk-dependent modulation of IL-7 
responsiveness in the mouse is specifi c for the 
pre-B cell stage, or alternatively, also occurs 
in earlier stages of B cell development, we 
crossed the Btk-defi cient mice onto a RAG-1-/- 
background. In these mice, B cell development is 
arrested at the CD43+ pro-B cell stage, in which 
the BCR-linked CD79a/CD79b heterodimers are 
expressed on the cell surface without associated 
µ H chains (39). Btk+ and Btk-RAG-1-/- mice 
contained similar numbers of CD43+B220+ pro-B 
cells in vivo (data not shown), but the expression 
of IL-7R was slightly different (~62% in Btk+ and 
~79% in Btk-RAG-1-/- mice). In [3H]thymidine 
incorporation experiments, IL-7-induced 
proliferation was signifi cantly enhanced in Btk-
RAG-1-/- pro-B cells, when compared with control 
Btk+RAG-1-/- pro-B cells (Fig. 6A). Whereas we 
did not detect signifi cant differences between the 
two groups of mice in the in vivo expression of 
the BP-1, the expression was elevated in the Btk-
RAG-1-/-BM cultures (Fig. 6B). Collectively, these 
results indicate that Btk-signaling can modulate 
the responsiveness to IL-7 of early B cell 
precursors, even before pre-BCR expression. 
Discussion 
Btk and pre-BCR signaling.   Signaling through 
the pre-BCR complex mediates the checkpoint 
function of µ H chain by inducing cell cycle entry 
and rapid down-regulation of the rearrangement 
machinery, thereby ensuring allelic exclusion (14, 
29). Subsequently, the proliferating pre-B cells 
exit the cell cycle, change the expression profi le 
of various cell surface markers, and perform Ig L 
chain rearrangements with sequential activation 
of the κ and the λ loci (14). In humans, mutations 
in the Btk gene result in XLA, which refl ects an 
almost complete block in B cell development 
at the pre-B cell stage (12, 13, 40). Similar to 
fi ndings in mice defi cient for the SLC component 
λ5 or the membrane form of the Ig µ H chain (41, 
42), most XLA patients lack the compartment of 
large cycling pre-B cells (13). Therefore, the XLA 
disease phenotype implicates Btk in the pre-BCR 
signaling-mediated expansion of those pre-B 
cells with a productive µ H chain rearrangement 
in humans. 
In contrast, Btk is not essential for the 
selective expansion of cµ+ pre-B cells in the 
mouse, as in Btk-defi cient mice the pre-B cell 
population is normal in size and contains normal 
proportions of cycling cells (16-19). In this report, 
we demonstrate that the mouse Btk is involved 
in later phases of pre-B cell differentiation. We 
compared the pre-B cell compartment in Btk+ 
mice and Btk- mice both in vivo and in vitro in 
IL-7-driven BM cultures. The absence of Btk 
resulted in (a) defective down-regulation of CD43 
and SLC expression, (b) impaired up-regulation 
of CD2 and CD25, (c) aberrant expression of 
BP-1, (d) a 3-h delay in B cell development in 
vivo at the small pre-B cell stage and reduced 
progression to surface Ig+ B cells in vitro, and (e) 
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a signifi cant increase in IL-7-driven proliferative 
expansion of pro-B and pre-B cells in vitro. 
Because Btk has been reported to be in the pre-
BCR signaling pathway in the mouse (5, 22), 
our fi ndings implicate pre-BCR signaling in the 
control of CD2, CD25, CD43, BP-1, and SLC 
expression, IL-7 responsiveness, and the transit 
time through the small pre-B cell stage. 
As pre-B cell production in Btk- mice is normal, 
we conclude that the ineffi cient down-regulation 
of BP-1, CD43, and SLC expression and up-
regulation of CD2 and CD25 do not affect the 
proliferative capacities of pre-B cells in vivo. 
Nevertheless, Btk- large pre-B cells manifested 
increased proliferative expansion in vitro, 
when compared with Btk+ cells. The fi nding of 
signifi cantly increased surface SLC expression 
on these Btk- large pre-B cells (when compared 
with Btk+ cells) would support the hypothesis by 
Melchers et al. (14) that large cµ+ pre-B cells stop 
cycling when they run out of a suffi cient number 
of assembled pre-BCR molecules per cell. This 
is not necessarily in confl ict with our fi nding that 
the increased cytoplasmic SLC expression in Btk- 
pre-B cells did not result in increased proliferation 
in vivo. It is very possible that only the level of 
membrane SLC expression may correlate with 
the proliferative capacity of pre-B cells, and we 
were unable to detect differences between Btk+ 
and Btk- large pre-B cells in vivo in membrane 
SLC expression levels. 
Btk and L chain rearrangement. We have 
previously found that Btk- mice show reduced 
λ L chain usage, which could either result from 
a defect in receptor editing or alternatively from 
a decreased rate or effi ciency of λ L chain 
rearrangement (20). Although by crossing 
3-83µδ autoantibody transgenic mice into Btk- 
mice we have shown that Btk is not essential 
for receptor editing (20), a possibility remained 
that the extent of L chain replacement events is 
reduced in Btk- mice. However, our BrdU-labeling 
experiments, in which we identifi ed a 3-h delay 
at the small pre-B cell stage in Btk- mice, clearly 
argue against this possibility. Reduction of the 
level of receptor editing in Btk- mice would have 
the opposite effect of a more rapid transit through 
the small pre-B cell compartment, as B cells 
targeted for receptor editing were recently shown 
to be specifi cally delayed in this compartment for 
at least 2 h (33). Therefore, the fi nding of a 3-h 
delay supports a role for Btk in the regulation of 
the initiation of L chain rearrangement events. As 
both κ+ and λ+ Btk- cells are equally delayed, this 
cannot explain the observed reduced λ usage in 
Btk- mice (20). However, we conclude that the 
absence of Btk specifi cally affects the production 
rate of λ+ immature B cells, as our linear 
regression analysis (Fig. 2C) revealed a lower 
slope value for λ+ cells in Btk- mice (1.3) than in 
Btk+ mice (1.7), while the values for κ+ cells were 
similar (1.2 and 1.3). 
In this context, it is unknown whether Btk 
signaling directly or indirectly regulates the 
activation of the L chain loci, or alternatively, 
whether Btk acts by mediating developmental 
progression to a pre-B cell stage in which L chain 
rearrangements are initiated. The latter possibility 
would be consistent with the delayed modulation 
of the expression of SLC, BP-1, CD43, CD2, 
and CD25. The fi nding that the expression of 
germline κ transcripts is fi rst detected in vivo 
in large cycling CD25+ pre-B cells would be 
consistent with a role for pre-BCR signaling the 
opening of the L chain loci for rearrangement 
(29, 43). However, additional experiments would 
be needed to address this issue, as it has been 
shown that productive L chain rearrangement can 
also be induced by IL-7 withdrawal of pre-BCR-
defi cient λ5-/- or JH-/- pre-B cells in vitro (14, 44). 
The size of the immature B cell pool and the 
turnover of immature B cells were reported to be 
essentially normal in xid or Btk- mice (16-18, 45). 
Nevertheless, we previously observed a selective 
disadvantage of Btk- cells at the transition from 
pre-B cells to immature B cells in the BM, which 
we determined in an in vivo competition analysis 
in Btk+/- heterozygous female mice (17). In the 
immature B cell subset, we found lacZ expression 
values of ~30%, whereas in the absence of a 
competitive disadvantage, Btk-/lacZ+ cells would 
be expected to represent ~50% of any B cell 
subpopulation. The fi nding of a 3-h delay in 
production of immature B cells in Btk- mice would 
explain the observed selective disadvantage of 
Btk-defi cient cells in Btk+/- female mice. 
Btk and IL-7 responsiveness. An inhibitory 
effect of Btk on proliferation of B-lineage cells 
in long-term Whitlock-Witte BM cultures has 
previously been reported (46). However, analysis 
of growth kinetics of cultures established from 
mixtures of WT and xid cells indicated that the 
observed differences resulted from changes in 
the BM microenvironment associated with the xid 
mutation. In contrast, our separate analyses of 
lacZ+ and lacZ- cells in the BM cultures from Btk+/- 
mice showed that increased IL-7 responsiveness 
is an intrinsic feature of Btk- pre-B cells. This 
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would be consistent with the fi nding of an 
increased frequency of CFU responsive to IL-7 
by limiting dilution analysis of day 15 fetal liver 
cells from CBA/N xid mice (47). 
Finally, crosses of Btk-defi cient and RAG-
1-defi cient mice showed that IL-7-dependent 
expansion in vitro is constrained by an inhibitory 
signal mediated by Btk, even before the 
expression of µ H chain. Cross-linking of the Igβ 
signaling component of the (pre-)BCR, which is 
expressed on the cell surface in cµ- pro-B cells 
in association with calnexin induced a rapid 
phosphorylation of several intracellular signaling 
molecules, including Btk (22, 48). Therefore, it is 
possible that Btk-mediated Igβ/calnexin signaling 
would serve to stop pro-B cell proliferation 
to facilitate V(D)J recombination, which is 
exclusively initiated in the G0/G1 cell cycle 
phase (49). This hypothesis may be supported 
by a signifi cant reduction of the level of VH to 
DJH rearrangements observed in Igβ-defi cient 
mice (50), which would then be explained by a 
reduced signal to make pro-B cells competent 
to undergo VH-DJH rearrangement (48). In this 
context, it has been shown previously that in later 
stages of B cell development, modulation of the 
IL-7 responsiveness is dependent on pre-BCR 
and BCR signaling (51, 52). However, it is very 
possible that in pro-B cells, Btk may function in 
a pathway that is unrelated to the Igβ/calnexin 
complex, as Btk has been implicated in signaling 
of various other receptors, including IL-5R, CD38, 
IL-10R, and FcεRI (1, 2). 
Taken together, our fi ndings implicate 
Btk in two different pathways in early B cell 
development. First, Btk is required for the effi cient 
developmental progression of cytoplasmic µ+ pre-
B cells, as Btk was shown to be involved in BP-1, 
CD43, and SLC down-regulation, CD2 and CD25 
up-regulation, and the rate of transit through 
the small pre-B cell compartment. Additional 
experiments are required to show whether Btk-
mediated pre-BCR signaling directly or indirectly 
infl uences the expression of SLC, germline κ, or 
λ transcripts or the RAG genes. Second, the IL-7-
driven BM culture experiments indicate a role for 
Btk as a pro- and pre-BCR associated negative 
regulator of IL-7 expansion. Although XLA 
patients may occasionally have a signifi cantly 
increased pro-B cell compartment (12, 53), in 
general there is no absolute pro-B expansion 
in XLA. Obviously, both in the mouse and in 
humans, other signaling molecules or pathways 
must be able to compensate for the loss of Btk in 
pro-B cells in vivo. 
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transducer of signals originating from the pre-B 
cell receptor (pre-BCR) and the BCR. 
The pre-BCR complex, which is comprised 
of µ H chain, the nonrearranging VpreB and λ5 
surrogate L chain (SLC) proteins, and the Ig-
α/CD79a and Ig-β/CD79b signaling components, 
is a key checkpoint in B cell development to 
monitor the expression of a functional Ig µ H 
chain (3, 4). Pre-BCR expression is essential 
for the proliferative expansion of cytoplasmic µ 
H chain-positive pre-B cells and the induction 
of progression into small pre-B cells in which Ig 
L chain rearrangement occurs (3, 4). Pre-BCR 
engagement leads to the formation of a lipid raft-
associated calcium signaling module composed 
of the tyrosine-phosphorylated signaling 
molecules Lyn, Syk, B cell linker protein (BLNK)/
Introduction
Bruton’s tyrosine kinase (Btk) is a member of the 
Tec family of cytoplasmic protein tyrosine kinases 
(PTK) and plays an essential role in B lymphocyte 
development and function (1, 2). Together with 
two other types of nonreceptor PTK, Syk and the 
Src family member Lyn, Btk acts as an important 
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SLP-65, phosphoinositide 3-kinase, Btk, Vav, and 
phospholipase Cγ2 (PLC-γ2) (5). 
The importance of Btk in pre-BCR checkpoint 
function in humans is evidenced by an almost 
complete arrest of B cell differentiation 
due to defective expansion of the earliest 
cytoplasmic µ H chain-positive pre-B cells in 
X-linked agammaglobulinemia (XLA) patients 
with mutations in the Btk gene (6, 7). XLA is 
characterized by an almost complete absence of 
peripheral B cells and plasma cells; serum levels 
of all Ig classes are very low. In contrast, mice 
with a targeted mutation in the Btk gene or CBA/N 
mice, which carry an R28C point mutation in the 
Btk pleckstrin homology (PH) domain, exhibit a 
milder disorder, x-linked immunodefi ciency (xid), 
mainly refl ecting poor survival of peripheral B 
cells (8-10). Btk-defi cient mice manifest a specifi c 
arrest of peripheral B cell development within 
the immature B cell pool at the progression of 
IgMhigh to IgMlow AA4+CD23+ transitional B cells 
(8-12). In these mice, the numbers of pre-B cells 
that are generated in the bone marrow (BM) are 
normal (8, 9, 13). Nevertheless, Btk is crucially 
involved in the regulation of the developmental 
progression of pre-B cells by limiting the IL-7-
driven expansion of large cycling pre-B cells (14, 
15). In in vitro BM cultures, Btk-defi cient pre-B 
cells showed increased IL-7-driven expansion 
and reduced developmental progression of 
large cycling into small resting pre-B cells and 
subsequently into Ig+ B cells (14). In addition, 
we recently demonstrated that Btk cooperates 
with the BLNK/SLP adapter molecule as a tumor 
suppressor that limits pre-B cell expansion (15). 
During the transition of large cycling to small 
resting cytoplasmic µ+ pre-B cells in the mouse, 
Btk-defi cient cells fail to effi ciently modulate the 
expression of SLC, the metallopeptidase BP-1, 
the adhesion molecule CD2, the IL-2R CD25, and 
the membrane sialoglycoprotein CD43 (14). Btk-
defi cient cells manifest a specifi c developmental 
delay within the small pre-B cell compartment 
of ~3 h in vivo. The fi nding of reduced λ L chain 
usage in Btk-defi cient mice implicates Btk in the 
regulation of the activation of the λ locus for V(D)J 
recombination in pre-B cells (16). 
Btk contains fi ve distinct domains: an N-
terminal PH domain, a Tec homology (TH) 
domain, a Src homology 3 (SH3) domain, 
an SH2 domain, and a C-terminal catalytic 
domain (Fig. 1A). Upon BCR stimulation, Btk 
activation is initiated by targeting the kinase to 
the plasma membrane through interactions of 
its PH domain with phosphatidylinositol-3,4,5-
trisphosphate, a second messenger generated 
by phosphoinositide 3-kinase (17, 18). In concert, 
the Lyn and Syk kinases are activated, resulting 
in transphorylation of Btk at position Y551, 
which promotes the catalytic activity of Btk and 
subsequently results in its autophosphorylation 
at position Y223 in the SH3 domain (Fig. 1A) 
(19, 20). Although Y223 phosphorylation has 
little discernible infl uence on Btk catalytic activity, 
it prevents binding to Wiskott Aldrich syndrome 
protein (WASP) and increases the affi nity to Syk 
(21). Concomitantly, Syk activation results in 
phosphorylation of BLNK/SLP65, which allows 
for the association of this adapter molecule with 
the Btk SH2 domain and with PLC-γ2 (2, 22). 
These interactions are critical to the activity of 
Btk and result in PLC-γ tyrosine phosphorylation, 
inositol trisphosphate production, and calcium 
mobilization. 
Although biochemical studies in cultured B 
cells and fi broblasts have provided important 
insights into the molecular mechanism of BCR-
mediated Btk activation, these systems have 
not allowed for the investigation of the role 
of the individual Btk domains in (pre-) BCR 
checkpoint functions in vivo. In this study, we 
addressed the functional signifi cance of Btk 
Y223 autophosphorylation and investigated 
whether Btk can also act as an adapter molecule, 
independent of its catalytic activity. Therefore, we 
generated transgenic mouse strains that express 
the autophosphorylation site mutant Y223F-Btk 
and K430R kinase-inactive Btk, under the control 
of the B cell-specifi c CD19 promoter region. We 
crossed these mice onto a Btk null background 
(10), and examined the in vivo effects of the 
Y223F and K430R mutations, in particular with 
respect to Ig λ L chain usage, pre-B cell surface 
marker modulation, and the proliferative response 
of pre-B cells to IL-7. 
Materials and Methods
Generation of Btk-transgenic mice.  Wild-type 
(WT)-Btk transgenic mice have been described 
previously (23). The human Btk transgenes 
consist of a ~6.3-kb genomic fragment containing 
the CD19 promoter region, a 0.3-kb fragment 
with the fi rst three exons of human Btk as 
cDNA sequence, as well as a 27.1-kb genomic 
DNA fragment, encompassing the Btk exons 
3–19 (23). Using double-stranded site-directed 
mutagenesis (Stratagene, La Jolla, CA), the 
Y223F and K430R mutations were introduced 
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into the constructs that were previously used to 
generate the WT-Btk mice (23). 
The Y223F mutation was created by 
replacement of AT by TC in exon 8 of human Btk 
in a 2.8-kb Cfr10I-Asp718 fragment (containing 
exons 8–11) in pBlueScript, using a mutation 
primer (5’-GCTGAAAAAGGTTGTGGCCCT
TTTCGATTACATG CCAATG-3’) and a 39-bp 
KpnI-BglII selection primer. The mutated Cfr10I-
Asp718 fragment was subsequently cloned into 
the WT-Btk transgene construct. The A-to-G 
replacement mutation K430R in exon 14 was 
created in a 2.1-kb Asp718-MunI fragment 
encompassing human Btk exon 12–14. A 40-bp 
mutation primer, 5’-CCAGTAGGACGTGGCCA
TCAGGATGATCAAAGAAGGCTCC-3’ and the 
39-bp KpnI-BglII selection primer was used. 
The mutated 2.1-kb Asp718-MunI fragment was 
ligated to a 9.2-kb MunI-Asp718 fragment, to 
yield a 11.3-kb Asp718 human Btk fragment, 
which was used to replace the 11.3-kb Asp718 
fragment in the WT-Btk construct (23). 
The ~34-kb MluI-NotI inserts from the Y223F-
Btk and K430R-Btk constructs were excised from 
the vector, gel purifi ed, and microinjected into the 
pronuclei of FVB-fertilized oocytes. Transgenic 
founder mice were identifi ed by Southern blotting 
and crossed with Btk null mice (10), which were 
bred onto a C57BL/6 background for more 
than eight generations. Sequence fi delity of 
the mutated fragments was confi rmed, both in 
plasmid DNA before subsequent cloning steps 
and in genomic DNA obtained from the F1 
transgenic mice generated. All mice were bred 
and maintained at the Erasmus MC animal care 
facility under specifi c pathogen-free conditions. 
Mouse genotyping.  Tail DNA was analyzed 
by Southern blotting of BamHI digests using a 
partial human Btk cDNA probe (bp 133-1153), 
as described previously (10, 23). Alternatively, 
the presence of Btk transgenes was evaluated 
by PCR, using the following primers: CD19prom, 
5’-TGCAATTAGTGGTGAACAAC-3’, and 
hmBtk.65R, 5’-AGATGCC AGGACTTGGAAGG-
3’. Endogenous mouse Btk WT alleles 
were identifi ed by an exon 9 forward primer 
( 5 ’ - C A C T G A A G C T G A G G A C T C C ATA G -
3’) and an exon 10 reverse primer (5’-
GAGTCATGTGCTTGGAATACCAC-3’). For Btk 
knockout alleles, primers were within the LacZ 
reporter (10): forward, 5’-TTCACTGGCCGT 
CGTTTTACAACGTCGTGA-3’, and reverse, 5’-
ATGTGAGCGAGTAACAACCC GTCGGATTCT-
3’. 
Flow cytometric analyses. Preparations 
of single-cell suspensions, standard and 
intracellular fl ow cytometry, and conjugated 
mAbs (BD PharMingen, Sunnyvale, CA) have 
been described previously (10, 14). The anti-SLC 
hybridoma LM34 (24) was kindly provided by A. 
Rolink (Basel, Switzerland); Abs were purifi ed 
using protein G columns and conjugated to biotin 
according to standard procedures. Mice were 
analyzed at the age of 8–16 wk. Transgenic Btk 
expression levels were quantifi ed by intracellular 
fl ow cytometry, using affi nity-purifi ed polyclonal 
rabbit anti-Btk (BD PharMingen) and FITC-
conjugated goat anti-rabbit Ig (Nordic, Capistrano 
Beach, CA). Median fl uorescence intensity (MFI) 
values were obtained by CellQuest software (BD 
Biosciences, San Diego, CA), whereby values for 
transgenic human Btk and endogenous murine 
Btk were corrected for background fl uorescence, 
as detected in Btk null mutant mice. Subsequently, 
the ratio of the MFI values of transgenic Btk over 
endogenous Btk was calculated. 
In vitro (pre-) B cell cultures.  IL-7-driven BM 
cultures and determination of IL-7-dependent 
proliferative responses of total BM cells have 
been described previously (14, 16). Mature B 
cell fractions were purifi ed from spleen, using 
standard NH4Cl lysis to deplete erythrocytes, 
followed by complement-mediated T cell lysis, 
as described previously (25). The enriched B cell 
fractions were cultured in vitro in the presence or 
absence of LPS, 5 µg/ml anti-CD40, or polyclonal 
goat anti-mouse IgM (Southern Biotechnology 
Associates, Birmingham, AL), as described 
previously (16). To measure DNA synthesis, 
cells were pulsed with [3H]thymidine for 16–20 
h, harvested, and counted using standard 
methods. For apoptosis assays, DNA content 
was determined in ethanol-fi xed cells, using 
propidium iodide. 
B cell stimulation and Western blotting 
analyses. For analyses of nuclear c-Rel 
expression, single-cell suspensions from spleen 
were depleted of erythrocytes by NH4Cl lysis and 
enriched for B cells by AutoMACS purifi cation, 
using biotinylated Abs to Gr-1, Ter119, CD4, 
CD8, and CD11b and magnetic streptavidin 
MicroBeads (Miltenyi Biotec, Sunnyvale, CA) 
for negative selection. Cells were stimulated 
with 10 µg/ml F(ab’)2 of polyclonal goat anti-
mouse IgM (Jackson ImmunoResearch, West 
Grove, PA) in RPMI 1640 at 37°C for 4 h. Total 
nuclear and cytoplasmic protein extracts were 
prepared according to Andrews and Faller (26). 
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strains, expressing Y223F (n = 5) and K430R (n = 
2) mutant Btk. These mice were crossed onto the 
Btk null background, and transgenic Btk protein 
expression was quantifi ed by intracellular fl ow 
cytometry. Median fl uorescence intensities of 
transgenic Btk were compared with endogenous 
Btk in B-lineage subpopulations (Fig. 1B; Table 
I). The different mouse lines exhibited a wide 
range of Btk protein expression levels, which 
were directly correlated with the transgene 
copy number, as estimated by Southern blotting 
analyses of genomic DNA samples from the 
mice. The expression of transgenic Btk increased 
as the B cell progenitors in the BM matured to 
surface Ig-expressing peripheral B cells (Table 
I). Expression of transgenic Btk protein was 
confi rmed by Western blotting analysis of BM and 
spleen cell suspensions, in which Btk protein was 
visible as a single ~77-kDa band for all transgenic 
Figure 1. Expression of Btk mutant transgenes during 
B cell development. A, Domains of Btk. The positions of 
the mutations and Btk-associated molecules are shown. 
The numbers represent the amino acid positions of the 
domain boundaries. B, Intracellular Btk expression in the 
indicated B-lineage subpopulations in BM and spleen. 
B220+ cells were gated and B-lineage subpopulations 
were defi ned on the basis of surface IgM/IgD expression 
(left) and analyzed for intracellular Btk expression (right). 
The results are displayed as histograms of a wild-type 
mouse (Btk+; thin lines) and a Y223F-Btk mutant 
transgenic mouse (AM-02; bold lines), compared with 
the background staining, as determined in Btk- mice 
(dashed lines). The values for the differences in MFI 
(∆MFI) are given. MZ = marginal zone.
Samples from equivalent cell numbers were 
resolved by SDS-PAGE, and proteins were 
transferred to nitrocellulose membrane, as 
described (10). Membranes were blocked with 
5% milk in TBS/0.05% Tween 20 for 1 h and 
incubated overnight with anti c-Rel (SC-071; 
Santa Cruz Biotechnology, Santa Cruz, CA), and 
subsequently with HRP-conjugated swine anti-
rabbit Ig. Densitometry analysis was conducted 
using ImageQuant analysis software (Molecular 
Dynamics, Sunnyvale, CA). 
For analyses of Bcl-xL and cyclin D2 induction, 
total splenocytes were depleted of erythrocytes 
and stimulated with 10 µg/ml polyclonal goat anti-
mouse IgM (Southern Biotechnology Associates) 
in RPMI 1640/10% FCS at 37°C. Total cell 
lysates were subjected to SDS-PAGE using 
standard procedures (27). Immunoblotting Abs 
used included: anti-Bcl-xL (2762; Cell Signaling 
Technology, Beverly, MA), anti-cyclin D2 (M-20; 
SC-593; Santa Cruz Biotechnology), and anti-
extracellular signal-regulated kinase 1/2 (SC-
094; Santa Cruz Biotechnology). 
For analysis of Btk expression and Btk in 
vitro kinase assays, single-cell suspensions 
from spleen were depleted of erythrocytes 
and enriched for B cells by AutoMACS 
purifi cation. B cell fractions were stimulated, 
as described above, for 5 and 10 min. Anti-Btk 
C-20 (Santa Cruz Biotechnology) was used for 
immunoblotting, while a polyclonal rabbot anti-Btk 
(kindly provided by V. Tybulewicz, London, U.K.) 
was used for immunoprecipitation. In vitro kinase 
assays were performed, as described previously 
(27). 
Ig detection and in vivo immunizations.  Levels 
of Ig subclasses in serum were measured by 
sandwich ELISA, as described previously (25). 
To measure thymus-independent responses, 
mice were injected i.p. with 50 µg of trinitrophenol 
(TNP)-Ficoll in PBS, and TNP-specifi c IgM and 
IgG3 were analyzed at day 7 in a TNP-specifi c 
ELISA (28). 
Results
Expression of Btk mutants in transgenic mice. 
We have previously described transgenic mice 
that express WT human Btk under the control of 
the CD19 promoter region (23). When these mice 
were mated onto a Btk-defi cient background, 
correction of all xid features was observed, 
indicating that in this system the Btk gene was 
appropriately targeted to both conventional 
and CD5+ B-1 cells. We now generated mouse 
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lines generated (data not shown). Because we 
aimed to investigate the role of Btk in particular 
at the pre-B cell to immature B cell progression, 
we mainly focused on those mouse strains that 
expressed physiological levels of transgenic Btk 
(1–2 x endogenous levels) in immature B cells in 
the BM. These transgenic lines, AM-02 (Y223F) 
and XK-24 (K430R), expressed high Btk levels in 
mature IgD+ peripheral B cells (Table I). 
B cell development in Btk mutant mice. To 
determine the effect of the Btk mutations on B 
cell development, we examined the size of the 
B cell subpopulations in spleen, peritoneal cavity, 
and BM in the mutant mice by fl ow cytometry. 
In these experiments, we also included WT-Btk 
transgenic mice, as well as nontransgenic Btk+ 
and Btk- littermates, which served as controls. 
The xid phenotype in Btk- mice is characterized 
by a specifi c defi ciency of mature IgMlowIgDhigh 
cells in the spleen and lack of CD5+ B-1 cells in 
the peritoneal cavity (8-10) (see Fig. 2, A and B). 
The only obvious difference between the BM B 
cell subpopulations of Btk-defi cient and control 
Btk+ mice is that the subpopulation of mature 
B220high-recirculating cells is reduced and has 
an aberrant IgMhigh phenotype (Fig. 2C). We 
previously reported (23) that CD19 promoter-
driven human WT-Btk expression restores 
these defects. We did not detect a signifi cant 
effect of the Y223 autophosphorylation site 
mutation, as also the expression of Y223F-Btk 
appeared to restore B cell numbers completely in 
spleen, peritoneal cavity, and BM (Fig. 2, A–C). 
Expression of low levels of Y223F-Btk (line AM-
05) (<20% of normal in immature B cells, not 
detectable with our fl ow cytometric assay) on 
the Btk null background rescued the presence of 
peritoneal CD5+ B-1 cells, but not the numbers or 
surface profi le of splenic B cells (data not shown). 
Considerable overexpression of Y223F-Btk (line 
UK-21, ~14x in immature B cells) was associated 
with deletion of IgMhigh immature B cells in the BM 
(data not shown), similar to our previous fi ndings 
in transgenic mice expressing the constitutive 
active Btk-mutant E41K (23). Interestingly, 
reconstitution with kinase-inactive K430R-Btk 
partially overcame the block in peripheral B cell 
maturation, when signifi cantly overexpressed. In 
these mice, the fraction of mature IgMlowIgDhigh B 
cells in the spleen was partially restored (~16%, 
compared with ~7% in Btk- mice and 30% in WT 
transgenic mice, Fig. 2A), and B220highIgMlow-
recirculating cells appeared in the BM (Fig. 
2C). However, we still did not detect CD5+ B-1 
Table I. Overview of transgenic lines expressing mutant 
Btk
a As determined by intracellular fl ow cytometry. The median fl uorescence 
intensities in the different B-lineage cell fractions of wild-type mice were set to 
1.0.  b These mice were described previously (23).
Figure 2. Flow cytometric analysis of B cell populations 
in Btk mutant mice. A, Surface IgM/IgD expression in the 
spleen with total splenic B cell numbers as mean values ± 
SEM. B, Surface CD19/CD5 expression in the peritoneal 
cavity. C, Surface IgM/B220 expression in the BM. Total 
lymphocytes were gated on the basis of forward and 
side scatter characteristics. Data are displayed as dot 
plots, and the percentages of cells within the indicated 
gates are given. Data shown are representative of 5–20 
animals examined within each group.
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cells in the peritoneum (Fig. 2B). When present 
on the Btk+ background, overexpression of 
K430R-Btk did not appear to result in adverse 
effects on B cell development (data not shown), 
indicating that in this respect the K430R-Btk 
did not act as a dominant-negative mutant. 
Collectively, these fi ndings show that expression 
of Y223F-Btk restored B cell development, 
indicating that Y223 autophosphorylation is not 
essential for the function of Btk signaling in 
directing B cell development. The limited, but 
detectable, correction of the xid phenotype in 
K430R transgenic mice indicates that Btk function 
is partly independent of its intrinsic enzymatic 
activity. Finally, the analyses showed that B-1 
B cell development is supported by low levels of 
Y223F-Btk, but not by kinase-inactive Btk. 
Ig λ L chain usage in Btk mutant mice. We 
previously showed that B cells from Btk-defi cient 
mice have a ~50% reduction in the frequency of 
Ig λ L chain expression, already at the immature 
B cell stage in the bone marrow (16). This fi nding 
implicated Btk in the regulation of the activation 
of the λ locus for V(D)J recombination in pre-B 
cells (16). 
To investigate the effects of the Y223F and 
K430R mutations on the ability of Btk to regulate 
λ usage, we analyzed immature B220lowIgM+IgD- 
B cells from the BM of a panel of Btk+, Btk-, 
and transgenic Btk mutant mice by four-color 
fl ow cytometry (Table II). Consistent with our 
previous report (16), we found reduced λ usage 
in Btk- mice, when compared with Btk+ or WT-
Btk transgenic mice (Table II). In Y223F-Btk 
mice, λ usage was still signifi cantly reduced, 
when compared with Btk+ mice (Table II) or with 
WT-Btk transgenic mice, which showed normal 
proportions of λ+ B cells (16). Thus, transgenic 
expression of physiological levels of Y223F-Btk 
could only partially correct λ usage in Btk- mice. 
Unexpectedly, expression of K430R-Btk fully 
reconstituted λ usage, as in K430R-Btk mice the 
proportions of λ L chain-expressing cells were 
similar to those in control Btk+ mice. 
In summary, these fi ndings indicate the 
differential requirement for Btk domains in 
the regulation of λ L chain usage: the Y223 
autophosphorylation site is important, but 
kinase activity does not appear to be critical. 
We conclude that in the context of the control of 
λ usage in early B cell development, Btk mainly 
functions as an adapter molecule, independent of 
its enzymatic activity. 
Pre-B cell maturation in Btk mutant mice. We 
previously showed that during the developmental 
progression of large cycling into small resting 
cytoplasmic µ+ pre-B cells, Btk-defi cient cells 
fail to effi ciently down-regulate the expression of 
BP-1 and SLC and up-regulate the expression of 
surface CD2 and CD25/IL-2R (14). To investigate 
the requirement for the different Btk domains in 
the modulation of these phenotypic markers, we 
analyzed their expression profi le in pre-B cells 
and immature B cells from Btk mutant mice by 
fl ow cytometry. 
As shown in Fig. 3A, Btk-defi cient pre-B cells 
have signifi cantly higher levels of cytoplasmic 
SLC and BP-1, but lower expression levels of 
CD2 and CD25. This aberrant marker profi le was 
fully corrected in transgenic mice expressing WT 
or Y223F Btk (Fig. 3A). By contrast, expression of 
K430R-Btk only partially restored Btk function in 
pre-B cell differentiation, as the expression levels 
of BP-1, cSLC, CD2, and CD25 in pre-B cells 
were intermediate between the values for Btk+ 
and Btk- mice (Fig. 3, A and B). Also, at the next 
developmental stage of immature B cells, the 
expression profi les of the BP-1, cSLC, CD2, and 
CD25 markers were fully corrected in WT and 
Y223F Btk mice and partially corrected in K430R-
Btk mice (data not shown, and Fig. 3C). 
In summary, these fi ndings demonstrate that 
the function of Btk in vivo in the induction of cell 
surface phenotype changes in cytoplasmic µ+ 
pre-B and immature B cells is not affected by loss 
of the Y223 autophosphorylation site and is only 
partially dependent on its kinase activity. 
Proliferative responses to IL-7 in Btk mutant 
mice.  Btk has an inhibitory effect on the 
proliferation of B cell precursors in long-term 
Whitlock-Witte BM cultures and in IL-7-driven 
cultures of BM or fetal liver cells (14, 29, 30). 
In [3H]thymidine incorporation experiments, 
after 5 days of culture in the presence of IL-7, 
Btk-defi cient total BM cells showed signifi cantly 
higher proliferative responses when compared 
with Btk+ cells (Fig. 4A). Expression of WT or 
Y223F Btk exhibited a similar inhibitory effect 
Table II. Ig λ L chain usage in Btk mutant mice  
a Number of mice per group 
b Values of p for difference with the group of Btk+ mice
c Mean values  ± SEM
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on IL-7-driven proliferation as intact endogenous 
Btk. Proliferative responses to IL-7 in K430R 
mutant mice were only slightly higher than those 
found in Btk+ mice. Therefore, we conclude that 
the function of Btk in down-regulation of IL-7-
driven proliferation is not critically affected by loss 
of Y223 autophosphorylation or kinase activity of 
Btk. 
Developmental progression of Btk mutant 
pre-B cells in vitro. In Btk-defi cient pre-B cells, 
the increased IL-7-driven proliferation in vitro 
is accompanied by reduced developmental 
progression from large cycling CD2- pre-B cells 
into noncycling small resting CD2+ pre-B cells, 
and subsequently into surface Ig+ B cells (14). 
To analyze the function of Btk domains in this 
context, total BM cell suspensions from the panel 
of mutant mice were cultured in the presence of 
100 U/ml IL-7. At day 5, the distribution of B220+ 
cells over six developmental fractions, µ- pro-B 
cells, CD2- µ+ large cycling pre-B cells, CD2- µ+ 
small pre-B cells, CD2+ µ+ small pre-B cells, 
IgM+IgD- immature B cells, and IgM+IgD+ mature 
B cells, was evaluated by fl ow cytometry (Fig. 
4B). Consistent with our previous fi ndings (14), 
we noticed that in the absence of Btk: (a) growth 
of cytoplasmic µ- cells was hardly supported, (b) 
progression from the CD2- into the CD2+ pre-B 
cell stage was impaired, and (c) the proportions of 
IgM+ immature and mature B cells were reduced, 
when compared with wild-type mice. The BM 
cultures from WT and Y223F Btk mice exhibited a 
subpopulation distribution that was similar to that 
in Btk+ control mice. Expression of the K430R-Btk 
transgene partly restored Btk function, as in the 
K430R cultures signifi cant fractions of µ- pro-B 
cells were found and CD2 expression was more 
effi ciently induced on µ+ small pre-B cells, when 
compared with cultures from Btk-defi cient mice 
(Fig. 4B). 
Taken together, these results show that 
the role of Btk signaling in the induction of the 
developmental progression of CD2- into CD2+ 
small pre-B cells and subsequently to surface Ig+ 
B cells in vitro is completely independent of Y223 
autophosphorylation. In this context, kinase-
inactive Btk is apparently partially active.
Kinase-independent adapter function of Btk in 
mature B cells. Because kinase-inactive Btk could 
partially restore developmental progression of 
pre-B cells, we examined mature B cell function in 
K430R-Btk mice to evaluate the overall ability of 
kinase-inactive Btk to complement other features 
of the xid phenotype. 
Btk-defi cient mice have severely decreased 
levels of IgM and IgG3 in the serum and do 
not mount specifi c Ab responses to T cell-
independent type II (TI-II) Ags in vivo, and xid B 
cells undergo apoptosis instead of proliferation 
in response to in vitro stimulation (8, 9, 31-33). 
The K430R-Btk transgene provided a signifi cant 
correction of the decreased levels of IgM in 
Figure 3. Phenotypic characterization of pre-B and 
immature B cells in Btk mutant mice. A, Expression 
profi les of cytoplasmic SLC, surface BP-1, CD2, 
and CD25 in pre-B cells of the indicated mice. Flow 
cytometry data are displayed as fi lled histograms, with 
background stainings of B220- cells (dashed lines) as 
negative controls. The percentages of positive cells 
are indicated. Data shown are representative of 5–20 
animals examined within each group. B and C, The 
K430R-Btk transgene partially corrects the expression of 
the indicated markers in pre-B cells (B) and B220lowIgM+ 
immature B cells (C). Differences between Btk+ and 
Btk- pre-B and immature B cells were signifi cant for 
all markers (t test; p < 0.005). Asterisks indicate 
signifi cance of differences between K430R-Btk and 
Btk- mice (*, p < 0.05; **, p < 0.0005). Cytoplasmic SLC 
and CD2 expression was investigated in B220lowIgM-cµ+ 
pre-B cells, while BP-1 and CD25 were analyzed in total 
B220lowIgM- pro-B/pre-B cell fractions (pro-B cells have 
very low proportions of BP-1+ or CD25+ cells).
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the serum of Btk-defi cient mice, while only a 
modest increase in IgG3 was observed (Fig. 5A). 
Expression of K430R-Btk in Btk-defi cient mice 
did not reconstitute the in vivo responsiveness 
of B cells to the TI-II Ag TNP-Ficoll. Moreover, 
K430R-Btk expression on a wild-type background 
even showed a dominant-negative effect on the 
production of TNP-specifi c IgM (Fig. 5B). 
When purifi ed splenic B cell suspensions were 
stimulated in vitro, K430R-Btk completely restored 
the proliferative responses to anti-CD40 and LPS 
(Fig. 6A), which are known to be affected by 
defective Btk function (8, 9, 34). In contrast, the 
rescue of the proliferative response to anti-IgM 
stimulation was modest (Fig. 6A). To determine 
the effect of the K430R-Btk transgene on B cell 
survival, purifi ed splenic B cells from Btk+, Btk-, 
WT-Btk, and K430R-Btk mice were cultured in 
vitro in medium alone, or in the presence of anti-
CD40, LPS, or anti-IgM. After 40 h, cells were 
stained with propidium iodide and examined 
by fl ow cytometry to determine the fraction of 
apoptotic cells, i.e., cells with sub-G1 amounts of 
DNA. The presence of the K430R-Btk transgene 
on the Btk null background strongly reduced 
the proportion of apoptotic cells, in all four 
culture conditions (Fig. 6B). Apoptosis levels of 
K430R-Btk B cells stimulated with anti-IgM were 
intermediate between the values for wild-type 
and Btk-defi cient mice. Taken together, these 
data indicate that kinase-inactive Btk can partially 
rescue the compromised cell cycle induction and 
cell survival of Btk-defi cient mature B cells.
Kinase-inactive Btk induces NF-κB activation 
Figure 4. Analysis of IL-7-driven BM cultures from 
Btk mutant mice. A, Proliferative response to IL-7, as 
determined by [3H]thymidine incorporation after 5 days 
of culture in the presence or absence of 100 U/ml IL-7. 
B, The distribution profi le over the indicated B-lineage 
subpopulations of day 5 IL-7-driven total BM cultures of 
the Btk mutant mice. Error bars are the SEM values from 
four to seven mice per group.
Figure 5. Partial correction of mature B cell function 
in K430R-Btk mice. A, Serum concentrations of IgM 
and IgG3 in Btk+ and Btk- mice, as well as K430R-Btk 
mice on the Btk+ and Btk- background. Mice were 2 mo 
of age, total Ig levels were determined by ELISA, and 
each symbol indicates an individual mouse (n = 5–7). B, 
Serum concentrations of TNP-specifi c IgM and IgG3 7 
days after in vivo TNP-Ficoll injection. For each serum 
dilution, the ODs are shown as mean values from 11–23 
mice in each group.
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upon BCR stimulation.  To explore the mechanism 
underlying the kinase-independent adapter 
function of Btk, we further investigated kinase- 
inactive Btk function in BCR signal transduction.
Consistent with a previous report (19), in vitro 
kinase assays of immunoprecipitated Btk from 
purifi ed splenic B cell fractions stimulated with 
anti-IgM Abs confi rmed that K430R-mutated Btk 
did not have any detectable autophosphorylation 
activity, even though high levels of K430R-Btk 
were expressed (Fig. 7A). 
Btk is known to have a critical role in BCR-
directed cell cycle induction (32, 33, 35), as well 
as nuclear translocation of NF-κB, which induces 
expression of the antiapoptotic survival protein 
Bcl-xL (31, 33, 36, 37). We thus evaluated the 
ability of K430R-Btk to activate NF-κB and induce 
Bcl-xL and cyclin D2 expression in response 
to BCR engagement. Western blot analysis of 
purifi ed splenic B cells that were stimulated with 
anti-IgM Abs for 4 h showed that, while induction 
of nuclear c-Rel was negligible in Btk-defi cient 
B cells, the fold inductions in K430R-Btk were 
close to those observed in Btk+ control mice 
(Fig. 7B). Under these conditions, the amounts 
of cytoplasmic c-Rel were similar in all three 
groups of mice. Furthermore, the induction of 
Bcl-xL and cyclin D2 after BCR stimulation, which 
was blocked in Btk-defi cient B cells, was partially 
restored in K430R-Btk transgenic mice (Fig. 7C). 
In summary, these results show that in mature 
B cells, K430R-Btk is able to transmit BCR 
signals that can activate NF-κB and induce Bcl-
xL and cyclin D2 expression, leading to cell cycle 
entry, proliferation, and rescue from apoptosis. 
Discussion
In vivo structure-function analysis for Btk. 
The characterization of 400 unique human Btk 
mutations, 155 of which represent missense 
mutations, in XLA families could in principle 
have allowed the identifi cation of in vivo 
structure-function effects of Btk. However, there 
is phenotypical heterogeneity among patients, 
Figure 6. Partial correction of mature B cell proliferation 
and survival in K430R-Btk mice. A, Proliferation, 
determined by [3H]thymidine incorporation, of cells 
cultured in medium alone, in the presence of LPS, anti-
CD40, or anti-IgM. B, Propidium iodide DNA content 
analysis of B cells following stimulation in vitro. Numbers 
indicate the proportion of cells ± SEM in the sub-G1 
fraction (%) in cell cycle analysis. Data (with mean 
± SEM values from two to four mice per group) are 
representative of three independent experiments.
Figure 7. K430R-Btk induces NF-κB activation 
upon BCR stimulation. A, SDS-PAGE of in vitro 
phosphorylated Btk immunoprecipitates from purifi ed 
splenic B cells (12 x 106) from wild-type and K430R-
Btk mice were left untreated or stimulated with anti-IgM 
for 5 min. For quantifi cation of Btk expression, equal 
proportions of the immunoprecipitates were analyzed 
by Western blotting using Btk-specifi c Abs. In agreement 
with a previous report (42), wild-type Btk showed 
detectable kinase activity also in unstimulated splenic B 
cells. B, Western analysis of nuclear and cytoplasmic c-
Rel expression. Equal numbers of purifi ed splenic B cells 
from the indicated mice were left untreated or stimulated 
with anti-IgM for 4 h (left). Induction of nuclear c-Rel was 
quantifi ed by densitometry, and results are shown as 
mean values and SEM from four mice per group (right). 
C, Induction of Bcl-xL and cyclin D2. Total splenocytes 
of the indicated mice were stimulated with anti-IgM 
and evaluated for the expression of Bcl-xL and cyclin 
D2 by immunoblotting using specifi c Abs. Membrane 
was reblotted with anti-extracellular signal-regulated 
kinase. Data are representative of four mice analyzed 
per group.
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even from single XLA pedigrees, and to date 
no correlation has been described between the 
type and position of the mutations and clinical or 
immunological XLA phenotype (38). Furthermore, 
the almost complete pre-B cell arrest in most 
XLA patients (6) complicates the analysis of 
the function of the individual Btk domains in 
developmental stages beyond the large µ+ pre-B 
cell. As a result, the role played by the various 
Btk domains in vivo in humans remained largely 
unknown. 
Analyses in the mouse to date have focused 
on the in vivo function of the Btk PH domain, 
which was shown to be absolutely essential in 
mature B cells. This was inferred from the fi nding 
of the same xid phenotype in CBA/N mice with 
the classical R28C PH domain mutation and 
in mice with a complete ablation of Btk protein 
generated by gene targeting (8-10). Apparently, 
the R28 residue in the PH domain is also 
essential for Btk function in pre-B cells, as we 
observed that, comparable to Btk-defi cient pre-B 
cells, also xid CBA/N pre-B cells manifested an 
impaired modulation of the phenotypic markers 
BP-1, SLC, CD2, and CD25, and an increased 
proliferative response to IL-7 (S. Middendorp and 
R. Hendriks, unpublished results). 
By using transgenic mice expressing Y223F 
and K430R mutant Btk, we now demonstrate a 
differential role of Y223 phosphorylation and Btk 
catalytic activity in developmental progression of 
cytoplasmic µ+ pre-B cells in vivo. In particular, 
we analyzed λ L chain usage; the modulation of 
BP-1, SLC, CD2, and CD25 expression; and the 
IL-7 responsiveness of pre-B cells, all of which 
were previously shown to be Btk dependent (14, 
16). In this study, we demonstrate that: (a) the 
Y223 autophosphorylation site is not essential for 
signaling developmental progression of pre-B or 
B cells, except for the role of Btk in the regulation 
of λ L chain usage; (b) in pre-B cells, Btk functions 
to a large extent as an adapter molecule; (c) in 
mature B cells kinase-inactive Btk can induce the 
activation of NF-κB upon BCR stimulation. 
The Y223 autophosphorylation site in the 
SH3 domain. Although phosphorylation of 
Y223F has little discernible infl uence on Btk 
catalytic activity, it is generally thought that full 
activity of Btk is dependent on phosphorylation 
of Y223. Y223 is located on the surface of the 
SH3 domain, and its phosphorylation prevents 
binding to WASP and increases the affi nity 
to Syk (21). The Y223F mutation dramatically 
potentiates the transforming activity of the gain-
of-function mutant E41K-Btk in fi broblasts (19). 
Moreover, the SH3 domain has specifi city for 
the N-terminal proline-rich region of the Btk TH 
domain, and therefore it has been hypothesized 
that intra- or intermolecular interaction between 
the TH and SH3 domain might have an important 
regulatory function (1). With the exception of 
λ L chain usage, we found that expression of 
Y223F-mutated Btk fully corrected all features 
of the Btk-defi cient phenotype, including pre-B 
cell maturation, differentiation of peripheral B 
cells, and B-1 cell development. Furthermore, we 
observed reconstitution of B cell function, both in 
total serum IgM and IgG3 levels, TI-II responses 
in vivo, and in proliferative responses to anti-IgM 
stimulation in vitro (R. Hendriks, unpublished). 
Taken together, these results indicate that Y223 
autophosphorylation-dependent interactions 
are not essential for B cell development and 
mature B cell function. This is consistent with 
previous observations that reconstitution of 
Btk-defi cient chicken DT 40 B cells with Y223F 
and WT Btk resulted in a similar rescue of BCR-
induced PLC-γ phosphorylation and calcium 
fl ux (39). Our fi ndings may also explain the 
remarkable absence of missense mutations in 
the Btk SH3 domain in a total of 155 missense 
mutations identifi ed to date in XLA families (38), 
while on the basis of SH3 domain size ~10 of 
these should be located within the SH3 domain. 
Nevertheless, the Y223 autophosphorylation 
site appears to be involved in the regulation of 
λ L chain usage. In this context, it is tempting to 
speculate that transcription factor II-I (TFII-I) is 
involved in the activation of the λ L chain locus for 
recombination, as the Y223F-Btk mutation also 
abrogates phosphorylation of a Btk substrate, 
the NF BAP-135/TFII-I (40). Obviously, additional 
experiments are required to demonstrate whether 
TFII-I plays any role in the regulation of gene 
rearrangements at the λ L chain locus. 
It is intriguing that mutation of the Y223 Btk 
autophosphorylation site partially affected λ L 
chain usage, while expression of kinase-inactive 
Btk restored λ usage completely. This may 
imply that the Y223F mutation does not only 
change the interaction of Btk with proteins that 
bind to the SH3 domain when phosphorylated 
at Y223, but also with proteins that bind to 
nonphosphorylated Y223, such as c-Cbl and 
WASP (21). Alternatively, the obtained results 
could be explained by a contribution of other 
kinases to phosphorylation of Btk at position 
Y223 in vivo, once Btk is recruited to the pre-BCR 
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signaling complex.
The kinase-inactive K430R-Btk mutant. The 
K430R mutation destroys the ATP-binding site, 
resulting in kinase-inactive Btk (19, 20). Expression 
of physiological levels of kinase-inactive Btk in 
early B cell development normalized λ L chain 
usage and partially reconstituted the impaired 
pre-B cell differentiation and IL-7 responsiveness 
in Btk-defi cient mice. These fi ndings imply that 
Btk partially functions as an adapter molecule, 
independent of its kinase activity, possibly in a 
larger complex together with other molecules that 
interact with Btk (Fig. 1A). Such a complex might 
include PTK that either bind directly to Btk, such 
as Fyn, Lyn, Hck, and Syk, or indirectly through 
the BLNK/SLP65 linker molecule, which binds to 
the Btk SH2 domain. It is therefore possible that 
Syk may partially compensate for kinase-inactive 
Btk and phosphorylate PLC-γ2 in a complex that 
contains activated BLNK/SLP65 and Btk. Our 
data indicate that, especially in the activation 
of the λ L chain locus for V(D)J recombination 
in pre-B cells, Btk mainly acts as an adapter 
molecule. Likewise, in mature B cells, the role 
of Btk in proliferation and survival upon LPS 
and anti-CD40 stimulation in vivo was found to 
be fully independent of Btk enzymatic function. 
Nevertheless, the (incomplete) induction of 
NF-κB, Bcl-xL, and cyclin D2 by K430R-Btk 
cannot fully rescue B cell development, as is 
particularly clear from the lack of reconstitution 
of the B-1 cell compartment and in vivo TI-II 
responses. In this context, it was recently shown 
that Btk participates in NF-κB induction by Toll-
like receptor 4, whereby K430R-Btk acts as a 
dominant-negative inhibitor of the LPS-induced 
activation of NF-κB in an astrocytoma and a 
monocytic cell line (41). Taken together, these 
fi ndings illustrate that the importance of the 
Btk kinase domain varies between the different 
Btk-mediated signaling pathways during B cell 
development and between the different signal 
transduction pathways. 
In summary, our fi ndings demonstrate the 
differential requirement for Btk domains in the 
developmental progression of cytoplasmic 
µ H chain-positive pre-B cells. We show that 
the regulation of Ig λ L chain usage is Y223 
dependent, but K430 independent, and that 
the modulation of pre-B cell marker expression 
is Y223 independent, but partially K430 
dependent. None of the two residues appear to 
be essential for Btk function in the regulation of 
IL-7 responsiveness. We therefore conclude 
that the control of Ig λ L chain usage, pre-B 
cell marker phenotype, and IL-7 responsiveness 
involve different downstream signaling pathways 
or molecules interacting with Btk. 
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Introduction
The precursor B cell receptor (pre-BCR) is a key 
checkpoint in B cell development to monitor the 
expression of a functional Ig µ H chain (1-3). The 
pre-BCR complex is comprised of µ H chain, 
the non-rearranging VpreB and λ5 surrogate 
light chain (SLC) proteins and the Ig-α/CD79a 
and Ig-β/CD79b signalling components. Pre-
BCR expression is essential for the proliferative 
expansion of cytoplasmic µ H chain positive pre-
B cells and the induction of progression into small 
pre-B cells in which Ig L chain rearrangement 
occurs (1-3). It is thought that the pre-BCR 
signals in a ligand-independent fashion, resulting 
in pre-BCR internalisation and the activation of 
various downstream signal transduction proteins. 
Mice defi cient for pre-BCR components, such 
as µ, Ig-α, Ig-β, SLC or the Syk tyrosine kinase 
exhibit a specifi c block in B cell development 
at the pre-B cell stage, refl ecting the inability of 
pre-B cells to proliferate and progress into large 
cycling pre-B cells. In contrast, disruption of 
(pre-)BCR signalling elements Bruton’s tyrosine 
kinase (Btk) and SLP-65 (also known as BASH or 
BLNK) are crucially involved in the regulation of 
the developmental progression of pre-B cells by 
limiting the IL-7 driven expansion of large cycling 
pre-B cells (4, 5). 
During the transition of large cycling into 
small resting cytoplasmic µ+ pre-B cells in the 
mouse, Btk-defi cient cells show defective down-
regulation of SLC, the metallopeptidase BP-1 
and the sialoglycoprotein CD43 and defective 
upregulation of the adhesion molecule CD2, 
the IL-2 receptor CD25 and MHC class II. 
Moreover, in an analysis of the kinetics of pre-
B cell differentiation in vivo, Btk-defi cient cells 
manifested a specifi c developmental delay within 
the small pre-B cell compartment of ~3 h, when 
compared with wild-type cells. In in vitro BM 
cultures, Btk-defi cient large cycling pre-B cells 
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showed increased IL-7 driven expansion and 
reduced developmental progression into non-
cycling CD2+CD25+SLC- small pre-B cells and 
subsequently into Ig+ B cells (5). Furthermore, the 
fi nding of reduced λ L chain usage in Btk-defi cient 
mice implicates Btk in the regulation of the 
activation of the λ locus for V(D)J recombination 
in pre-B cells (6). 
Although these fi ndings suggest that 
Btk is directly involved in the regulation of 
IL-7 responsiveness, cell surface marker 
expression and the activation of light chain gene 
rearrangements in pre-B cells, it remains possible 
that Btk is only required for the developmental 
progression of large pre-B cells into a small pre-B 
cells stage in which subsequently surface marker 
changes and L chain rearrangements are induced 
in a Btk-independent fashion. To distinguish 
between these two possibilities, we employed 
transgenic mice expressing the constitutive active 
Btk mutants E41K or E41K-Y223F to investigate 
whether Btk signalling can induce cell surface 
marker modulation and L chain rearrangements, 
independent of the differentiation stage, e.g. also 
in µ H chain negative pro-B cells. 
The gain-of-function mutant E41K shows 
increased membrane localisation and 
phosphorylation in quiescent cells, independent 
of phosphatidyl-inositol 3-kinase (PI3K) 
activity (7, 8). Normally, Btk is targeted to the 
plasma membrane through interactions of 
its pleckstrin homology (PH) domain with the 
second messenger phosphatidyl-inositol-3,4,5-
trisphosphate (PIP3) generated by PI3K, which 
is activated by BCR engagement (9, 10). Upon 
BCR stimulation, Btk is transphosphorylated at 
Y551 in the SH3 domain, possibly by Syk or the 
Src-like kinase Lyn (11, 12). This phosphorylation 
promotes its catalytic activity, and subsequently 
results in Btk autophosphorylation at Y223. (12, 
13). Concomitantly, Syk activation results in 
phosphorylation of the adapter molecule SLP-
65, which allows the association of SLP-65 with 
the Btk SH2 domain and with phospholipase 
Cγ2 (PLCγ2) (14, 15). These interactions are 
critical to the activity of Btk and result in PLCγ2 
tyrosine phosphorylation, inositol trisphosphate 
production and calcium mobilisation. It has been 
shown that E41K-Btk induces transformation 
of 3T3 fi broblasts in soft agar cultures, and 
this capacity is augmented by mutation of the 
main autophosphorylation site (Y223F; (7, 
13)). Expression of E41K-Btk in Ramos B cells 
enhances the sustained increase in intracellular 
calcium following BCR cross-linking (16). In 
transgenic mice, which use either the B-cell 
specifi c CD19 promoter or the MHC class II 
Ea locus control region to express E41K-Btk, 
B cell development is arrested in the BM or the 
spleen, respectively (17, 18). These fi ndings 
suggest that expression of the E41K-Btk mimics 
BCR occupancy by autoantigens. Moreover, we 
recently demonstrated that low-level expression 
of an E41K-Y223F-Btk double mutant transgene 
could partially rescue the pre-B cell arrest in 
SLP-65-defi cient pre-B cells and prevent pre-B 
cell tumour formation in SLP-65-/- mice. This 
observation indicates that, in the absence of SLP-
65, expression of E41K-Y223F-Btk enhances 
pre-BCR signalling (19).
To examine the effects of the E41K and 
E41K-Y223F Btk mutations in pro- and pre-BCR 
signalling in vivo, we analysed transgenic mice 
expressing these gain-of-function Btk mutants 
under the control of the CD19 promoter region. In 
addition to the mice described previously (18, 19), 
we generated mice that express various levels of 
the E41K-Y223F double mutant Btk and crossed 
these mice onto the Btk null background (20). 
In particular, we analysed the effects of these 
constitutively active Btk mutants on cell surface 
marker and L chain expression in cytoplasmic µ 
H chain negative pro-B cells.
Materials and Methods
Generation of Btk-transgenic mice. The WT 
and E41K transgenic mice have been previously 
described (18). The human Btk transgenes 
consist of a ~6.3 kb genomic fragment containing 
the CD19 promoter region, a 0.3 kb fragment 
with the fi rst three exons of human Btk as cDNA 
sequence, as well as a 27.1 kb genomic DNA 
fragment, encompassing the Btk exons 3-19 (18). 
Using double stranded site-directed mutagenesis 
(Stratagene, La Jolla, CA) the Y223F mutation 
was introduced into the construct that was 
previously used to generate the CD19-BtkWT and 
CD19-BtkE41K mice (18). The Y223F mutation 
was created by replacement of AT by TC in exon 
8. The ~34 kb MluI-NotI insert from the E41K-
Y223F-Btk construct was excised from the vector, 
gel-purifi ed and micro-injected into the pronuclei 
of FVB fertilised oocytes. Transgenic founder 
mice were identifi ed by Southern blotting and 
crossed with Btk null mice (20), which were bred 
onto a C57BL/6 background for >8 generations. 
Sequence fi delity of the mutated fragments 
was confi rmed, both in plasmid DNA prior to 
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subsequent cloning steps and in genomic DNA 
obtained from the F1 transgenic mice generated. 
Mice were bred and maintained at the Erasmus 
MC animal care facility under specifi c pathogen 
free conditions.
Mouse Genotyping. Tail DNA was analysed 
by Southern blotting of BamHI digests using a 
partial human Btk cDNA probe (bp 133-1153), as 
described previously (18, 20). Alternatively, the 
presence of Btk transgenes, endogenous mouse 
Btk WT or Btk KO alleles were evaluated by PCR, 
as described previously (19, 21). 
Flow cytometric analyses.  Preparations of 
single-cell suspensions, standard and intracellular 
FCM, and conjugated monoclonal antibodies 
(Becton Dickinson Pharmingen, Sunnyvale, CA) 
have been described previously (5, 20). The anti-
SLC hybridoma LM34 ((22) was kindly provided 
by A. Rolink, Basel Institute for Immunology, 
Basel, Switzerland); antibodies were purifi ed 
using protein G columns and conjugated to biotin 
according to standard procedures. In vivo 5’-
bromo-2’deoxyuridine (BrdU) labelling and FCM 
BrdU detection has been previously described 
(5). Mice were analysed at the age of 8-16 
weeks. Transgenic Btk expression levels were 
quantifi ed, using median fl uorescence intensity 
(MFI) values obtained by CellQuest software 
(BD), whereby values for transgenic human Btk 
and endogenous murine Btk were corrected for 
background fl uorescence, as detected in Btk null 
mutant mice. Subsequently, the ratio of the MFI 
values of transgenic Btk over endogenous Btk 
was calculated.
In vitro (pre-)B cell cultures.  IL-7 driven BM 
cultures and determination of IL-7 dependent 
proliferative responses of total BM cells have 
been described previously (5, 6). 
Results
Constitutively active Btk induces a 
developmental arrest at the immature B cell 
stage.  We previously reported the generation 
of transgenic mice, which express wild-type 
(WT), Y223F (n=5 independent lines), E41K 
(n=3 independent lines), and E41K-Y223F (n=1) 
human Btk under the control of the CD19 promoter 
region (18). We now generated three additional 
E41K-Y223F transgenic lines, expressing higher 
levels of this double mutant and crossed these 
mice onto the Btk null background. 
To determine the effect of expression of the 
individual Btk mutations on B cell development, 
we examined the size of the individual B-lineage 
subpopulations in the BM by FCM. Figure 1A 
shows that Btk-defi ciency mainly affects the 
B220high population of mature recirculating cells, 
which is reduced in size and has an IgMhigh 
phenotype (5, 20, 23). As reported previously (18, 
21), transgenic expression of  WT-Btk or Y223F-
Btk corrected this defect, while expression of the 
E41K-Btk mutant resulted in an almost complete 
block of B cell development at the transition 
of IgMlow to IgMhigh B220lowIgD- immature B cell 
stage in the BM (Figure 1A). We now observed 
that expression of the E41K-Y223F-Btk double 
mutant was also associated with an arrest at the 
immature B cell stage. 
The extent of B cell deletion in the E41K single 
and the E41K-Y223F double mutants varied 
between the individual transgenic lines generated 
(Figure 1B). A correlation was observed with the 
expression levels of the Btk transgenes, as 
quantifi ed in the immature B cell population by 
comparing median fl uorescence intensities of 
transgenic human Btk with endogenous Btk (21) 
(Figure 1C). Differences in expression levels 
of transgenic Btk protein were confi rmed by 
western blotting analysis of BM and spleen cell 
suspensions, in which Btk protein was visible 
as a single ~77 kDa band for all transgenic 
lines generated (data not shown). These results 
demonstrate that the effects of the E41K and the 
E41K-Y223F mutants are dose-dependent and 
that deletion of IgMhigh immature B cells in the BM 
already occurs when mutant Btk is expressed at 
low physiological levels (~20-40% of normal in 
immature B cells).
Since we aimed to investigate the role of Btk 
in early B cell development, we focused on those 
transgenic lines that expressed physiological 
levels of transgenic Btk in immature B cells in 
the BM. However, as expression of transgenic 
Btk increased as B cell progenitors matured, 
these transgenic lines, LF-03 (E41K) and AM-
06 (E41K-Y223F), expressed low Btk levels in 
pro-B/pre-B cells (~20-60% of normal) and high 
levels in mature peripheral B cells (up to 4 times 
normal values). 
Deletion of immature B cells in E41K-Btk 
mice was further substantiated in kinetic studies 
with the thymidine analogue BrdU, which is 
specifi cally incorporated into the DNA of large 
cycling cytoplasmic µ+ pre-B cells (24, 25). BM 
cells were stained with an Ab specifi c for BrdU, in 
conjunction with cell surface marker analysis for 
B220, IgD and κ L chain. At various time points 
after injection, the proportions of the pre-B cell 
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subpopulations that incorporated BrdU were 
similar in the Btk+, Btk- and E41K-Btk mice (data 
not shown), indicating that pre-B cell expansion 
is comparable in the three groups of mice. 
However, the absolute numbers of κ+ immature 
B cells generated in the BM of E41K-Btk mice 
were limited and decreased after 24 hours (Fig. 
1D), indicating a short life span of E41K-Btk 
immature B cells, consistent with the arrest of B 
cell development found at this stage. 
Collectively, these fi ndings show that 
expression of the E41K-Btk, either on its own or 
in combination with the Y223F mutation, resulted 
in a dose-dependent arrest of B cell development 
at the immature B cell stage in the BM.  
Constitutively active Btk corrects pre-B cell 
maturation defects in Btk-defi cient mice. We 
previously showed that during the developmental 
progression of large cycling into small resting 
cytoplasmic µ+ pre-B cells, Btk-defi cient cells 
fail to effi ciently downregulate the expression of 
BP-1 and SLC and upregulate the expression 
of surface CD2 and CD25/IL2-R (5). To analyse 
whether transgenic expression of E41K-Btk or 
E41K-Y223F-Btk could correct these defects, 
we analysed the SLC, BP-1, CD2 and CD25 
expression profi le in pre-B cells from Btk mutant 
and control mice. We performed four-color FCM 
experiments of BM cell suspensions, using 
monoclonal antibodies to B220 and IgM or Ig κ L 
chain, together with various additional antibodies. 
As shown in Fig. 2, Btk-defi cient pre-B cells have 
signifi cantly higher levels of cytoplasmic SLC 
and BP-1, but lower expression levels of CD2 
and CD25. This aberrant marker profi le was fully 
corrected in transgenic mice expressing WT, 
E41K or E41K-Y223F double mutant Btk (Fig. 2). 
Complete reconstitution was also found in mice 
with low-level transgene expression, such as the 
E41K-Btk line NR01 or the E41K-Y223F-Btk line 
MK13 (data not shown). 
In summary, these fi ndings demonstrate that 
the in vivo function of Btk as a regulator of cellular 
maturation of pre-B cells is neither enhanced nor 
reduced by the E41K or E41K-Y223F mutation.
Constitutively active Btk supports IL-7 driven 
expansion of pro-B cells in vitro. Btk has an 
inhibitory effect on the proliferation of pre-B cells 
Figure 1. B cell developmental arrest in transgenic mice expressing constitutively active Btk. (A) Flow cytometric 
analysis of surface expression of IgM and B220 on total lymphocytes in the BM, which were gated on the basis of 
forward and side scatter characteristics. Percentages of total lymphocytes within the indicated gates are given. Data 
shown are representative of 3-20 animals examined within each group. (B) Dose-dependent decrease of the IgMlow and 
IgMhigh immature B220lowIgD- B cell subpopulations in E41K and E41K-Y223F transgenic mice. Absolute cell numbers 
of the two immature B cell subpopulations in Btk+ control mice were set to 100%. Error bars are SEM values from 
4-11 mice per group. (C) Tg expression levels in immature B cells, as determined by FCM. B220+IgM+IgD- cells were 
analyzed for intracellular Btk expression and the differences in median fl uorescence intensities between the indicated 
mice and background values (in Btk- mice) were calculated and compared to endogenous Btk expression in wild type 
mice, which was set to 100%. (D) Production of κ+ immature B cells over time, as calculated from the total numbers of 
κ+ immature B cells and the percentages of BrdU+ cells in this population. Error bars are SEM values from 3-9 mice per 
group. As the transit time through the small pre-B cell stage is ~11 hrs in Btk- mice (as compared with ~8 hrs Btk+ mice), 
no signifi cant population of BrdU+ κ+ immature B cells was found in Btk- mice 10 hrs after BrdU injection. 
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in long-term Whitlock-Witte BM cultures and in IL-
7 driven cultures of BM or fetal liver cells (5, 26, 
27). In [3H] thymidine incorporation experiments 
after 5 days of culture in the presence of IL-7, 
Btk-defi cient total BM cells showed signifi cantly 
higher proliferative responses when compared 
with Btk+ cells. This defect was largely corrected 
when E41K-Btk or E41K-Y223F-Btk was 
expressed (Fig. 3A).
To analyse the effects of constitutive active 
Btk in IL-7 driven BM cultures in more detail, 
total BM cell suspensions from the panel of 
mutant mice were cultured in the presence of 100 
U/ml IL-7 and at day 5, the distribution of B220+ 
cells over six developmental fractions, µ- pro-B 
cells, µ+ large cycling pre-B cells, CD2- µ+ small 
pre-B cells, CD2+ µ+ small pre-B cells, IgM+IgD- 
immature B cells and IgM+IgD+ mature B cells, 
was evaluated by FCM (Fig. 3B). Consistent with 
our previous fi ndings (5), we noticed that in the 
absence of Btk (i) growth of cytoplasmic µ- cells is 
hardly supported, (ii) progression from the CD2- 
into the CD2+ pre-B cell stage was impaired, and 
(iii) the proportions of IgM+ immature and mature 
B cells were reduced, when compared with wild-
type mice. The BM cultures from WT and E41K-
Y223F (line AM06) transgenic mice exhibited a 
subpopulation distribution that was similar to that 
in Btk+ control mice. 
In contrast to the selective outgrowth of 
cytoplasmic and surface µ+ cells generally 
found in IL-7 BM cultures (5, 28, 29), we noticed 
substantial growth of cytoplasmic µ- pro-B cells 
in cultures from E41K and E41K-Y223F mutant 
mice (Fig. 3B). This phenomenon was dose 
dependent, as BM cultures from the mouse 
strains expressing lower levels of E41K-Btk or 
E41K-Y223F (e.g. NR01 or AM06) contained 
pro-B cell fractions similar to cultures from wild-
type mice (data not shown). The preferential 
outgrowth of µ- pro-B cells in E41K-Btk or 
E41K-Y223F BM cultures refl ected an increased 
expansion of µ- pro-B cells in absolute numbers 
and was observed both at high (100U/ml) and low 
(10U/ml) IL-7 concentrations (Shown for E41K-
Btk in Fig. 3C). As it has been reported that the 
expression of an Ig H chain transgene increases 
the IL-7 responsiveness of µ- pro-B cells (29), our 
fi ndings are consistent with the hypothesis that 
expression of constitutively active Btk can mimic 
pre-BCR signalling in this respect. 
To investigate whether E41K-Btk expression 
would also support the expansion of pro-B cells 
in vivo, we crossed E41K-Btk mice with RAG-1-/- 
mice, in which B cell development is arrested at 
the CD43+B220+ pro-B cell stage. However, the 
size of the CD43+B220+ pro-B cell populations 
in E41K-Btk RAG-1-/- and non-transgenic RAG-
1-/- mice were comparable (data not shown), 
indicating that E41K-Btk expression does not 
signal substantial proliferation of pro-B cells in 
vivo.
E41K-Btk supports premature cell surface 
marker changes and L chain expression 
in µ- pro-B cells. To examine the ability of 
activated Btk to mimic pre-BCR activation 
and consequently signal premature cellular 
maturation of cytoplasmic µ- pro-B cells in vivo, 
we compared CD19+B220+ cytoplasmic µ- pro-B 
cells in the BM from Btk+, Btk-, E41K-Btk, and 
E41KY223F mutant mice. In these cells, we 
analysed the expression of SLC and κ L chain 
in the cytoplasm, and CD2, CD25, MHC class II 
and BP-1 on the cell surface (Fig. 4). E41K-Btk 
pro-B cells showed reduced expression of SLC 
and increased levels of CD2, CD25, MHC class 
II and κ L chain, when compared with Btk+ or Btk- 
pro-B cells (Fig. 4). In all four groups of mice, the 
pro-B cells lacked signifi cant BP-1 expression. A 
similar effect on the expression of CD2, CD25, 
MHC class II and κ L chain in pro-B cells was also 
observed in mice expressing high levels of the 
E41K-Y223F double mutant (AM-07), but not in 
WT-Btk mice (data not shown). These phenotypic 
marker changes induced by E41K-Btk in pro-B 
Figure 2. Phenotypic characterization of pre-B cells in 
Btk mutant mice.  Expression profi les of cytoplasmic 
SLC, surface BP-1, CD2 and CD25 in B220+IgM- pre-
B cell subpopulations of the indicated mice. Data are 
displayed as fi lled histograms, with background stainings 
of B220- cells (dashed lines) as negative controls. The 
percentages of positive cells are indicated. Data shown 
are representative of 3-20 animals examined within 
each group. Cell populations analysed were cytoplasmic 
µ+ surface IgM- pre-B cells (for CD2 and SLC) or total 
surface IgM- pro-B and pre-B cells (for BP-1 and CD25). 
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cells refl ected the phenotypic changes that are 
normally induced by pre-BCR signalling during 
the developmental progression of large cycling to 
small resting pre-B cells. These fi ndings therefore 
indicate that expression of E41K-Btk or E41K-
Y223F can mimic pre-BCR signals.  
Discussion
Several lines of evidence show that the E41K 
gain-of-function mutation, which is associated 
with enhanced Btk membrane localization, 
activation and calcium-signalling in cultured cell 
lines (7, 8, 13, 16), represents an activated form 
of Btk in murine B cells in vivo. Expression of 
E41K (a) enhances blast formation of splenic B 
cells in culture (17), (b) drives peripheral B cells 
effi ciently into IgM plasma cell differentiation 
in vivo (18), (c) induces the expression of the 
early activation antigen CD69 on peripheral B 
cells (R.W.H., unpublished), and (d) signifi cantly 
increases Ig λ usage (6). In addition, unstimulated 
E41K-Y223F-Btk expressing mature splenic B 
cells showed increased tyrosine phosphorylation 
(19) and the presence of E41K-Y223F-Btk 
prevented tumour formation in SLP-65-defi cient 
pre-B cells. Apparently, E41K-Y223F-Btk breaks 
the positive feedback loop of SLP-65-defi cient 
large cycling pre-B cells which are arrested 
in development and cannot effi ciently down-
regulate pre-BCR expression, which signals for 
their proliferation (19). 
In this report, we found that E41K-Btk and 
E41K-Y223F-Btk had no additional effects in 
pre-B cells, in terms of the cell surface marker 
Figure 3. Analysis of IL-7 driven BM cultures 
from Btk mutant mice. (A) Proliferative 
response to IL-7, as determined by 
[3H]thymidine incorporation after 5 days of 
culture in the presence or absence of 100 
U/ml IL-7. (B) The distribution profi le over 
the indicated B-lineage subpopulations 
of day 5 IL-7 driven total BM cultures of 
the Btk transgenic mice. Error bars are 
SEM values from 3-7 mice per group. (C) Expansion of cytoplasmic µ- pro-B and cµ+ pre-B cells during 
culture with 10 or 100 U/ml IL-7. The bars indicate the expansion at day 5, as compared with the IgM- 
B220+ pro/pre-B cell numbers at the start of the culture, which were set to one.
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profi le changes or proliferative response to IL-7. 
The fi nding of similar effects of E41K-Btk, E41K-
Y223F-Btk and wild-type Btk would be consistent 
with the hypothesis that the pre-BCR signals in 
constitutively active way (1-3, 30). In contrast, 
E41K-Btk or E41K-Y223F-Btk expression in µ- pro-
B cells signalled their developmental progression 
in vivo in terms of cell surface expression of 
CD2 and CD25 and L chain rearrangements, 
all of which are normally induced upon pre-BCR 
signalling. Y223 is located on the surface of 
the SH3 domain and its mutation dramatically 
potentiates the transforming activity of E41K-Btk 
in fi broblasts (13). However, we were unable 
to detect any in vivo potentiating effects of the 
Y223F mutation on the phenotype of E41K-Btk 
mice, when combined in E41K-Y223F-Btk double 
mutant mice. This further supports our previous 
conclusion that Y223 autophosphorylation-
dependent interactions are not essential for Btk 
function during B cell development (21). 
We found that ~16% of all E41K-Btk pro-B cells 
expressed detectable levels of κ L chain proteins 
in the cytoplasma. Since only 1 out of 3 L chain 
rearrangements will be productive (and assuming 
that in the absence of Ig H chain µ protein κ+ and 
κ− pro-B cells do not manifest differences in 
survival, expansion or differentiation capacities) 
we conclude that V-to-J rearrangements will be 
present in approximately half of the total pro-B 
cell fraction in E41K-Btk mice. It is currently 
not clear whether E41K-Btk and E41K-Y223F 
signalling affect V(D)J recombination activity, 
κ locus accessibility or both. However, it is 
tempting to speculate that the transcription factor 
IRF-4 acts as a downstream target of Btk, as 
IRF-4 was recently shown to be important for the 
down-regulation of pre-BCR expression in large 
cycling pre-B cells and for the induction of germ-
line Ig κ transcription in Abelson-transformed 
pre-B cell lines (31, 32). Given that κ transcription 
is also impaired in SLP-65−/− immature B cells 
(33), further experiments should demonstrate the 
connection between Btk/SLP-65 signalling, IRF-4 
and Ig κ rearrangements.
We conclude that E41K-Btk and E41K-Y223F-
Btk refl ect constitutively active forms of Btk that 
mimic pre-BCR signalling in pro-B cells, resulting 
in the induction and successful completion of 
Ig κ L chain rearrangements as well as surface 
expression of the maturation markers CD2 and 
CD25. It is therefore unlikely that in the pre-
BCR checkpoint Btk-mediated signalling is only 
required for the progression of pre-B cells into 
a stage in which surface marker changes and 
L chain rearrangements are induced in a Btk-
independent fashion. In contrast, our fi ndings 
strongly support the hypothesis that Btk-mediated 
signalling directly induces cellular maturation and 
the initiation of L chain rearrangements in pre-B 
cells.
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Abstract
Expression of the pre-B cell receptor (pre-BCR) leads to activation of the adaptor molecule 
SLP-65 and the cytoplasmic kinase Btk. Mice defi cient for one of these signaling proteins 
have an incomplete block in B cell development at the stage of large cycling pre-BCR+CD43+ 
pre-B cells. Our recent fi ndings of defective SLP-65 expression in ~50% of childhood pre-
B acute lymphoblastic leukemias and spontaneous pre-B cell lymphoma development 
in SLP-65-/- mice demonstrate that SLP-65 acts as a tumor suppressor. To investigate 
cooperation between Btk and SLP-65, we characterized the pre-B cell compartment in 
single and double mutant mice, and found that the two proteins have a synergistic role in 
the developmental progression of large cycling into small resting pre-B cells. We show that 
Btk/SLP-65 double mutant mice have a dramatically increased pre-B cell tumor incidence 
(~75% at 16 wk of age), as compared with SLP-65 single defi cient mice (<10%). These 
fi ndings demonstrate that Btk cooperates with SLP-65 as a tumor suppressor in pre-B 
cells. Furthermore, transgenic low-level expression of a constitutive active form of Btk, 
the E41K-Y223F mutant, prevented tumor formation in Btk/SLP-65 double mutant mice, 
indicating that constitutive active Btk can substitute for SLP-65 as a tumor suppressor. 
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Introduction
B lymphocytes develop in the BM through distinct 
stages that are characterized by differential 
expression of various cell surface markers and 
the ordered rearrangement of Ig heavy (H) and 
light (L) chain gene segments (1, 2). In pro-B 
cells, productive V(D)J recombination of the Ig 
H chain gene leads to surface expression of 
the pre-B cell receptor (pre-BCR), which acts 
as a checkpoint in early B cell development to 
monitor the expression of a functional Ig µ H 
chain. The pre-BCR is transiently expressed 
on the cell surface and is essential for the 
proliferative expansion of cytoplasmic µ H chain 
positive pre-B cells and for the induction of 
developmental progression into small pre-B cells 
in which Ig L chain rearrangement occurs (1, 2). 
The pre-BCR complex is comprised of µ H chain, 
the nonrearranging VpreB and λ5 surrogate light 
chain (SLC) proteins and the Igα/CD79a and Igβ/
CD79b signaling components. The importance of 
the pre-BCR checkpoint function is evidenced by 
an arrest of B cell differentiation at the pro-B to 
pre-B cell transition both in agammaglobulinemia 
patients and in mice with mutations in 
any of these pre-BCR components (1-3). 
Cell surface expression of the pre-BCR in 
the absence of a ligand appears to be suffi cient 
to activate downstream signaling pathways (4, 
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5). This activation involves the formation of a 
lipid raft-associated calcium signaling module, 
composed of the tyrosine phosphorylated 
signaling molecules Lyn, Syk, SLP-65 (also 
known as B cell linker protein BLNK or BASH), 
phosphoinositide 3-kinase (PI3K), Bruton’s 
tyrosine kinase (Btk), Vav, and phospholipase 
Cγ2 (PLCγ2). As a result, the activation of PLCγ2 
induces calcium signaling and subsequently 
nuclear factor (NF)-κB activation (6-8). Additional 
checkpoints follow when functional L chain 
gene recombination in pre-B cells results in the 
expression of the B cell receptor (BCR) and 
when the resulting immature B cells progress 
to mature B cells. Mice defi cient for any of the 
(pre)-BCR signaling proteins exhibit essentially 
similar immunological phenotypes, characterized 
by reduced numbers of mature peripheral B cells, 
absence of B-1 B cells, reduced levels of serum 
IgM and IgG3, lack of in vivo responses to T cell–
independent type II antigens, and reduced in vitro 
responses to anti-IgM and LPS stimulation (9). 
Several lines of evidence show that the 
adaptor molecule SLP-65 and the cytoplasmic 
kinase Btk are crucially involved in the regulation 
of the developmental program of pre-B cells, in 
particular by limiting pre-B cell expansion and 
promoting differentiation of large cycling to small 
resting pre-B cells. Both SLP-65–defi cient and 
Btk-defi cient mice show a partial block at the 
pre-B cell stage, characterized by an impaired 
developmental progression from large cycling 
CD43+ into small resting CD43- pre-B cells 
(10-14). In an analysis of the kinetics of pre-B 
cell differentiation in vivo, Btk-defi cient cells 
manifested a specifi c developmental delay within 
the small pre-B cell compartment, when compared 
with WT cells (14). By introduction of a transgenic 
BCR into SLP-65-defi cient mice, it was shown 
that in the absence of SLP-65 the production 
of κ light chain is decreased and cellular 
maturation of developing B cell is delayed (15). 
Reintroduction of SLP-65 into SLP-65-defi cient 
pre-B cells led to pre-BCR down-regulation and 
enhanced differentiation (16). Furthermore, SLP-
65-/- and Btk-defi cient pre-B cells show enhanced 
proliferative expansion in vitro in the presence of 
IL-7, when compared with WT cells (14, 16-17). 
A synergistic role of SLP-65 and Btk in B cell 
development was demonstrated by the almost 
complete block in B cell development at the 
CD43+ pre-BCR+ preB cell stage in SLP-65/Btk 
double mutant mice (18). 
We recently reported that SLP-65-/- mice 
spontaneously develop pre-B cell lymphomas 
expressing large amounts of pre-BCR on their 
cell surface (16). Moreover, also ~50% of human 
childhood preB acute lymphoblastic leukemias 
(ALL) showed a complete loss or a drastic 
reduction of SLP-65 expression. Injection of 
murine SLP-65-/- pre-B cells into immunodefi cient 
mice resulted in tumor development, while 
reconstitution of SLP-65 expression in these cells 
eliminated their tumorgenic capacity (19). Tyr96, 
which is the binding site for Btk, was identifi ed 
as a crucial residue for the SLP-65 tumor 
suppressor function. Although Btk-defi cient mice 
do not develop pre-B cell tumors, the possibility 
remains that Btk cooperates with SLP-65 as a 
tumor suppressor in pre-B cells. To investigate 
cooperation between Btk and SLP-65, we 
characterized the pre-B cell compartment in 
single and double mutant mice in detail. We 
show that Btk/SLP-65 double mutant mice 
have a high incidence of pre-B cell lymphoma 
and that transgenic expression of low levels of 
the constitutive active E41K-Y223F Btk mutant 
prevents tumor formation in SLP-65/Btk double 
mutant mice. 
Materials and Methods
Mice. Btk-defi cient mice (20) were on 
the C57BL/6 background. Btk WT alleles 
were identifi ed by an exon 9 forward primer 
( 5 ’ - C A C T G A A G C T G A G G A C T C C ATA G -
3’) and an exon 10 reverse primer (5’-
GAGTCATGTGCTTGGAATACCAC -3’). For Btk 
KO alleles, primers were within the LacZ reporter 
(20), forward: 5’-TTCACTGGCCGTCGTTTTAC
AACGTCGTGA-3’, and reverse: 5’-ATGTGAGC
GAGTAACAACCCGTCGGATTCT-3’. SLP-65-
defi cient mice (10) were on the Balb/c background 
and genotyped with the following primers: Neo2A 
5’-CGGAGAACCTGCGTGCAATC-3’ and gxBr 
5’-GAGTCCGAATGTTCATCTG-3’ (KO allele) 
and WtI 5’-TCAAACCTG GGTCTCAGAA-
3’ and gxBr (WT allele). The presence of 
the BtkAct transgene was evaluated by PCR, 
using the following primers: CD19prom: 5’-
TGCAATTAGTGGTGAACAAC-3’ and 
hmBtk.65R: 5’-AGATGCCAGGACTTGG AAGG-
3’. 
The BtkAct transgene consist of a ~6.3 kb 
genomic fragment containing the CD19 promoter 
region, a 0.3 kb fragment with the fi rst three exons 
of human Btk as cDNA sequence, as well as a 
27.1 kb genomic DNA fragment, encompassing 
the Btk exons 3–19 (21). Using double stranded 
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site-directed mutagenesis (Stratagene) the 
Y223F mutation, the replacement of AT by TC 
in exon 8, was introduced into the construct that 
was previously used to generate CD19-BtkE41K 
mice. The ~34 kb MluI-NotI insert from the E41K-
Y223F-Btk construct was excised from the vector, 
gel-purifi ed and micro-injected into the pronuclei 
of FVB fertilized oocytes. Transgenic founder 
mice were identifi ed by Southern blotting of 
BamHI digests using a partial human Btk cDNA 
probe (bp 133–1153), as described previously 
(20, 21), and crossed with Btk null mice. All mice 
were bred and maintained at the Erasmus MC 
animal care facility under specifi c pathogen free 
conditions. Statistical analyses of Kaplan-Meier 
tumor-free survival estimates of the various 
mouse groups were performed using SPSS 
10.1.0 (SPSS Inc.). 
Cell Culture and Flow Cytometry. IL-7 
driven BM cultures and determination of IL-
7–dependent proliferative responses of total BM 
cells have been described previously (14, 22). 
Preparations of single-cell suspensions, standard 
and intracellular fl ow cytometry, and conjugated 
monoclonal antibodies (Becton Dickinson) have 
been described previously (14, 20). The anti-SLC 
hybridoma LM34 (23) was kindly provided by A. 
Rolink (University of Basel, Basel, Switzerland); 
antibodies were purifi ed using protein G columns 
and conjugated to biotin according to standard 
procedures. 
Western Blotting Analysis.  For analysis of Btk 
expression and protein phosphorylation, single-
cell suspensions from spleen were depleted of 
erythrocytes by NH4Cl lysis and enriched for B 
cells by AutoMACS purifi cation, using biotinylated 
antibodies to Gr-1, Ter119, CD4, CD8, and CD11b 
and magnetic streptavidin MicroBeads (Miltenyi 
Biotec) for negative selection. B-lineage cells 
were purifi ed from BM by AutoMACS using anti-
B220 MicroBeads for positive selection. Splenic 
B cell fractions were stimulated with 10 µg/ml 
F(ab’)2 fragment of polyclonal goat-anti–mouse 
IgM (Jackson ImmunoResearch Laboratories) in 
RPMI1640 at 37°C for 5 min. Western blotting was 
performed as described (20), using anti-Btk C-20, 
anti-Erk1/2 SC-094 (Santa Cruz Biotechnology, 
Inc.), or anti-phosphotyrosine P-Tyr-100 (Cell 
Signaling Technology). 
Results and Discussion
Pre-B Cell Maturation Defects in Btk, SLP-65, 
and Double Mutant Mice. Btk or SLP-65 single 
mutant mice have a partial block, while double 
mutant mice have an almost complete arrest at 
the pre-B cell stage in the BM (10-14, 18). As a 
result, the reduction of the numbers of mature 
B cells in the spleen of double mutant mice is 
much more drastic, when compared with Btk or 
SLP-65 single mutant mice (reference 18; Fig. 1 
A). We have previously shown that Btk-defi cient 
cells fail to effi ciently modulate the expression of 
developmentally regulated cell surface markers 
during the transition of large cycling into small 
resting cytoplasmic µ+ pre-B cells (14). In 
particular, in Btk-defi cient small pre-B cells the 
down-regulation of the pro-B/large pre-B stage-
specifi c markers SLC, the sialoglycoprotein 
CD43, and the metallopeptidase BP-1 and the 
up-regulation of CD2 and CD25/interleukin-2 
receptor, which are fi rst expressed on small 
preB cells, are impaired (14). To analyze the 
effect of SLP-65 inactivation or the concomitant 
defi ciency of SLP-65 and Btk on pre-B cell 
maturation, we compared the expression of 
these developmentally regulated markers in 
WT, Btk-defi cient, SLP-65-defi cient, and double 
mutant mice by fl ow cytometry. As MHC class 
II expression is also initiated at the pre-B cell 
stage (24), we included surface expression of 
MHC class II of cytoplasmic µ+ pre-B cells in the 
analyses. 
When compared with Btk-defi cient cells, 
SLP-65-/- pre-B cells manifested a slightly more 
pronounced defect in the down-regulation of 
CD43, BP-1, and SLC and in the up-regulation of 
CD25, CD2, and MHC class II expression (Fig. 1 
B). Consistent with the reported almost complete 
arrest at the pre-BCR+ stage (18), SLP-65/Btk 
double mutant pre-B cells had high forward 
scatter characteristics, were positive for CD43, 
BP-1, and SLC expression and showed very low 
surface expression of CD25, CD2, and MHCII 
(Fig. 1 B). 
Collectively, these fi ndings show that SLP-
65 and Btk have a synergistic role in the 
developmental progression of large cycling into 
small resting cytoplasmic µ+ pre-B cells. 
Defi cient Differentiation of Btk and SLP-65 
Mutant Pre-B Cells In Vitro.  Cytoplasmic µ+ pre-
B cells undergo rapid cell division in response 
to IL-7 in vitro, whereby subsequent removal 
of IL-7 strongly induces exit from cell cycle and 
further differentiation into surface IgM+ B cells 
(25). We previously reported that Btk and SLP-65 
single mutant pre-B cells manifest an enhanced 
proliferative response to IL-7 (14, 16). When we 
compared total BM cells from Btk and SLP-65 
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single mutants and the double mutant, these three 
groups of mice showed similar [3H]thymidine 
incorporation values after 5 d of culture in the 
presence of 100 U/ml IL-7 (Fig. 2 A). When total 
BM cell suspensions from WT mice were cultured 
in the presence of IL-7 for 7 d, the majority of cells 
consisted of B220+ cytoplasmic µ+ pre-B cells that 
were surface µ- or µlow, while a signifi cant fraction 
(~20–30%) performed productive κ L chain 
rearrangements and matured to surface IgM+IgD- 
or IgM+IgD+ B cell stages (Fig. 2 B, thin lines). 
In contrast, the IL-7 driven BM cultures from 
Btk and SLP-65 single or double mutant mice 
consisted almost exclusively of large µ+ SLC+ pre-
B cells which did not express κ L chains in their 
cytoplasm (Fig. 2 B, thin lines). 
To analyze the differentiation capacity of 
pre-B cells, BM cells were cultured in the 
presence of IL-7 for 5 d and subsequently for 
2 d on S17 stroma cells in the absence of IL-
7. Under these conditions, WT cells acquired 
low FSC characteristics and ~50% of the cells 
showed productive κ L chain rearrangement and 
differentiated into IgM+IgD+ cells. In contrast, the 
cultures from Btk-defi cient mice contained no 
IgD-positive cells, a smaller fraction (~25%) of 
cytoplasmic κ+ cells, and a signifi cant proportion 
of SLC+ cells. The defects were more pronounced 
in the cultures from SLP-65-/- and Btk/SLP-65 
double mutant mice, which were characterized by 
an ineffi cient exit from cell cycle and a dominance 
of SLC+κ- pre-B cells. In this respect, these two 
groups of mice were not signifi cantly different. 
Only when BM cells were cultured in the 
presence of limiting concentrations of IL-7 for 7 d, 
a difference between SLP-65 single mutant and 
SLP-65/Btk double mutant mice was noticed (Fig. 
2 C). At low IL-7 concentrations, preB cell division 
was limited and cells rapidly differentiated into 
surface IgM+ B cells. Within the population of 
small noncycling B220+ cells, the percentage 
of surface IgM+ cells was lower in SLP-65/Btk 
double mutant mice, when compared with WT, 
Btk, or SLP-65 single mutant mice. These results 
indicate that, in the absence of SLP-65, Btk 
functions to enhance differentiation to sIgM+ B 
cells at low IL-7 concentrations. 
Taken together, these fi ndings show that in the 
presence of IL-7 Btk, SLP-65, and double mutant 
pre-B cells show increased proliferation and 
enhanced pre-BCR expression, when compared 
with WT pre-B cells. The ability to down-regulate 
SLC expression and to differentiate into IgM+ B 
cells upon IL-7 withdrawal, is mildly affected in 
Btk-defi cient mice, more severely in SLP-65-
/- mice, and even more so in SLP-65/Btk double 
mutant mice. 
Btk/SLP-65 Double Mutant Mice Have a High 
Incidence of Pre-B Cell Lymphoma.       SLP- 
65-/- mice develop spontaneous pre-B cell 
tumors, with a frequency of <10% at 16 wk of 
age (16). When we followed a panel of SLP-65 
single mutant mice up to 16 wk, ~5% (3 out of 
66) developed a lymphoma. Remarkably, when 
SLP-65/Btk double mutant mice were followed 
for 16 wk, a signifi cantly enhanced frequency 
of tumor development was noticed, because 
75% of these mice (12 out of 16) developed a 
pre-B cell lymphoma. In these mice external 
Figure 1. Impaired pre-B cell maturation in Btk-defi cient, 
SLP-65-defi cient, and Btk/SLP-65 double mutant 
mice. (A) Flow cytometric analysis of surface IgM/IgD 
expression on total lymphoid cells in the spleen. (B) 
Expression profi les of B220 and IgM on total lymphoid 
cells in the BM (top). The B220+IgM- pro-/pre-B cell 
fraction was gated and analyzed for the indicated 
markers (bottom). Data are displayed as dot plots and 
the percentages of cells within the indicated quadrants 
or gates are given. Data shown are representative of 
four mice examined within each group.
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examination revealed either directly the presence 
of solid tumors, mainly close to the scapula, or 
indirectly as the mice displayed pareses of the 
hind limbs. In general, the mice also developed 
splenomegaly, and enlargement of the lymph 
nodes. Comparable tumors were not found in WT 
or Btk-defi cient mice (less than 1/4,000 mice). 
The Kaplan-Meier tumor-free survival curves for 
the SLP-65 single and SLP-65/Btk double mutant 
mice are shown in Fig.3 A. 
These results demonstrate that defi ciency of 
Btk strongly increases the frequency of tumor 
formation in SLP-65-/- mice, indicating that Btk 
cooperates with SLP-65 as a tumor suppressor 
in preB cells. 
Constitutive Active BtkAct Prevents Pre-B Cell 
Tumor Formation in Btk/SLP-65 Double Mutant 
Mice.   The fi nding that Btk apparently cooperated 
with SLP-65 as a tumor suppressor prompted us 
to investigate whether transgenic expression of 
a constitutive active Btk mutant could prevent 
tumor development in SLP-65-defi cient mice. 
The PH domain gain-of-function mutant E41K 
shows increased membrane localization and 
phosphorylation in quiescent cells, independent 
of PI3K activity and induces transformation of 
3T3 fi broblasts in soft agar cultures (26, 27). 
This capacity is augmented by mutation of the 
main autophosphorylation site in the Btk SH3 
domain (Y223F; reference 28). In Ramos B cells 
expression of E41K-Btk enhances the sustained 
increase in intracellular [Ca2+] after BCR cross-
linking (29). Thus, the E41K mutant and the 
E41K-Y223F double mutant represent activated 
Figure 2. Analysis of IL-7 driven BM 
cultures from Btk and SLP-65 mutant 
mice. (A) Proliferative response to 100 U/
ml IL-7, as determined by [3H]thymidine 
incorporation after 5 d of culture. Bars 
represent mean cpm and SEM of 
triplicate cultures. (B) Forward scatter 
(FSC) values and expression profi les 
of IgM, IgD, SLC, and cytoplasmic κ L 
chain of IL-7 driven BM cultures from 
the indicated mice. Data are displayed 
as histogram overlays of B220+ cells, 
either cultured under proliferating 
conditions (with 100 U/ml IL-7 for 7 
d, thin lines) or under differentiating 
conditions (after 5 d of culture with IL-
7 and subsequently without IL-7 for 2 
d, bold lines). The percentages shown 
represent the fractions of the cells that 
are within the indicated marker under 
the two different culture conditions. (C) 
Percentage of surface IgM+ cells within 
the fraction of small FSC B220+ cells 
after 7 d of culture in the presence of 
the indicated concentrations of IL-7. 
Data are representative of four mice 
per group.
Figure 3. (A) Kaplan-Meier tumor-free 
survival estimates for Btk-defi cient 
(dotted line), SLP-65-/- (thin line), and 
Btk-SLP-65-/- mice (bold line). Tumor-
free survival in Btk-SLP-65-/- mice was 
signifi cantly reduced (P < 0.0001 by 
log-rank) compared with SLP-65-/- mice. 
(B) Kaplan-Meier tumor-free survival 
estimates for SLP-65-/- (thin line) and 
BtkActSLP-65-/- mice (dotted line). Tumor-
free survival in BtkActSLP-65-/- mice was 
signifi cantly enhanced (P = 0.04 by log-
rank) compared with SLP-65-/- mice.
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forms of Btk. When E41K-Btk was expressed at 
physiological levels in transgenic mice under the 
control of the B cell–specifi c CD19 promoter, B 
cell development was arrested at the immature 
B cells in the BM (probably because the E41K-
Btk mutant mimics BCR occupancy by auto-
antigens), while residual B cells were effi ciently 
driven into IgM plasma cell differentiation (21). 
We recently generated a panel of 7 independent 
E41K-Btk (n = 3) or E41K-Y223F-Btk (n = 4) 
transgenic mouse lines, which were crossed onto 
the Btk null background. Expression of the two 
different mutants resulted in parallel phenotypes, 
whereby the deletion at the immature B cell 
stage was dose-dependent (unpublished data). 
From this panel we selected a low-copy E41K-
Y223F-Btk transgenic mouse strain (BtkAct), 
in which the extent of the B cell arrest was 
limited, while the fi nding of enhanced protein 
tyrosine phosphorylation in splenic B cells and 
signifi cantly increased serum IgM levels provided 
evidence for the constitutive active nature of BtkAct 
in vivo (see below; Fig. 4, A-C). 
BtkAct mice were crossed onto the Btk/SLP-65 
double mutant background and a panel of 20 
transgenic mice was followed for 8 mo. At this 
age, the fraction of SLP-65-/- mice that developed 
a preB cell lymphoma increased to 18% (12 out 
of 66; Fig. 3 B). In contrast, none of the BtkAct 
transgenic mice on the Btk/SLP-65 double 
mutant background developed lymphoma (Fig. 
3 B). When these BtkAct mice were killed at 8 mo, 
no evidence for ongoing pre-B cell proliferation 
was found: pre-B cell numbers in the BM were 
not increased and splenomegaly or pre-B cell 
infi ltrations into the spleen were absent. 
These fi ndings show that substitution of 
endogenous Btk by low levels of constitutively 
activated Btk prevents tumor formation in SLP-
65–defi cient mice. Therefore, we conclude that 
BtkAct can substitute for SLP-65 as a tumor 
suppressor in pre-B cells. 
Low Level BtkAct Expression Can Partially 
Substitute for the Absence of Btk and SLP-
65. BtkAct protein expression was analyzed 
by Western blotting of purifi ed B cell fractions 
from BM and spleen, in which Btk protein was 
visible as a single ~77 kD band (Fig. 4 A). 
Figure 4. Low-level BtkAct expression can partially substitute for the absence of Btk and SLP-65. (A) Western blotting 
analysis of Btk expression in WT and BtkAct B cells from BM and spleen. Membrane was reblotted with anti-Erk. (B) 
Protein tyrosine phosphorylation in extracts of untreated and anti-IgM stimulated WT or BtkAct splenic B cells, analyzed 
by immunoblotting with a phosphotyrosine (pY)-specifi c antibody. Membrane was reblotted with anti-Erk. (C) Serum 
concentrations of IgM and IgG3 in the indicated mutant mouse strains. Mice were 2 mo of ages and each symbol 
represents an individual animal. (D) Flow cytometric analysis of surface IgM/IgD expression on total lymphoid cells 
in the spleen of the indicated mice. (E) Expression profi les of B220 and IgM on total lymphoid cells in the BM of the 
indicated mice (top). The B220+IgM- pro-/pre-B cell fractions were gated and analyzed for CD43/FSC and cytoplasmic 
SLC and µ H chain (bottom). Data are displayed as dot plots and the percentages of cells within the indicated quadrants 
or gates are given. Data shown are representative of four mice examined within each group.
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Quantifi cation of Btk signals using Erk1/2 as a 
loading control showed that BtkAct expression 
was low (up to ~20% of the physiological 
levels). This was confi rmed in intracellular fl ow 
cytometry experiments by comparison of median 
fl uorescence intensities of transgenic BtkAct 
and endogenous Btk (unpublished data). The 
analysis of unstimulated and anti-IgM stimulated 
splenic B cells by immunoblotting with a 
phosphotyrosine-specifi c antibody revealed that 
BtkAct B cells exhibit enhanced protein tyrosine 
phosphorylation in vivo (Fig. 4 B). 
To evaluate the capacity of BtkAct to drive 
peripheral B cells into plasma cell differentiation, 
we determined serum IgM and IgG3 levels in 2-
mo-old BtkAct mice, both on a Btk-defi cient and on 
a Btk/SLP-65 double-defi cient background, with 
nontransgenic WT, Btk-, SLP-65-/-, and Btk/SLP-
65 double-defi cient mice as controls. Consistent 
with previous reports, the serum levels of IgM 
and IgG3 in mice defi cient for Btk or SLP-65 were 
signifi cantly decreased (10-12, 30). In Btk/SLP-
65 double mutant mice IgM levels equally low and 
IgG3 levels were even more reduced (Fig. 4 C). 
When BtkAct was expressed on the Btk-defi cient 
background, the levels of IgM in the serum were 
increased with a factor of ~5–10 and IgG3 levels 
were in the normal range, when compared with 
WT mice. Also the frequencies of IgM-producing 
cells in spleen and BM, as determined in an 
ELISPOT assay, were increased in these BtkAct 
mice (unpublished data). Expression of BtkAct 
completely corrected IgM levels and signifi cantly 
restored IgG3 levels in Btk/SLP-65 double mutant 
mice (Fig. 4 C). 
Flow cytometric analyses of the spleen 
revealed that low-level expression of BtkAct did not 
rescue the decrease in splenic B cell numbers in 
Btk-defi cient mice (Fig. 4 D). On the other hand, 
BtkAct expression also did not result in signifi cant 
deletion of peripheral B cells, in contrast to 
our previous fi ndings in mice expressing 
physiological levels of the E41K-Btk mutant (21). 
Expression of BtkAct partially restored the almost 
complete absence of splenic B cells in Btk/SLP-
65 double mutant mice, whereby their surface 
IgM/IgD profi les were similar to those in SLP-65 
single mutant mice (see Figs. 1 A and 4 D). In the 
bone marrow, expression of the BtkAct transgene 
corrected the maturation defects of Btk-defi cient 
cµ+ pre-B cells, i.e., the down-regulation of CD43 
and SLC expression and the up-regulation of CD2, 
CD25, and MHC class II expression (unpublished 
data; shown for CD43 and SLC in Fig. 4 E). In 
SLP-65-/- mice, substitution of endogenous Btk by 
very low levels of constitutively activated Btk was 
associated with a reduction of the percentages of 
SLC+ and CD43+ c?+ pre-B cells (Fig. 4 E). 
Taken together, comparison of SLP-65-/- and 
BtkAct SLP-65-/- mice with respect to serum Ig 
concentration and the maturation of pre-B cells in 
vivo indicate that low-level BtkAct expression can 
partially substitute for the absence of SLP-65. 
Characterization of Pre-B Cell Tumors. All 
pre-B cell tumors characterized expressed high 
levels of SLC and Ig µ H chain in their cytoplasm, 
irrespective of the Btk genotype of the SLP-65-
/- mice (Fig. 5 A). The two Btk+/- SLP-65-/- mice 
present in our panel of mutant mice also rapidly 
developed pre-B cell tumors. Because of the 
presence of a LacZ reporter in the targeted Btk 
allele, we could evaluate the X-chromosome 
inactivation status of the lymphoma cells (20). As 
Figure 5. Characterization of pre-B cell tumors by fl ow 
cytometry. (A) Dot plots for cytoplasmic SLC and µ H 
chain in gated B220+ cells from tumor samples from the 
indicated mice, grown for 1 to 3 wk in the presence of 
IL-7. (B) Flow cytometric analysis of lacZ expression 
in gated CD19+B220+ pre-B lymphoma cells in a lymph 
node from a Btk+/-SLP-65-/- mouse. (C) Phenotype of 
two pre-B cell lymphoma cultures, showing variable 
expression of cytoplasmic κ L chain, CD43, and CD2. 
Cell suspensions were stained for the indicated markers 
in combination with B220, and the results are displayed 
as dot plots of gated B220+ cells. (D) Phenotype of two 
separate tumor cell suspensions derived from BM and 
mesenteric lymph node from a single mouse, which were 
cultured in the presence of Il-7 for 7 d.
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a result of the process of random X-chromosome 
inactivation in Btk+/- heterozygous females, each 
X chromosome is active in about half of the pre-B 
cells. Similar to fi ndings in lymphoma cells from 
male Btk-SLP-65-/- mice, we observed that the 
majority of lymphoma cells from Btk+/-SLP-65-/- 
mice were LacZ+. These results indicate that the 
Btk+/- lymphoma cells carried the disrupted Btk 
allele on the active X chromosome and therefore 
were functionally Btk-defi cient (Fig. 5 B). 
As both Btk and SLP-65 are crucially 
involved in the modulation of pre-B cell surface 
makers and the initiation of Ig L chain gene 
rearrangement during the transition of large 
cycling into small resting cytoplasmic µ+ pre-
B cells, we were interested in the phenotype 
of pre-B cell lymphoma cells. Most pre-B cell 
lymphomas contained a (minor) fraction of 
cells that coexpressed κ L chain and SLC in 
their cytoplasma and showed variable surface 
expression of the developmentally regulated 
markers, such as CD43 and CD2 (Fig. 5 C). In 
general, the expression of SLC and cell surface 
markers remained stable when the tumor cells 
were cultured in the presence of IL-7. Some of 
these cell lines became IL-7 independent or lost 
expression of the IL-7R, as detectable by fl ow 
cytometry (unpublished data). When we cultured 
pre-B lymphoma cells derived from different 
tissues from a single Btk/SLP-65 double mutant 
mouse in vitro, we found that a BM-derived cell 
culture mainly consisted of κ L chain positive 
cells, while a lymph node–derived cell culture 
was essentially κ L chain negative. Nevertheless, 
both cultures expressed high levels of CD43 and 
low levels of CD2 (Fig. 5 D). 
Collectively, these results show that in the 
tumors the ordered differential expression of 
stage-specifi c pre-B cell markers (CD43, SLC, and 
BP-1 on large cycling pre-B cells but CD2, CD25, 
and MHCII on small resting pre-B cells) is lost. 
Furthermore, the fi nding of variable percentages 
of κ L chain expressing cells in the pre-B cell 
lymphomas suggests that in the absence of SLP-
65 Ig L chain locus rearrangements are initiated 
in large cycling pre-BCR+ cells. 
Btk and SLP-65 Cooperate as Tumor 
Suppressors.  By crossing SLP-65-/- mice with 
mice that were either Btk-defi cient or expressed 
a constitutive active form of Btk we have 
demonstrated in this report that (a) Btk and SLP-
65 have synergistic roles in the developmental 
progression of large cycling into small resting 
pre-B cells, (b) the concomitant defi ciency of Btk 
signifi cantly enhanced tumor formation in SLP-65-
/- mice, and (c) expression of BtkAct prevents tumor 
formation in Btk/SLP-65 double mutant mice. We 
therefore conclude that BtkAct compensates for 
loss of SLP-65 tumor suppressor function, either 
by promoting pre-B cell differentiation or limiting 
pre-B cell expansion independent of SLP-65. 
In contrast to SLP-65-/- mice, Btk/SLP-65 
double mutant mice exhibit an almost complete 
arrest at the large cycling pre-BCR+ pre-B cell 
stage. Thus, it is conceivable that the increased 
frequency of malignant transformation in Btk/SLP-
65 double mutant mice refl ects the increased pool 
size of proliferating pre-B cells with a reduced 
ability to progress into CD43- small resting pre-B 
cells, when compared with SLP-65 single mutant 
mice. Alternatively, the absence of Btk may alter 
the proliferative capacities of SLP-65-/- pre-B cells 
in a signaling pathway different from the pre-
BCR. In this respect, the IL-7R pathway would 
be an attractive candidate, as Btk-defi cient RAG-
1-/- pro-B cells were shown to have an increased 
responsiveness to IL-7, when compared with 
Btk+ RAG-1-/- pro-B cells (14). A third possibility 
would be that the concomitant absence of 
Btk and SLP-65 precludes the effi cient down-
regulation of RAG enzyme levels upon pre-BCR 
signaling (1, 2). The fi nding of SLC and κ L chain 
coexpression in the pre-B cell tumors suggests 
that Ig L chain rearrangements have occurred in 
large pre-BCR+ cycling pre-B cells. This implies 
that the V(D)J recombination machinery is active 
in SLP-65-/- cycling pre-B cells, which may cause 
DNA damage contributing to the induction of 
secondary mutations required for malignant 
transformation. Further experiments comparing 
Btk+ and Btk- SLP-65-defi cient preB cell tumor 
cells should identify the nature of the cooperation 
between Btk and SLP-65 as tumor suppressors. 
In this context, we found that Btk expression 
levels vary considerably between different pre-B 
cell lines established from SLP-65-/- mice. Btk 
was not detectable in 1 out of 6 SLP-65-/- pre-B 
cell lines by Western blotting, suggesting that 
Btk could be a target for secondary mutations in 
SLP-65-/- mice (unpublished data). As SLP-65 is 
implicated in childhood pre-B ALL (19), the fi nding 
of cooperation between Btk and SLP-65 may also 
have important implications for our understanding 
of the etiology of this malignancy in humans. 
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Abstract
Bruton’s tyrosine kinase (Btk) and the B cell linker protein SLP-65 have a synergistic role 
at the transition of large cycling into small resting pre-B cells. SLP-65/Btk double defi cient 
mice manifest an almost complete block in B cell development at the large cycling pre-B 
cell stage, which is associated with a high incidence of pre-B cell lymphoma. We have 
recently shown that Btk partially acts as an adapter molecule, independent of its catalytic 
activity. Here, we investigated whether Btk adapter function is dependent on the presence 
of SLP-65, which in this context might serve as a scaffold molecule to bring other kinase 
proteins in close proximity to Btk and its substrates. To this end, we crossed transgenic 
mice expressing the kinase-inactive K430R-Btk mutant onto a SLP-65-defi cient 
background. We observed that kinase-inactive Btk was able to rescue the severe 
developmental arrest at the pre-B cell stage present in SLP-65/Btk double defi cient mice, 
indicating that SLP-65 is not required for Btk adapter function. Moreover, expression 
of kinase-inactive Btk signifi cantly reduced the high frequency of pre-B cell lymphoma 
found in SLP-65/Btk double defi cient mice. Therefore, we conclude that in SLP-65-
defi cient pre-B cells Btk exerts its tumor suppressor function as an adapter protein. 
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Abbreviations used in this paper: BCR, B cell receptor; 
BM, bone marrow; Btk, Bruton’s tyrosine kinase; SLC, 
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Introduction
A mature B cell receptor (BCR) is composed of 
two Immunoglobulin (Ig) heavy (H) and two light 
(L) chains. During B cell development, fi rst the µ 
H chain is rearranged in pro-B cells and together 
with the non-rearranging VpreB and λ5 surrogate 
light chain (SLC) proteins and the Ig-α/CD79a 
and Ig-β/CD79b signalling components, the 
pre-BCR complex is formed. Expression of a 
pre-BCR on the cell surface acts as a checkpoint 
to monitor the expression of a functional Ig 
µ H chain, resulting from successful V(D)J 
recombination 1,2. The pre-BCR is transiently 
expressed on the cell surface and is essential 
for the induction of proliferative expansion of 
pre-B cells and their developmental progression 
into small pre-B cells in which Ig L chain 
rearrangement occurs. It appears that the pre-
BCR has a ligand-independent signal transducing 
capacity which involves the formation of a lipid 
raft-associated signalling module, composed 
of the tyrosine phosphorylated proteins Lyn, 
Syk, B cell linker protein SLP-65 (also known 
as BLNK or BASH), phosphoinositol 3-kinase 
(PI3K), Bruton’s tyrosine kinase (Btk), Vav and 
phospholipase Cγ2 (PLCγ2) 3-5. Activation of 
PLCγ2 induces hydrolysis of phosphatidylinositol 
bisphosphate (PIP2) into inositol trisphosphate 
(IP3) and diacylglycerol (DAG), which activate 
calcium signalling and protein kinase C (PKC), 
respectively.
By analogy with the BCR in mature B cells, Btk 
is most likely phosphorylated in pre-B cells by Syk 
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or the Src-family tyrosine kinase Lyn and recruited 
to the membrane by binding of the Btk-PH 
domain to the PI3K product phosphatidylinositol 
trisphosphate (PIP3) 6. In this signalling pathway 
SLP-65, when phosphorylated by Syk, plays 
an essential role as it provides docking sites 
for Btk as well as PLCγ2, thereby bringing Btk 
in close proximity with PLCγ2. This model was 
recently challenged by the observation that in 
mature B cells Btk is essential for the recruitment 
of phosphatidylinositol phosphate 5-kinases 
(PIP5K) to the membrane 7. Activation of PIP5K 
leads to local PIP2 synthesis by phosphorylation 
of phosphatidylinositol phosphate (PIP). As PIP2 
is the substrate for both PLCγ2 and PI3K, Btk was 
found to be the regulator of a positive feedback 
loop by providing the substrate for both its up- 
and downstream targets 7. 
Although Btk phosphorylates and activates 
PLCγ2 8, several lines of investigation have 
shown that Btk can also act as adaptor molecule 
independent of its catalytic activity. Expression of 
kinase-inactive Btk mutants have been shown to 
partially 7,9 or fully 10 reconstitute BCR-induced 
calcium mobilization in Btk-defi cient chicken DT40 
and human A20 mature B cell lines. In addition, 
phosphorylation of PLCγ2 upon BCR stimulation 
appears to be unaffected in human Btk-defi cient 
B cell lines 11.  More recently, we have shown 
that transgenic expression of the kinase-inactive 
K430R-Btk mutant in vivo partially restored Btk-
dependent defects in the transition of large into 
small pre-B cells in BM of Btk-defi cient mice 12. 
Furthermore, the association of Btk with PIP5K 
was shown to be independent of the enzymatic 
activity of Btk in A20 B cells that were infected 
with viruses expressing kinase-dead Btk 7.
Recently we and others have shown that both 
SLP-65 and Btk are essential for the regulation of 
pre-B cell development, in particular by limiting 
pre-B cell expansion at the transition of large 
cycling into small pre-B cells 13-17. A synergistic 
role of SLP-65 and Btk was demonstrated by 
the almost complete block in B cell development 
at the pre-BCR+ pre-B cell stage in SLP-65/Btk 
double defi cient mice, compared to the partial 
block at this stage in SLP-65 or Btk single mutant 
mice 18-20. It was reported that SLP-65- mice 
spontaneously develop pre-B cell lymphomas 
expressing high levels of the pre-BCR on the 
cell surface 19,21. Although Btk-defi cient mice 
do not develop pre-B cell tumors, we recently 
found that Btk cooperates with SLP-65 as a 
tumor suppressor as the incidence of pre-B cell 
lymphomas was signifi cantly higher in SLP-
65/Btk double mutant mice (~75% at 16 weeks 
of age), when compared with SLP-65 single 
defi cient mice (<10%). Moreover, transgenic 
expression of the constitutive active E41K-Y223F 
Btk mutant, which shows enhanced membrane 
localisation 22,23, prevented tumor formation in 
Btk/SLP-65 double defi cient mice 20. 
The mechanism by which Btk exerts its 
function in pre-B cells independent of its catalytic 
activity is currently unknown. Kinase-inactive Btk 
may act as an adapter protein by using SLP-65 
as a scaffold molecule to bring other tyrosine 
kinase proteins, such as Syk, in close proximity 
with PLCγ2. Alternatively, it is possible that the 
adapter function of Btk is independent of SLP-
65, since activated kinase-inactive Btk has the 
capacity to recruit PIP5K to the membrane, 
thereby activating the positive feedback loop 
for synthesis of the PLCγ2 substrate PIP2. In 
this study, we investigated if SLP-65 is required 
for the adapter function of Btk and investigated 
developmental progression of pre-B cells and 
the frequency of pre-B cell tumor formation in 
K430R-Btk transgenic mice on a Btk/SLP-65 
double defi cient background. 
Materials and Methods
Mice and genotyping.  Btk-defi cient mice 24 and 
SLP-65-defi cient mice 13 were on the C57BL/6 
and Balb/c background, respectively.  WT or KO 
alleles were identifi ed as described previously 17, 
20. The presence of the Btk-K430R transgene was 
evaluated by PCR 12. 
Cell culture and Flow cytometry.  Preparations 
of single-cell suspensions, primary pre-B cell 
BM cultures, determination of IL-7 dependent 
proliferative responses of total BM cells and 
standard and intracellular fl ow cytometry have 
been described previously 17,24,25. The hybridoma 
LM34 (anti-SLC; 26) was kindly provided by A. 
Rolink (University of Basel, Basel, Switzerland). 
Ig detection in serum.  Levels of Ig subclasses 
in serum were measured by sandwich ELISA, as 
described previously 27. 
Western blotting. BM cells from SLP-65-
defi cient mice were cultured for 5 days in the 
presence of 100U/ml IL-7 (Sigma-Aldrich, St. 
Louis, MO). Cells from SLP-65-/- pre-B cell 
lymphomas were cultured in IMDM/10% FSC. 
For analysis of Btk phosphorylation, cells were 
stimulated with 10 µg/ml F(ab’)2 fragment 
of polyclonal goat-anti-mouse IgM (Jackson 
Immuno Research, Westgrove, PA) in RPMI1640 
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at 37oC. Lysates of unstimulated or stimulated 
cells were blotted with anti-phosphotyrosine 
(α-pTyr-100, Cell Signaling Technology, Beverly, 
MA) or incubated overnight at 4oC with α-pTyr-
100 before samples were blotted using standard 
SDS-PAGE procedures 28. Anti-Btk C-20 
(SantaCruz Biotechnology,Santa Cruz, CA) was 
used for Btk-specifi c immunoblotting. 
Results
SLP-65 is not required for pre-BCR-induced 
tyrosine phosphorylation of Btk. The fi nding that 
Btk and SLP-65 have a synergistic function in 
the developmental progression of large cycling 
into small resting pre-B cells, suggests that 
the two proteins can at least partially act in 
separate pathways. This would however be 
in apparent confl ict with the observation that 
SLP-65 is required for BCR-induced tyrosine 
phosphorylation and subsequent activation of 
Btk in chicken DT40 B cells 29. To address this 
issue, we investigated Btk phosphorylation in the 
absence of SLP-65 by stimulation of cultured pre-
B cells from SLP-65 defi cient mice with antibodies 
directed against the Igµ H chain protein. Blotting 
total cellular lysated with a pTyr-specifi c 
monoclonal antibody was used to monitor the 
stimulation of the cells. Tyrosine phosphorylated 
proteins were immunoprecipitated from total 
cellular lysates using pTyr-specifi c mAb and 
Btk protein was identifi ed by blotting with a 
Btk-specifi c antibody. As shown in Fig. 1A, 
Igµ stimulation in SLP-65 defi cient pre-B cells 
resulted in Btk phosphorylation. Similarly, we 
analysed Btk-specifi c phosphorylation in pre-
B lymphoma cell lines derived from SLP-65 
defi cient mice (Fig. 1B). These fi ndings show 
that, in contrast to previous fi ndings in chicken B 
cells, Btk can be phosphorylated in the absence 
of SLP-65 upon pre-BCR stimulation in murine 
pre-B cells. 
Transgenic K430R-Btk expression partially 
corrects the defects in B cell development in 
Btk/SLP-65 double mutant mice. Mice defi cient 
for either Btk or SLP-65 have a partial block in 
B cell development at the pre-B cell stage in the 
BM, while Btk/SLP-65 double defi cient mice have 
Figure 1. Btk is phosphorylated in the absence of SLP-
65. (A) BM B cells from SLP-65 mice was cultured for 5 
days in the presence of IL-7. Cells were harvested and 
stimulated with polyclonal anti-IgM F(ab’)2 fragments 
for the time indicated. Stimulation was analysed by 
Western blotting of total lysates using anti-pTyr mAbs. 
Total lysates were immuno-precipitated with anti-pTyr 
and tyrosine phosphorylation of Btk was analysed by 
Western blotting using Btk-specifi c Abs. (B) Cultured 
cells from two different SLP-65-/- pre-B cell lymphomas 
(BL#1 and BL#2) were analysed for Btk-specifi c 
phosphorylation as described in (A). 
Table 1. Absolute numbers of B cells in spleen and B cell subpopulations in bone marrow
a Absolute number as mean ± SEM (x 106). b The absolute numbers of splenic B220+ cells in K430R-Btk/SLP-65-/- was 
signifi cantly different from the value in SLP-65 single defi cient mice (P=0.008) and in Btk/SLP-65 double defi cient 
mice (P=0.002). c pro- and pre-B, immature and mature B cell subsets of BM B220+ cells.
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an almost complete block at this stage 13-18. As a 
result, the reduction in mature B cell numbers in 
double mutant mice is much more severe, when 
compared to Btk or SLP-65 single mutant mice 
18,20.  We have previously shown that expression 
of transgenic kinase-inactive K430R-Btk is able 
to partially rescue the block in peripheral B cell 
maturation in Btk-defi cient mice, indicating that 
Btk function is in part independent of its kinase 
activity.
To investigate whether SLP-65 is required 
for Btk adapter function, we replaced the 
endogenous wild-type Btk by kinase-inactive Btk 
by crossing K430R-Btk transgenic mice onto a 
Btk/SLP-65 double defi cient background. We 
analysed the size of the B cell subpopulations in 
spleen and BM by fl ow cytometry. In agreement 
with reported fi ndings 18,20, we observed a severe 
reduction in the size of the peripheral B cell 
population in Btk/SLP-65 double defi cient mice, 
when compared with wild-type mice or either of 
the single defi cient mice (Table 1; Fig. 2A). In 
addition, the residual B cells present in the spleen 
differentiated into IgMhighIgDhigh B cells, but failed 
to downregulate IgM (Fig. 2A). We found that the 
fractions of IgMhighIgDhigh (~6% in K430R-Btk/SLP-
65-/- mice, compared with ~8% in SLP-65-/- mice 
and ~1% in Btk/SLP-65 double defi cient mice) 
and IgMlowIgDhigh mature B cells (~3%, ~8% and 
undetectable, respectively, in these three groups 
of mice) in the spleen were partially restored (Fig. 
2A). However, the absolute B cell numbers in the 
spleen of K430R-Btk/SLP-65-/- mice are still low 
(~4 x 106) when compared with SLP-65 single 
defi cient mice (~11 x 106; Table 1). 
In the BM, the proportions of IgM+ B cells 
in K430R-Btk/SLP-65-/- (~15%) were similar to 
those in SLP-65 single defi cient mice (~14%) and 
were increased when compared with Btk/SLP-65 
double defi cient mice (~7%; Fig. 2B).  In a more 
detailed analysis of the B220+ population in which 
we analysed IgM/IgD expression profi les, we 
found that K430R-Btk/SLP-65-/- mice contained 
a signifi cantly larger fraction of IgM+IgDhigh 
recirculating B cells (~6%), when compared with 
Btk/SLP-65 double defi cient mice (~1%, Fig. 1C).
In summary, these results show that expression 
of kinase-inactive Btk is able to partially rescue 
the severe B cell differentiation defect in Btk/SLP-
65 double defi cient mice, resulting in a phenotype 
that is similar to that of SLP-65 defi cient mice. 
Therefore, these data indicate that the role 
of Btk as an adapter protein is at least in part 
independent of SLP-65.
Transgenic K430R-Btk expression partially 
corrects the pre-B cell defects in Btk/SLP-65 
double mutant mice. We have previously shown 
that Btk and SLP-65 are required for effi cient 
transition of large cycling into small resting 
cytoplasmic µ+ (cµ+) pre-B cells 17,20. In particular, 
the downregulation of the pro-B/large pre-B cell-
specifi c expression of SLC, CD43 and BP-1 and 
the upregulation of CD2, CD25 and MHC class 
II on small pre-B cells, were impaired in Btk and 
SLP-65 single mutant mice. A synergistic role 
for Btk and SLP-65 in this context is clear from 
the more pronounced defects in the modulation 
Figure 2. K430R-Btk partially corrects the defects 
in B cell development in Btk/SLP-65 double mutant 
mice. The phenotypic characterization of the B-lineage 
compartment in spleen and BM of K430R-Btk/SLP-65-
/- mice is compared to Btk- and SLP-65 single defi cient 
and Btk/SLP-65 double defi cient mice. (A) Splenic 
lymphoid cells were electronically gated on the basis 
of forward and side scatter and surface expression of 
IgM/IgD is plotted. (B-C) Lymphoid cells from BM were 
gated and analysed for (B) B220/IgM and (C) IgM/IgD 
expression. Data are presented as dot plots and the 
percentages within the indicated quadrants or gates are 
given. The plots are representative for 3-7 mice of each 
genotype.
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of most of these markers in Btk/SLP-65 double 
defi cient mice, perhaps with the exception of 
BP-1 and CD2 17,20. In addition, we reported that 
kinase-inactive Btk is able to partially restore the 
defects at the pre-B cell stage in Btk-defi cient 
mice 12. To analyse the effects of kinase-inactive 
Btk on pre-B cell maturation in the absence 
of SLP-65, we now compared the expression 
of developmentally regulated markers by fl ow 
cytometric analysis of the surface IgM- pro-B/
pre-B cell fraction of Btk+, Btk-, and K430R-Btk 
transgenic mice, either on a SLP-65+ or a SLP-65- 
background (Fig. 3). These analyses show that 
kinase-inactive Btk is able to rescue the defects 
found in IgM-cµ+ pre-B cells of Btk/SLP-65 double 
defi cient mice, as the observed expression levels 
of cSLC, CD43, CD25 and MHC class II are 
comparable in K430R-Btk SLP-65-/- mice (34%, 
45%, 38%, and 27%, respectively) and SLP-65-/- 
single defi cient mice (36%, 65%, 60% and 19%) 
(Fig. 3).
In summary, these results show that 
transgenic expression of kinase-inactive Btk is 
able to reduce the severe developmental defects 
in Btk/SLP65 double defi cient pre-B cells to a 
level present in SLP-65 single defi cient mice. 
Therefore, we conclude that the adapter function 
of Btk in pre-B cells in vivo apparently does not 
require SLP-65.
The effects of K430R-Btk expression on serum 
Ig levels. Btk- and SLP-65- defi cient mice have 
severely decreased levels of IgM and IgG3, 
while other isotypes are not or only moderately 
affected, when compared with wild-type levels 
13,20,30. Furthermore, we have found that kinase-
inactive Btk could signifi cantly restore the 
decreased levels of IgM in serum of Btk-defi cient 
mice, but only a modest increase in IgG3 was 
Figure 3. K430R-Btk partially corrects the pre-B cell defects in Btk/SLP-65 double mutant mice. The B220+IgM- pro-
/pre-B cell population in BM of Btk+, Btk-, or K430-Btk on a SLP-65+ or SLP-65- background was gated and analysed 
for (A) CD25/FSC, (B) CD43/FSC, (C) cSLC/cµ and (D) MHC class II/cµ expression profi les. Data are displayed as dot 
plots and the percentage of cells within the indicated quadrants is given. Data shown are representative of 3-7 mice 
analysed within each group. 
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observed 12. As shown in Fig. 4, serum levels 
of all isotypes are lower in Btk/SLP-65 double 
defi cient mice, when compared to either of the 
single mutant littermates. In accordance with 
the previous fi ndings that the kinase activity of 
Btk is not absolutely required for plasma cell 
differentiation 12, we now found that serum levels 
of IgM, IgG1, IgG2a, IgG2b and IgA in K430R 
transgenic Btk/SLP-65 double defi cient mice 
are similar to the levels found in SLP-65 single 
defi cient mice (Fig. 4). Only the levels of IgG3 
in Btk-, SLP-65-, Btk/SLP-65 double defi cient 
and K430R-Btk/SLP-65-/- mice are all lower than 
wild-type levels and close to the lower threshold 
of the ELISA. These results are in agreement 
with previous fi ndings in K430R-Btk mice 12 and 
further indicate that also with respect to late B 
cell and plasma differentiation, in the absence of 
SLP-65 Btk mainly acts as an adapter protein.
Kinase-inactive Btk functions as a tumor 
suppressor in SLP-65-defi cient pre-B cells. We 
recently reported that concomitant defi ciency 
of Btk strongly increased the frequency of pre-
B cell lymphoma formation in SLP-65- mice, 
indicating that Btk cooperates with SLP-65 as a 
tumor suppressor in pre-B cells 20. To investigate 
whether the tumor suppressor function of Btk is 
dependent on its kinase activity, we examined 
the capacity of K430R-Btk to substitute for Btk by 
following a panel of 43 K430R transgenic mice 
for ~30 weeks. At this age, the fraction of SLP-
65- mice that developed a pre-B cell lymphoma 
was ~15% (17 out of 118), whereas the Btk/SLP-
65 double defi cient mice showed a frequency of 
~40% (39 out of 97). In contrast, only six out of 
43 (~14%) K430R-Btk/SLP-65-defi cient mice 
died of a pre-B cell lymphoma (Fig. 5). From 
these results we conclude that kinase-inactive 
Btk can substitute for Btk as a tumor suppressor 
in SLP-65 defi cient mice, and therefore that the 
tumor suppressor function of Btk in pre-B cells is 
independent of its kinase activity.
Discussion
In this study we examined the adapter function 
of Btk in the absence of SLP-65. To this end, 
we crossed kinase-inactive K430R-Btk mutant 
mice with SLP-65-defi cient mice and examined 
B cell development in BM and spleen and the 
marker modulation during the transition of large 
into small pre-B cells in vivo by detailed fl ow 
cytometric analysis. Furthermore, we analysed 
serum Ig levels and the incidence of pre-B cell 
tumor formation. We found that expression of 
transgenic kinase-inactive Btk was largely able to 
rescue the severe defects present in SLP-65/Btk 
Figure 4. Kinase-inactive Btk restores 
the low serum Ig levels in Btk/SLP-
65 double mutant mice.  Serum 
concentrations of IgM, IgG1, IgG2a, 
IgG2b, IgG3 and IgA are shown for the 
indicated mouse strains. Mice were 2 mo 
of age and each symbol represents an 
individual animal.
Figure 5. Tumor suppressor function of Btk is not 
dependent on its kinase activity in SLP-65-defi cient pre-
B cells. Kaplan-Meier tumor-free survival estimates for 
SLP-65-/-, Btk/SLP-65 double defi cient and  K430R-Btk/
SLP-65-/- mice. Tumor-free survival in Btk/SLP-65 double 
defi cient mice was signifi cantly reduced compared with 
SLP-65- mice (P<0.00001, by log-rank) and to K430R-
Btk/SLP-65-/- mice (P<0.035). Tumor free survival in 
SLP-65- and K430R-Btk/SLP-65-/- was not signifi cantly 
different. 
Btk functions as an adapter molecule in the absence of SLP-65
157
double defi cient mice to such an extent that the 
resulting phenotype was similar to that of SLP-65 
single defi cient mice. In particular, we found that 
SLP-65 is not required for the function of Btk as 
an adapter molecule that signals the upregulation 
of CD25 and MHC class II expression and 
the downregulation of CD43 and SLC chain 
expression and acts as a tumor suppressor in 
pre-B cells. Therefore, we conclude that the Btk 
kinase domain is not required for its function as 
a tumor suppressor in SLP-65 defi cient pre-B 
cells. 
The mechanism by which kinase-inactive 
Btk may act as a tumor suppressor in pre-B 
cells remains unknown. However, together 
with recently published fi ndings, our data 
would support the presence of a parallel SLP-
65-independent escape route in pre-B cells 
in which Btk activates PLCγ2 by recruiting 
PIP5K, thereby providing substrate for PLCγ2 7. 
Engagement of the pre-B cell receptor leads to 
activation of Src family kinases, phosphorylation 
of immunoreceptor tyrosine-based activation 
motifs (ITAMs) on Ig-α and Ig-β and recruitment, 
phosphorylation and activation of Syk. By 
analogy with the BCR in mature B cells, in a SLP-
65 dependent pathway, Syk also phosphorylates 
SLP-65 and Btk is activated by Src kinases or 
Syk by phosphorylation at Y551 and subsequent 
autophosphorylation at Y223 31,32. Activated 
Btk then induces tyrosine phosphorylation of 
PLCγ2 9. Production of IP3 and DAG by PLCγ2 
induces calcium mobilization and PKC activation, 
respectively. The mobilization of intracellular 
calcium is one of the major targets of BCR 
signaling and is critical for the regulation of 
multiple transcription factors such as NFκB and 
Nuclear Factor of Activated T cells (NFAT) 33-36.
However, it recently became apparent that, 
next to this pathway, kinase-inactive Btk is 
able to recruit PIP5K, thereby activating a 
positive feedback loop for PIP2 synthesis, the 
substrate for PI3K and PLCγ2 7. PI3K products 
are necessary to localize Btk to the plasma 
membrane after its activation and inhibition of 
PI3K blocks Btk-dependent PLCγ2 activation 
37. Furthermore, in reconstituted myeloma 
cells, CD19 has been shown to be necessary 
for effi cient BCR-mediated activation of Btk 38, 
most likely through the PI3K pathway and the 
production of PIP3 in concert with Lyn-mediated 
phosphorylation of Btk 39,40. 
Taken together, these data provide the 
biochemical basis for a parallel SLP-65-
independent escape route when Btk is not able to 
phosphorylate PLCγ2 directly: upon activation by 
Lyn or Syk, Btk is able to bind to PIP3 and PIP5K 
is recruited and provides substrate for PLCγ2 
and PI3K. This mechanism may also explain the 
phenotype of CD19/SLP-65 double defi cient mice 
21. In these mice, pre-B cell differentiation was 
completely blocked and they manifested a high 
frequency of pre-B cell lymphoma development, 
a phenotype quite similar as the phenotype of 
Btk/SLP-65 double defi cient mice 18,20.  Therefore, 
we propose that the SLP-65-independent parallel 
PLCγ2 activation pathway requires both Btk (as 
an adapter protein) and CD19-dependent PIP3 
synthesis by PI3K.
The possibility remains that SLP-65 defi ciency 
can be compensated by the presence of 
redundant proteins, as the concomitant absence 
of LAT in SLP-65-/- mice resulted in an almost 
complete block at the large pre-B cell stage 41. 
Furthermore, it was shown that LAT recruits 
PLCγ2 to the pre-BCR by association with Ig-α 
and the SLP-65 homologue SLP-76 upon pre-
BCR engagement. These results indicate that 
LAT/SLP-76 can rescue PLCγ2 activation in the 
absence of SLP-65 41. However, in this model 
the capacity of LAT/SLP-76 to replace SLP-65 
function would be dependent on the presence of 
Btk as an adapter molecule. Further experiments 
are required to investigate if Btk can interact with 
LAT or SLP-76. 
In summary our results, in combination 
with recent reports about alternative signalling 
pathways, indicate that membrane recruitment of 
Btk, leading to activation of PIP5K and PLCγ2 is 
suffi cient for Btk function as a tumor suppressor in 
pre-B cells. In this SLP-65-independent pathway, 
Btk functions as an adapter protein, independent 
of its catalytic activity. 
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Abstract
In the mouse, Bruton’s tyrosine kinase (Btk) is essential for effi cient developmental 
progression of CD43+CD2- large cycling into CD43-CD2+ small resting pre-B cells in 
the bone marrow and of IgMhigh transitional type 2 B cells into IgMlow mature B cells in 
the spleen. In this study, we show that the impaired induction of cell surface changes 
in Btk-defi cient pre-B cells was still noticeable in κ+ immature B cells, but was largely 
corrected in λ+ immature B cells. As λ gene rearrangements are programmed to follow κ 
rearrangements and λ expression is associated with receptor editing, we hypothesized 
that the transit time through the pre-B cell compartment or receptor editing may affect 
the extent of the cellular maturation defects in Btk-defi cient B cells. To address this 
issue, we used 3-83µδ transgenic mice, which prematurely express a complete B cell 
receptor and therefore manifest accelerated B cell development. In Btk-defi cient 3-
83µδ mice, the IgM+ B cells in the bone marrow exhibited a very immature phenotype 
(pre-BCR+CD43+CD2-) and were arrested at the transitional type 1 B cell stage upon 
arrival in the spleen. However, these cellular maturation defects were largely restored 
when Btk-defi cient 3-83µδ B cells were on a centrally deleting background and therefore 
targeted for receptor editing. Providing an extended time window for developing B cells by 
enforced expression of the antiapoptotic gene Bcl-2 did not alter the Btk dependence of 
their cellular maturation. We conclude that premature B cell receptor expression amplifi es 
the cellular maturation defects in Btk-defi cient B cells, while extensive receptor editing 
reduces these defects. 
Address correspondence and reprint requests to Dr. 
Rudolf W. Hendriks, Department of Immunology, Room 
Ee851, Erasmus MC Rotterdam, P.O. Box 1738, NL-
3000 DR Rotterdam, The Netherlands. E-mail address: 
r.hendriks@erasmusmc.nl
Abbreviations used in this paper: BCR, B cell receptor; 
SLC, surrogate L chain; BM, bone marrow; Btk, Bruton’s 
tyrosine kinase; Tg, transgenic; WT, wild type; cµ, 
cytoplasmic µ H chain; BrdU, 5-bromo-2-deoxyuridine; 
T1/2, transitional type 1 and 2. 
Introduction
The generation of B cells from progenitor cells is 
a complex process involving the transit of cells 
through several critical developmental stages. 
Developing B cell precursors in the bone marrow 
pass several checkpoints at which they are 
subject to choices between survival, proliferation, 
or cell death dependent on the presence of 
functional Ig H and L chains. Expression of 
the pre-B cell receptor (pre-BCR) complex, 
comprised of µ H chain, the VpreB and λ5 surrogate 
L chain (SLC) proteins, and the Igα/CD79a and 
Igβ/CD79b signaling components, is essential 
for IL-7-dependent proliferative expansion of 
cytoplasmic µ H chain positive (cµ+) pre-B cells 
(1, 2). In addition, the pre-BCR triggers the 
inhibition of further H chain rearrangements, 
known as allelic exclusion, as well as drastic 
changes of pre-B cell surface phenotype. 
Furthermore, the down-regulation of proliferation 
in large cycling pre-B cells and the induction 
of progression into small resting pre-B cells, in 
which Ig L chain rearrangement is initiated, are 
regulated by the pre-BCR. Signaling proteins 
involved in the downstream pathway of the pre-
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BCR include the Lyn, Syk, and Bruton’s tyrosine 
kinase (Btk) tyrosine kinases, phosphoinositide 
3-kinase (consisting of p85 and p110 subunits), 
the B cell linker protein BLNK/SLP-65 and the 
phospholipase Cγ2. Cytoplasmic µ+ pre-B cells 
of mice defi cient for the pre-BCR components 
λ5, VpreB, membrane µ H chain, Igα, or Igβ or the 
pre-BCR signaling molecules Syk or p85α do not 
enter the expansion phase (reviewed in Ref. 3). 
In contrast, absence of the pre-BCR signaling 
proteins Btk and BLNK/SLP-65 was shown to be 
associated with defects in cell cycle exit, resulting 
in a high incidence of pre-B cell tumors (4-8). 
In SLP-65-defi cient mice, and even more so in 
Btk/SLP-65 double mutant mice, large cycling 
pre-B cells are trapped in a positive feedback 
loop as they are arrested in development and 
cannot effi ciently down-regulate pre-BCR 
expression, which signals for proliferation (7-
9). Mutations in the Btk gene result in X-linked 
agammaglobulinemia in humans and x-linked 
immunodefi ciency (xid) in the mouse (10). X-
linked agammaglobulinemia is characterized by a 
severe arrest of B cell development at the pre-B 
cell stage, and consequently peripheral B cells 
and Abs of all subclasses are almost completely 
absent. xid mice manifest a milder phenotype 
associated with an impairment of peripheral B 
cell maturation, without a major early block in B 
cell development in the bone marrow (BM). As 
a result, peripheral B cells are present in lower 
numbers and serum IgM and IgG3 levels are 
low. 
Recently, we have shown that pre-B cell 
differentiation in Btk-defi cient mice is impaired 
(5, 8). During the transition of large cycling into 
small resting pre-B cells, Btk-defi cient mice 
fail to effi ciently modulate the expression of 
SLC, the metallopeptidase BP-1, the adhesion 
molecule CD2, the IL-2R CD25, MHC class 
II, and the membrane sialoglycoprotein CD43. 
Moreover, in an analysis of the kinetics of pre-
B cell differentiation in vivo, Btk-defi cient cells 
manifested a specifi c developmental delay within 
the small pre-B cell compartment of ~3 h when 
compared with wild type (WT) cells. Despite the 
similar absolute numbers of immature B cells 
generated in both mice, Btk- immature B cells are 
phenotypically different from WT immature B cells. 
The impaired induction of cell surface changes in 
Btk-defi cient small pre-B cells is still noticeable 
at the immature B cell stage, in particular with 
regard to the expression levels of BP-1 and CD2 
(5). In this respect, we now found that κ L chain-
positive immature B cells are more affected by 
the lack of Btk than λ L chain-positive immature B 
cells. Given that λ gene rearrangements in pre-B 
cells are programmed to occur ~24 h later than 
κ rearrangements, it is possible that the transit 
time through the pre-B cell compartment may 
affect the differentiation defects in Btk-defi cient 
B cells. Alternatively, as λ L chain expression is 
often associated with receptor editing, the BCR 
signaling events that induce receptor editing may 
also facilitate cellular maturation. 
To distinguish between these possibilities, 
we modifi ed the kinetics of B cell development 
by crossing Btk-defi cient mice with 3-83µδ-
transgenic (Tg) mice, which carry a BCR 
transgene consisting of prerearranged µ and 
δ H chain genes as well as a κ L chain gene 
(11). Because the expression of the 3-83µδ 
transgene is under the control of the Ig H chain 
enhancer, the 3-83µδ BCR is expressed from 
the pro-B cell stage onward. The 3-83µδ BCR 
specifi cally recognizes MHC class I molecules 
of the H2-Kk/b allotype (11), and thus refl ects 
an innocuous BCR in mice that have an H2-Kd 
background. Mice with such a nonautoreactive 
background (also called nondeleting mice) 
contain a virtually monoclonal B cell population. 
Since the prematurely expressed 3-83µδ BCR is 
able to promote B cell development, it appears 
that this BCR can functionally replace the pre-
BCR and consequently B cell development 
is accelerated (11-13). In contrast, when the 
3-83µδ BCR is expressed in mice of the MHC 
class I H2-Kb background, all B cells generated 
are autoreactive and are targeted for continued 
L chain gene rearrangement, a process known 
as receptor editing, to survive (14-16). B cells in 
these centrally deleting mice are delayed in the 
small pre-B cell stage due to the receptor editing 
process (17, 18). 
By crossing Btk-defi cient mice with 3-83µδ Tg 
mice on a nondeleting or a deleting MHC class 
I background, we were able to study the effects 
of Btk on cellular maturation of B cell precursors 
undergoing accelerated development or receptor 
editing, respectively. Furthermore, we tested 
whether providing an extended time window 
per cell for the induction of cell surface marker 
changes, by the enforced expression of the 
Bcl-2 apoptosis inhibitor, would facilitate cellular 
maturation in Btk-defi cient pre-B cells. 
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Materials and Methods
Mice and genotyping.  Btk-defi cient mice (19) 
were crossed onto the C57BL/6 background 
for more than eight generations. 3-83µδ mice 
(11) were on a nondeleting B10.D2 background. 
Endogenous Btk WT alleles were identifi ed 
as described previously (5). Expression of a 
3-83µδ was identifi ed by a 3-83 Vκ forward 
primer (5’-CAGCTTCCTGCTAATCAGTGCC-
3’) and a 3-83 Jκ2 reverse primer (5’-
TGGTCCCCCCTCCGAACGTG-3’) (11). MHC I 
background was determined by FACS analysis of 
peripheral blood samples by using mAbs against 
H2-Kb and H2-Kd (below). The presence of the Eµ-
2–22 Bcl-2 transgene was evaluated by PCR (20). 
Flow cytometric analysis. Preparations 
of single-cell suspensions, standard and 
intracellular fl ow cytometry, and determination 
of β-galactosidase activity by loading cells with 
fl uorescein-β-D-galactopyranoside substrate 
have been described previously (5, 19, 21). The 
hybridomas LM34 (anti-SLC; (22)) and PB493 
(anti-AA4.1; (23)) were kindly provided by A. 
Rolink (University of Basel, Basel, Switzerland). 
The anti-3-83µδ hybridoma 54-1 (15) was 
kindly provided by D. Nemazee (The Scripps 
Research Institute, La Jolla, CA). Hybridoma 
Abs were purifi ed using protein G columns 
and conjugated to biotin according to standard 
methods or used unlabeled in combination with 
PE- or allophycocyanin-conjugated goat anti-
rat secondary Abs. The following mAbs were 
obtained from BD PharMingen (San Diego, 
CA): FITC-conjugated anti-CD21 (7G6), anti-
CD22 (Cy34.1), and anti-CD62L (MEL-14); 
PE-conjugated anti-MHC class II (M5/114), 
anti-CD19 (1D3), anti-IgM (R6-60.2), anti-CD23 
(B3B4), and anti-H2-Kd (SF1–1.1); PerCP- and 
allophycocyanin-conjugated anti-B220 (RA3-
6B2) and anti-CD19 (1D3); biotinylated anti-
Ly6C (ER-MP20), anti-CD23 (B3B4), and anti-
H2-Kb (AF6-88.5). Unlabeled anti-CD21 (7G6; 
BD PharMingen) was biotinylated according 
to standard methods and FITC-conjugated 
anti-IgD (11-26) was obtained from Southern 
Biotechnology Associates (Birmingham, AL). 
In vivo 5’-bromo-2’deoxyuridine (BrdU) labeling 
and detection and all other mAbs used were 
described previously (5).
 IL-7-driven BM cultures. Primary pre-B cell 
BM cultures and determination of IL-7-dependent 
proliferative responses of total BM cells have 
been described previously (5, 20). 
Results
In Btk-defi cient mice, κ+ and λ+ immature B 
cells show differences in cellular maturation. 
During the progression of large cycling into 
small resting cµ H chain-positive pre-B cells, 
Btk-defi cient mice manifest defective down-
regulation of BP-1, CD43, and SLC and impaired 
up-regulation of CD2, CD25, and MHC class II, 
as shown by fl ow cytometric analysis (Fig. 1, 
A and B and Refs. 5 and 8). In this study, we 
have also included the mAb PB493 recognizing 
the complement component C1q-like receptor 
C1qRp, also known as AA4.1 (24). This marker 
is expressed on all B lineage cells in the BM, but 
in the spleen only on those B cells that refl ect 
recently immigrated immature B cells (23). In Btk-
defi cient mice, we found increased proportions of 
PB493+ cells in the B220+IgM- B cell precursor 
compartment when compared with Btk+ mice (Fig. 
1B), indicating that the modulation of expression 
of this marker is also Btk dependent. As shown in 
Fig. 1B, the proportions of cells that express µ H 
chain in their cytoplasm within the surface IgM- B 
cell precursor fractions are similar in Btk-defi cient 
and WT mice. 
We previously found that the ineffi cient 
induction of cell surface phenotype changes 
in Btk-defi cient mice was still noticeable in 
immature B cells, in particular for BP-1 and CD2 
(5). In a separate analysis of κ and λ L chain-
positive B220lowIgM+ immature B cells, we now 
observed that elevated expression of BP-1 was 
more pronounced in Btk-defi cient κ+ immature 
B cells when compared with λ+ cells. Reduced 
expression of CD2, MHC class II and CD25 was 
limited to κ+ immature B cells, while λ+ immature 
B cells manifested essentially normal surface 
expression of these markers (Fig. 1C and data 
not shown). 
In summary, these fi ndings indicate that in 
Btk-defi cient mice the impaired modulation of 
developmentally regulated markers in small pre-
B cells results in very immature phenotype of κ+ 
B cells in the BM, while λ+ B cells appear less 
affected. 
Btk-defi cient 3-83µδ mice show amplifi ed B 
cell differentiation defects. We hypothesized that 
the observed differences in surface phenotype 
between Btk-defi cient κ+ and λ+ immature B 
cells may refl ect the programmed sequential 
activation of the κ and λ loci. In pre-B cells, 
λ gene rearrangements are programmed to 
occur ~24 h later than κ rearrangements, and 
thus λ+ immature B cells have resided for a 
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longer period of time within the small pre-B cell 
compartment (25, 26). Therefore, the extent of 
the differentiation defects in Btk-defi cient B cells 
may correlate with the rate of transit through 
the pre-B cell compartment. To directly test this 
hypothesis, we crossed Btk-defi cient mice with 
3-83µδ Tg mice, which prematurely express a 
prerecombined BCR that functionally replaces 
the pre-BCR. As a result, B cells spend little or 
no time in the small pre-B cell stage and B cell 
development is accelerated signifi cantly. 
Total BM cell suspensions from Btk+ and Btk- 
3-83µδ mice were analyzed by fl ow cytometry 
(Fig. 2). Irrespective of the presence of Btk, the 
B lineage compartment in 3-83µδ mice mainly 
consisted of B220low immature B cells that 
were cµ+ and also expressed IgM on the cell 
surface. However, the B220low immature B cell 
fraction present in Btk- 3-83µδ mice contained 
very few IgD+ B cells (<2%) when compared 
with Btk+ 3-83µδ mice (23% IgD+ cells; Fig. 2A). 
Furthermore, the BM of Btk- 3-83µδ mice did 
not contain mature B220highIgDhigh recirculating 
B cells. Next, the expression pattern of several 
developmental markers was analyzed in the 
B220lowIgM+ immature B cell compartment. In WT 
mice, immature B cells did not express SLC, BP-
1, and CD43, were low for PB493 and CD25, and 
positive for CD2 and MHC class II (Fig. 1C and 
Ref. 5). However, due to the expression of the 
3-83µδ transgene in WT mice, the B220lowIgM+ 
compartment had a more immature phenotype: 
CD43+/low, PB493high, CD25low, and CD2low. Notably, 
Btk-defi cient 3-83µδ mice showed signifi cantly 
impaired B cell maturation, as the B220lowIgM+ 
B cells expressed substantial levels of CD43 and 
SLC and lacked expression of CD2 and CD25 
(Fig. 2B), when compared with their Btk+ 3-83µδ 
Figure 1. Phenotypic characterization of the B lineage 
compartment in BM of Btk+ and Btk- mice. A, BM 
lymphoid cells were electronically gated on the basis of 
forward and side scatter and expression of B220 vs IgM 
is plotted. B, B220lowIgM- pro- and pre-B cells were gated 
and expression of several developmentally regulated 
markers is shown as histograms. Numbers indicate 
percentage of cells positive for the indicated marker and 
plots are representative for ~20 mice of each genotype. 
C, B220lowIgM+ immature B cells were gated and 
expression of Igλ and BP-1 or CD2 is shown. Numbers 
indicate percentage of BP-1- or CD2-positive cells within 
λ+ or κ+ immature B cells. Plots are representative for 
four mice of each genotype.
Figure 2. Phenotypic characterization of the BM B 
cell compartment in Btk+ and Btk- 3-83µδ mice. A, BM 
lymphoid cells were gated and plotted for B220 and cµ 
(upper part). B220high and B220low cells were separately 
gated and IgM/IgD profi les of both populations are 
shown (lower part). B, The B220low B cell population 
was further analyzed for expression of various 
developmentally regulated markers, as shown in the 
histograms. The percentages of cells within the indicated 
gates or quadrants are given. Data represent six to eight 
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littermates. The expression of MHC class II on 
B220lowIgM+ B cells did not appear to be affected 
by the premature BCR expression. 
These results indicate that a prematurely 
expressed 3-83µδ BCR was only partially able 
to functionally replace the pre-BCR, as the 
modulation of expression of developmentally 
regulated markers was impaired. In Btk-defi cient 
3-83µδ mice, this defect was even stronger, as 
evidenced by an almost complete absence of 
down-regulation of CD43 and SLC and induction 
of CD2 and CD25 in IgM+ B cells in the BM.
Btk-defi cient 3-83µδ mice manifest a severe 
reduction of B cell numbers in the spleen. Total 
splenic cell suspensions from Btk+ and Btk- 3-
83µδ mice were analyzed by fl ow cytometry 
and compared with non-Tg littermates. The xid 
phenotype of Btk-defi cient mice is characterized 
by a specifi c defi ciency of mature IgMlowIgDhigh 
B cells in the spleen, resulting in a reduction 
of the B cell numbers by ~50% (19, 27, 28). 
As previously described (16), expression of the 
3-83µδ transgene on a WT background only 
marginally affected the splenic B cell numbers. 
Surprisingly, we observed a profound reduction 
of the size of the splenic B cell population in Btk- 
3-83µδ mice, as <2 x 106 B cells were present 
compared with ~20 x 106 B cells in Btk+ 3-83µδ 
mice (Fig. 3A and Table I). 
This severe reduction of splenic B cells in 
Btk- 3-83µδ mice may refl ect a reduced survival 
capacity of Btk- 3-83µδ B cells in the BM or in 
the spleen. Alternatively, it is possible that the 
absence of Btk affects the signals transmitted 
by the 3-83µδ BCR in such a way that these 
B cells are considered autoreactive and are 
therefore deleted. Autoreactive B cells down-
regulate surface IgM expression and are subject 
to receptor editing at the immature B cell stage in 
the BM (12, 14, 16, 29). However, fl ow cytometric 
analyses did not provide evidence for autoreactive 
characteristics of Btk- 3-83µδ B cells. The B cells 
were IgMhigh and did not edit their BCR, as they 
were mainly positive for the anti-idiotypic Ab 54-1 
for the expression of CD43 and CD2 on IgM+ cells and expression of PB493, CD22, and CD62L on CD19+ cells. 
A–C, The percentages of cells within the indicated gates or quadrants are given; data represent three to eight 
mice analyzed per genotype. D, Expression of lacZ in splenic B cells of Btk+/- non-Tg and 3-83µδ heterozygous 
female mice. Splenic B cells were gated using IgM and IgD expression profi les, and LacZ expression in these 
populations was compared with lacZ expression in ER-MP20high BM monocyte precursor cells. Mean percentages 
± SD values of lacZ-positive cells within the indicated gates were plotted and signifi cance between non-Tg and 3-
83µδ mice was evaluated by Student’s t test (*, p ≤ 0.01). Data represent four to fi ve mice analyzed per genotype. 
E, BrdU incorporation in spleen after a single dose of BrdU injection in Btk+ and Btk- 3-83µδ mice. The absolute 
number of BrdU+ cells was calculated within the B220+IgMhighIgD-/low B cell population. Mean values of two to six 
mice per time point were plotted.
Figure 3. Phenotypic characterization of B cell 
compartments in spleens of Btk+ and Btk- non-Tg 
and 3-83µδ mice. A, Splenic lymphoid cells were 
gated and IgM/IgD expression profi les are plotted. B, 
B220+ cells were gated and analyzed for expression 
profi les of 54-1/Igλ (upper part) and CD21/CD23 
(lower part). C, B220+ cells were gated and analyzed 
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and κ L chain, both in BM and in spleen (Figs. 2, 
A and B, and 3, A and B). 
The residual B cell population in Btk- 3-83µδ 
spleens mainly consisted of immature IgMhigh 
IgD-/low that were CD21- and CD23-, indicating 
that these B cells were recent immigrants from 
the BM arrested at the stage of transitional type 
1 (T1) B cells (Fig. 3B and Table I; Refs. 30 
and 31). This was confi rmed by an evaluation 
of additional developmentally regulated cell 
surface markers. As shown in Fig. 3C, splenic 
B cells in Btk+ and Btk- non-Tg mice and in Btk+ 
3-83µδ mice are largely CD43-, PB493-, CD2high, 
CD22high, and CD62L+. In contrast, Btk- 3-83µδ B 
cells showed signifi cantly increased expression 
of the immature markers CD43 and PB493 and 
reduced expression of the maturation markers 
CD2, CD22, and CD62L. Taken together, only a 
small number of peripheral B cells reached the 
stage of T2 cells (IgMhigh, IgD+, CD21+, CD23+; 
Refs. 30 and 31) and mature IgMlow IgD+ cells 
were virtually absent (Fig. 3 and Table I). The 
expression levels of SLC, BP-1, CD25, and 
MHC class II were similar in the four groups of 
mice (data not shown). Despite the low B cell 
numbers and their immature phenotype, splenic 
architecture was not seriously disturbed in Btk- 
3-83µδ mice as B/T cell separation was normal 
and small regions with marginal zone B cells 
and macrophages were present, as analyzed by 
immunohistochemistry (data not shown). 
In summary, these fi ndings show that 
peripheral Btk+ 3-83µδ B cells differentiated 
normally. By contrast, Btk-defi cient 3-83µδ mice 
exhibited a severe reduction of B cell numbers in 
the spleen, whereby the residual B cells present 
were Id positive and mainly had an immature T1 
surface phenotype.
Btk-defi cient 3-83µδ B cells are rapidly deleted 
upon arrival in the spleen. The fi nding that the 
proportions of B220+ B lineage cells in BM of Btk+ 
3-83µδ mice were not signifi cantly different from 
those in Btk- 3-83µδ mice (5.5% ± 1.2 and 4.5% 
± 1.8, respectively) implied that the numbers of B 
cells generated in the BM of Btk+ and Btk- 3-83µδ 
mice were comparable. Therefore, the severe 
decrease in splenic B cell numbers in Btk- 3-
83µδ mice may be caused by defective homing 
of immature B cells from the BM into the spleen 
or alternatively by rapid deletion upon arrival in 
the spleen. To distinguish between these two 
possibilities, we investigated the competition 
between Btk+ and Btk- 3-83µδ B cells in vivo. 
We analyzed heterozygous Btk+/- female mice, 
which have the Btk-lacZ+ allele on the active X 
chromosome in ~50% of all cells, due to random 
X chromosome inactivation. However, when in 
these mice B lineage cells reach a differentiation 
stage in which Btk is required, the Btk-lacZ+ cells 
will be arrested in development and consequently 
the proportions of Btk- lacZ+ cells decrease below 
50% (19). 
BM and spleen cell suspensions from Btk+/- 
non-Tg and 3-83µδ mice were compared for 
the proportions of lacZ-expressing cells by 
using fl uorescein-di-β-galactopyranoside as a 
substrate in conjunction with surface labeling 
of B220, IgM, and IgD. Irrespective of the 
presence of the 3-83µδ transgene, the spleens 
of Btk+/- mice contained detectable fractions of 
lacZ+ B cells, indicating that homing of B cells 
from the BM into the spleen was not altered by 
the expression of the 3-83µδ BCR (Fig. 3D). 
Moreover, the immature IgM+IgD- fraction in 3-
83µδ mice contained >50% lacZ+ cells, showing 
that Btk-defi cient B cells accumulated due to the 
differentiation arrest. Consistent with previous 
Table I. Absolute number of B cell subsets in spleen
a Absolute number as mean ± SEM (x106)
b Values of P for the difference in absolute numbers of B220+ cells compared with Btk+ littermates, determined by Student’s t  test
c T1, T2, and mature B cell subsets of B220+ cells
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fi ndings (19), a dramatic selection against Btk-
lacZ+ cells occurred during B cell differentiation 
in the spleen: the immature IgM+IgD-/low cell 
populations still contained substantial proportions 
of Btk-lacZ+ cells, whereas in the IgMlowIgDhigh 
mature B cell population these cells were virtually 
absent (Fig. 3D). 
To confi rm that Btk-defi cient 3-83µδ B cells 
were deleted upon arrival in the spleen, we 
performed BrdU-labeling experiments in vivo. 
Btk+ or Btk- 3-83µδ mice were injected with a 
single dose of BrdU, which is incorporated into 
the DNA of large cycling pre-B cells in the BM (17, 
25, 32). The amount of BrdU incorporation was 
found to be similar in BM B cells from both types 
of mice (data not shown). One, 2, or 3 days after 
BrdU injection, spleen cell suspensions were 
stained for B220, IgM, and IgD in conjunction with 
intracellular staining for BrdU. B220+IgMhighIgD-
/low cells were gated and the absolute number of 
BrdU+ cells was calculated. We found that in Btk+ 
3-83µδ mice the number of BrdU+IgMhighIgD-/low B 
cells accumulated over time (Fig. 3E). In contrast, 
the number of BrdU+ cells in Btk- 3-83µδ mice 
remained low, indicating that the number of cells 
arriving in the spleen was similar to the number of 
cells that was deleted. 
From these fi ndings, we conclude that Btk- 3-
83µδ immature B cells migrated normally from 
the BM into the spleen, but upon arrival these B 
cells did not further differentiate and were deleted 
within 24 h. 
Btk- 3-83µδ BM B cells show defi cient 
developmental progression in vitro. To investigate 
whether the ineffi cient 3-83µδ BCR-mediated 
induction of cell phenotype changes in Btk- B 
cells in vivo were paralleled in BM cultures in 
vitro, IL-7-driven BM cultures were performed 
as described previously (5, 33). Total BM cells 
from Btk+ and Btk- non-Tg and 3-83µδ mice 
were cultured in the presence of 100 U/ml IL-7 
for 5 days and proliferation was quantifi ed in 
[3H]thymidine incorporation experiments (Fig. 
4A). Consistent with our previous report (5), Btk- 
non-Tg BM cultures showed signifi cantly higher 
proliferative responses to IL-7 when compared 
with Btk+ cultures. Proliferative responses to IL-7 
were similar in Btk+ and Btk- 3-83µδ BM cultures. 
To evaluate developmental progression in vitro, 
BM cells were cultured in the presence of IL-7 
for 5 days and recultured in the absence of IL-
7 on S17 stromal cells for 48 h. As previously 
described (5), under these conditions, WT 
pre-B cells differentiated into immature B cells 
expressing CD2, IgM, and IgD, whereas Btk-
defi cient pre-B cells were not able to effi ciently 
up-regulate CD2 and IgD expression (Fig. 4B). In 
BM cultures from Btk+ 3-83µδ mice, expression of 
CD2 and IgD was induced on the B cells, but Btk- 
3-83µδ B cells were not able to up-regulate CD2 
and IgD upon IL-7 withdrawal (Fig. 4B). 
These data show that also under in vitro 
conditions, developmental progression of Btk- 3-
83µδ BCR-expressing B cells is impaired, as is 
clear from low CD2 and IgD induction upon IL-7 
withdrawal. 
Receptor editing can compensate for 
developmental defects in Btk- 3-83µδ mice. To 
investigate whether receptor editing and the 
resulting delay at the small pre-B cell stage in the 
BM could compensate for the cellular maturation 
defects in Btk- 3-83µδ mice, we targeted 3-83µδ 
B cells for receptor editing by crossing the 3-
83µδ mice onto a centrally deleting MHC class 
I background. 
When we analyzed the BM of Btk+ and 
Btk- 3-83µδ centrally deleting mice by fl ow 
cytometry, we found that B220+cµ+ cells had 
down-regulated surface expression of IgM and 
CD19 and were also low for the anti-idiotypic Ab 
54-1, confi rming the autoreactive nature of the 
Figure 4. Analysis of IL-7-driven BM cultures from 
Btk+ and Btk- non-Tg and 3-83µδ mice. A, Proliferative 
responses of total BM cells as determined by 
[3H]thymidine incorporation after 5 days of culture with 
or without IL-7. Means ± SD values for two to four mice 
per genotype were plotted. B, After 5 days of culture with 
IL-7, cells were washed and recultured for 48 h on S17 
stromal cells in the absence of IL-7. Expression profi les 
of B220/CD2 on live cells (upper part) and of IgM/IgD 
on B220+ gated cells (lower part) are shown. Data are 
representative of fi ve mice analyzed per group.
Chapter 4
172
B cell compartment (Fig. 5A). The expression 
profi les of developmentally regulated surface 
markers on B220lowcµ+ cells in Btk+ 3-83µδ 
mice were similar to those found in non-Tg WT 
immature B cells, i.e., SLC-CD43-CD2+ (Fig. 
5B). Remarkably, Btk- 3-83µδ centrally deleting 
mice manifested an almost complete correction 
of marker expression profi les when compared 
with Btk- 3-83µδ nondeleting mice: expression of 
SLC and CD43 was low and CD2 was present 
on a large fraction of cells (cf Figs. 5B and 2B). 
Therefore, we conclude that extended receptor 
editing in the BM could almost completely correct 
the Btk-dependent defects in B cell surface 
marker expression of 3-83µδ immature B cells 
in the BM. 
The spleens of 3-83µδ-deleting mice contained 
very few B cells, irrespective of the presence of 
Btk (Fig. 5C and Table I). As a result, the total 
splenic B cell numbers in Btk- 3-83µδ mice were 
comparable on the nondeleting (~1.2 x 106) and 
the deleting MHC class I background (~2.1 x 106; 
Table I). Those Btk+ and Btk- B cells present in the 
spleen of 3-83µδ-deleting mice have essentially 
lost 54-1 expression and show increased Ig λ L 
chain usage due to receptor editing (cf Figs. 5C 
and 3B). Remarkably, we found that the residual 
B cells in the spleens of Btk+ and Btk- 3-83µδ-
deleting mice had similar IgM/IgD and CD21/
CD23 profi les (Fig. 5C), had similar expression 
levels of CD43, CD2, CD19, and MHC class II, 
and were negative for SLC, BP-1, and CD25 (Fig. 
5D and data not shown). 
In summary, these data indicate that both 
Btk+ and Btk- 3-83µδ B cells that were targeted 
for receptor editing have reduced maturation 
defects when compared with Btk+ and Btk- 3-
83µδ B cells on a nondeleting background. The 
expression of the developmentally regulated 
markers is completely corrected in edited Btk+ 
3-83µδ peripheral B cells, while in edited Btk- 
3-83µδ cells the cellular maturation defects are 
comparable to those found in non-Tg Btk- B cells 
(Figs. 1 and 2). 
Bcl-2 overexpression does not rescue Btk-
dependent marker modulation. We investigated 
whether the observed correction of marker 
modulation in editing Btk-defi cient pre-B cells 
was dependent on additional signals that follow 
the engagement of an autoreactive BCR with 
autoantigen or alternatively resulted from the 
developmental delay in the small pre-B cell stage 
associated with receptor editing. To this end, Btk-
defi cient mice were crossed with Tg mice that 
express the antiapoptotic Bcl-2 gene, which is 
assumed to provide an extended time window 
per cell for Ig L chain rearrangement (34). When 
we compared the B cell compartment in Btk+ and 
Btk- Eµ-Bcl-2 Tg mice, we found that enforced 
expression of Bcl-2 only slightly improved cellular 
maturation of pre-B and immature B cells in the 
absence of Btk (cf Figs. 6, A and B, and 1). 
Figure 5. Phenotypic characterization of the B cell 
compartment in Btk+ and Btk- 3-83µδ mice on a centrally 
deleting background. A and B, BM lymphoid cells were 
gated and plotted for the expression of B220 and cµ. 
B220+cµ+ cells were gated and plotted for IgM/IgD and 
54-1/Igλ expression profi les (A) and analyzed for the 
expression of the indicated markers (B). C, Splenic 
lymphoid cells were gated and analyzed for IgM/IgD 
expression and for CD21/CD23 and 54-1/Igλ expression 
profi les on B220+ gated cells. D, Expression pattern of 
the indicated markers on B220+ cells. The percentages 
of cells within the indicated gates or quadrants are given. 
Data represent 8–20 mice analyzed per genotype.
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Next, we investigated whether Bcl-2 
expression could rescue the developmental 
defects observed in Btk- 3-83µδ nondeleting 
mice. Therefore, Btk-defi cient 3-83µδ mice were 
crossed with Eµ-Bcl-2 Tg mice on a non-deleting 
MHC class I background. Overexpression of Bcl-
2 did not rescue cellular maturation of Btk- 3-83µδ 
immature B cells, as expression of SLC, BP-1, 
CD43, and PB493 was not down-regulated and 
expression of CD25, CD2, and IgD was hardly 
induced (Fig. 6C and data not shown). The BM B 
cells in Btk+ and Btk- 3-83µδ/Bcl-2 double Tg mice 
were all 54-1+ (data not shown) and did not show 
increased λ usage (<0.3%). The absolute number 
of splenic B cells in Btk- 3-83µδ/Bcl-2 double 
Tg mice was corrected when compared with 
Btk- 3-83µδ mice and the B cells in the spleen 
were not arrested at the T1 stage (Fig. 6D and 
Table I). The B cells in Btk- 3-83µδ/Bcl-2 double 
Tg spleens were largely IgMhighCD21+CD23+, 
indicating an almost complete block in B cell 
development from transitional stage T2 into the 
mature B cell compartment. Compared with their 
Btk- 3-83µδ single Tg littermates, a larger fraction 
of splenic B cells in Btk- 3-83µδ/Bcl-2 double 
Tg mice differentiated into CD21+CD23+ B cells 
(>80% compared with <50%, respectively; Fig. 
6D). 
From these data, we conclude that an extended 
time window per cell for pre-B cell differentiation 
by enforced expression of Bcl-2 was not suffi cient 
to rescue the maturation defects in Btk-defi cient 
pre-B cells. However, the expression of Bcl-2 
rescued the peripheral B cell arrest at the T1 
stage in Btk- 3-83µδ mice and consequently B 
cells were arrested at the T2 stage, as in non-Tg 
Btk-defi cient mice. 
Discussion
Btk is essential at two distinct steps in B 
cell development in the mouse (a) at the 
developmental progression of CD43+CD2- large 
cycling into CD43-CD2+ small resting pre-B 
cells and (b) at the checkpoint for selection of 
immature IgMhigh T2 cells into the pool of long-
lived IgMlow mature B cells (5, 19, 28, 30, 31, 35, 
36). In this report, we show that in Btk-defi cient 
mice premature expression of the 3-83µδ BCR 
amplifi es the cellular maturation defects in 
immature B cells in the BM and results in an arrest 
of peripheral B cell development at the transition 
of T1 into T2 cells in the spleen. Both defects are 
largely restored when Btk-defi cient 3-83µδ mice 
are crossed onto a centrally deleting background 
where the B cells were targeted for receptor 
editing. In contrast, enforced expression of the 
apoptosis inhibitor Bcl-2, which prolongs (pre-) 
Figure 6. Bcl-2 expression does not rescue 
developmental defects in Btk-defi cient non-Tg or 3-83µδ 
mice. A, BM B220lowIgM- pro- and pre-B cells of Btk+ 
and Btk- Bcl-2 Tg mice were gated and expression of 
several developmentally regulated markers is shown as 
histograms. Numbers indicate percentage of cells positive 
for the indicated marker and plots are representative for 
two to four mice of each genotype. B, BM B220lowIgM+ 
immature B cells were gated and expression of Igλ and 
BP-1 or CD2 is shown. Numbers indicate percentage of 
BP-1- or CD2-positive cells within λ+ or κ+ immature B 
cells. C, BM B220low cells of Btk+ and Btk- 3-83µδ/Bcl-2 
double Tg mice were gated and analyzed for expression 
of several developmentally regulated markers as shown 
in the histograms. D, Splenic lymphoid cells were 
gated and analyzed for IgM/IgD expression and for 
CD21/CD23 and 54-1/Igλ expression profi les on B220+ 
gated cells. The percentages of cells within the indicated 
gates or quadrants are given. Data represent three mice 
analyzed per genotype.
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B cell life span, does not rescue the maturation 
defects in Btk-defi cient 3-83µδ immature B cells 
in the BM, but does restore the development of 
T2 B cells in the spleen. 
Expression of the pre-BCR triggers IL-7-driven 
proliferative expansion, allelic exclusion, cellular 
maturation of pre-B cells, and the initiation of L 
chain rearrangement (1, 2). We have previously 
shown that Btk has an important function in 
the regulation of the substantial changes in 
cell phenotype that accompanies pre-B cell 
maturation, including down-regulation of SLC, 
CD43, and BP-1, and up-regulation of CD2, 
CD25, and MHC class II (5, 8). However, the 
functional signifi cance of the modulation of the 
individual surface markers at the pre-B cell 
stage is largely unknown, with the exception of 
SLC. The down-regulation of SLC expression 
is assumed to limit the capacity of pre-B cells 
to proliferate. Hence, after several divisions, 
these cycling cells fall into a resting state where 
L chain rearrangement is initiated. At this stage 
of B cell development, Btk and SLP-65 have 
synergistic roles as tumor suppressors to limit 
pre-B cell expansion, most likely by signaling 
the down-regulation of SLC expression (8). 
Recent analyses of RNA expression profi les 
identifi ed a major change in gene expression 
at the transition from cycling into resting pre-B 
cells, as ~1000 genes were found with differential 
expression with a magnitude of >2 (37, 38). In 
fl ow cytometric analyses, we observed similar 
differences between Btk-defi cient and WT B cells 
for surface and intracellular expression of CD2, 
CD25, and MHC class II in cµ+ pre-B cells (S.M. 
and R.W.H., unpublished results), indicating that 
the absence of Btk affects the initiation of the 
expression of these genes rather than transport 
of existing protein from cytoplasmic stores to 
the cell surface. It is therefore possible that Btk 
is directly or indirectly involved in the regulation 
of a substantial proportion of the genes required 
for the initiation of new differentiation programs in 
resting pre-B cells. 
In this context, we found that premature 
expression of the prerearranged 3-83µδ BCR, 
which accelerates B cell development (34, 39), is 
not completely able to replace pre-BCR function, 
as cellular maturation in these mice was impaired, 
when compared with non-Tg mice. Nevertheless, 
the aberrant phenotype of 3-83µδ immature B 
cells did not seem to signifi cantly affect their 
capabilities for further maturation in the spleen. 
In contrast, in the absence of Btk we found a 
much more defective modulation of marker 
expression in the BM and a severe decrease in 
absolute B cell numbers in the spleen, refl ecting 
an almost complete arrest of B cell development 
at the transition of T1 to T2 immature B cells 
in the spleen. This contrasts with the arrest in 
non-Tg Btk-defi cient mice, which is at the next 
developmental transition from T2 into mature B 
cells. 
The cells generated in the BM of the Btk- 3-
83µδ mice were shown to home into the spleen, 
even in the presence of competitive Btk+ 3-83µδ 
B cells. In BrdU-labeling studies, we showed that 
the numbers of B cells immigrating from the BM 
in the spleen within 24 h is similar in Btk+ and Btk- 
3-83µδ mice. However, Btk- 3-83µδ B cells are 
effi ciently deleted upon arrival in the spleen. It is 
not likely that the elimination of Btk- 3-83µδ B cells 
is due to autoreactivity of the 3-83µδ BCR as (a) 
the deletion of B cells takes place in the spleen 
and not in the BM; (b) immature B cells in the BM 
did not manifest down-regulation of CD19 and 
IgM surface expression; (c) most splenic B cells 
express the 3-83µδ Id 54-1, indicating that they 
did not perform receptor editing; and (d) when the 
Btk- 3-83µδ B cells were on a centrally deleting 
background, the induction of receptor editing 
even increased survival of T2 peripheral B cells. 
Instead, our fi nding that the early T1 to T2 block 
could be restored by enforced Bcl-2 expression 
indicates that Btk is required for the survival of T2 
cells that carry the 3-83µδ BCR. Interestingly, 3-
83µδ Tg and 3-83µδ Bcl-2 double Tg Lyn-/- B cells 
were also found to be arrested at the T1 and T2 
immature B cell stage in the spleen, respectively 
(40), further supporting synergistic roles for 
Lyn and Btk in peripheral B cell survival (41). In 
this respect, the function of CD45 and CD19 in 
peripheral B cell survival appears to be different, 
as 3-83µδ Tg CD45-/- and CD19-/- mice showed 
relatively mild defects in the transitional B cell 
compartment in the spleen (39, 42, 43). 
We have previously shown that lack of Btk did 
not abolish the receptor editing competence of 
immature B cells (20). Surprisingly, we found that 
when Btk-defi cient 3-83µδ mice were crossed 
onto a centrally deleting background and the B 
cells were targeted for receptor editing, both the 
cellular maturation defects of immature B cells 
in the BM and the defective T1 to T2 transition 
of splenic B cells are restored. It has been 
shown that B cells with an autoreactive BCR 
are delayed for 2–12 h in the small pre-B cells 
compartment where L chain rearrangements 
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take place (17, 18). This delay may provide an 
extended time window per cell, which could be 
suffi cient to compensate for the impaired cellular 
maturation of Btk- pre-B cells. Alternatively, it is 
also possible that engagement of the BCR with 
membrane-bound autoantigens induces distinct 
Btk-independent signaling pathways that drive 
cellular maturation of editing immature B cells. 
However, enforced expression of Bcl-2 did not 
improve cellular maturation of non-Tg or 3-83µδ 
Btk-defi cient immature B cells, indicating that 
increased life span is not suffi cient to correct 
the Btk-mediated pre-BCR maturation signals. 
Therefore, our observations would be consistent 
with the hypothesis that an autoreactive BCR 
undergoing receptor editing transmits an 
additional unique signal that enhances cellular 
maturation of editing pre-B/immature B cells, next 
to the signals required for the receptor editing 
events, such as expression of the recombination-
activating gene proteins. Such an additional signal 
would not be provided by an innocuous BCR, 
as on a nondeleting MHC class I background 
3-83µδ immature B cells showed defective 
cellular maturation. Additional experiments are 
required to investigate whether BCR stimulated 
by autoantigens indeed provide maturation 
signals for editing cells and whether such signals 
affect the capacity of immature B cells to continue 
receptor editing or their sensitivity to Ag-induced 
apoptosis (13). 
In this context, the fi nding that in Btk-defi cient 
mice κ+ B cells show a more profound cellular 
maturation defect than λ+ B cells may suggest 
that in these mice λ+ B cells have performed 
extensive receptor editing. This may be supported 
by our previous analysis of the kinetics of pre-B 
cell differentiation in vivo (5, 20). We observed 
that in Btk-defi cient mice, λ+ B cells manifest a 
specifi c developmental delay within the small 
pre-B cell compartment of ~3 h, accompanied 
by a decreased production rate. Therefore, the 
residual λ+ B cell population in Btk-defi cient mice 
may develop relatively late and consequently 
contain more cells that have performed receptor 
editing. Additional experiments are required to 
directly determine the extent of receptor editing 
in Btk-defi cient mice. 
In conclusion, we have shown that in 
the absence of Btk 3-83µδ B cells are quite 
effi ciently deleted during their development, 
whether they are on a nondeleting background 
or on a centrally deleting background. On the 
nondeleting background, the premature BCR 
expression amplifi es the cellular maturation 
defects in Btk-defi cient immature B cells, fi nally 
resulting in defective survival at the T1 to T2 
transition in the spleen. On the autoreactive 
MHC class I background, most immature B cells 
are deleted in the BM, but cellular maturation 
defects are signifi cantly reduced and edited B 
cells that reach the spleen no longer exhibit the 
T1 to T2 arrest. Our results suggest that at the 
immature B cell stage in the BM, BCR stimulation 
by autoantigens does not only induce receptor 
editing, but also enhances cellular maturation. 
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1. Introduction
Btk-defi cient mice manifest an almost complete block during late B cell 
development in the spleen, resulting in very low numbers of circulating B cells 
(1-4). In contrast, XLA patients, who also have defects in the Btk gene, were 
shown to have an almost complete block in pre-B cell development, resulting in 
very low numbers of immature B cells already in the BM (5, 6). Previous studies 
using targeted Btk/LacZ mice indicated a role for Btk at an earlier stage in B cell 
development in the mouse as well, because a selective disadvantage was found for 
Btk-defi cient cells at the pre-B to immature B cell stage transition (7). In addition, 
studies using a mouse pre-B cell line (2) and Tec/Btk double defi cient mice (8) 
Figure 1. Summary of the functions of signalling pathways downstream of the BCR and its 
immature forms in early B cell development in the bone marrow. For the pro-BCR and the 
pre-BCR on B cell precursors and the BCR on immature B cells, Btk-independent and Btk-
dependent functions are indicated.
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indicated a role for Btk downstream the pre-BCR. 
To study the role of Btk during pre-B cell development in the mouse in more 
detail, we made use of the Btk/LacZ mouse model, which was generated by 
inactivation of the Btk gene by insertion of a LacZ reporter gene (7). From the 
results presented in this thesis, we can conclude that Btk plays an important role 
at the pre-BCR checkpoint (Figure 1). Our fi ndings demonstrate that Btk directly 
regulates L chain rearrangement (Chapter 1), pre-B cell differentiation (Chapter 2) 
and cellular maturation of immature B cells (Chapter 4). Furthermore, we and others 
have found that the interaction of Btk with the linker protein SLP-65 is required for 
proper signalling at the pre-BCR checkpoint and analysis of mice defi cient for both 
proteins revealed a role for Btk as a tumor suppressor (Chapter 3 and Ref. (9)). 
Next to its role in pre-BCR and BCR signalling, we have found that Btk also acts 
downstream the pro-BCR (Figure 1; Chapters 2.1 and 2.3). 
Table 1. Phenotype of different Btk mutant mice
 a Spontaneous mutation in CBA/N mice; similar phenotype as Btk-null mutant mice
  b Expression of transgenic human Btk mutants under the control of the B cell specifi c promoter CD19
References: (7, 10-17)
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To analyse the function of Btk during B cell development, not only Btk null 
mutant mice were analysed, but also various transgenic mouse models with 
specifi c gain-of-function or loss-of-function mutations were studied. The transgenic 
human Btk constructs were placed under the control of the B cell specifi c CD19 
promoter to ensure expression from the pro-B cell stage onwards. These transgenic 
mouse models were crossed onto a Btk-defi cient background and the effects of the 
specifi c point mutations on B cell development were characterized (Table 1). Mice 
carrying the E41K gain-of-function mutant, the Y223F autophosphorylation mutant, 
the E41K/Y223F double mutant and the K430R kinase-inactive mutant provided 
information on the role of the individual domains of Btk in pre-B cell development 
(Chapters 1.1, 2.2 and 2.3). An interesting and unexpected aspect of our fi ndings 
is that we have found that Btk can also function as an adapter molecule, next to its 
role as a tyrosine kinase protein (Chapter 2.2 and 3.2). 
Pre-BCR signalling pathways
Studies in Btk-defi cient cells showed that Btk is an important regulator of BCR-
induced calcium mobilization (18, 19). The mobilization of intracellular calcium 
is one of the major targets of BCR signalling and is critical for the regulation of 
multiple transcription factors such as NF-κB and Nuclear Factor of Activated T 
cells (NFAT) (20-23). In Btk-defi cient cells defects in sustained calcium infl ux 
resulted in decreased phosphorylation of phospholipase Cγ2 (PLCγ2) resulting 
in impaired inositol-trisphosphate (IP3) and diacylglycerol (DAG) production. As 
a consequence, lymphocytes defective in Tec family kinases show decreased 
activation of multiple downstream targets dependent on IP3 and DAG production, 
including activation of NF-κB, NFAT, MAP kinases and PKC (24, 25).  However, 
NF-κB induction might not be essential for pre-BCR checkpoint function, as B cell 
Figure 2. Activated Btk (or Tec) can bind to PIP3 and PIP5K with its PH domain (Btk-PH). 
This stimulates a positive feedback loop in BCR signalling by activating PIP5K to increase the 
hydrolysis of PIP into PIP2, the substrate for both PI3K and PLCγ2. PLCγ2 activation results 
in production of DAG and IP3, important for calcium mobilization and NF-κB activation. For 
details and abbreviations, see text.
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development is unimpaired in mice defi cient for various NF-κB subunits (26). By 
contrast, the downstream Ras/Raf/MEK/MAP kinase pathway (Figure 4) is a key 
regulatory signalling cascade, as its activation can induce proliferation and cellular 
maturation of pre-B cells, as well as Ig L chain gene rearrangement (Figure 4; (27-
29)).
Although Btk has been implicated in direct phosphorylation of PLCγ2, tyrosine 
phosphorylation of PLCγ2 was still observed in cells defi cient for Tec family kinases, 
despite the calcium defects (18, 19, 24). Overexpression of wild type or kinase 
inactive Btk has been shown to increase PIP3 levels and to partially rescue calcium 
mobilization in Btk-defi cient DT40 cells (30, 31). This indicates that other molecules 
also contribute to the phosphorylation and activation of PLCγ2.
Recently, Btk as well as Tec were found to be able to associate directly with 
phosphatidylinositol-4-phosphate 5-kinase (PIP5K) through their PH domains, 
thereby acting as a shuttle to bring PIP5K to the plasma membrane and into lipid 
rafts. PIP5K is the enzyme that generates phosphatidylinositol bisphophate (PIP2), 
by the phosphorylation of phosphatidylinositol phosphate (PIP), as was observed in 
Figure 3. (A) Signalling pathways downstream the pre-BCR including the SLP-65 dependent 
route. (B) Signalling pathway in the absence of SLP-65. This pathway is not dependent on 
kinase activity of Btk. Double lines refl ect the link between Btk, SLP-65 and PLCγ2, straight 
arrows refl ect activation and bended arrows refl ect enzymatic conversions involving the 
enzyme attached to the arrow. For details and abbreviations, see text.
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A20 mature B cells (Figure 2; (32)). PIP2 is the substrate for both PLCγ2 and PI3K 
and PI3K phosphorylates PIP2 to generate PIP3 molecules that bind and activate 
proteins with PH domains, such as Btk (33). By activating PIP5K, Btk provides 
more PIP2 substrate for both PI3K, required for Btk activation, and PLCγ2, the 
downstream target of Btk, generating a positive feedback loop to sustain both Btk 
activation and PLCγ2 activity (Figure 2). This PIP5K shuttle function of Btk was 
found to be independent of Btk kinase activity (32).
As shown in chapter 2.2, we found that in the pre-BCR signal transduction 
pathway, Btk can partially function as an adapter molecule, independent of its 
kinase activity (17). Expression of kinase-inactive Btk in early B cell development 
normalized λ L chain usage and partially restored the impaired pre-B cell 
differentiation and IL-7 responsiveness in Btk-defi cient mice (Table 1). From these 
fi ndings, we concluded that Btk was able to function at least partially as an adapter 
molecule next to its role as a tyrosine kinase protein. Btk may act as an adapter 
molecule by using SLP-65 as a scaffold molecule to bring other kinase proteins 
such as Syk in close proximity with PLCγ2. However, our fi ndings in K430R-
Btk transgenic mice on a SLP-65 defi cient background indicate that even in the 
absence of SLP-65, Btk was able to exert its function as an adapter molecule 
(Chapter 3.2). The recent fi nding that kinase-inactive Btk was able to activate 
the positive feedback loop for PIP2 synthesis leads to the suggestion of parallel 
signalling pathways downstream the pre-BCR as described in Figure 3.
In contrast to the function of Btk in early B cell development, the kinase function 
of Btk was more important during later stages of B cell development, as T cell 
independent antibody responses were still defective and B-1 cells were still absent 
(Table 1). We have shown that although K430R-Btk did not phosphorylate other 
proteins, the NF-κB pathway was activated leading to induction of Bcl-xL and cyclin 
D2 expression (Chapter 2.2; (17)). These results indicate that the requirement for 
Btk kinase activity varies between the different Btk-mediated signalling pathways 
during B cell development and between the different signal transduction routes.  
2. Pro-BCR signalling
The physiological functions of the pro-BCR (Figure 1) and its signal transduction 
pathways have not been identifi ed. At the pro-B cell stage, the construction of the Ig 
µ H chain is initiated fi rst by recombination of D to JH elements and subsequently VH 
elements are recombined with the D-JH segment. Next, IL-7R signalling regulates 
further VH to DJH recombination. When a VH to DJH rearrangement is successful, 
a µ H chain protein is formed and associates with the SLC and Ig-α/β proteins, 
which together are expressed on the cell surface as the pre-BCR complex. As a 
consequence of pre-BCR expression, the pro-B cell is transferred to the cµ+ large 
pre-B cell compartment.
In mice defi cient for the recombination activating genes (RAG)-1 or RAG-2, 
no rearrangements take place and as a result, B cell development is blocked at 
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the pro-B cell stage. The fi nding that Btk-RAG- pro-B cells showed an increased 
proliferation in response to IL-7 when compared with Btk+RAG- pro-B cells indicates 
that Btk is involved in pro-BCR signalling and that pro-BCR signalling can limit pro-B 
cell proliferation (Chapter 2.1; (16)). Another piece of evidence for the involvement 
of Btk in pro-BCR signalling is the fi nding that in cµ- pro-B cells of the gain-of-
function E41K-Btk mutant mice expression of cytoplasmic κ L chain and surface 
CD2, CD25 and MHC class II was induced and expression of SLC, BP-1 and CD43 
was downregulated (Chapter 2.3). This indicates that constitutive active Btk can 
induce a pre-B cell-specifi c differentiation program in pro-B cells. In summary, 
these results suggest that pro-BCR expression results in a weak downstream 
signal, activating Btk among other signalling proteins, possibly to regulate low-level 
IL-7 driven proliferation of pro-B cells. 
3. Pre-BCR signalling 
Signalling at the pre-BCR checkpoint is required for the induction of clonal 
expansion of cµ+ pre-B cells, and subsequently downregulation of this proliferation, 
cellular maturation by modulating the expression of cell surface and intracellular 
markers during the transition of large into small pre-B cells and initiation of L chain 
rearrangement in small pre-B cells. 
It could be argued that Btk does not directly regulate the downregulation of IL-
7- driven proliferation, modulation of SLC, CD43, BP1, CD2, CD25 and MHC class 
II expression and activation of L chain gene rearrangements but instead induces 
the transition of large cycling into small resting pre-B cells, in which Ig L chain 
rearrangements and cellular maturation take place in an Btk-independent fashion. 
However, the observations in E41K-Btk mutant mice indicate that activation of Btk 
can directly regulate pre-BCR checkpoint functions, because we found that L chain 
rearrangement and induction of CD2, CD25 and MHC class II expression, which 
normally takes place in small pre-B cells, was already induced in pro-B cells by 
transgenic expression of constitutively active Btk (Table 1; Chapter 2.3). 
Another possible mechanism for the action of Btk would be that Btk signalling 
affects the general kinetics of pre-B cell differentiation. In such a model, Btk-defi cient 
pre-B cells only need more time for the transition of the large cycling into the small 
resting pre-B cell stage, as Btk is required for effi cient cellular maturation of large 
pre-B cells (Chapter 2.1; (16)). However, by crossing Btk-defi cient mice with mice 
transgenic for the anti-apoptosis protein Bcl-2, which provides an extended time 
window per cell, we found that overexpression of Bcl-2 could not rescue the cellular 
maturation defects in Btk-defi cient mice (Chapter 4; (34)). Therefore, Btk does not 
only affect the kinetics of pre-B cell differentiation, but also provides signals that 
regulate effi cient pre-B cell development. Together these results indicate that Btk 
directly induces the downregulation of IL-7 driven proliferation, the modulation of 
SLC, CD43, BP1, CD2, CD25 and MHC class II expression and Ig L chain locus 
opening upon pre-BCR signalling.
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3.1  Termination of proliferation
As SLP-65 or Btk mutant pre-B cells manifest signifi cantly increased proliferative 
expansion in response to IL-7 (Chapter 2.1; (16, 35)), it can be concluded that the 
pre-BCR-mediated signalling pathway essential for proliferation, i.e. the Ras/Raf/
MEK/MAP kinase cascade, should be independent of SLP-65 or Btk. In agreement 
Figure 4. Pre-B cell receptor signalling model. Proliferation is induced in a SLP-65/Btk-
independent pathway involving Erk MAP kinase. Phosphorylated SLP-65 provides binding 
sites for Btk and PLCγ2 SH2 domains. This SLP-65/Btk-dependent pathway is essential 
to signal termination of proliferation by down-regulation of surrogate light chain (SLC) and 
interleukin-7 receptor (IL-7R) expression and κ L chain opening. IRF-4 might regulate the 
large to small pre-B transition in part by down-regulating SLC gene expression and by direct 
induction of enhancer-dependent κ L chain locus opening (37).
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with this, pre-BCR engagement induced Erk activation in the absence of SLP-65 or 
Btk, and inhibition of Erk activation prevented survival of SLP65-/- pre-B cells (35, 
36). Therefore, two separate signalling pathways exist downstream the pre-BCR, 
one proliferative pathway that is independent of SLP-65 and Btk and results in Erk 
activation, and a second anti-proliferative pathway that involves SLP-65 and Btk 
(Figure 4).
In cells receiving an additional pre-BCR signal, higher levels of phosphorylated 
Erk MAP kinase were produced in response to low amounts of IL-7 (38). As Erk 
activation is implicated in pre-BCR-induced clonal expansion (27, 36), these 
fi ndings demonstrate that the pre-BCR and IL-7R signalling pathways intersect 
functionally (Figure 4). 
An additional connection between pre-BCR and IL-7R signalling is clear from 
the observed SLP-65-mediated repression of IL-7Rα transcription and cell surface 
expression at the transition of large cycling into small resting pre-B cells (39, 40). 
Furthermore, introduction of a rearranged L chain in an IL-7R positive pre-B cell line 
resulted in loss of IL-7 responsiveness (41). This inhibition of proliferative signalling 
through the IL-7R might be mediated through an inhibitory molecule that is recruited 
by the BCR to the cytoplasmic domain of the IL-7Rα chain. Taken together, these 
observations indicate that there are multiple levels by which IL-7 responsiveness is 
regulated by the BCR and its immature forms.
Two recent discoveries have provided new insights into the cell-autonomous 
mechanism by which the pre-BCR exerts its key checkpoint function. First, 
evidence was provided that pre-BCR triggering does not require exogenous ligands 
to induce clonal expansion (42), and second, the downstream component SLP-65 
was shown to act as a feedback inhibitor of pre-BCR signalling (35, 40, 43). 
Although Btk-defi cient mice do not develop pre-B cell tumors, we have shown 
that Btk co-operates with SLP-65 as a tumor suppressor in pre-B cells (Chapter 
3.1; (43)). Btk/SLP-65 double mutant mice have a dramatically increased pre-B 
cell tumor incidence, as compared to SLP-65 single defi cient mice. Conversely, 
transgenic low-level expression of a constitutive active form of Btk prevented tumor 
formation in Btk/SLP-65 double mutant mice, indicating that constitutive active 
Btk can substitute for SLP-65 as a tumor suppressor (Chapter 3.1; (43)). The 
importance of Btk and SLP-65 for the induction of proliferation upon BCR cross-
linking in mature cells has been well documented. However, quite surprisingly, it 
now appears that SLP-65 and Btk have an opposite role in pre-B cells, where they 
terminate proliferative expansion and serve as tumor suppressors. Unexpectedly, 
the tumor suppressor function of Btk was also shown to be independent of the 
kinase activity of Btk as the incidence of pre-B cell tumor formation was signifi cantly 
reduced in K430R-Btk SLP-65- mice when compared to Btk/SLP-65 double defi cient 
mice (Chapter 3.2).
3.2  Cellular maturation of pre-B cells 
Recent RNA expression profi le studies have indicated that a major change in 
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gene expression takes place at the transition from large cycling into small resting 
pre-B cells, as proliferation ceases and new differentiation programs are initiated 
(44). Pro-B cells express the membrane sialoglycoprotein CD43, SLC and the 
metallopeptidase BP-1, which are downregulated upon pre-BCR signalling. In 
contrast the adhesion molecule CD2, the IL-2 receptor CD25 and MHC class II are 
upregulated upon pre-BCR signalling and are expressed on small pre-B cells. The 
importance of the modulation of the expression of these proteins is not yet clear. 
However, CD43, CD2 and IL-2 do not appear to be required at the pre-B cell stage 
as knockout mice for these genes did not show any defects in B cell development 
(45-47). Although the role of the CD43, BP-1, CD2 and CD25 proteins during B cell 
development is unknown, their expression pattern provides a way to analyse the 
effi ciency of pre-BCR signalling in respect to the cellular maturation of pre-B cells 
in vivo (48-51).
It was found that the signalling proteins Btk and SLP-65 play a crucial role at 
the transition of large into small pre-B cells as Btk or SLP-65-defi cient mice fail 
to effi ciently modulate the expression SLC, BP-1, CD43, CD2, CD25 and MHC 
class II (Chapters 2.1 and 3.1; (16, 40, 43)). In addition, SLP-65 reconstitution 
experiments in Igµ+Pax5-/- pre-B cells indicated that SLP-65 is involved in the 
transcriptional repression of RAG-1, RAG-2, terminal deoxynucleotidyl transferase 
(TdT) and IL-7Rα and in the posttranslational down-regulation of cell surface c-kit 
expression (39). Therefore, it can be concluded that pre-BCR signalling regulates 
cellular maturation of pre-B cells and this signalling requires the activation of both 
Btk and SLP-65. 
Interestingly, targeted inactivation of the transcription factors interferon 
regulatory factor (IRF)-4 and IRF-8 is associated with a phenotype that is remarkably 
similar to that of SLP-65-defi cient mice: a developmental block at the pre-B cell 
stage, whereby IRF-4,8-/- pre-B cells are cycling and fail to down-regulate the pre-
BCR (37). As IRF-4,8-/- pre-B cells express normal levels of SLP-65, it is attractive 
to hypothesise that IRF-4 and -8 function as crucial downstream nuclear targets 
of SLP-65 signalling. Consistent with this hypothesis, it was recently shown that in 
Abelson-transformed pre-B cell lines, expression of IRF-4 and Spi-B was suffi cient 
to induce germ-line Ig κ transcription (52). Importantly, the presence of the v-Abl 
kinase in these cell lines represses the expression of IRF-4, Spi-B and several 
pre-BCR signalling components including SLP-65 (52). SLP65-defi cient mice show 
defects in germline κ transcription and κ gene rearrangement in pre-B cells, while 
also κ transcription in immature B cells is impaired (40, 53). Concomitant absence 
of CD19 appears to enhance the defects in transcriptional activation of the κ locus 
in SLP65-defi cient mice. This might explain the virtually complete arrest of B cell 
development at the pre-B cell transition in SLP-65/CD19 double mutant mice (40). 
Future experiments should demonstrate the molecular connection between CD19, 
SLP-65 and Btk signalling, IRF-4 and Ig κ gene rearrangements.
General discussion
190
3.3  Ig L chain locus opening
Btk-defi cient mice exhibit a specifi c developmental delay of ~3h within the 
small pre-B cell compartment and have reduced λ L chain usage, implicating Btk in 
the regulation of L chain locus accessibility for V(D)J recombination (Chapters 1.1 
and 2.1; (15, 16)).
We have analysed the initiation of L chain rearrangement in small pre-B cells 
and the usage of κ or λ L chain in immature B cells of Btk-defi cient mice.  We 
have found that Btk-defi cient mice have a reduced λ L chain usage of ~50% 
(Chapter 1.1; (15)). This reduction in λ usage was shown to be dependent on the 
autophosphorylation site Y223 and not of the kinase domain of Btk, as λ usage 
was reduced in Y223F and normal in K430R transgenic mice (Chapter 2.2; (17)). In 
gain-of-function E41K transgenic mice, λ usage was increased when compared to 
wild type mice (Chapter 1.1; (15)). These fi ndings implicate a differential role for the 
individual Btk domains in the regulation of λ L chain rearrangement. 
The reduction in λ usage in Btk-defi cient mice could be the result of defective 
receptor editing. However, when we analysed Btk-defi cient 3-83µδ transgenic 
mice on a deleting (autoreactive) MHC class I background, we found comparable 
numbers of B cells with edited receptors compared to 3-83µδ deleting mice with 
endogenous Btk (Chapter 1.1; (15)), indicating that Btk is not required for receptor 
editing.
The fi nding of increased λ L chain rearrangement in Bcl-2 transgenic mice 
indicates that the extent of secondary rearrangement events in pre-B cells with a 
non-functional L chain rearrangement was dependent on the lifespan of the pre-B 
cells (54). Furthermore, it was shown that the opening of the λ locus takes more 
time than opening of the κ locus (55). However, the overexpression of Bcl-2 did not 
alter the Btk-dependent frequency of λ usage (Chapter 1.1; (15)). Therefore, we 
conclude that the infl uence of Btk on λ usage is not at the level of regulating the 
lifespan of pre-B cells.   
By analysis of the frequency of signal broken ends (SBE) that are formed 
during the V(D)J recombination process under the infl uence of RAG activity, we 
were able to determine that Btk was involved in the regulation of the accessibility 
of the L chain loci (Chapter 1.2). We compared surface Ig- pre-B cells in which L 
chain rearrangement was initiated by IL-7 withdrawal in IL-7 driven BM cultures 
from Btk+ and Btk- mice. In addition, we analysed the frequency of specifi c SBE in 
sorted large and small pre-B and immature B cell populations of both type of mice. 
In summary, we found that Btk-defi cient mice had lower frequencies of Jλ-specifi c 
SBE when compared to wild type mice, which supports the hypothesis that Btk 
signalling affects the regulation of λ L chain recombination. 
Taken together, the fi ndings that in Btk-defi cient mice (1) the frequency of λ-
expressing immature B cells is reduced,  (2) Jλ-specifi c SBE in pre-B cells are low, 
(3) Bcl-2 expression does not change the Btk dependent λ usage, and (4) receptor 
editing appears unaffected, indicate that Btk is involved in the regulation of V(D)J 
recombination at the λ L chain locus. 
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3.4  Migration and adhesion
Integrin-mediated migration as well as cell-cell and cell-matrix adhesion plays 
an important role in B cell development and function. Early B cell development in 
the BM occurs in defi ned microenvironments and is controlled by integrin α4β1-
mediated interactions with fi bronectin in the extracellular matrix and with vascular 
cell adhesion molecule (VCAM)-1-expressing BM stromal cells (56-59). Integrins 
also mediate the trans-endothelial migration of mature B cells required for their 
recirculation and homing and play a key role in antigen-specifi c B cell differentiation 
(60-63). 
Recently it has been shown that the BCR controls integrin activity through Btk 
and PLCγ2 (64). In particular, Btk-defi cient pre-B cells showed a ~50% lower basal 
adhesion in comparison to wild type pre-B cells. Consistent with ligand-independent 
constitutive signalling by the pre-BCR, in wild type cells this basal adhesion could 
not be enhanced by PMA-stimulation. However, in Btk-defi cient pre-B cells the 
basal adhesion could be enhanced up to the level of adhesion of control pre-B 
cells. These observations suggest that Btk plays a role in the regulation of pre-
BCR-controlled integrin activity in pre-B cells, which may be required for retention 
of pre-B cells in the proper microenvironment and their transition into immature B 
cells. The proliferation of cµ+ pre-B cells is reduced in XLA patients as well as in 
α4 integrin-defi cient mice when compared to control pre-B cells. Moreover, as pre-
BCR signalling requires the activation of Btk, it was suggested that loss of control 
of integrin-mediated adhesion by the pre-BCR might contribute to the proliferation 
defects in XLA pre-B cells (64). 
4. BCR signalling in immature B cells
It is established knowledge that Btk plays an important role in the signal transduction 
pathway downstream the BCR. The most obvious defect in Btk-defi cient mice is 
the reduction of the size of the mature B cell population in the periphery, caused 
by a block in splenic B cell differentiation. However, analysis in Btk-defi cient mice 
revealed that B220lowIgM- immature B cells still expressed high levels of cSLC and 
BP-1 and were low in CD2 and CD25 expression (Chapters 2.1 and 2.2; (16, 17)). 
Together with the fi ndings of a 3h delay in the appearance of immature B cells, 
these results indicate that Btk also regulates the cellular maturation of immature B 
cells in the BM.
By analysing the 3-83µδ transgenic mice on a non-deleting background, we 
found that premature expression of the 3-83µδ BCR amplifi ed cellular maturation 
defects in immature B cells in the BM of Btk-defi cient mice and these cells were 
able to enter the spleen, but were effi ciently deleted within 24h upon arrival. The 
residual B cells were shown to have a PB493+IgMhighIgD-/lowCD21-CD23- immature 
phenotype, refl ecting a block at the transition of T1 into T2 B cells (Chapter 4; 
(34)). This block was rescued by crossing these mice with Bcl-2 transgenic mice, 
indicating that there was a survival problem for the T2 cells in Btk- 3-83µδ non-
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deleting mice. We also found that in Btk-defi cient 3-83µδ transgenic mice on a 
deleting background the cellular maturation defects of immature B cells in the BM 
were restored. In addition, the T1 to T2 transition of splenic B cells was corrected. 
These results suggest that when B cells are targeted for receptor editing, the 
autoreactive BCR transmits an additional unique Btk-independent signal signal that 
enhances cellular maturation of immature B cells that are in the process of receptor 
editing (Chapter 4; (34)). 
5. Future prospects
The transition of large into small pre-B cells is a highly organized process that 
results in a series of events: (1) allelic exclusion, (2) enhanced rearrangement of 
L chain genes, (3) downregulation of RAG and SLC, (4) alterations in cell surface 
phenotype and (5) extensive proliferation of the pre-B cell population. Additional 
studies in both human and murine models of immunodefi ciency should help to 
elucidate the exact control of Btk in these critical events. 
Fundamental aspects of pre-BCR signalling
The fi ndings presented in this thesis provide a detailed analysis of the role 
of Btk in early B cell development in the mouse. Still, for some aspects of B cell 
development it is not yet clear if they are dependent on Btk activation. 
For example, it is not known if Btk is involved in Dµ RF2 counterselection (see 
General introduction, page 9). The observations that in mice defi cient for λ5 or 
SLP-65, Dµ RF2 counterselection is abolished but allelic exclusion remains intact 
(40, 65) clearly indicate that the signalling pathways for the two types of inhibition 
of VH to DJH recombination are not identical. It is therefore attractive to speculate 
that Dµ RF2 counterselection refl ects partial signalling: Dµ protein does not induce 
developmental progression or proliferation, but it does induce the SLP-65 dependent 
premature down-regulation of IL-7 responsiveness, which would terminate further 
VH gene recombination (66) and strongly reduce their proliferative or survival 
capacities, when compared with Dµ-negative pro-B cells. In this model, SLP-65-
defi cient Dµ-expressing pro-B cells would not down-regulate IL-7R expression and 
therefore RF2 counterselection is abolished. As Btk and SLP-65 are involved in 
parallel signalling pathways and have a synergistic role at the pre-BCR checkpoint, 
it is very well possible that Btk also has a role in Dµ RF2 counterselection. 
 Although we have shown that constitutive active E41K-Btk induced κ 
L chain rearrangement in pro-B cells and that in Btk-defi cient mice λ L chain 
expression was reduced and Jλ-specifi c SBE were low, the exact mechanism of 
how Btk can regulate L chain locus opening is not understood and will be subject 
of future research. For L chain rearrangement, the RAG genes and transcription 
factors, such as IRF-4 and Spi-B, have to be activated. It is possible that Btk 
regulates the activation of these factors indirectly via the activation of other 
proteins that are downstream in the signal transduction pathway. In this context, it 
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was demonstrated that the Btk protein is able to associate directly with transcription 
factors, such as TFII-I (67) and Bright (68) and Btk is able to shuttle into the nucleus 
where it may directly regulate gene transcription (69).  
Further studies are necessary to determine the exact pathway from Btk to the 
regulation of IL-7 driven proliferation, L chain rearrangement and induction of CD2, 
CD25 and MHC class II expression upon pre-BCR signalling.  One of the models 
that may be instrumental for this is the E41K gain-of-function mutant mouse. These 
mice could be crossed with µMT mice, in which B cell development is blocked at the 
pro-B cell stage, as they are not able to express the µ H chain on the cell surface. 
In E41K/µMT double mutant mice the induction of L chain rearrangement could be 
studied in pro-B cells, without the contamination of pre-B cells that are also in the 
process of L chain rearrangement. It would be possible to examine the initiation of 
L chain rearrangement in more detail by determining the expression of κ, λ or µ 
sterile transcripts by RT-PCR and the frequency of signal broken ends of specifi c H 
and L chain loci by LM-PCR. Moreover, expression-profi ling studies could identity 
transcription or recombination factors induced by Btk-signalling and proteomic 
studies could give information about how protein complexes are assembled and 
connected in the signalling network. These data would provide more insight in the 
role of Btk in these processes.
Btk and agammaglobulinemia patients
The main future prospect for studies to the role of Btk in mouse B cell 
development is to correlate the acquired knowledge to the role of Btk in human B 
cell development.  
Recently it was found that defective SLP-65 expression occurred in ~50% of 
childhood pre-B acute lymphoblastic leukaemias (ALL) demonstrating that SLP-65 
acts as a tumor suppressor in pre-B cells also in man and indicates that loss of SLP-
65 and the accompanying pre-B cell differentiation arrest may be one of the primary 
causes of pre-B ALL (70). The loss of SLP-65 protein was found to be due to the 
incorporation of alternative exons into SLP-65 transcripts, leading to premature stop 
codons. Likewise, in another study ~50% of childhood pre-B ALL cases manifested 
aberrant Btk transcripts predicted to encode Btk proteins with a substantial kinase 
domain deletion (71). As no clear correlation was observed between SLP-65-
defi ciency, Igµ expression or the presence of additional genetic abnormalities such 
as translocations (70), further studies are necessary to elucidate the signifi cance 
of SLP-65- or Btk-defi ciency in the process of malignant transformation of pre-B 
cells in humans. In this context, it is important to note that in contrast to the mouse, 
defi ciency of SLP-65 or Btk in agammaglobulinaemia patients is not associated 
with increased but with a lack of pre-B cell expansion (72, 73). This makes it diffi cult 
to envisage how human pre-B ALL can originate from SLP-65 or Btk-defi cient B-cell 
precursors, which do not proliferate in vivo. Moreover, it can be concluded that the 
function of SLP-65 and Btk in the regulation of pre-B cell proliferation in humans 
and the mouse is apparently different.
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Our fi ndings on the role of Btk in pre-B cell development in Btk-defi cient 
mice made it clear that Btk in man and mouse functions at a similar stage in B 
cell development. Although we cannot fully explain the differences in severity of 
disease between the two species, this may be related to the fact that pre-B cell 
development in the mouse, in contrast to man, is highly dependent on IL-7. The 
signal from the IL-7R was suggested to activate the Ras/Raf/MEK/MAP kinase 
pathway independent of the presence of Btk or SLP-65 (Figure 4). The selection 
of late pro-B cells to microenvironments with low concentrations of IL-7 allows the 
selective proliferation of pre-BCR-expressing cells as the concomitant expression 
of the IL-7R and the BCR provides a signal of higher magnitude. Up to this date, 
no IL-7-like growth factor has been found to regulate early B cell development in 
man. This may indicate that the selection of pre-BCR-expressing cells in man is 
absolutely dependent on pre-BCR signalling and the activation of Btk, as there is 
no alternative pathway to induce proliferation. Mice that are defi cient in IL-7 or its 
receptor have a block in B cell development at the pro- to pre-B cell transition (74-
76). In contrast, patients with severe combined immunodefi ciency due to mutations 
in the genes for the α or γc chain of the IL-7R, have normal numbers of immature 
B cells (77, 78). This further indicates that there are signifi cant differences in the 
regulation of early B cell development in mouse versus man. 
 Another possible way to explain the differences between the XLA and xid 
phenotypes is the fact that there is at least one family member of Btk, Tec, which 
may take over some of the Btk-dependent functions in the absence of Btk in mice. 
This was indicated by the fi ndings that the Tec/Btk double defi cient mouse showed 
a much more severe defect at the pre-B cell stage than either single defi cient mice 
(8).  Although it was shown that Tec is expressed in human B cell lines of different 
developmental stages (79), the extent of which Tec is able to compensate for Btk-
defi ciency in human XLA is not known. 
Until now, only one patient with agammaglobulinemia was found to have a 
mutation in the gene encoding SLP-65 (80). The fact that this patient showed a 
severe block at the pre-B cells stage indicates that the family member of SLP-65, 
SLP-76, or alternative pathways of B cell differentiation that are independent of 
SLP-65, can not compensate for the absence of SLP-65 in man. 
Although treatment of XLA with antibiotics and gamma globulin therapy is 
very effective, the repetitive administration of these medicines is not equivalent 
to a natural immune system. Furthermore, about 10% of patients have signifi cant 
problems with the therapies and XLA patients are always at risk for developing 
chronic pulmonary infections (81, 82). Therefore, gene therapy is an attractive 
possibility for future corrections of the disease. 
Using mouse models, the effi ciency of gene transfer strategies and the obtained 
correction of the xid phenotype can be investigated. It was shown that expression 
of a human cDNA transgene under the control of the MHC class II promoter could 
correct the defects in Btk-defi cient mice (83). Furthermore, in contrast to the fact 
that certain protein tyrosine kinases have been implicated in tumor formation when 
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mutated or overexpressed, it was shown that overexpression of Btk did not cause 
any unfavourable effects (12). In a bone marrow transplantion animal study, Btk-
defi cient mice showed a correction of the B cell defect even when only a small 
fraction of donor bone marrow cells expressed normal Btk (84). Recently it was 
found that B cell defects in unirradiated Btk-defi cient mice that have not received 
any immunosuppressive therapy was completely corrected when a small amount 
of BM cells from a congenic donor with normal Btk was given (85). These fi ndings 
suggest that in patients with XLA, the engraftment of a small number of stem cells 
or B cell precursors from a donor with Btk might provide signifi cant clinical benefi t 
(86). Therefore, it is worthwhile to further develop gene therapy strategies that 
would cure agammaglobulinemia patients in the near future.
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Summary
Signalling from the BCR or its immature form, the pre-BCR, was shown to be crucial for B 
cell development. Gene-targeted mice have defi ned differential roles of components of the 
(pre-) BCR complex or its downstream signalling pathways. One of the proteins involved in 
(pre-) BCR signalling is the cytoplasmic protein Bruton’s tyrosine kinase (Btk). Mice defi cient 
in Btk have B cell differentiation defects resulting in an X-linked immunodefi ciency (xid) 
phenotype. The xid phenotype is characterized by a reduction in the number of peripheral 
B cells and the residual B cell have an immature phenotype, indicating that the lack of Btk 
causes a block in peripheral B cell differentiation. Btk-defi cient mice have low levels of 
serum IgM and IgG3, peritoneal B-1 cells are lacking and these mice are not able to respond 
normally to infection with T cell independent antigens. In contrast, humans with mutations 
in the Btk gene develop the much more severe X-linked agammaglobulinemia (XLA), which 
is characterized by an almost complete block at the pre-B cell stage in the BM, indicating 
a role for Btk at the pre-BCR checkpoint. Boys with XLA have almost no peripheral B cells 
and have very low serum levels of all Ig classes. Therefore, XLA patients hardly respond 
to bacterial antigens, but treatment with antibiotics and gamma globulin therapy is very 
effective. To determine the exact role of Btk during early B cell development in the mouse 
bone marrow, we studied pre-BCR checkpoint functions in the Btk-defi cient mice. 
Pre-BCR signalling regulates the clonal expansion of pre-B cells and subsequent 
downregulation of the V(D)J recombinase system ensures allelic exclusion. Furthermore, 
downregulation of surrogate light chain (SLC) and IL-7R expression terminates the 
proliferation of large pre-B cells and induces differentiation into small pre-B cells when the 
cells have stopped cycling. Modulating the expression of various cell surface and intracellular 
proteins regulates cellular maturation during the transition of large into small pre-B cells. In 
small pre-B cells, the rearrangement machinery is activated again and L chain recombination 
is initiated. Functional L chain rearrangement leads to the expression of the BCR on the cell 
surface and the cells are transferred to the IgM+ immature B cell compartment. 
  In chapter 1, the role of Btk in Ig L chain rearrangement is described. We found 
that in Btk-defi cient mice the frequency of Ig λ-expressing immature B cells was reduced 
by ~50%. This reduction in λ usage was not caused by defective receptor editing or by a 
survival problem for immature B cells in the BM, as transgenic expression of an autoreactive 
BCR or overexpression of the anti-apoptotic protein Bcl-2, respectively, did not alter the Btk-
dependence of λ usage. Analysis of Jλ-specifi c signal broken ends, that are formed during 
the process of λ locus recombination, revealed that Btk regulates the V(D)J recombination 
activity at the λ L chain locus as the frequency of Jλ signal broken ends was very low in Btk-
defi cient mice, when compared with wild type mice. Taken together, these fi ndings indicate 
that Btk is involved in the activation of V(D)J recombination at the λ L chain locus. 
Chapter 2 covers the main theme of this thesis, i.e. the role of Btk at the pre-BCR 
checkpoint. By analysis of the pre-BCR checkpoint functions in vivo we found that Btk is 
required for the effi cient transition of large cycling into small resting pre-B cells. In this 
respect, we found that Btk-defi cient cells failed to effi ciently modulate the expression of 
CD43, SLC, CD2 and CD25 and that the cells manifested a specifi c developmental delay 
within the small pre-B cell stage of ~3h, when compared with wild-type cells. To examine the 
function of the individual domains of Btk in pre-BCR signalling in vivo, we analysed transgenic 
mice that express various Btk mutants, including the E41K gain-of-function PH domain 
mutant, the Y223F autophosphorylation site mutant, the E41K-Y223F double mutant, and 
the K430R kinase-inactive mutant. We crossed these mice onto the Btk null background, 
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and investigated the role of the individual Btk domains at the pre-BCR checkpoint.  
Studies in Btk-defi cient mice transgenic for kinase-inactive K430R-Btk indicated that Btk 
functions at least partially as an adapter protein at the pre-BCR checkpoint, but kinase activity 
of Btk is absolutely required during later stages of B cell development. The E41K gain-of-
function Btk mutant mice revealed that Btk is directly involved in the regulation of κ L chain 
rearrangement, the induction of cellular maturation and IL-7 responsiveness. Furthermore, 
these mice exhibited an increased Ig λ usage in immature B cells, further indicating a direct 
role for Btk in L chain rearrangement. When the autophosphorylation site Y223 of Btk was 
inactivated, no obvious B cell defects were observed. However, expression of the Y223F-
Btk transgene could not fully rescue the reduction of λ L chain usage in Btk-defi cient mice. 
Collectively, the analyses of these mutant Btk transgenic mouse models provided detailed 
information on the role of the individual domains of Btk in pre-B cell development and 
revealed that the requirement for Btk varies signifi cantly between the different Btk-mediated 
signalling pathways during B cell development. 
Chapter 3 describes the synergistic role of Btk and SLP-65 during pre-B cell 
differentiation. Both proteins play a role in parallel pathways downstream of the pre-BCR 
and it has been shown that concomitant absence of Btk in SLP-defi cient mice increased 
the developmental defects at the pre-BCR checkpoint. We further defi ned this synergy and 
identifi ed an unexpected role for Btk as tumor suppressor in SLP-65 defi cient mice. We found 
a dramatically increased pre-B cell tumor incidence in Btk/SLP-65 double mutant mice, when 
compared with SLP-65 single defi cient mice. Furthermore, by crossing the kinase-inactive 
K430R-Btk mutant with SLP-65 defi cient mice, we found that Btk functions as an adapter 
protein in a SLP-65 independent way. 
In chapter 4, we show that the impaired induction of cell surface changes in Btk-
defi cient pre-B cells was still noticeable in κ+ immature B cells, but was largely corrected 
in λ+ immature B cells. To fi nd out if the transit time through the pre-B cell compartment or 
receptor editing may affect the extent of the cellular maturation defects in Btk-defi cient B 
cells, we employed 3-83µδ transgenic mice, which prematurely express a complete B cell 
receptor (BCR) and therefore manifest accelerated B cell development. In Btk-defi cient 3-
83µδ mice, the immature B cells in the bone marrow exhibited a very immature phenotype 
(pre-BCR+CD43+CD2- and were arrested upon arrival in the spleen at the stage of the T1 
transitional B cell. However, these cellular maturation defects were largely restored when 
Btk-defi cient 3-83µδ B cells were targeted for receptor editing in mice with a centrally deleting 
background. We concluded that premature BCR expression amplifi ed the cellular maturation 
defects in Btk-defi cient B cells, while extensive receptor editing reduced these defects.
In conclusion, we obtained important information about the role of Btk at the pre-B cell 
receptor checkpoint in the mouse. This information will also be helpful for further studies 
on the functional defects in XLA patients and future strategies to correct these defects. 
Moreover, our studies defi ned a role for downstream pre-BCR signalling molecules as 
tumor suppressors in the context of pre-B cell leukaemia. 
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Samenvatting voor iedereen
Het immuunsysteem beschermt het lichaam tegen infecties. Wanneer lichaamsvreemde 
stoffen, antigenen, het lichaam binnendringen kunnen gespecialiseerde cellen deze 
antigenen rechtstreeks of via de activatie van andere cellen opruimen. Zo zijn er B cellen 
die na activatie antistoffen kunnen produceren tegen bacteriële antigenen. Een antistof 
wordt ook wel immuunglobuline (Ig) of B cel receptor (BCR) genoemd en bestaat uit twee 
zogenaamde zware en twee lichte eiwitketens die het antigeen kunnen binden en daarmee 
de specifi citeit van de BCR bepalen. Omdat er een grote variatie aan antigenen het lichaam 
binnen kan komen, moeten de antistoffen zo gemaakt worden dat ze een uiteenlopende 
specifi citeit hebben. B cellen ontwikkelen zich volgens een vast patroon via verschillende 
fases en vindt voor een groot deel plaats in het beenmerg. Tijdens de B cel ontwikkeling 
worden de eiwitketens van de immuunglobulines gemaakt. Eerst worden er zware ketens 
in elkaar gezet en voordat de B cel zich verder mag ontwikkelen worden de zware ketens 
getest. De zware ketens moeten goed kunnen binden met de nog te vormen lichte ketens 
van de BCR. Daarom worden de zware ketens eerst aan surrogaat lichte ketens gebonden 
en dit wordt als een complex op de celmembraan van de vroege B cel, de pre-B cel geplaatst. 
Dit complex van zware en surrogaat lichte ketens wordt ook wel het pre-B cel receptor 
(pre-BCR) complex genoemd. De pre-BCR is gekoppeld aan eiwitten die signalen kunnen 
doorgeven naar de celkern en daardoor worden er, zodra de pre-BCR op de membraan 
staat, signalen doorgegeven naar de celkern dat de cel door kan gaan met uitrijpen. Als 
de zware ketens niet goed zijn, kunnen ze niet aan surrogaat lichte ketens binden of zullen 
er geen of te weinig signalen doorgegeven worden en zal de cel niet doorgaan met de 
ontwikkeling. Omdat het maken van een zware keten een ingewikkeld proces is, zal de cel 
die hier succesvol in is geweest een aantal keren delen zodat er meer cellen komen met 
dezelfde zware keten. Daarna komt de cel in een rustfase en worden de lichte ketens van 
het immuunglobuline gemaakt. Als de lichte eiwitketens goed zijn worden ze aan de zware 
ketens gebonden en als een B cel receptor (BCR) complex op de membraan van de B cel 
gezet. De lichte ketens hebben ook een grote variatie in structuur en daarmee krijgt iedere 
B cel een unieke BCR met een unieke specifi citeit. B cellen die een BCR op hun membraan 
hebben worden immature B cellen genoemd. De BCR geeft de immature B cel signalen door 
om naar de milt te gaan om daar verder uit te rijpen tot een antistofproducerende B cel. 
Er zijn veel verschillende eiwitten betrokken bij de ontwikkeling van de B cel. Vooral 
eiwitten die het pre-BCR complex vormen of betrokken zijn bij het doorgeven van signalen 
vanaf de pre-BCR zijn erg belangrijk voor een goede B cel ontwikkeling. Eén van de betrokken 
eiwitten is het Bruton’s tyrosine kinase (Btk) eiwit. Btk is een zogenaamd signaleringseiwit 
en speelt een rol in het doorgeven van de signalen vanaf de pre-BCR en de BCR. 
Bij mensen komt een erfelijke ziekte voor waarbij een mutatie in het gen dat codeert 
voor het Btk eiwit resulteert in een niet-functionerend Btk eiwit. Deze ziekte heet X-
gebonden agammaglobulinemia (XLA), of de ziekte van Bruton. Het gen voor Btk ligt op het 
X-chromosoom en de aandoening komt daarom alleen voor bij jongens. Als het Btk eiwit 
niet werkt, kunnen de B cellen niet volledig uitrijpen tot antistof-producerende cellen en de 
XLA patiëntjes hebben daardoor bijna geen antistoffen in hun bloed. De patiëntjes hebben 
nauwelijks weerstand tegen bacteriën en ze hebben vooral last van infecties in de bovenste 
luchtwegen. Door behandeling met antibiotica en cocktails met algemene antistoffen kunnen 
de patiëntjes prima met de ziekte leven, maar ze zijn wel volledig afhankelijk van deze 
behandeling. Nader onderzoek heeft uitgewezen dat de B cel ontwikkeling bij XLA patiënten 
bijna volledig geblokkeerd is op het pre-B cel stadium in het beenmerg. De cellen die een 
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goede zware keten hebben gemaakt kunnen het pre-BCR complex wel op de membraan 
zetten, maar omdat signalen vanaf de pre-BCR niet goed worden doorgegeven door de 
afwezigheid van Btk, ondergaat de cel geen celdelingen. Daardoor is de ontwikkeling van de 
B cel ernstig verstoord en zijn er maar zeer weinig B cellen die zich tot antistofproducerende 
cel ontwikkelen. 
Bij muizen heeft Btk een vergelijkbare rol in de B cel ontwikkeling. Ook bij muizen 
veroorzaakt een mutatie in Btk een probleem in de B cel ontwikkeling en hebben de muizen 
een X-gebonden immunodefi ciëntie (xid) fenotype. Echter, bij xid muizen ontstaan de 
grootste problemen pas later tijdens de B cel ontwikkeling, namelijk pas tijdens de uitrijping 
in de milt. Ook xid muizen hebben bijna geen rijpe B cellen en hebben zeer weinig antistoffen 
in het bloed. Hoewel de rol van Btk in xid muizen minder opvallend is tijdens de vroege B 
cel ontwikkeling, heeft eerder onderzoek aangetoond dat Btk hier wel een rol speelt. Om 
de exacte rol van Btk in de vroege B cel ontwikkeling nader te bestuderen is in ons lab een 
muis gemaakt waarbij het Btk gen verstoord is. Deze muizen kunnen geen normaal Btk eiwit 
maken en hebben daardoor een xid fenotype. 
De signalen vanaf de pre-BCR reguleren de celdeling van pre-B cellen met een goede 
zware keten en het stoppen van deze delingen om vervolgens te beginnen met het maken 
van de lichte ketens. De overgang van delende naar rustende pre-B cel gaat gepaard 
met de modulatie van de expressie van vele eiwitten, sommige worden op de membraan 
gezet terwijl andere eraf gehaald worden. Door te kijken welke eiwitten er wel of niet op de 
membraan staan, kan de B cel ontwikkeling gevolgd worden en door deze resultaten in Btk-
defi ciënte muizen te vergelijken met controle muizen kan de rol van Btk bepaalt worden in 
de ontwikkeling van de pre-B cel. 
In hoofdstuk 1 wordt de rol van Btk in het maken van de lichte ketens beschreven. 
We hebben gevonden dat de hoeveelheid cellen die een zogenaamde lambda lichte keten 
tot expressie brengen met 50% verminderd is in Btk-defi ciënte muizen ten opzichte van 
controle muizen.  Ons onderzoek heeft aangetoond dat Btk betrokken is bij het toegankelijk 
maken van het gen dat codeert voor deze lambda lichte ketens hetgeen de expressie van 
lambda kan beïnvloeden.
Hoofdstuk 2 beschrijft de rol van Btk in het pre-BCR complex, het controlepunt voor de 
zware ketens. We hebben gevonden dat Btk vereist is voor de goede overgang van delende 
naar rustende pre-B cel. Btk-defi ciënte cellen kunnen de modulatie van de verschillende 
oppervlakte eiwitten niet effi ciënt reguleren en daardoor zijn de pre-B cellen ongeveer 3 uur 
vertraagd in hun ontwikkeling in vergelijking met controle pre-B cellen. 
Het Btk eiwit bestaat uit 5 domeinen, ieder met een eigen functie. Zo is het PH-domein 
betrokken bij de binding van Btk aan het membraan van de cel. De SH-domeinen zijn 
betrokken bij de binding van andere signaleringseiwitten en het kinase-domein kan andere 
eiwitten activeren.  Door mutaties in de verschillende domeinen aan te brengen en deze 
als transgen in muizen tot expressie te laten brengen kan de functie van ieder domein in 
detail onderzocht worden. De resultaten van het onderzoek met deze transgene muizen is 
beschreven in hoofdstuk 2 en samengevat blijkt dat de noodzakelijkheid voor de aanwezigheid 
van Btk erg verschilt tussen de verschillende Btk-afhankelijke signaleringsroutes tijdens de 
vroege en late B cel ontwikkeling.  Zo is de functie van het kinase-domein van groter belang 
in de signaalroute vanaf de BCR dan vanaf de pre-BCR.  
Een ander eiwit dat betrokken is in de signaleringsroute vanaf de pre- en BCR is het 
verbindingseiwit SLP-65. Muizen die SLP-65 niet hebben, hebben een vergelijkbaar defect 
in de vroege B cel ontwikkeling als Btk-defi ciënte muizen. Het defect in SLP-65 defi ciënte 
muizen wordt vooral veroorzaakt doordat de pre-B cellen niet makkelijk kunnen stoppen 
207
met delen. Waarschijnlijk  ontstaan er hierdoor in 10% van deze muizen pre-B cel tumoren. 
Er is aangetoond dat in de afwezigheid van zowel Btk als SLP-65 de defecten op het pre-B 
cel stadium zijn vergroot. In ons lab zijn de defecten nader onderzocht en hebben we een 
onverwachte rol voor Btk gevonden als tumor onderdrukker in SLP-65 defi ciënte muizen. De 
frequentie van de ontwikkeling van pre-B cel tumoren was ernstig toegenomen Btk/SLP-65 
defi ciënte muizen in vergelijking met muizen die alleen het SLP-65 eiwit niet hebben. 
In hoofdstuk 4 laten we zien dat de vertraagde modulatie van eiwitexpressie in  immature 
Btk-defi ciënte cellen minder evident is in cellen die de lambda lichte keten tot expressie 
brengen in vergelijking met cellen die de kappa lichte keten hebben gebruikt. Aangezien 
de lambda-positieve cellen langer in het beenmerg verblijven dan kappa-positieve cellen, 
hebben we onderzocht of de tijd waarin een B cel zich ontwikkelt van belang is voor de 
maturatie van Btk-defi ciënte cellen. We hebben gevonden dat specifi eke receptor signalen 
ervoor zorgen dat de maturatie van Btk-defi ciënte cellen beter gaat dan wanneer cellen niet 
zo’n specifi ek signaal krijgen. 
Samenvattend hebben we veel belangrijke informatie verzameld over de rol van Btk in 
het pre-BCR complex in de muis. Deze informatie kan behulpzaam zijn voor verder studies 
naar de functionele defecten die XLA patiënten ondervinden en voor toekomstige strategieën 
om deze defecten te corrigeren met bijvoorbeeld gentherapie. Verder hebben we gevonden 
dat signalerings moleculen onder de pre-BCR als tumor onderdrukkers kunnen functioneren 
in relatie tot pre-B cel leukemie. 
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List of abbreviations
BCR  B cell receptor
BLNK   B cell linker protein (see also SLP-65) 
BM  Bone marrow
BrdU  Bromodeoxyuridine
Btk   Bruton’s tyrosine kinase
DAG   Diacylglycerol
H  Immunoglobulin heavy chain
Ig   Immunoglobulin
IL-7   Interleukin-7
IL-7R   Interleukin-7 receptor
IP3  Inositol trisphosphate
IRF   Interferon regulatory factor
ITAM   Immunoreceptor tyrosine-based activation motif
κ  Immunoglobulin kappa light chain
L   Immunoglobulin light chain
λ   Immunoglobulin lambda light chain
µ   Immunoglobulin µ heavy chain
MHC   Major histocompatibility complex
NFAT   Nuclear factor in activated T cells
NF-κB  Nuclear factor κB
PI3K   Phosphatidylinositol 3-kinase
PIP   Phosphatidylinositol phosphate
PIP2   Phosphatidylinositol biphosphate
PIP3   Phosphatidylinositol trisphosphate
PIP5K  Phosphatidylinositol phosphate 5-kinases
PKC   Protein kinase C
PLCγ2  Phospholipase Cγ2
Pre-BCR  Precursor B cell receptor
RAG   Recombination activating gene
SLC   Surrogate light chain
SLP-65  SH2-domain leukocyte protein of 65 kD (see also BLNK)
Xid   X-linked immunodefi ciency
XLA   X-linked agammaglobulinemia
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Dankwoord
Zo, dat zit erop. Ik zeg altijd maar zo: je moet er wel wat voor doen, maar dan heb 
je ook wat. Gelukkig heb ik dit werk niet alleen gedaan en wil ik een aantal mensen 
bedanken voor hun betrokkenheid. Ga er maar even voor zitten, want ik ben niet 
kort van stof. 
Uiteraard is een AIO niets zonder een goede begeleiding in de duistere wereld 
van het onderzoek. Ik moet zeggen dat ik het bijzonder goed heb getroffen met 
mijn superbegeleider Rudi. Rudi, zonder jou was dit zeker niet zo‛n mooi boekje 
geworden. Ik had van tevoren niet gedacht dat het een boek zou worden met 
vijf gepubliceerde artikelen, twee bijna submitted papers en een review-artikel 
(en half-af een hoofdstuk). Je hebt me aangestoken met jouw enthousiasme en 
gedrevenheid en ik streef ernaar net zo‛n goede wetenschapper te worden als jij. 
Menigmaal raakten we verzeild in uitvoerige discussies als we wilden uitvogelen wat 
de oorzaak was van soms onverwachte resultaten. Meestal kwamen we er wel uit en 
bedachten we weer nieuwe kleuringen, nieuwe experimenten of nieuwe kruisingen 
om de hypotheses te toetsen. Verder sta je altijd voor iedereen klaar met raad 
en daad en zo ook voor mij waardoor we de meest ingenieuze experimenten 
hebben kunnen uitvoeren. Gelukkig was ook mijn gebrek aan rekenkundige kennis 
geen probleem en kon ik mijn rekenfratsen door jou laten nakijken zodat ik geen 
stommiteiten zou uithalen. Ook waardeer ik je geduld als ik een deadline weer eens 
iets te letterlijk nam; ik hoop dat jij er in ieder geval niet wakker van hebt gelegen 
☺. Kortom, ik heb ontzettend veel van je geleerd en daar wil ik je heel erg voor 
bedanken. En nu maar hopen dat ik het ook allemaal op eigen houtje kan... 
Natuurlijk heb ik ook heel veel geleerd van mijn labgenootjes van 853.
Gemma, bedankt voor je collegialiteit en je kennis van labzaken. Ook al konden 
we niet altijd samen door één deur en was het niet altijd even gezellig, ik heb veel 
van je geleerd zowel van technische als van sociale zaken. Succes met alles en ik 
hoop dat je binnenkort je plannen kunt waarmaken en een paar maanden op reis kan 
gaan.
Het was erg leuk (en nuttig) dat mijn kennis over T cellen weer een beetje werd 
opgefrist door het GATA werk van Jan-Piet en Kam-Wing. 
Jan-Piet, ik ben erg benieuwd naar je resultaten van de karyotypering en de 
micro-arrays. Succes met de laatste drie jaar van je AIO-schap. Maak je vooral 
geen zorgen: voor je het weet vliegen de resultaten je om de oren. 
Kam-Wing, it was nice to hear about your complex experiments, it kept my 
brain fl exible. Good luck with your “other carreer” as a reporter. Hope to read 
more in the newspaper ☺. 
En zo hoor ik ook nog wat over ingewikkelde klonering strategieën van Petra. 
Petra, succes met het construct, je badkamer en de ES-cellen. Ik hoop dat je snel 
wat muisjes hebt rondlopen (in het EDC, niet in je badkamer ☺). 
Door Rogier leer ik dat ik mijn routines moet kunnen onderbouwen met goede 
argumenten, anders doet hij het gewoon op een andere (trouwens vaak ook goed 
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werkende) manier. Ik ben benieuwd wat je allemaal voor mooie resultaten haalt! 
Hou je me op de hoogte van je pre-B cellen in de milt?
En natuurlijk wil ik Esther bedanken. Je was een ideale stagiaire en nu een 
gezellige collega. Ik ben erg trots dat je je diploma zo glansrijk hebt gehaald en 
dat we nu samen een artikel bij elkaar hebben gepipetteerd.  Binnenkort kan het 
K430R/SLP verhaal de deur uit en zonder jouw hulp had ik afgelopen zomer dat 
3-83 verhaal nooit afgekregen. Als ik weer eens een mega-experiment had bedacht 
vond je het geen enkel probleem om vroeg in de ochtend af te spreken en te helpen 
in het muizenhuis en in het lab. Het opzetten van de RT-PCRs, de verdunningsreeks 
van de LM-PCR, het maken van een tumorcurve, het waren allemaal klussen die niet 
altijd even leuk waren maar wel heel netjes door jou zijn uitgevoerd: bedankt! 
Rudi, Gemma, Rogier, Jan-Piet, Kam-Wing, Petra, Esther, onze nieuwste collega 
Van en mijn oud-labgenootjes Katty, Martijn, Marten, Jane, Annabrita, Femke, 
Marleen, Berlinda, Tanja en alle anderen, bedankt voor de gezelligheid.  
Hoewel ik soms enige mate van werkverslaving vertoon, ben ik ook nog wel eens 
sociaal actief geweest. Tegenwoordig worden er iedere maand zogenaamde AIO-
borrels gehouden (waar trouwens iedereen welkom is, in tegenstelling tot wat veel 
mensen denken) en zijn we al drie keer op AIO-weekend geweest. Hoewel dat 
laatste natuurlijk ook een serieuze bedoeling had, was het iedere keer weer erg 
gezellig. Daarom wil ik alle AIO‛s bedanken voor het organiseren van deze “social 
events” en voor de nodige afl eiding. Hier wil ik vooral Tanja, Lizette en Sacha 
even noemen, de AIO‛s uit “mijn jaar”. Ik heb er veel aan gehad om ervaringen en 
informatie uit wisselen en ik zal jullie zeker nog niet met rust laten. Reken er maar 
op dat ik van de partij ben op jullie promoties! Succes met de laatste loodjes!
In de periode van mijn AIO-schap heb ik ook meegewerkt aan onderzoek dat iets 
verder van mijn eigen onderzoek afstond. Het leuke hiervan is dat ik daardoor mede-
auteur ben geworden op een aantal artikelen. Bij deze wil ik Marcel Spaargaren en 
Esther Beuling van de afdeling Pathologie van het AMC in Amsterdam en Peter 
Bouwman, Pieter-Fokko van Loo en Sjaak Philipsen van de afdeling Celbiologie van 
het Erasmus MC bedanken voor hun prettige, leerzame en leuke samenwerking. Ik 
ben ook een maand te gast geweest in het lab van Prof. Mark Schlissel in Berkeley 
waar ik door Stefan Muljo ben ingewerkt in de techniek van de LM-PCR. Mark and 
Stefan, thank you very much for your time and effort to teach me. After gathering 
all kinds of samples, I fi nally got the PCRs running in the lab and hopefully this work 
will be fi nished and published soon (see Chapter 1.2).
Verder zijn er nog een aantal mensen die (technische) ondersteuning hebben 
verleend tijdens mijn tijd hier. Uiteraard Marcia en Wendy die begonnen zijn aan 
de lay-out van dit boekje. Jammer dat het niet helemaal goed gegaan was, maar ik 
heb toch nog veel gehad aan jullie tips. Straks zal ik uitgebreid uitleggen hoe ik het 
gedaan heb en dan worden de toekomstige boekjes net zo mooi als deze (al zeg ik 
het zelf). Tar, bedankt dat je toch een aantal fi guren voor mij hebt gescand. En ik 
wil Rob bedanken voor het feit dat ik de tijd heb gekregen om mijn werk netjes af 
te ronden.
Dankwoord
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Dankwoord
En dan mijn paranimfjes Ellemieke en Lideweij. Ik vind het echt hartstikke leuk 
dat jullie zo goed voor mij zorgen en meedenken met wat er allemaal geregeld moet 
worden. Ik ben ervan overtuigd dat jullie de beste paranimfen zullen zijn die een 
promovendus zich kan wensen, en het wordt vast een hele leuke dag 19 mei! 
Jet en Boudewijn, mama en B, bedankt voor jullie steun. Natuurlijk voor het 
feit dat ik kon gaan studeren, maar het is ook erg goed om te weten dat jullie er 
altijd zijn en willen helpen waar en hoe je maar kan. Zo hebben jullie zelfs mijn 
ingewikkelde teksten doorgeploeterd om te kijken of de Engelse grammatica er een 
beetje goed uitzag. Gelukkig viel het mee, maar ik weet nu zeker dat er geen gekke 
dingen in staan, toch? 
En natuurlijk Edwin. Ook al verklaarde je me soms voor gek en was je het er niet 
altijd mee eens, ik heb alle tijd in dit project kunnen stoppen die ik wilde. Zeker het 
laatste jaar liep het soms nog wel eens de spuigaten uit, maar je ging gewoon mee 
in het weekend of kwam me na je werk ophalen. Ook kon ik uren tegen je aanpraten 
als ik een keer gestrest was om het een of ander. En, niet te vergeten, dankzij jou 
staan er nu super mooie fi guren in het boekje en ziet de lay-out er goed uit.  
Dus beste lezers, ik weet dat de meeste van jullie alleen de laatste bladzijdes 
van dit boekje zullen lezen, maar plaatjes kijken is in dit geval ook de moeite 
waard!
Sabine
1 april 2004
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